Patent Publication Number: US-2023148601-A1

Title: Novel heteroaryl-triazole compounds as pesticides

Description:
The present invention relates to novel heteroaryl-triazole compounds, to formulations and compositions comprising such compounds and to their use in the control of animal pests including arthropods and insects in plant protection and to their use for the control of ectoparasites on animals. 
     Certain heteroaryl-triazole compounds of formula I (R 3b =hydrogen) are disclosed for the use in controlling ectoparasites on animals in WO 2017/192385 and for the use in controlling animal pests including arthropods and insects in the field of plant protection in WO 2019/170626 and WO 2019/215198. Further, the patent applications WO 2019/197468, WO 2019/201835, WO 2019/202077 and WO 2019/206799 disclose certain heteroaryl-triazole compounds for the use in controlling ectoparasites on animals and for the control of animal pests including arthropods and insects in the field of plant protection. WO 2020/002563, WO 2020/053364, WO 2020/053365, WO 2020/079198, WO 2020/094363, WO 2020/169445, WO 2020/182649, WO 2020/188014, WO 2020/188027 and WO 2020/193341 describe azole-amide compounds all of which can be used as insecticides. 
     Modern plant protection products and veterinary ectoparasiticides have to meet many demands, for example in relation to efficacy, persistence, spectrum and resistance breaking properties. Questions of toxicity, the combinability with other active compounds or formulation auxiliaries play a role, as well as the question of the expense that the synthesis of an active compound requires. Furthermore, resistances may occur. For all these reasons, the search for novel crop protection compositions or veterinary ectoparasiticides cannot be considered to be complete, and there is a constant need for novel compounds having properties which, compared to the known compounds, are improved at least in respect of individual aspects. 
     It was an object of the present invention to provide compounds which widen the spectrum of the pesticides in various aspects. 
     The present invention therefore provides compounds of the general formula (I) 
     
       
         
         
             
             
         
       
     
     in which (Configuration 1-1):
     X is O or S;   Y is a direct bond or optionally substituted CH 2 ;   R 1  is hydrogen; C 1 -C 6 alkyl optionally substituted with one substituent selected from —CN, —CONH 2 , —COOH, —NO 2  and —Si(CH 3 ) 3 ; C 1 -C 6 haloalkyl; C 2 -C 6 alkenyl; C 2 -C 6 haloalkenyl; C 2 -C 6 alkynyl; C 2 -C 6 haloalkynyl; C 3 -C 4 cycloalkyl-C 1 -C 2 alkyl-wherein the C 3 -C 4 cycloalkyl is optionally substituted with one or two halogen atoms; oxetan-3-yl-CH 2 — or benzyl optionally substituted with halogen atoms or C 1 -C 3 haloalkyl;   R 2  is phenyl, pyridine, pyrimidine, pyrazine or pyridazine, wherein the phenyl, pyridine, pyrimidine, pyrazine or pyridazine is substituted with a total of one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon bonded to the C═X— group and at least one and up to three substituent(s) are independently selected from group A consisting of
       hydroxy and in each case optionally substituted C 3 -C 6 cycloalkoxy, —OCO—C 1 -C 3 alkyl, —OSO 2 —C 1 -C 6 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, phenoxy and heterocyclyloxy;   and C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 3 alkoxy, C 2 -C 4 alkenyloxy and C 2 -C 4 haloalkenyloxy, wherein the C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 3 alkoxy, C 2 -C 4 alkenyloxy and C 2 -C 4 haloalkenyloxy is substituted with one to three substituents selected from the group consisting of
           ═O (oxo), ═S (thiono), hydroxy, —CN, —COOH, —CSNH 2 , —NO 2 , —NH 2 , —SF 5 , —SiMe 3 ;   and in each case optionally substituted C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl, C 1 -C 6 haloalkylthio, C 1 -C 6 haloalkylsulfinyl, C 1 -C 6 haloalkylsulfonyl, —OCONH—C 1 -C 6 alkyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CONR 41 R 42 , —NR 42 COR 41 , —CO 2 C 1 -C 6 alkyl, —C(═NOC 1 -C 6 alkyl)H, —C(═NOC 1 -C 6 alkyl)-C 1 -C 6 alkyl;   and optionally substituted phenyl and heterocyclyl, wherein the heterocyclyl is selected from the group consisting of saturated and partially unsaturated 4- to 10-membered heterocyclyl, 5-membered heteroaryl, 6-membered heteroaryl, 9-membered heteroaryl and 10-membered heteroaryl;   
           and the other one to two optional substituent(s) are each independently selected from group B consisting of
           halogen, hydroxy, —NH 2 , —CN, SF 5 , —COOH, —CONH 2 , —NO 2 ,   and in each case optionally substituted C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 haloalkylthio;   
           
       R 3a , R 3b  are independently selected from the group consisting of hydrogen, halogen and —CN;
       and C 1 -C 6 alkyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2 , in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkyl sulfinyl, C 1 -C 6 alkylsulfonyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHCO—C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)CO—C 1 -C 6 alkyl, —CO 2 C 1 -C 6 alkyl, —CONH(C 1 -C 6 alkyl), and —CON(C 1 -C 6 alkyl) 2 ;   and in each case optionally substituted C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl;   and benzyl wherein the phenyl substituent is optionally substituted with one to five substituents, each independently selected from the group consisting of halogen, hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2 , —SF 5  and in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, and C 1 -C 6 alkylsulfonyl;   and heterocyclyl-C 1 -C 6 alkyl wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered saturated and partially unsaturated heterocyclyl, 5-membered heteroaryl and 6-membered heteroaryl, each of which is optionally substituted by one to three substituents independently selected from the group consisting of halogen, ═O (oxo), hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2  and in each case optionally substituted C 1 -C 6 alkyl, and C 1 -C 6 alkoxy;   or   
       R 3a , R 3b  form together with the carbon to which they are connected a C 3 -C 6 -carbocyclic or 3- to 6-membered heterocyclic ring system, optionally substituted with one to two substituents, each independently selected from the group consisting of halogen, —CN, in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy and C 1 -C 6 haloalkoxy;   R 4  is pyridine, pyrimidine, pyrazine or pyridazine, wherein the pyridine, pyrimidine, pyrazine or pyridazine is substituted with two to three substituents independently selected from the group consisting of
       halogen, hydroxy, C 3 -C 4 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy;   or   
       R 4  is pyridine, pyrimidine, pyrazine or pyridazine, wherein the pyridine, pyrimidine, pyrazine or pyridazine is substituted with a total of one to three substituent(s), provided at least one and up to three substituent(s) are independently selected from group A consisting of
       —CN, —COOH, —NO 2 , —SF 5 , —NH 2 , substituted C 3 -C 4 cycloalkyl;   and C 1 -C 3 alkyl and C 1 -C 3 alkoxy, both substituted by one to three substituents independently selected from the group consisting of —NH 2 , —OH, —NO 2 , —CN, —SH, CO 2 C 1 -C 4 alkyl, —CONH 2 , SF 5 , —SO 2 NH 2 , C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 5 -C 6 cycloalkenyl, C 2 -C 4 alkynyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , N—C 1 -C 4 alkanoylamino, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 alkynyloxy, C 3 -C 4 cycloalkoxy, C 5 -C 6 cycloalkenyloxy, C 1 -C 4 alkoxy carbonyl, C 2 -C 4 alkenyloxycarbonyl, C 2 -C 4 alkynyloxycarbonyl, C 6 -,C 10 -,C 14 -aryloxycarbonyl, C 1 -C 4 alkanoyl, C 2 -C 4 alkenylcarbonyl, C 2 -C 4 alkynylcarbonyl, C 6 -,C 10 -,C 14 -arylcarbonyl, C 1 -C 4 alkylthio, C 1 -C 4 haloalkylthio, C 3 -C 4 cycloalkylthio, C 2 -C 4 alkenylthio, C 5 -C 6 cycloalkenylthio, C 2 -C 4 alkynylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 haloalkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylsulfonyl, —SO 2 —NH(C 1 -C 6 alkyl), —SO 2 —N(C 1 -C 6 alkyl) 2 , C 1 -C 4 alkylphosphinyl, C 1 -C 4 alkylphosphonyl, C 1 -C 4 alkylaminocarbonyl, N,N-di-C 1 -C 4 alkylaminocarbonyl, N—C 1 -C 4 alkanoylaminocarbonyl, N—C 1 -C 4 alkanoyl-N—C 1 -C 4 alkylaminocarbonyl, C 6 -,C 10 -,C 14 -aryl, C 6 -,C 10 -,C 14 -aryloxy, benzyl, benzyloxy, benzylthio, C 6 -,C 10 -,C 14 -arylthio, C 6 -,C 10 -,C 14 -arylamino, benzylamino, heterocyclyl, heteroaryl and trialkylsilyl, and substituents bonded via a double bond, such as C 1 -C 4 alkylidene (e.g. methylidene or ethylidene), an oxo group, an imino group and a substituted imino group;   and in each case optionally substituted —CO 2 —C 1 -C 6 alkyl, C 5 -C 6 cycloalkyl, C 4 -C 6 alkyl, C 4 -C 6 haloalkyl, C 4 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylsulfanyl, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl, C 1 -C 6 haloalkylthio, C 1 -C 6 haloalkylsulfinyl, C 1 -C 6 haloalkylsulfonyl, C 2 -C 4 alkenylsulfanyl, C 2 -C 4 alkenylsulfinyl, C 2 -C 4 alkenylsulfonyl, C 2 -C 4 alkinylsulfanyl, C 2 -C 4 alkinylsulfinyl, C 2 -C 4 alkinylsulfonyl, phenylsulfanyl, phenylsulfinyl, phenylsulfonyl, S—C 1 -C 6 alkylsulfinimidoyl, S—C 3 -C 6 cycloalkylsulfinimidoyl, S—C 2 -C 6 alkenylsulfinimidoyl, S—C 2 -C 6 alkinylsulfinimidoyl, S-phenylsulfinimidoyl, S—C 1 -C 6 alkylsulfonimidoyl, S—C 3 -C 6 cycloalkylsulfonimidoyl, S—C 2 -C 6 alkenylsulfonimidoyl, S—C 2 -C 6 alkinylsulfonimidoyl, S-phenylsulfonimidoyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —C(═NOC 1 -C 6 alkyl)H, —C(═NOC 1 -C 6 alkyl)-C 1 -C 6 alkyl, phenyl and 5- to 6-membered heteroaryl;   and the following substructures S1 to S6, in which the bond to the pyridine, pyrimidine, pyrazine or pyridazine is marked with a # and Z is CO or CS and Y 1  is independently selected from CO or SO 2 :   
       

     
       
         
         
             
             
         
       
         
         
           
             R 41  is hydrogen or in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, —C 1 -C 6 alkyl-C 3 -C 6 cycloalkyl and phenyl; 
             R 42  is hydrogen or in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 haloalkyl and C 3 -C 6 cycloalkyl; 
             R 43  is independently selected from in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl and phenyl; 
           
         
          and the other one to two optional substituent(s) are each independently selected from group B consisting of
       halogen and hydroxy;   and in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl and C 1 -C 6 alkoxy;   
     
          or 
         R 4  is a 5-membered heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of
       halogen, hydroxy, —CN, —COOH, —NO 2 , —SF 5 , —NH 2 ;   and in each case optionally substituted —CO 2 —C 1 -C 6 alkyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylsulfanyl, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl, C 1 -C 6 haloalkylthio, C 1 -C 6 haloalkylsulfinyl, C 1 -C 6 haloalkylsulfonyl, C 2 -C 4 alkenylsulfanyl, C 2 -C 4 alkenylsulfinyl, C 2 -C 4 alkenylsulfonyl, C 2 -C 4 alkinylsulfanyl, C 2 -C 4 alkinylsulfinyl, C 2 -C 4 alkinylsulfonyl, phenylsulfanyl, phenylsulfinyl, phenylsulfonyl, S—C 1 -C 6 alkylsulfinimidoyl, S—C 3 -C 6 cycloalkylsulfinimidoyl, S—C 2 -C 6 alkenylsulfinimidoyl, S—C 2 -C 6 alkinylsulfinimidoyl, S-phenylsulfinimidoyl, S—C 1 -C 6 alkylsulfonimidoyl, S—C 3 -C 6 cycloalkylsulfonimidoyl, S—C 2 -C 6 alkenylsulfonimidoyl, S—C 2 -C 6 alkinylsulfonimidoyl, S-phenylsulfonimidoyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —C(═NOC 1 -C 6 alkyl)H, —C(═NOC 1 -C 6 alkyl)-C 1 -C 6 alkyl, phenyl and 5- to 6-membered heteroaryl;   and the substructures S1 to S6, in which the bond to the 5-membered heteroaryl is marked with a # and Z is CO or CS and Y 1  is independently selected from CO or SO 2 :   
     
          or 
         R 4  is a heterocyclic ring which is selected from the group consisting of 4- to 10-membered saturated or partially unsaturated heterocyclyl, 9-membered heteroaryl and 10-membered heteroaryl, each of which is optionally substituted by one to three substituents independently selected from the group consisting of
       halogen, ═O (oxo), ═S (thiono), hydroxy, —CN, —COOH, —SO 2 NH 2 , —CONH 2 , —CSNH 2 , —NO 2 , —SF 5 , —NH 2 ;   
     
       
    
     and in each case optionally substituted —CO 2 —C 1 -C 6 alkyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyl-C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylsulfanyl, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl, C 1 -C 6 haloalkylthio, C 1 -C 6 haloalkylsulfinyl, C 1 -C 6 haloalkylsulfonyl, C 2 -C 4 alkenylsulfanyl, C 2 -C 4 alkenylsulfinyl, C 2 -C 4 alkenylsulfonyl, C 2 -C 4 alkinylsulfanyl, C 2 -C 4 alkinylsulfinyl, C 2 -C 4 alkinylsulfonyl, phenylsulfanyl, phenylsulfinyl, phenylsulfonyl, S—C 1 -C 6 alkylsulfinimidoyl, S—C 3 -C 6 cycloalkylsulfinimidoyl, S—C 2 -C 6 alkenylsulfinimidoyl, S—C 2 -C 6 alkinylsulfinimidoyl, S-phenylsulfinimidoyl, S—C 1 -C 6 alkylsulfonimidoyl, 5-C 3 -C 6 cycloalkylsulfonimidoyl, S—C 2 -C 6 alkenylsulfonimidoyl, S—C 2 -C 6 alkinylsulfonimidoyl, S-phenylsulfonimidoyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —C(═NOC 1 -C 6 alkyl)H, —C(═NOC 1 -C 6 alkyl)-C 1 -C 6 alkyl, phenyl and 5- to 6-membered heteroaryl;
         and the substructures S1 and S6, in which the bond to the heterocyclic ring is marked with a # and Z is CO or CS and Y 1  is independently selected from CO or SO 2 :       R 5  is selected from the group of hydrogen, halogen;
       and in each case optionally substituted C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, (C 1 -C 6 alkoxy) 2 CH—, —CO 2 C 1 -C 6 alkyl, —C(═NOC 1 -C 6 alkyl)H, —C(═NOC 1 -C 6 alkyl)-C 1 -C 6 alkyl;   and C 1 -C 6 alkyl and C 1 -C 6 haloalkyl, wherein the C 1 -C 6 alkyl and C 1 -C 6 haloalkyl is optionally substituted with one to three substituents selected from the group consisting of
           halogen, ═O (oxo), ═S (thiono), hydroxy, —CN, —NO 2 , —SF 5 , —SiMe 3 ;   and in each case optionally substituted C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy.   
           
       

     The present invention furthermore provides compounds of the general formula (I) 
     in which (Configuration 1-2):
     X is O or S;   Y is a direct bond or optionally substituted CH 2 ;   R 1  is hydrogen; C 1 -C 6 alkyl optionally substituted with one substituent selected from —CN, —CONH 2 , —COOH, —NO 2  and —Si(CH 3 ) 3 ; C 1 -C 6 haloalkyl; C 2 -C 6 alkenyl; C 2 -C 6 haloalkenyl; C 2 -C 6 alkynyl; C 2 -C 6 haloalkynyl; C 3 -C 4 cycloalkyl-C 1 -C 2 alkyl-wherein the C 3 -C 4 cycloalkyl is optionally substituted with one or two halogen atoms; oxetan-3-yl-CH 2 — or benzyl optionally substituted with halogen atoms or C 1 -C 3 haloalkyl;   R 2  is phenyl, pyridine, pyrimidine, pyrazine or pyridazine, wherein the phenyl, pyridine, pyrimidine, pyrazine or pyridazine is substituted with a total of one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon bonded to the C═X— group and at least one and up to two substituent(s) are independently selected from a group consisting of
       C 3 -C 6 cycloalkoxy, optionally substituted with one to two substituents selected from the group consisting of
           halogen, ═O (oxo), —CN,   C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 alkyl substituted with one to two substituents selected from the group consisting of
           —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 alkylcarbonyl and C 3 -C 6 cycloalkylcarbonyl, wherein C 1 -C 6 alkylcarbonyl and C 3 -C 6 cycloalkylcarbonyl are optionally substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 alkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 haloalkyl substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 haloalkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 2 -C 6 alkenyloxy substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 alkylSO 2 O— substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   phenyl-C 1 -C 3 haloalkyl and phenyl-C 1 -C 3 alkoxy, wherein the phenyl is optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   heterocyclyloxy and heterocyclyl-C 1 -C 3 alkoxy, wherein the heterocyclyl is selected from the group consisting of saturated and partially unsaturated 4- to 6-membered heterocyclyl, 5-membered heteroaryl, 6-membered heteroaryl, each of which optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           and the other optional substituent is selected from a group consisting of
           hydrogen, halogen, hydroxy, —NH 2 , —CN, —NO 2 , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl and C 1 -C 3 haloalkylsulfonyl;   
           
       R 3a , R 3b  are independently selected from the group consisting of hydrogen, halogen and —CN;
       and C 1 -C 6 alkyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2 , in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkyl sulfinyl, C 1 -C 6 alkylsulfonyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHCO—C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)CO—C 1 -C 6 alkyl, —CO 2 C 1 -C 6 alkyl, —CONH(C 1 -C 6 alkyl), and —CON(C 1 -C 6 alkyl) 2 ;   and in each case optionally substituted C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl;   and benzyl wherein the phenyl substituent is optionally substituted with one to five substituents, each independently selected from the group consisting of halogen, hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2 , —SF 5  and in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, and C 1 -C 6 alkylsulfonyl;   and heterocyclyl-C 1 -C 6 alkyl wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered saturated and partially unsaturated heterocyclyl, 5-membered heteroaryl and 6-membered heteroaryl, each of which is optionally substituted by one to three substituents independently selected from the group consisting of halogen, ═O (oxo), hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2  and in each case optionally substituted C 1 -C 6 alkyl, and C 1 -C 6 alkoxy;   or   
       R 3a , R 3b  form together with the carbon to which they are connected a C 3 -C 6 -carbocyclic or 3- to 6-membered heterocyclic ring system, optionally substituted with one to two substituents, each independently selected from the group consisting of halogen, —CN, in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy and C 1 -C 6 haloalkoxy;   R 4  is selected from one of the following substructures T1 to T6, in which the bond to the triazole is marked with a #:   

     
       
         
         
             
             
         
       
         
         
           
             wherein 
             X 1  is the following substructure S4-a, in which the bond to the pyridine, pyrimidine, pyrazine or thiazole is marked with a # 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             
               
                 R 41  is hydrogen or in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, —C 1 -C 6 alkyl-C 3 -C 6 cycloalkyl and phenyl, 
                 R 42  is hydrogen or in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 haloalkyl and C 3 -C 6 cycloalkyl; 
               
             
             X 2  is —CN or X 1 ; 
           
         
         R 5  is selected from the group of hydrogen, halogen;
       and in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, (C 1 -C 6 alkoxy) 2 CH—, —CO 2 C 1 -C 6 alkyl, —C(═NOC 1 -C 6 alkyl)H, —C(═NOC 1 -C 6 alkyl)-C 1 -C 6 alkyl.   
     
       
    
     The compounds of the formula (I) likewise encompass any diastereomers or enantiomers and E/Z isomers which exist, and also salts and N-oxides of compounds of the formula (I), and the use thereof for control of animal pests. 
     Preferred radical definitions for the formulae specified above and hereinafter are given below. 
     The present invention furthermore provides compounds of the general formula (I) 
     in which (Configuration 1-3):
     X is O or S;   Y is a direct bond or optionally substituted CH 2 ;   R 1  is hydrogen; C 1 -C 6 alkyl optionally substituted with one substituent selected from —CN, —CONH 2 , —COOH, —NO 2  and —Si(CH 3 ) 3 ; C 1 -C 6 haloalkyl; C 2 -C 6 alkenyl; C 2 -C 6 haloalkenyl; C 2 -C 6 alkynyl; C 2 -C 6 haloalkynyl; C 3 -C 4 cycloalkyl-C 1 -C 2 alkyl-wherein the C 3 -C 4 cycloalkyl is optionally substituted with one or two halogen atoms; oxetan-3-yl-CH 2 — or benzyl optionally substituted with halogen atoms or C 1 -C 3 haloalkyl;   R 2  is phenyl, pyridine, pyrimidine, pyrazine or pyridazine, wherein the phenyl, pyridine, pyrimidine, pyrazine or pyridazine is substituted with a total of one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon bonded to the C═X— group and at least one and up to two substituent(s) are independently selected from a group consisting of
       C 3 -C 6 cycloalkoxy, optionally substituted with one to two substituents selected from the group consisting of
           halogen, ═O (oxo), —CN,   C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 alkyl substituted with one to two substituents selected from the group consisting of
           —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 alkylcarbonyl and C 3 -C 6 cycloalkylcarbonyl, wherein C 1 -C 6 alkylcarbonyl and C 3 -C 6 cycloalkylcarbonyl are optionally substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 alkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 haloalkyl substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 haloalkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 2 -C 6 alkenyloxy substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   C 1 -C 6 alkylSO 2 O— substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   phenyl-C 1 -C 3 haloalkyl and phenyl-C 1 -C 3 alkoxy, wherein the phenyl is optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           or   heterocyclyloxy and heterocyclyl-C 1 -C 3 alkoxy, wherein the heterocyclyl is selected from the group consisting of saturated and partially unsaturated 4- to 6-membered heterocyclyl, 5-membered heteroaryl, 6-membered heteroaryl, each of which optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl,   
           and the other optional substituent is selected from a group consisting of
           hydrogen, halogen, hydroxy, —NH 2 , —CN, —NO 2 , C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl and C 1 -C 3 haloalkylsulfonyl;   
           
       R 3a , R 3b  are independently selected from the group consisting of hydrogen, halogen and —CN;
       and C 1 -C 6 alkyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2 , in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkyl sulfinyl, C 1 -C 6 alkylsulfonyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHCO—C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)CO—C 1 -C 6 alkyl, —CO 2 C 1 -C 6 alkyl, —CONH(C 1 -C 6 alkyl), and —CON(C 1 -C 6 alkyl) 2 ;   and in each case optionally substituted C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl;   and benzyl wherein the phenyl substituent is optionally substituted with one to five substituents, each independently selected from the group consisting of halogen, hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2 , —SF 5  and in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, and C 1 -C 6 alkylsulfonyl;   and heterocyclyl-C 1 -C 6 alkyl wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered saturated and partially unsaturated heterocyclyl, 5-membered heteroaryl and 6-membered heteroaryl, each of which is optionally substituted by one to three substituents independently selected from the group consisting of halogen, ═O (oxo), hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2  and in each case optionally substituted C 1 -C 6 alkyl, and C 1 -C 6 alkoxy;   or   
       R 3a , R 3b  form together with the carbon to which they are connected a C 3 -C 6 -carbocyclic or 3- to 6-membered heterocyclic ring system, optionally substituted with one to two substituents, each independently selected from the group consisting of halogen, —CN, in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy and C 1 -C 6 haloalkoxy;   R 4  is selected from one of the following substructures T1 to T6, in which the bond to the triazole is marked with a #:   

     
       
         
         
             
             
         
       
         
         
           
             wherein 
             X 1  is the following substructure S4-a, in which the bond to the pyridine, pyrimidine, pyrazine or thiazole is marked with a # 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             
               
                 R 41  is hydrogen or in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, —C 1 -C 6 alkyl-C 3 -C 6 cycloalkyl and phenyl, 
                 R 42  is hydrogen or in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 haloalkyl and C 3 -C 6 cycloalkyl; 
               
             
             X 2  is —CN or X 1 ; 
           
         
         R 5  is selected from the group of hydrogen, halogen;
       and in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, (C 1 -C 6 alkoxy) 2 CH—, —CO 2 C 1 -C 6 alkyl, —C(═NOC 1 -C 6 alkyl)H, —C(═NOC 1 -C 6 alkyl)-C 1 -C 6 alkyl.   
     
       
    
     The compounds of the formula (I) likewise encompass any diastereomers or enantiomers and E/Z isomers which exist, and also salts and N-oxides of compounds of the formula (I), and the use thereof for control of animal pests. 
     Preferred radical definitions for the formulae specified above and hereinafter are given below. 
     Preference (Configuration 2-1) is given to the compounds of the formula (I) in which
     X is O or S;   Y is a direct bond or CH 2 ;   R 1  is hydrogen; C 1 -C 3 alkyl optionally substituted with one substituent selected from —CN, —CONH 2 , —COOH, —NO 2  and —Si(CH 3 ) 3 ; C 1 -C 3 haloalkyl; C 2 -C 4 alkenyl; C 2 -C 4 haloalkenyl; C 2 -C 4 alkynyl; C 2 -C 4 haloalkynyl; C 3 -C 4 cycloalkyl-C 1 -C 2 alkyl-wherein the C 3 -C 4 cycloalkyl is optionally substituted with one or two halogen atoms; oxetan-3-yl-CH 2 —; or benzyl optionally substituted with halogen atoms or C 1 -C 3 haloalkyl;   R 2  is phenyl, pyridine, pyrimidine, pyrazine or pyridazine, wherein the phenyl, pyridine, pyrimidine, pyrazine or pyridazine is substituted with a total of one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon bonded to the C═X— group and at least one and up to two substituent(s) are independently selected from group A consisting of
       hydroxy and C 3 -C 6 cycloalkoxy, —OCO—C 1 -C 3 alkyl, —OSO 2 —C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl;   and phenoxy and heterocyclyloxy, wherein the heterocyclyl is selected from the group consisting of saturated and partially unsaturated 4- to 6-membered heterocyclyl, 5-membered heteroaryl, 6-membered heteroaryl, and the phenoxy or heterocyclyloxy is optionally substituted with one to two substituents, each independently selected from the group consisting of halogen, —CN, C 1 -C 3 alkyl and C 1 -C 3 haloalkyl;   and C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 3 alkoxy, C 2 -C 4 alkenyloxy and C 2 -C 4 haloalkenyloxy, wherein the C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 3 alkoxy, C 2 -C 4 alkenyloxy and C 2 -C 4 haloalkenyloxy is substituted with one to three substituents selected from the group consisting of
           halogen, ═O (oxo), ═S (thiono), hydroxy, —CN, —COOH, —CSNH 2 , —NO 2 , —NH 2 , —SF 5 , —SiMe 3 ,   and C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfonyl, C 3 -C 6 cycloalkylkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl, C 1 -C 4 haloalkylthio, C 1 -C 4 haloalkylsulfinyl, C 1 -C 4 haloalkylsulfonyl, —OCONH—C 1 -C 4 alkyl, —NH(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl) 2 , —CONR 41 R 42 , —NR 42 COR 41 , —CO 2 C 1 -C 4 alkyl, —C(═NOC 1 -C 4 alkyl)H, —C(═NOC 1 -C 4 alkyl)-C 1 -C 4 alkyl;   
           and phenyl-C 1 -C 3 alkyl, phenyl-C 1 -C 3 haloalkyl, phenyl-C 1 -C 3 haloalkoxy, phenyl-C 1 -C 3 alkoxy, heterocyclyl-C 1 -C 3 alkyl, heterocyclyl-C 1 -C 3 haloalkyl, heterocyclyl-C 1 -C 3 haloalkoxy, heterocyclyl-C 1 -C 3 alkoxy, wherein the heterocyclyl is selected from the group consisting of saturated and partially unsaturated 5- to 6-membered heterocyclyl, 5-membered heteroaryl, 6-membered heteroaryl and wherein the phenyl or heterocyclyl is optionally substituted by one to three substituents independently selected from the group consisting of halogen, ═O (oxo), —CN, C 3 -C 4 cycloalkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy;   
        and the other one to two optional substituent(s) are each independently selected from group B consisting of
       halogen, —CN, SF 5 —NO 2 , C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy and C 1 -C 3 haloalkylthio;   
       R 3a , R 3b  are independently selected from the group consisting of hydrogen, halogen, and —CN;
       and C 1 -C 4 alkyl optionally substituted by one to three substituents independently selected from the group consisting of hydroxy, —CN, —COOH, —CONH 2 , —NO 2 , —NH 2 , C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylthio, C 1 -C 4 haloalkylsulfinyl, C 1 -C 4 haloalkylsulfonyl;   and C 3 -C 6 cycloalkyl optionally substituted with one to two substituents selected from the group consisting of halogen, —CN, —COOH, —CONH 2 , C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy;   and C 1 -C 4 haloalkyl optionally substituted with one to two substituents selected from the group consisting of hydroxy, —CN, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy;   
       R 4  is pyridine, pyrimidine, pyrazine or pyridazine, wherein the pyridine, pyrimidine, pyrazine or pyridazine is substituted with two to three substituents independently selected from the group consisting of
       halogen, hydroxy, C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy;   
        or   R 4  is pyridine, pyrimidine, pyrazine or pyridazine, wherein the pyridine, pyrimidine, pyrazine or pyridazine is substituted with a total of one to three substituent(s), provided at least one and up to two substituent(s) are independently selected from group A consisting of
       —CN, —COOH, —NO 2 , —SF 5 , —NH 2 , substituted C 3 -C 4 cycloalkyl;   and C 1 -C 3 alkyl and C 1 -C 3 alkoxy, both substituted by one to two substituents independently selected from the group consisting of —CN, —CO 2 C 1 -C 4 alkyl, —CONH 2 , SF 5 , —SO 2 NH 2 , C 3 -C 4 cycloalkyl, —NH(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl) 2 , N—C 1 -C 4 alkanoylamino, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkoxycarbonyl, C 6 -,C 10 -,C 14 -aryloxycarbonyl, C 1 -C 4 alkanoyl, C 1 -C 4 alkylthio, C 1 -C 4 haloalkylthio, C 3 -C 4 cycloalkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 haloalkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylsulfonyl, —SO 2 —NH(C 1 -C 4 alkyl), —SO 2 —N(C 1 -C 4 alkyl) 2 , N—C 1 -C 4 alkylaminocarbonyl, NA-di-C 1 -C 4 alkylaminocarbonyl, N—C 1 -C 4 alkanoylaminocarbonyl, N—C 1 -C 4 alkanoyl-N—C 1 -C 4 alkylaminocarbonyl, heterocyclyl, heteroaryl, and substituents bonded via a double bond, such as C 1 -C 4 alkylidene (e.g. methylidene or ethylidene), an oxo group, an imino group and a substituted imino group;   and —CO 2 —C 1 -C 4 alkyl, C 4 -C 6 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 3 -C 6 cycloalkylsulfanyl, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl, C 1 -C 4 haloalkylthio, C 1 -C 4 haloalkylsulfinyl, C 1 -C 4 haloalkylsulfonyl, —NH(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl) 2 , —C(═NOC 1 -C 4 alkyl)H, —C(═NOC 1 -C 4 alkyl)-C 1 -C 4 alkyl;   and phenyl and 5- to 6-membered heteroaryl, wherein the phenyl or 5- to 6-membered heteroaryl is optionally substituted by one to three substituents independently selected from the group consisting of halogen, —CN, and in each case optionally substituted C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3  alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3  alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 6 cycloalkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl, and C 1 -C 3 haloalkylsulfonyl;   and the following substructures S1 to S6, in which the bond to the pyridine, pyrimidine, pyrazine or pyridazine is marked with a # and Z is CO or CS and Y 1  is independently selected from CO or SO 2 :   
       

     
       
         
         
             
             
         
       
         
         
           
             
               
                 R 41  is hydrogen or in each case optionally substituted C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkyl-C 3 -C 6 cycloalkyl and phenyl; 
                 R 42  is hydrogen and in each case optionally substituted C 1 -C 4 alkyl, C 1 -C 4 haloalkyl and C 3 -C 6 cycloalkyl; 
                 R 43  is independently selected from in each case optionally substituted C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl and phenyl; 
               
             
           
         
          and the other one to two optional substituent(s) are each independently selected from group B consisting of
       halogen and hydroxy;   and C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 haloalkyl and C 1 -C 4 alkoxy;   
     
          or 
         R 4  is a 5-membered heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of
       halogen, hydroxy, —CN, —COOH, —NO 2 , —SF 5 , —NH 2 ;   and —CO 2 —C 1 -C 4 alkyl, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alky C 1 -C 4 alkylsulfonyl, C 3 -C 6 cycloalkylsulfanyl, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl, C 1 -C 4 haloalkylthio, C 1 -C 4 haloalkylsulfinyl, C 1 -C 4 haloalkylsulfonyl, —NH(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl) 2 , —C(═NOC 1 -C 4 alkyl)H, —C(═NOC 1 -C 4 alkyl)-C 1 -C 4 alkyl;   and phenyl and 5- to 6-membered heteroaryl, wherein the phenyl or 5- to 6-membered heteroaryl is optionally substituted by one to three substituents independently selected from the group consisting of halogen, —CN, and in each case optionally substituted C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 6 cycloalkylthio, C 3 -C 6 cycloalkylsulfinyl, C 3 -C 6 cycloalkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl, and C 1 -C 3 haloalkylsulfonyl;   and the substructures S1 to S6, in which the bond to the 5-membered heteroaryl is marked with a # and Z is CO or CS and Y 1  is independently selected from CO or SO 2 ;   
     
         R 5  is selected from the group of hydrogen, halogen;
       and C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, (C 1 -C 4 alkoxy) 2 CH—, —CO 2 C 1 -C 4 alkyl, —C(═NOC 1 -C 4 alkyl)H, —C(═NOC 1 -C 4 alkyl)-C 1 -C 4 alkyl;   and C 1 -C 4 alkyl and C 1 -C 4 haloalkyl, wherein the C 1 -C 4 alkyl and C 1 -C 4 haloalkyl is optionally substituted with one to three substituents selected from the group consisting of
           halogen, ═O (oxo), ═S (thiono), hydroxy, —CN, —NO 2 , —SF 5 , —SiMe 3 ;   and in each case optionally substituted C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy.   
           
     
       
    
     Preference (Configuration 2-2) is also given to the compounds of the formula (I) in which
     X is O or S;   Y is a direct bond or CH 2 ;   R 1  is hydrogen; C 1 -C 3 alkyl optionally substituted with one substituent selected from —CN, —CONH 2 , —COOH, —NO 2  and —Si(CH 3 ) 3 ; C 1 -C 3 haloalkyl; C 2 -C 4 alkenyl; C 2 -C 4 haloalkenyl; C 2 -C 4 alkynyl; C 2 -C 4 haloalkynyl; C 3 -C 4 cycloalkyl-C 1 -C 2 alkyl-wherein the C 3 -C 4 cycloalkyl is optionally substituted with one or two halogen atoms; oxetan-3-yl-CH 2 —; or benzyl optionally substituted with halogen atoms or C 1 -C 3 haloalkyl;   R 2  is phenyl, pyridine, pyrimidine, pyrazine or pyridazine, wherein the phenyl, pyridine, pyrimidine, pyrazine or pyridazine is substituted with a total of one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon bonded to the C═X— group and at least one and up to two substituent(s) are independently selected from a group consisting of
       C 3 -C 6 cycloalkoxy, optionally substituted with one to two substituents selected from the group consisting of
           halogen, ═O (oxo), —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkyl substituted with one to two substituents selected from the group consisting of
           —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkylcarbonyl and C 3 -C 6 cycloalkylcarbonyl, wherein C 1 -C 3 alkylcarbonyl and C 3 -C 6 cycloalkylcarbonyl are optionally substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 haloalkyl substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 haloalkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 2 -C 4 alkenyloxy substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   and C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkylSO 2 O— substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   and C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   phenyl-C 1 -C 3 haloalkyl and phenyl-C 1 -C 3 alkoxy, wherein the phenyl is optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   heterocyclyloxy and heterocyclyl-C 1 -C 3 alkoxy, wherein the heterocyclyl is selected from the group consisting of saturated and partially unsaturated 4- to 6-membered heterocyclyl, 5-membered heteroaryl, 6-membered heteroaryl, each of which optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           and the other optional substituent is selected from a group consisting of
           hydrogen, halogen, hydroxy, —NH 2 , —CN, —NO 2 , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl and C 1 -C 3 haloalkylsulfonyl;   
           
       R 3a , R 3b  are independently selected from the group consisting of hydrogen, halogen, and —CN;
       and C 1 -C 4 alkyl optionally substituted by one to three substituents independently selected from the group consisting of hydroxy, halogen —CN, —COOH, —CONH 2 , —NO 2 , —NH 2 , C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylthio, C 1 -C 4 haloalkylsulfinyl, C 1 -C 4 haloalkylsulfonyl;   and C 3 -C 6 cycloalkyl optionally substituted with one to two substituents selected from the group consisting of halogen, —CN, —COOH, —CONH 2 , C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy;   and C 1 -C 4 haloalkyl optionally substituted with one to two substituents selected from the group consisting of hydroxy, —CN, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy;   
       R 4  is selected from one of the following substructures T1 to T6, in which the bond to the triazole is marked with a #:   

     
       
         
         
             
             
         
       
         
         
           
             wherein 
             X 1  is the following substructure S4-a, in which the bond to the pyridine, pyrimidine, pyrazine or thiazole is marked with a # 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             
               
                 R 41  is hydrogen or in each case optionally substituted C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkyl-C 3 -C 6 cycloalkyl and phenyl; 
                 R 42  is hydrogen and in each case optionally substituted C 1 -C 4 alkyl, C 1 -C 4 haloalkyl and C 3 -C 6 cycloalkyl; 
               
             
             X 2  is —CN or X 1 ; 
           
         
         R 5  is selected from the group of hydrogen, halogen;
       and C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, (C 1 -C 4 alkoxy) 2 CH—, —CO 2 C 1 -C 4 alkyl, —C(═NOC 1 -C 4 alkyl)H, —C(═NOC 1 -C 4 alkyl)-C 1 -C 4 alkyl.   
     
       
    
     Preference (Configuration 2-3) is also given to the compounds of the formula (I) in which
     X is O or S;   Y is a direct bond or CH 2 ;   R 1  is hydrogen; C 1 -C 3 alkyl optionally substituted with one substituent selected from —CN, —CONH 2 , —COOH, —NO 2  and —Si(CH 3 ) 3 ; C 1 -C 3 haloalkyl; C 2 -C 4 alkenyl; C 2 -C 4 haloalkenyl; C 2 -C 4 alkynyl; C 2 -C 4 haloalkynyl; C 3 -C 4 cycloalkyl-C 1 -C 2 alkyl-wherein the C 3 -C 4 cycloalkyl is optionally substituted with one or two halogen atoms; oxetan-3-yl-CH 2 —; or benzyl optionally substituted with halogen atoms or C 1 -C 3 haloalkyl;   R 2  is phenyl, pyridine, pyrimidine, pyrazine or pyridazine, wherein the phenyl, pyridine, pyrimidine, pyrazine or pyridazine is substituted with a total of one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon bonded to the C═X— group and at least one and up to two substituent(s) are independently selected from a group consisting of
       C 3 -C 6 cycloalkoxy, optionally substituted with one to two substituents selected from the group consisting of
           halogen, ═O (oxo), —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkyl substituted with one to two substituents selected from the group consisting of
           —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkylcarbonyl and C 3 -C 6 cycloalkylcarbonyl, wherein C 1 -C 3 alkylcarbonyl and C 3 -C 6 cycloalkylcarbonyl are optionally substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloaklkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 haloalkyl substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 haloalkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 2 -C 4 alkenyloxy substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   and C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkylSO 2 O— substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   and C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   phenyl-C 1 -C 3 haloalkyl and phenyl-C 1 -C 3 alkoxy, wherein the phenyl is optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   heterocyclyloxy and heterocyclyl-C 1 -C 3 alkoxy, wherein the heterocyclyl is selected from the group consisting of saturated and partially unsaturated 4- to 6-membered heterocyclyl, 5-membered heteroaryl, 6-membered heteroaryl, each of which optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           and the other optional substituent is selected from a group consisting of
           hydrogen, halogen, hydroxy, —NH 2 , —CN, —NO 2 , C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl and C 1 -C 3 haloalkylsulfonyl;   
           
       R 3a , R 3b  are independently selected from the group consisting of hydrogen, halogen, and —CN;
       and C 1 -C 4 alkyl optionally substituted by one to three substituents independently selected from the group consisting of hydroxy, halogen —CN, —COOH, —CONH 2 , —NO 2 , —NH 2 , C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylthio, C 1 -C 4 haloalkylsulfinyl, C 1 -C 4 haloalkylsulfonyl;   and C 3 -C 6 cycloalkyl optionally substituted with one to two substituents selected from the group consisting of halogen, —CN, —COOH, —CONH 2 , C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy;   and C 1 -C 4 haloalkyl optionally substituted with one to two substituents selected from the group consisting of hydroxy, —CN, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy;   
       R 4  is selected from one of the following substructures T1 to T6, in which the bond to the triazole is marked with a #:   

     
       
         
         
             
             
         
       
         
         
           
             wherein 
             X 1  is the following substructure S4-a, in which the bond to the pyridine, pyrimidine, pyrazine or thiazole is marked with a # 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             
               
                 R 41  is hydrogen or in each case optionally substituted C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkyl-C 3 -C 6 cycloalkyl and phenyl; 
                 R 42  is hydrogen and in each case optionally substituted C 1 -C 4 alkyl, C 1 -C 4 haloalkyl and C 3 -C 6 cycloalkyl; 
               
             
             X 2  is —CN or X 1 ; 
           
         
         R 5  is selected from the group of hydrogen, halogen;
       and C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, (C 1 -C 4 alkoxy) 2 CH—, —CO 2 C 1 -C 4 alkyl, —C(═NOC 1 -C 4 alkyl)H, —C(═NOC 1 -C 4 alkyl)-C 1 -C 4 alkyl.   
     
       
    
     Further preferred (Configuration 3-1) are the compounds of the formula (I) in which
     X is O or S;   Y is a direct bond;   R 1  is hydrogen; C 1 -C 3 alkyl optionally substituted with one substituent selected from —CN, —NO 2  and —Si(CH 3 ) 3 ; C 3 -C 4 cycloalkyl-C 1 -C 2 alkyl-wherein the C 3 -C 4 cycloalkyl is optionally substituted with one or two halogen atoms; or benzyl optionally substituted with halogen atoms or C 1 -C 3 haloalkyl;   R 2  is phenyl or pyridine, optionally substituted with one to two substituents, provided the substituent(s) are not on either carbon adjacent to the carbon bonded to the C═X group and at least one and up to two substituent(s) are independently selected from group A consisting of
       hydroxy and C 3 -C 6 cycloalkoxy, —OCO—C 1 -C 3 alkyl, —OSO 2 —C 1 -C 3 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl,   and phenoxy, wherein the phenoxy is optionally substituted with one to two substituents, each independently selected from the group consisting of halogen, —CN, C 1 -C 3 alkyl and C 1 -C 3 haloalkyl;   and heterocyclyloxy, wherein the heterocyclyl is selected from the group consisting of saturated 4- to 6-membered heterocyclyl containing one oxygen atom;   and C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 3 alkoxy, C 2 -C 4 alkenyloxy and C 2 -C 4 haloalkenyloxy, wherein the C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 3 alkoxy, C 2 -C 4 alkenyloxy and C 2 -C 4 haloalkenyloxy is substituted with one to two substituents selected from the group consisting of
           halogen, ═O (oxo), —CN;   and C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl;   
           and phenyl-C 1 -C 3 haloalkyl, phenyl-C 1 -C 3 alkoxy and heterocyclyl-C 1 -C 3 alkyl, wherein the heterocyclyl is selected from the group consisting of pyrazolyl, triazolyl and tetrazolyl and the phenyl or heterocyclyl is optionally substituted by one to three substituents independently selected from the group consisting of halogen, ═O (oxo), —CN, C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy;   and heterocyclyl-C 1 -C 3 alkoxy, wherein the heterocyclyl is selected from the group consisting of saturated 4- to 6-membered heterocyclyl containing one oxygen atom;   and the other optional substituent is selected from group B consisting of
           halogen, hydroxy, —NH 2 , —CN, SF 5 , —COOH, —CONH 2 , —NO 2 , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, and C 1 -C 3 haloalkylthio;   
           
       R 3a , R 3b  are independently selected from the group consisting of hydrogen; C 1 -C 3 alkyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, —CN, C 3 -C 4 cycloalkyl, and C 1 -C 3 alkoxy; C 3 -C 4 cycloalkyl; C 1 -C 3 haloalkyl;   R 4  is pyridine, pyrimidine, pyrazine or thiazole, wherein the pyridine, pyrimidine, pyrazine or thiazole is substituted with a total of one to two substituent(s), provided one substituent is selected from group A consisting of
       —CN, —NO 2 , —NH 2 , substituted C 3 -C 4 cycloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylsulfanyl, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl, C 1 -C 3 haloalkylsulfonyl, —CO 2 C 1 -C 3 alkyl, —C(═NOC 1 -C 3 alkyl)H, C(═NOC 1 -C 3 alkyl)-C 1 -C 3 alky 1;   and the following substructures S1, S2, S4 and S5, in which the bond to the pyridine, pyrimidine, pyrazine, pyridazine or thiazole is marked with a # and Z is CO or CS:   
       

     
       
         
         
             
             
         
       
         
         
           
             and the other optional substituent is selected from group B consisting of
           halogen, —CN;   and C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl, C 1 -C 3 haloalkylsulfonyl, C 3 -C 4 cycloalkylsulfanyl, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl;   
         
           
         
          R 41  is hydrogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl and C 3 -C 4 cycloalkyl; 
          R 42  is hydrogen, C 1 -C 3 alkyl and C 1 -C 3 haloalkyl; 
          R 43  is C 1 -C 3 alkyl, C 1 -C 3 haloalkyl and C 3 -C 4 cycloalkyl; 
         R 5  is hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 3 -C 4 cycloalkyl, or C 1 -C 3 alkoxy. 
       
    
     Also further preferred (Configuration 3-2) are the compounds of the formula (I) in which
     X is O or S;   Y is a direct bond;   R 1  is hydrogen; C 1 -C 3 alkyl optionally substituted with one substituent selected from —CN, —NO 2  and —Si(CH 3 ) 3 ; C 3 -C 4 cycloalkyl-C 1 -C 2 alkyl-wherein the C 3 -C 4 cycloalkyl is optionally substituted with one or two halogen atoms; or benzyl optionally substituted with halogen atoms or C 1 -C 3 haloalkyl;   R 2  is phenyl or pyridine, substituted with one to two substituents, provided the substituent(s) are not on either carbon adjacent to the carbon bonded to the C═X group and at least one and up to two substituent(s) are independently selected from a group consisting of
       C 3 -C 6 cycloalkoxy, optionally substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   
           or   C 1 -C 3 alkyl substituted with one to two substituents selected from the group consisting of
           —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkylcarbonyl and C 3 -C 4 cycloalkylcarbonyl, optionally substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl,   
           or   C 1 -C 3 alkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 haloalkyl substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 haloalkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 2 -C 4 alkenyloxy substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   and C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkylSO 2 O— substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   and C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   phenyl-C 1 -C 3 haloalkyl and phenyl-C 1 -C 3 alkoxy, wherein the phenyl is optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy,   
           or   heterocyclyloxy and heterocyclyl-C 1 -C 3 alkoxy, wherein the heterocyclyl is selected from the group consisting of a saturated 4- to 6-membered heterocyclyl containing one oxygen atom, and the heterocyclyl phenyl is optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy,   
           and the other optional substituent is selected from a group consisting of
           hydrogen, halogen, hydroxy, —NH 2 , —CN, —NO 2 , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl and C 1 -C 3 haloalkylsulfonyl;   
           
       R 3a , R 3b  are independently selected from the group consisting of hydrogen; C 1 -C 3 alkyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, —CN, C 3 -C 4 cycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkyl;   R 4  is selected from one of the following substructures T1 to T6, in which the bond to the triazole is marked with a #:   

     
       
         
         
             
             
         
       
         
         
           
             wherein 
             X 1  is the following substructure S4-a, in which the bond to the pyridine, pyrimidine, pyrazine or thiazole is marked with a # 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             
               
                 R 41  is hydrogen, C 1 -C 3 alkyl, C 1 -C 3 cyanoalkyl, C 1 -C 3 haloalkyl and C 3 -C 4 cycloalkyl; 
                 R 42  is hydrogen, C 1 -C 3 alkyl and C 1 -C 3 haloalkyl; 
               
             
             X 2  is —CN or X 1 ; 
           
         
         R 5  is hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 3 -C 4 cycloalkyl, or C 1 -C 3 alkoxy. 
       
    
     Also further preferred (Configuration 3-3) are the compounds of the formula (I) in which
     X is O or S;   Y is a direct bond;   R 1  is hydrogen; C 1 -C 3 alkyl optionally substituted with one substituent selected from —CN, —NO 2  and —Si(CH 3 ) 3 ; C 3 -C 4 cycloalkyl-C 1 -C 2 alkyl-wherein the C 3 -C 4 cycloalkyl is optionally substituted with one or two halogen atoms; or benzyl optionally substituted with halogen atoms or C 1 -C 3 haloalkyl;   R 2  is phenyl or pyridine, substituted with one to two substituents, provided the substituent(s) are not on either carbon adjacent to the carbon bonded to the C═X group and at least one and up to two substituent(s) are independently selected from a group consisting of
       C 3 -C 6 cycloalkoxy, optionally substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   
           or   C 1 -C 3 alkyl substituted with one to two substituents selected from the group consisting of
           —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkylcarbonyl and C 3 -C 4 cycloalkylcarbonyl, optionally substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl,   
           or   C 1 -C 3 alkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 haloalkyl substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 haloalkoxy substituted with one to two substituents selected from the group consisting of
           ═O (oxo), —CN,   C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 2 -C 4 alkenyloxy substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   and C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   C 1 -C 3 alkylSO 2 O— substituted with one to two substituents selected from the group consisting of
           halogen, —CN,   and C 3 -C 4 cycloalkyl, C 3 -C 4 halocycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl,   
           or   phenyl-C 1 -C 3 haloalkyl and phenyl-C 1 -C 3 alkoxy, wherein the phenyl is optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy,   
           or   heterocyclyloxy and heterocyclyl-C 1 -C 3 alkoxy, wherein the heterocyclyl is selected from the group consisting of a saturated 4- to 6-membered heterocyclyl containing one oxygen atom, and the heterocyclyl phenyl is optionally substituted by one to three substituents independently selected from the group consisting of
           halogen, —CN,   C 1 -C 3 alkyl, C 3 -C 4 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy,   
           and the other optional substituent is selected from a group consisting of
           hydrogen, halogen, hydroxy, —NH 2 , —CN, —NO 2 , C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 haloalkyl, C 1 -C 3  alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3  alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 3 -C 4 cycloalkylkylthio, C 3 -C 4 cycloalkylsulfinyl, C 3 -C 4 cycloalkylsulfonyl, C 1 -C 3 haloalkylthio, C 1 -C 3 haloalkylsulfinyl and C 1 -C 3 haloalkylsulfonyl;   
           
       R 3a , R 3b  are independently selected from the group consisting of hydrogen; C 1 -C 3 alkyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, —CN, C 3 -C 4 cycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkyl;   R 4  is selected from one of the following substructures T1 to T6, in which the bond to the triazole is marked with a #:   

     
       
         
         
             
             
         
       
         
         
           
             wherein 
             X 1  is the following substructure S4-a, in which the bond to the pyridine, pyrimidine, pyrazine or thiazole is marked with a # 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             
               
                 R 41  is hydrogen, C 1 -C 3 alkyl, C 1 -C 3 cyanoalkyl, C 1 -C 3 haloalkyl and C 3 -C 4 cycloalkyl; 
                 R 42  is hydrogen, C 1 -C 3 alkyl and C 1 -C 3 haloalkyl; 
               
             
             X 2  is —CN or X 1 ; 
           
         
         R 5  is hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 3 -C 4 cycloalkyl, or C 1 -C 3 alkoxy. 
       
    
     Particularly preferred (Configuration 4-1) are the compounds of the formula (I) in which
     X is O;   Y is a direct bond;   R 1  is hydrogen;   R 2  is selected from the following substructure(s) Q1, in which the bond to the C═X-group is marked with a #:   

     
       
         
         
             
             
         
       
         
         R 21  is hydroxy, cyanomethyl, 1-cyanoethyl, 2-cyanopropan-2-yl, cyclopropyl(difluoromethyl), (methylsulfanyl)methyl, (methylsulfinyl)methyl, (methylsulfonyl)methyl, 2-ethoxy-1,1-difluoro-2-oxo-ethyl, (methylsulfanyl)methoxy, (methylsulfinyl)methoxy, (methylsulfonyl)methoxy, 1-cyano-1-methyl-ethoxy, oxetan-3-yloxy, tetrahydro-2H-pyran-4-yloxy, tetrahydro-2H-pyran-4-ylmethoxy, (3,3-dichloroprop-2-en-1-yl)oxy, (2,3,3-trichloroprop-2-en-1-yl)oxy, (2,2-difluorocyclopropyl)methoxy, (2,2-dichlorocyclopropyl)methoxy, (1,2,2-trichlorocyclopropyl)methoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, 2,2-dichlorovinyl, (3,4-dimethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl, acetoxy, cyclopropylcarbonyl, methanesulfonyloxy;
       or benzyloxy, 1-phenylethoxy, phenoxy, pyrazol-1-ylmethyl or difluoro(phenyl)methyl, wherein the benzyloxy, 1-phenylethoxy, phenoxy, pyrazol-1-ylmethyl or difluoro(phenyl)methyl is optionally substituted with one substituent selected from the group consisting of halogen, CN, C 1 -C 3 alkyl and C 1 -C 3 haloalkyl;   
     
         R 22  is hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, iso-propyl, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy; 
         R 3a  is hydrogen; 
         R 3b  is selected from the group consisting of hydrogen and methyl; 
         R 4  is selected from one of the following substructures S50, S51 and S52, in which the bond to the triazole is marked with a #: 
       
    
     
       
         
         
             
             
         
       
         
         X 41  is selected from —CN and —CONR 41 R 42 , 
         X 42  is selected from —CN and —CONR 41 R 42 , 
         X 43  is selected from —CN, —NO 2  and —CONR 41 R 42 , 
         R 41  is hydrogen, methyl, ethyl or cyclopropyl; 
         R 42  is hydrogen, methyl or ethyl; 
         R 5  is hydrogen, methyl, ethyl, cyclopropyl, methoxy or ethoxy. 
       
    
     Also particularly preferred (Configuration 4-2) are the compounds of the formula (I) in which
     X is O;   Y is a direct bond;   R 1  is hydrogen;   R 2  is selected from the following substructure(s) Q1 and Q2, in which the bond to the C═X— group is marked with a #:   

     
       
         
         
             
             
         
       
         
         
           
             wherein 
             R 21  is cyclopropyloxy, (2,2-dichlorocyclopropyl)oxy, cyanomethyl, 2-cyanopropan-2-yl, cyclopropyl(difluoromethyl), 2-cyanopropan-2-yloxy, cyclopropylmethoxy, (2,2-difluorocyclopropyl)methoxy, (2,2-dichlorocyclopropyl)methoxy, (3,3-dichloroprop-2-en-1-yl)oxy, (2,3,3-trichloroprop-2-en-1-yl)oxy, 
             R 22  is hydrogen, fluorine, chlorine, bromine, iodine, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, methylsulfonyl, difluoromethylsulfonyl or trifluoromethyl sulfonyl; 
           
         
         R 3a  is hydrogen; 
         R 3b  is hydrogen or methyl; 
         R 4  is selected from one of the following substructures T1 to T6, in which the bond to the triazole is marked with a #: 
       
    
     
       
         
         
             
             
         
       
         
         
           
             wherein 
             X 1  is the following substructure S4-a, in which the bond to the pyridine, pyrimidine, pyrazine or thiazole is marked with a # 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             
               
                 R 41  is hydrogen, methyl, ethyl or cyclopropyl; 
                 R 42  is hydrogen, methyl or ethyl 
               
             
             X 2  is —CN or X 1 ; 
           
         
         R 5  is hydrogen, methyl, ethyl or cyclopropyl. 
       
    
     Also particularly preferred (Configuration 4-3) are the compounds of the formula (I) in which
     X is O;   Y is a direct bond;   R 1  is hydrogen;   R 2  is selected from the following substructure(s) Q1 and Q2, in which the bond to the C═X— group is marked with a #:   

     
       
         
         
             
             
         
       
         
         
           
             wherein 
             R 21  is cyclopropyloxy, (2,2-dichlorocyclopropyl)oxy, cyanomethyl, 2-cyanopropan-2-yl, cyclopropyl(difluoromethyl), cyclopropylcarbonyl, 2-cyanopropan-2-yloxy, cyclopropylmethoxy, (2,2-difluorocyclopropyl)methoxy, (2,2-dichlorocyclopropyl)methoxy, (3,3-dichloroprop-2-en-1-yl)oxy, (2,3,3-trichloroprop-2-en-1-yl)oxy, difluoro-(4-fluorophenyl)methyl, 
             R 22  is hydrogen, fluorine, chlorine, bromine, iodine, cyclopropyl, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, methylsulfonyl, difluoromethylsulfonyl or trifluoromethylsulfonyl; 
           
         
         R 3a  is hydrogen; 
         R 3b  is hydrogen or methyl; 
         R 4  is selected from one of the following substructures T1 to T6, in which the bond to the triazole is marked with a #: 
       
    
     
       
         
         
             
             
         
       
         
         
           
             wherein 
             X 1  is the following substructure S4-a, in which the bond to the pyridine, pyrimidine, pyrazine or thiazole is marked with a # 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             
               
                 R 41  is hydrogen, methyl, ethyl or cyclopropyl; 
                 R 42  is hydrogen, methyl or ethyl 
               
             
             X 2  is —CN or X 1 ; 
           
         
         R 5  is hydrogen, methyl, ethyl or cyclopropyl. 
       
    
     Very particularly preferred (Configuration 5-1) are the compounds of the formula (I) in which
     X is O;   Y is a direct bond;   R 1  is hydrogen;   R 2  3-(1-cyanoethyl)phenyl, 3-(2,3,3-trichloroallyloxy)-5-(trifluoromethyl)phenyl, 3-(2-cyanopropan-2-yl)-5-(trifluoromethoxy)phenyl, 3-(2-cyanopropan-2-yl)-5-(trifluoromethyl)phenyl, 3-(2-cyanopropan-2-yl)-5-isopropylphenyl, 3-(3,3-dichloroallyloxy)-5-(trifluoromethyl)phenyl, 3-(cyanomethyl)-5-fluorophenyl, 3-(cyanomethyl)phenyl, 3-(cyclopropylmethoxy)-5-methylphenyl, 3-(methylsulfinylmethoxy)-5-(trifluoromethyl)phenyl, 3-(oxan-4-ylmethoxy)-5-(trifluoromethyl)phenyl, 3-(oxan-4-yloxy)-5-(trifluoromethyl)phenyl, 3-[(2,2-dichlorocyclopropyl)methoxy]-5-(trifluoromethyl)phenyl, 3-[(2-chlorophenyl)methoxy]-5-(trifluoromethyl)phenyl, 3-[(3-chlorophenyl)methoxy]-5-(trifluoromethyl)phenyl, 3-[(4-chlorophenyl)methoxy]-5-(trifluoromethyl)phenyl, 3-[1-(2-chlorophenyl) ethoxy]-5-(trifluoromethyl)phenyl, 3-[1-(3-chlorophenyl)ethoxy]-5-(trifluoromethyl)phenyl, 3-[1-(4-chlorophenyl) ethoxy]-5-(trifluoromethyl)phenyl, 3-acetyloxy-5-chlorophenyl, 3-benzyloxy-5-(trifluoromethyl)phenyl, 3-bromo-5-(2,2-dichloroethen-1-yl)phenyl, 3-bromo-5-(2,3,3-trichloroallyloxy)phenyl, 3-bromo-5-[difluoro-(4-fluorophenyl)methyl]phenyl, 3-bromo-5-cyclopropyloxyphenyl, 3-chloro-5-(2-cyanopropan-2-yl)phenyl, 3-chloro-5-(4-chlorophenoxy)phenyl, 3-chloro-5-(4-fluorophenoxy)phenyl, 3-chloro (cyanomethyl)phenyl, 3-chloro-5-(cyclopropylcarbonyl)phenyl, 3-chloro (methylsulfonylmethyl)phenyl, 3-chloro-5-[(3,4-dimethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl]phenyl, 3-chloro-5-[[4-(trifluoromethyl)-1H-pyrazol yl]methyl]phenyl, 3-chloro-5-methylsulfonyloxyphenyl, 3-chloro-5-phenoxyphenyl, 3-cyclobutyloxy-5-methylphenyl, 3-cyclopentyloxy-5-methylphenyl, 3-hydroxy (trifluoromethyl)phenyl, or 3-methyl-5-(oxetan-3-yloxy)phenyl;   R 3a  is hydrogen;   R 3b  is methyl;   R 4  5-cyanopyridin-2-yl, 5-cyano-1,3-thiazol-2-yl, 5-(dimethylaminocarbonyl)-1,3-thiazol-2-yl, or 5-nitro-1,3-thiazol-2-yl;   R 5  is hydrogen, methyl, cyclopropyl or methoxy.   

     Also very particularly preferred (Configuration 5-2) are the compounds of the formula (I) in which
     X is O;   Y is a direct bond;   R 1  is hydrogen;   R 2  3-bromo-5-(cyclopropoxy)phenyl, 3-cyclopropyloxy-5-(trifluoromethoxy)phenyl, 3-bromo-5-(2,2-dichlorocyclopropyl)oxyphenyl,
       3-chloro-5-(cyanomethyl)phenyl, 3-(cyanomethyl)-5-(trifluoromethoxy)phenyl, 3-chloro-5-(2-cyanopropan-2-yl)phenyl, 3-(2-cyanopropan-2-yl)-5-(trifluoromethyl)phenyl, 3-(2-cyanopropan-2-yl)-5-(trifluoromethoxy)phenyl, 3-(2-cyanopropan-2-yl)-5-methylsulfonylphenyl,   3-chloro-5-(2-cyanopropan-2-yloxy)phenyl, 3-bromo-5-(2-cyanopropan-2-yloxy)phenyl,   3-bromo-5-[cyclopropyl(difluoro)methyl]phenyl,   3-bromo-5-[(2,2-difluorocyclopropyl)methoxy]phenyl, 3-bromo-5-[(2,2-dichlorocyclopropyl)methoxy]phenyl, 3-[(2,2-dichlorocyclopropyl)methoxy]-5-(trifluoromethyl)phenyl,   3-[(2,3,3-trichloroprop-2-en-1-yl)oxy]-5-(trifluoromethyl)phenyl, 3-bromo-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]phenyl,   or 2-chloro-6-(2-cyanopropan-2-yl)pyridin-4-yl;   
       R 3a  is hydrogen;   R 3b  is methyl;   R 4  5-[[ethyl(methyl)amino]carbonyl]pyridin-2-yl, 5-cyanopyrazin-2-yl, 6-cyanopyrimidin-4-yl, 6-(aminocarbonyl)pyrimidin-4-yl, 5-cyano-1,3-thiazol-2-yl, 5-(methylcarbamoyl)-1,3-thiazol-2-yl, or 5-(dimethylaminocarbonyl)-1,3-thiazol-2-yl;   R 5  is hydrogen, methyl, or cyclopropyl.   

     Also very particularly preferred (Configuration 5-3) are the compounds of the formula (I) in which
     X is O;   Y is a direct bond;   R 1  is hydrogen;   R 2  3-bromo-5-(cyclopropoxy)phenyl, 3-cyclopropyloxy-5-(trifluoromethoxy)phenyl, 3-bromo-5-(2,2-dichlorocyclopropyl)oxyphenyl,
       3-chloro-5-(cyanomethyl)phenyl, 3-(cyanomethyl)-5-(trifluoromethoxy)phenyl, 3-chloro-5-(2-cyanopropan-2-yl)phenyl, 3-(2-cyanopropan-2-yl)-5-(trifluoromethyl)phenyl, 3-(2-cyanopropan-2-yl)-5-(trifluoromethoxy)phenyl, 3-(2-cyanopropan-2-yl)-5-methylsulfonylphenyl,   3-chloro-5-(cyclopropylcarbonyl)phenyl,   3-chloro-5-(2-cyanopropan-2-yloxy)phenyl, 3-bromo-5-(2-cyanopropan-2-yloxy)phenyl,   3-bromo-5-[cyclopropyl(difluoro)methyl]phenyl, 3-(2-cyanopropan-2-yloxy)-5-cyclopropylphenyl,   3-bromo-5-[(2,2-difluorocyclopropyl)methoxy]phenyl, 3-bromo-5-[(2,2-dichlorocyclopropyl)methoxy]phenyl, 3-[(2,2-dichlorocyclopropyl)methoxy]-5-(trifluoromethyl)phenyl, 3-[(2,3,3-trichloroprop-2-en-1-yl)oxy]-5-(trifluoromethyl)phenyl, 3-bromo-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]phenyl,   3-bromo-5-[difluoro-(4-fluorophenyl)methyl]phenyl,   or 2-chloro-6-(2-cyanopropan-2-yl)pyridin-4-yl;   
       R 3a  is hydrogen;   R 3b  is methyl;   R 4  5-[[ethyl(methyl)amino]carbonyl]pyridin-2-yl, 5-cyanopyrazin-2-yl, 6-cyanopyrimidin-4-yl, 6-(aminocarbonyl)pyrimidin-4-yl, 6-(methylaminocarbonyl)pyrimidin-4-yl, 5-cyano-1,3-thiazol-2-yl, 5-(methylcarbamoyl)-1,3-thiazol-2-yl, or 5-(dimethylaminocarbonyl)-1,3-thiazol-2-yl;   R 5  is hydrogen, methyl, or cyclopropyl.   

     In a further preferred embodiment, the invention relates to compounds of the formula (I′) 
     
       
         
         
             
             
         
       
     
     in which the structural elements R 1 , R 2 , R 3a , R 3b , R 4 , R 5  and Y have the meanings given in Configuration (1-1) or the meanings given in Configuration (2-1) or the meanings given in Configuration (3-1) or the meanings given in Configuration (4-1) or the meanings given in Configuration (5-1). 
     In a further preferred embodiment, the invention relates to compounds of the formula (I′) 
     
       
         
         
             
             
         
       
     
     in which the structural elements R 1 , R 2 , R 3a , R 3b , R 4 , R 5  and Y have the meanings given in Configuration (1-2) or the meanings given in Configuration (2-2) or the meanings given in Configuration (3-2) or the meanings given in Configuration (4-2) or the meanings given in Configuration (5-2). 
     In a further preferred embodiment, the invention relates to compounds of the formula (I″) in which R 3b  is C 1 -C 3 alkyl, especially preferred Me, and R 3a  is H and 
     
       
         
         
             
             
         
       
     
     in which the structural elements R 1 , R 2 , R 4 , R 5  and Y have the meanings given in Configuration (1-1) or the meanings given in Configuration (2-1) or the meanings given in Configuration (3-1) or the meanings given in Configuration (4-1) or the meanings given in Configuration (5-1). 
     In a further preferred embodiment, the invention relates to compounds of the formula (I″) in which R 3b  is C 1 -C 3 alkyl, especially preferred Me, and R 3a  is H and 
     
       
         
         
             
             
         
       
     
     in which the structural elements R 1 , R 2 , R 4 , R 5  and Y have the meanings given in Configuration (1-2) or the meanings given in Configuration (2-2) or the meanings given in Configuration (3-2) or the meanings given in Configuration (4-2) or the meanings given in Configuration (5-2). 
     In a further preferred embodiment, the invention relates to compounds of the formula (I″) in which R 3b  is C 1 -C 3 alkyl, especially preferred Me, and R 3a  is H and 
     
       
         
         
             
             
         
       
     
     in which the structural elements R 1 , R 2 , R 4 , R 5  and Y have the meanings given in Configuration (1-3) or the meanings given in Configuration (2-3) or the meanings given in Configuration (3-3) or the meanings given in Configuration (4-3) or the meanings given in Configuration (5-3). 
     In a further preferred embodiment, the invention relates to compounds of the formula (I′″) in which R 3b  is C 1 -C 3 alkyl, especially preferred Me, and R 3a  is H and 
     
       
         
         
             
             
         
       
     
     in which the structural elements R 1 , R 2 , R 4 , R 5  and Y have the meanings given in Configuration (1-1) or the meanings given in Configuration (2-1) or the meanings given in Configuration (3-1) or the meanings given in Configuration (4-1) or the meanings given in Configuration (5-1). 
     In a further preferred embodiment, the invention relates to compounds of the formula (I′″) in which R 3b  is C 1 -C 3 alkyl, especially preferred Me, and R 3a  is H and 
     
       
         
         
             
             
         
       
     
     in which the structural elements R 1 , R 2 , R 4 , R 5  and Y have the meanings given in Configuration (1-2) or the meanings given in Configuration (2-2) or the meanings given in Configuration (3-2) or the meanings given in Configuration (4-2) or the meanings given in Configuration (5-2). 
     In a further preferred embodiment, the invention relates to compounds of the formula (I′″) in which R 3b  is C 1 -C 3 alkyl, especially preferred Me, and R 3a  is H and 
     
       
         
         
             
             
         
       
     
     in which the structural elements R 1 , R 2 , R 4 , R 5  and Y have the meanings given in Configuration (1-3) or the meanings given in Configuration (2-3) or the meanings given in Configuration (3-3) or the meanings given in Configuration (4-3) or the meanings given in Configuration (5-3). 
     Furthermore the invention covers the following intermediate compounds and salts thereof (see table 2): 
     Intermediate 5A: 3-chloro-5-(2-cyanopropan-2-yl)benzoic acid
 
Intermediate 9A: 3-chloro-5-(cyclopropylcarbonyl)benzoic acid
 
Intermediate 10A: 3-[(methylsulfinyl)methoxy]-5-(trifluoromethyl)benzoic acid
 
Intermediate 25A: 3-(cyanomethyl)-5-(trifluoromethoxy)benzoic acid
 
Intermediate 26A: sodium 3-(2-cyanopropan-2-yl)-5-(trifluoromethoxy)benzoate/3-(2-cyanopropan-2-yl)-5-(trifluoromethoxy)benzoic acid
 
Intermediate 28A: 3-bromo-5-(2,2-dichlorovinyl)benzoic acid
 
Intermediate 35A: 3-bromo-5-[difluoro(4-fluorophenyl)methyl]benzoic acid
 
Intermediate 48A: 3-chloro-5-[(methylsulfonyl)methyl]benzoic acid
 
Intermediate 50A: 3-(cyclopropoxy)-5-(trifluoromethoxy)benzoic acid
 
Intermediate 51A: 3-bromo-5-(1-cyano-1-methyl-ethoxy)benzoic acid
 
Intermediate 52A: 3-chloro-5-(1-cyano-1-methyl-ethoxy)benzoic acid
 
Intermediate 54A: 5-[5-[(1S)-1-aminoethyl]-1,2,4-triazol-1-yl]pyrazine-2-carbonitrile hydrochloride
 
Intermediate 58A: 6-[5-[(1S)-1-aminoethyl]-3-cyclopropyl-1,2,4-triazol-1-yl]pyrimidine-4-carbonitrile hydrochloride
 
Intermediate 59A: 6-[5-[(1S)-1-aminoethyl]-3-cyclopropyl-1,2,4-triazol-1-yl]pyrimidine-4-carboxamide hydrochloride
 
Intermediate 60A: 3-chloro-6-(1-cyano-1-methyl-ethyl)pyridine-4-carboxylic acid
 
Intermediate 61A: 6-{5-[(1S)-1-aminoethyl]-3-methyl-1H-1,2,4-triazol-1-yl}-N-ethyl-N-methylnicotinamide hydrochloride
 
Intermediate 69A: 3-(cyanomethyl)-5-(methylsulfonyl)benzoic acid
 
Intermediate 70A: 3-(2-cyanopropan-2-yl)-5-(methylsulfonyl)benzoic acid
 
Intermediate 72A: 3-(1-cyano-1-methyl-ethoxy)-5-cyclopropyl-benzoic acid
 
     The compounds of the formula (I) may possibly also, depending on the nature of the substituents, be in the form of stereoisomers, i.e. in the form of geometric and/or optical isomers or isomer mixtures of varying composition. This invention provides both the pure stereoisomers and any desired mixtures of these isomers, even though it is generally only compounds of the formula (I) that are discussed here. 
     However, preference is given in accordance with the invention to using the optically active, stereoisomeric forms of the compounds of the formula (I) and salts thereof. 
     The invention therefore relates both to the pure enantiomers and diastereomers and to mixtures thereof for controlling animal pests, including arthropods and particularly insects. 
     If appropriate, the compounds of the formula (I) may be present in various polymorphic forms or as a mixture of various polymorphic forms. Both the pure polymorphs and the polymorph mixtures are provided by the invention and can be used in accordance with the invention. 
     Definitions 
     The person skilled in the art is aware that, if not stated explicitly, the expressions “a” or “an” as used in the present application may, depending on the situation, mean “one (1)”, “one (1) or more” or “at least one (1)”. 
     For all the structures described herein, such as ring systems and groups, adjacent atoms must not be —O—O— or —O—S—. 
     Structures having a variable number of possible carbon atoms (C atoms) may be referred to in the present application as C lower limit of carbon atoms —C upper limit of carbon atoms  structures (C LL -C UL  structures), in order thus to be stipulated more specifically. Example: an alkyl group may consist of 3 to 10 carbon atoms and in that case corresponds to C 3 -C 10 alkyl. Ring structures composed of carbon atoms and heteroatoms may be referred to as “LL- to UL-membered” structures. One example of a 6-membered ring structure is toluene (a 6-membered ring structure substituted by a methyl group). 
     If a collective term for a substituent, for example C LL -C UL alkyl, is at the end of a composite substituent, for example C LL -C UL cycloalkyl-C LL -C UL alkyl, the constituent at the start of the composite substituent, for example the C LL -C UL cycloalkyl, may be mono- or polysubstituted identically or differently and independently by the latter substituent, for example C LL -C UL alkyl. All the collective terms used in this application for chemical groups, cyclic systems and cyclic groups can be stipulated more specifically through the addition “C LL -C UL ” or “LL- to UL-membered”. 
     In the definitions of the symbols given in the above formulae, collective terms which are generally representative of the following substituents were used: 
     Halogen relates to elements of the 7th main group, preferably fluorine, chlorine, bromine and iodine, more preferably fluorine, chlorine and bromine, and even more preferably fluorine and chlorine. 
     Examples of heteroatom are N, O, S, P, B, Si. Preferably, the term “heteroatom” relates to N, S and O. 
     According to the invention, “alkyl”—on its own or as part of a chemical group—represents straight-chain or branched hydrocarbons preferably having 1 to 6 carbon atoms, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,2-dimethylpropyl, 1,3-dimethylbutyl, 1,4-dimethy lbutyl, 2,3-dimethy lbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethy lbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethylbutyl and 2-ethylbutyl. Preference is also given to alkyls having 1 to 4 carbon atoms such as, inter alia, methyl, ethyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl or t-butyl. The inventive alkyls may be substituted by one or more identical or different radicals. 
     According to the invention, “alkenyl”—on its own or as part of a chemical group—represents straight-chain or branched hydrocarbons preferably having 2 to 6 carbon atoms and at least one double bond, for example vinyl, 2-propenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl propenyl and 1-ethyl-2-methyl-2-propenyl. Preference is also given to alkenyls having 2 to 4 carbon atoms such as, inter alia, 2-propenyl, 2-butenyl or 1-methyl-2-propenyl. The inventive alkenyls may be substituted by one or more identical or different radicals. 
     According to the invention, “alkynyl”—on its own or as part of a chemical group—represents straight-chain or branched hydrocarbons preferably having 2 to 6 carbon atoms and at least one triple bond, for example 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1-methyl-2-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-4-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl, 1-ethyl-1-methyl-2-propynyl and 2,5-hexadiynyl. Preference is also given to alkynyls having 2 to 4 carbon atoms such as, inter alia, ethynyl, 2-propynyl or 2-butynyl-2-propenyl. The inventive alkynyls may be substituted by one or more identical or different radicals. 
     According to the invention, “cycloalkyl”—on its own or as part of a chemical group—represents mono-, bi- or tricyclic hydrocarbons preferably having 3 to 10 carbons, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl or adamantyl. Preference is also given to cycloalkyls having 3, 4, 5, 6 or 7 carbon atoms such as, inter alia, cyclopropyl or cyclobutyl. The inventive cycloalkyls may be substituted by one or more identical or different radicals. 
     According to the invention, “alkylcycloalkyl” represents mono-, bi- or tricyclic alkylcycloalkyl preferably having 4 to 10 or 4 to 7 carbon atoms, for example methylcyclopropyl, ethylcyclopropyl, isopropylcyclobutyl, 3-methylcyclopentyl and 4-methylcyclohexyl. Preference is also given to alkylcycloalkyls having 4, 5 or 7 carbon atoms such as, inter alia, ethylcyclopropyl or 4-methylcyclohexyl. The inventive alkylcycloalkyls may be substituted by one or more identical or different radicals. 
     According to the invention, “cycloalkylalkyl” represents mono-, bi- or tricyclic cycloalkylalkyl preferably having 4 to 10 or 4 to 7 carbon atoms, for example cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl and cyclopentylethyl. Preference is also given to cycloalkylalkyls having 4, 5 or 7 carbon atoms such as, inter alia, cyclopropylmethyl or cyclobutylmethyl. The inventive cycloalkylalkyls may be substituted by one or more identical or different radicals. 
     According to the invention, “hydroxyalkyl” represents a straight-chain or branched alcohol preferably having 1 to 6 carbon atoms, for example methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, s-butanol and t-butanol. Preference is also given to hydroxyalkyl groups having 1 to 4 carbon atoms. The inventive hydroxyalkyl groups may be substituted by one or more identical or different radicals. 
     According to the invention, “alkoxy” represents a straight-chain or branched O-alkyl preferably having 1 to 6 carbon atoms, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, s-butoxy and t-butoxy. Preference is also given to alkoxy groups having 1 to 4 carbon atoms. The inventive alkoxy groups may be substituted by one or more identical or different radicals. 
     According to the invention, “alkylthio”, or “alkylsulfanyl” represents straight-chain or branched S-alkyl preferably having 1 to 6 carbon atoms, for example methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, s-butylthio and t-butylthio. Preference is also given to alkylthio groups having 1 to 4 carbon atoms. The inventive alkylthio groups may be substituted by one or more identical or different radicals. 
     According to the invention, “alkylsulfinyl” represents straight-chain or branched alkylsulfinyl preferably having 1 to 6 carbon atoms, for example methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, isobutylsulfinyl, s-butylsulfinyl and t-butylsulfinyl. Preference is also given to alkylsulfinyl groups having 1 to 4 carbon atoms. The inventive alkylsulfinyl groups may be substituted by one or more identical or different radicals and embrace both enantiomers. 
     According to the invention, “alkylsulfonyl” represents straight-chain or branched alkylsulfonyl preferably having 1 to 6 carbon atoms, for example methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, s-butylsulfonyl and t-butylsulfonyl. Preference is also given to alkylsulfonyl groups having 1 to 4 carbon atoms. The inventive alkylsulfonyl groups may be substituted by one or more identical or different radicals. 
     According to the invention, “cycloalkylthio” or “cycloalkylsulfanyl” represents —S-cycloalkyl preferably having 3 to 6 carbon atoms, for example cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio. Preference is also given to cycloalkylthio groups having 3 to 5 carbon atoms. The inventive cycloalkylthio groups may be substituted by one or more identical or different radicals. 
     According to the invention, “cycloalkylsulfinyl” represents —S(O)-cycloalkyl preferably having 3 to 6 carbon atoms, for example cyclopropylsulfinyl, cyclobutylsulfinyl, cyclopentylsulfinyl, cyclohexylsulfinyl. Preference is also given to cycloalkylsulfinyl groups having 3 to 5 carbon atoms. The inventive cycloalkylsulfinyl groups may be substituted by one or more identical or different radicals and embrace both enantiomers. 
     According to the invention, “cycloalkylsulfonyl” represents —SO 2 -cycloalkyl preferably having 3 to 6 carbon atoms, for example cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, cyclohexylsulfonyl. Preference is also given to cycloalkylsulfonyl groups having 3 to 5 carbon atoms. The inventive cycloalkylsulfonyl groups may be substituted by one or more identical or different radicals. 
     According to the invention, “phenylthio”, or “phenylsulfanyl” represents —S-phenyl, for example phenylthio. The inventive phenylthio groups may be substituted by one or more identical or different radicals. 
     According to the invention, “phenylsulfinyl” represents —S(O)-phenyl, for example phenylsulfinyl. The inventive phenylsulfinyl groups may be substituted by one or more identical or different radicals and embrace both enantiomers. 
     According to the invention, “phenylsulfonyl” represents —SO 2 -phenyl for example phenylsulfonyl. The inventive phenylsulfonyl groups may be substituted by one or more identical or different radicals. 
     According to the invention, “alkylcarbonyl” represents straight-chain or branched alkyl-C(═O) preferably having 2 to 7 carbon atoms such as methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, s-butylcarbonyl and t-butylcarbonyl. Preference is also given to alkylcarbonyls having 1 to 4 carbon atoms. The inventive alkylcarbonyls may be substituted by one or more identical or different radicals. 
     According to the invention, “alkoxycarbonyl”—alone or as a constituent of a chemical group—represents straight-chain or branched alkoxycarbonyl, preferably having 1 to 6 carbon atoms or having 1 to 4 carbon atoms in the alkoxy moiety, for example methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, s-butoxycarbonyl and t-butoxycarbonyl. The inventive alkoxycarbonyl groups may be substituted by one or more identical or different radicals. 
     According to the invention, “alkylaminocarbonyl” represents straight-chain or branched alkylaminocarbonyl having preferably 1 to 6 carbon atoms or 1 to 4 carbon atoms in the alkyl moiety, for example methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, s-butylaminocarbonyl and t-butylaminocarbonyl. The inventive alkylaminocarbonyl groups may be substituted by one or more identical or different radicals. 
     According to the invention, “N,N-dialkylaminocarbonyl” represents straight-chain or branched N,N-dialkylaminocarbonyl having preferably 1 to 6 carbon atoms or 1 to 4 carbon atoms in the alkyl moiety, for example N,N-dimethylaminocarbonyl, N,N-diethylaminocarbonyl, N,N-di(n-propylamino)carbonyl, N,N-di(isopropylamino)carbonyl and N,N-di-(s-butylamino)carbonyl. The inventive N,N-dialkylaminocarbonyl groups may be substituted by one or more identical or different radicals. 
     According to the invention, “aryl” represents a mono-, bi- or polycyclic aromatic system having preferably 6 to 14, especially 6 to 10, ring carbon atoms, for example phenyl, naphthyl, anthryl, phenanthrenyl, preferably phenyl. In addition, aryl also represents fused polycyclic systems such as tetrahydronaphthyl, indenyl, indanyl, fluorenyl, biphenyl, where the bonding site is on the aromatic system. The inventive aryl groups may be substituted by one or more identical or different radicals. 
     Examples of substituted aryls are the arylalkyls, which may likewise be substituted by one or more identical or different radicals in the C 1 -C 4 alkyl and/or C 6 -C 14 aryl moiety. Examples of such arylalkyls include benzyl and phenyl-1-ethyl. 
     According to the invention the term “polycyclic” ring refers to fused, bridged and spirocyclic carbocyclic and heterocyclic rings as well as ring systems linked through single or double bonds. 
     According to the invention, “heterocycle”, “heterocyclic ring” or “heterocyclic ring system” represents a carbocyclic ring system having at least one ring in which at least one carbon atom is replaced by a heteroatom, preferably by a heteroatom from the group consisting of N, O, S, P, B, Si, Se, and which is saturated, unsaturated or heteroaromatic and may be unsubstituted or substituted, where the bonding site is on a ring atom. Unless defined differently, the heterocyclic ring contains preferably 3 to 9 ring atoms, especially 3 to 6 ring atoms, and one or more, preferably 1 to 4, especially 1, 2 or 3, heteroatoms in the heterocyclic ring, preferably from the group consisting of N, O, and S, although no two oxygen atoms should be directly adjacent. The heterocyclic rings usually contain not more than 4 nitrogen atoms and/or not more than 2 oxygen atoms and/or not more than 2 sulphur atoms. In the case of optionally substituted heterocyclyl, the invention also embraces polycyclic ring systems, for example 8-azabicyclo[3.2.1]octanyl, 1-azabicyclo[2.2.1l]heptyl, 1-oxa-5-azaspiro[2.3]hexyl or 2,3-dihydro-1H-indole. 
     Inventive heterocyclyl groups are, for example, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dihydropyranyl, tetrahydropyranyl, dioxanyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, thiazolidinyl, oxazolidinyl, dioxolanyl, dioxolyl, pyrazolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxetanyl, oxiranyl, azetidinyl, aziridinyl, oxazetidinyl, oxaziridinyl, oxazepanyl, oxazinanyl, azepanyl, oxopyrrolidinyl, dioxopyrrolidinyl, oxomorpholinyl, oxopiperazinyl and oxepanyl. 
     Of particular significance are heteroaryls, i.e. heteroaromatic systems. According to the invention, the term heteroaryl represents heteroaromatic compounds, i.e. completely unsaturated aromatic heterocyclic compounds which fall under the above definition of heterocycles. Preference is given to 5- to 7-membered rings having 1 to 3, preferably 1 or 2, identical or different heteroatoms from the group above. Inventive heteroaryls are, for example, furyl, thienyl, pyrazolyl, imidazolyl, 1,2,3- and 1,2,4-triazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-, 1,3,4-, 1,2,4- and 1,2,5-oxadiazolyl, azepinyl, pyrrolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-, 1,2,4- and 1,2,3-triazinyl, 1,2,4-, 1,3,2-, 1,3,6- and 1,2,6-oxazinyl, oxepinyl, thiepinyl, 1,2,4-triazolonyl and 1,2,4-diazepinyl. The inventive heteroaryl groups may also be substituted by one or more identical or different radicals. 
     According to the invention, the substituent ═O (oxo) can replace two hydrogen atoms of a methylene (CH 2 ) group or the lone pairs of a sulfur, nitrogen and phosphorous atom which bears only substituents other than hydrogen. For example the radical C 2 -alkyl becomes for example —COCH 3  through substitution by ═O (oxo) while the heterocycle thietan-3-yl-becomes for example 1-oxothietan-3-yl through substitution by one ═O (oxo) group or 1,1-dioxothietan-3-yl through substitution by two ═O (oxo) groups. 
     According to the invention, the substituent ═S (thiono) can replace two hydrogen atoms of a methylene (CH 2 ) group. For example the radical C 2 -alkyl becomes for examples —CSCH 3  through substitution by ═S (thiono). 
     The expression “optionally substituted” as used herein means that the optionally substituted group either is substituted with further substituents or is not substituted with further substituents. 
     The term “in each case optionally substituted” means that a group/substituent, such as a alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cycloalkyl, aryl, phenyl, benzyl, heterocyclyl and heteroaryl radical, is substituted, meaning, for example, a substituted radical derived from the unsubstituted base structure, where the substituents, for example, one (1) substituent or a plurality of substituents, preferably 1, 2, 3, 4, 5, 6 or 7, are selected from a group consisting of amino, hydroxyl, halogen, nitro, cyano, isocyano, mercapto, isothiocyanato, C 1 -C 4 carboxyl, carbonamide, SF 5 , aminosulphonyl, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 5 -C 6 cycloalkenyl, C 2 -C 4 alkynyl, N-mono-C 1 -C 4 alkylamino, N,N-di-C 1 -C 4 alkylamino, N—C 1 -C 4 alkanoylamino, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 alkynyloxy, C 3 -C 4 cycloalkoxy, C 5 -C 6 cycloalkenyloxy, C 1 -C 4 alkoxycarbonyl, C 2 -C 4 alkenyloxycarbonyl, C 2 -C 4 alkynyloxycarbonyl, C 6 -,C 10 -,C 14 -aryloxycarbonyl, C 1 -C 4 alkanoyl, C 2 -C 4 alkenylcarbonyl, C 2 -C 4 alkynylcarbonyl, C 6 -,C 10 -,C 14 -arylcarbonyl, C 1 -C 4 alkylthio, C 1 -C 4 haloalkylthio, C 3 -C 4 cycloalkylthio, C 2 -C 4 alkenylthio, C 5 -C 6 cycloalkenylthio, C 2 -C 4 alkynylthio, C 1 -C 4 alkylsulfinyl, including both enantiomers of the C 1 -C 4 alkylsulfinyl group, C 1 -C 4 haloalkylsulfinyl, including both enantiomers of the C 1 -C 4 haloalkylsulfinyl group, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylsulfonyl, N-mono-C 1 -C 4 alkylamino sulfonyl, N,N-di-C 1 -C 4 alkylamino sulfonyl, C 1 -C 4 alkylphosphinyl, C 1 -C 4 alkylphosphonyl, including both enantiomers of C 1 -C 4 alkylphosphinyl and C 1 -C 4 alkylphosphonyl, N—C 1 -C 4 alkylaminocarbonyl, N,N-di-C 1 -C 4 alkylaminocarbonyl, N—C 1 -C 4 alkanoylaminocarbonyl, N—C 1 -C 4 alkanoyl-N—C 1 -C 4 alkylaminocarbonyl, C 6 -,C 10 -,C 14 -aryl, C 6   − ,C 10 -,C 14 -aryloxy, benzyl, benzyloxy, benzylthio, C 6 -,C 10 -,C 14 -arylthio, C 6 -,C 10 -,C 14 -arylamino, benzylamino, heterocyclyl and trialkylsilyl, substituents bonded via a double bond, such as C 1 -C 4 alkylidene (e.g. methylidene or ethylidene), an oxo group, an imino group and a substituted imino group. When two or more radicals form one or more rings, these may be carbocyclic, heterocyclic, saturated, partly saturated, unsaturated, for example including aromatic rings and with further substitution. The substituents mentioned by way of example (“first substituent level”) may, if they contain hydrocarbonaceous components, optionally have further substitution therein (“second substituent level”), for example by one or more of the substituents each independently selected from halogen, hydroxyl, amino, nitro, cyano, isocyano, azido, acylamino, an oxo group and an imino group. The term “(optionally) substituted” group preferably embraces just one or two substituent levels. 
     The inventive halogen-substituted chemical groups or halogenated groups (for example alkyl or alkoxy) are mono- or polysubstituted by halogen up to the maximum possible number of substituents. Such groups are also referred to as halo groups (for example haloalkyl). In the case of polysubstitution by halogen, the halogen atoms may be the same or different, and may all be bonded to one carbon atom or may be bonded to a plurality of carbon atoms. Halogen is especially fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine and more preferably fluorine. More particularly, halogen-substituted groups are monohalocycloalkyl such as 1-fluorocyclopropyl, 2-fluorocyclopropyl or 1-fluorocyclobutyl, monohaloalkyl such as 2-chloroethyl, 2-fluoroethyl, 1-chloroethyl, 1-fluoroethyl, chloromethyl, or fluoromethyl; perhaloalkyl such as trichloromethyl or trifluoromethyl or CF 2 CF 3 , polyhaloalkyl such as difluoromethyl, 2-fluoro-2-chloroethyl, dichloromethyl, 1,1,2,2-tetrafluoroethyl or 2,2,2-trifluoroethyl. Further examples of haloalkyls are trichloromethyl, chlorodifluoromethyl, dichlorofluoromethyl, chloromethyl, bromomethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 2-chloro-2,2-difluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl and pentafluoro-t-butyl. Preference is given to haloalkyls having 1 to 4 carbon atoms and 1 to 9, preferably 1 to 5, identical or different halogen atoms selected from fluorine, chlorine and bromine. Particular preference is given to haloalkyls having 1 or 2 carbon atoms and 1 to 5 identical or different halogen atoms selected from fluorine and chlorine, such as, inter alia, difluoromethyl, trifluoromethyl or 2,2-difluoroethyl. Further examples of halogen-substituted compounds are haloalkoxy such as OCF 3 , OCHF 2 , OCH 2 F, OCF 2 CF 3 , OCH 2 CF 3 , OCH 2 CHF 2  and OCH 2 CH 2 Cl, haloalkylsulfanyls such as difluoromethylthio, trifluoromethylthio, trichloromethylthio, chlorodifluoromethylthio, 1-fluoroethylthio, 2-fluoroethylthio, 2,2-difluoroethylthio, 1,1,2,2-tetrafluoroethylthio, 2,2,2-trifluoroethylthio or 2-chloro-1,1,2-trifluoroethylthio, haloalkylsulfinyls such as difluoromethylsulfinyl, trifluoromethylsulfinyl, trichloromethylsulfinyl, chlorodifluoromethylsulfinyl, 1-fluoroethylsulfinyl, 2-fluoroethylsulfinyl, 2,2-difluoroethylsulfinyl, 1,1,2,2-tetrafluoroethylsulfinyl, 2,2,2-trifluoroethylsulfinyl and 2-chloro-1,1,2-trifluoroethylsulfinyl, haloalkylsulfinyls such as difluoromethylsulfinyl, trifluoromethylsulfinyl, trichloromethylsulfinyl, chlorodifluoromethylsulfinyl, 1-fluoroethylsulfinyl, 2-fluoroethylsulfinyl, 2,2-difluoroethylsulfinyl, 1,1,2,2-tetrafluoroethylsulfinyl, 2,2,2-trifluoroethylsulfinyl and 2-chloro-1,1,2-trifluoroethylsulfinyl, haloalkylsulfonyl groups such as difluoromethylsulfonyl, trifluoromethylsulfonyl, trichloromethylsulfonyl, chlorodifluoromethylsulfonyl, 1-fluoroethylsulfonyl, 2-fluoroethylsulfonyl, 2,2-difluoroethylsulfonyl, 1,1,2,2-tetrafluoroethylsulfonyl, 2,2,2-trifluoroethylsulfonyl and 2-chloro-1,1,2-trifluoroethylsulfonyl. 
     In the case of radicals having carbon atoms, preference is given to those having 1 to 4 carbon atoms, especially 1 or 2 carbon atoms. Preference is generally given to substituents from the group of halogen, e.g. fluorine and chlorine, (C 1 -C 4 )alkyl, preferably methyl or ethyl, (C 1 -C 4 )haloalkyl, preferably trifluoromethyl, (C 1 -C 4 )alkoxy, preferably methoxy or ethoxy, (C 1 -C 4 )haloalkoxy, nitro and cyano. Particular preference is given here to the substituents methyl, methoxy, fluorine and chlorine. 
     Substituted amino such as mono- or disubstituted amino means a radical from the group of the substituted amino radicals which are N-substituted, for example, by one or two identical or different radicals from the group of alkyl, hydroxy, amino, alkoxy, acyl and aryl; preferably N-mono- and N,N-dialkylamino, (for example methylamino, ethylamino, N,N-dimethylamino, N,N-diethylamino, N,N-di-n-propylamino, N,N-diisopropylamino or N,N-dibutylamino), N-mono- or N,N-dialkoxyalkylamino groups (for example N-methoxymethylamino, N-methoxyethylamino, N,N-di(methoxymethyl)amino or N,N-di(methoxyethyl)amino), N-mono- and N,N-diarylamino, such as optionally substituted anilines, acylamino, N,N-diacylamino, N-alkyl-N-arylamino, N-alkyl-N-acylamino and also saturated N-heterocycles; preference is given here to alkyl radicals having 1 to 4 carbon atoms; here, aryl is preferably phenyl or substituted phenyl; for acyl, the definition given further below applies, preferably (C 1 -C 4 )-alkanoyl. The same applies to substituted hydroxylamino or hydrazino. 
     Substituted amino also includes quaternary ammonium compounds (salts) having four organic substituents on the nitrogen atom. 
     Optionally substituted phenyl is preferably phenyl which is unsubstituted or mono- or polysubstituted, preferably up to trisubstituted, by identical or different radicals from the group of halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkoxy, (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )haloalkoxy, (C 1 -C 4 )alkylthio, (C 1 -C 4 )haloalkylthio, (C 1 -C 4 )alkylsulfinyl (C 1 -C 4 )haloalkylsulfinyl, (C 1 -C 4 )alkylsulfonyl (C 1 -C 4 )haloalkylsulfonyl, cyano, isocyano and nitro, for example o-, m- and p-tolyl, dimethylphenyls, 2-, 3- and 4-chlorophenyl, 2-, 3- and 4-fluorophenyl, 2-, 3- and 4-trifluoromethyl- and 4-trichloromethylphenyl, 2,4-, 3,5-, 2,5- and 2,3-dichlorophenyl, o-, m- and p-methoxyphenyl, 4-heptafluorophenyl. 
     Optionally substituted cycloalkyl is preferably cycloalkyl which is unsubstituted or mono- or polysubstituted, preferably up to trisubstituted, by identical or different radicals from the group of halogen, cyano, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkoxy, (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl and (C 1 -C 4 )haloalkoxy, especially by one or two (C 1 -C 4 )alkyl radicals. 
     Inventive compounds may occur in preferred embodiments. Individual embodiments described herein may be combined with one another. Not included are combinations which contravene the laws of nature and which the person skilled in the art would therefore rule out on the basis of his/her expert knowledge. Ring structures having three or more adjacent oxygen atoms, for example, are excluded. 
     Isomers 
     Depending on the nature of the substituents, the compounds of the formula (I) may be in the form of geometric and/or optically active isomers or corresponding isomer mixtures in different compositions. These stereoisomers are, for example, enantiomers, diastereomers, atropisomers or geometric isomers. Accordingly, the invention encompasses both pure stereoisomers and any mixture of these isomers. 
     Methods and Uses 
     The invention also relates to methods for controlling animal pests, in which compounds of the formula (I) are allowed to act on animal pests and/or their habitat. The control of the animal pests is preferably conducted in agriculture and forestry, and in material protection. Preferably excluded herefrom are methods for the surgical or therapeutic treatment of the human or animal body and diagnostic methods carried out on the human or animal body. 
     The invention furthermore relates to the use of the compounds of the formula (I) as pesticides, in particular crop protection agents. 
     In the context of the present application, the term “pesticide” in each case also always comprises the term “crop protection agent”. 
     The compounds of the formula (I), having good plant tolerance, favourable homeotherm toxicity and good environmental compatibility, are suitable for protecting plants and plant organs against biotic and abiotic stressors, for increasing harvest yields, for improving the quality of the harvested material and for controlling animal pests, especially insects, arachnids, helminths, in particular nematodes, and molluscs, which are encountered in agriculture, in horticulture, in animal husbandry, in aquatic cultures, in forests, in gardens and leisure facilities, in the protection of stored products and of materials, and in the hygiene sector. 
     Within the context of the present patent application, the term “hygiene” is understood to mean any and all measures, procedures and practices which aim to prevent disease, in particular infectious disease, and which serve to protect the health of humans and animals and/or to protect the environment, and/or which maintain cleanliness. In accordance with the invention, this especially includes measures for cleaning, disinfection and sterilisation of, for example, textiles or hard surfaces, especially surfaces of glass, wood, concrete, porcelain, ceramics, plastic or also of metal(s), and for ensuring that these are kept free of hygiene pests and/or their excretions. Preferably excluded from the scope of the invention in this regard are surgical or therapeutic treatment procedures applicable to the human body or to the bodies of animals and diagnostic procedures which are carried out on the human body or on the bodies of animals. 
     The term “hygiene sector” thus covers all areas, technical fields and industrial applications in which these hygiene measures, procedures and practices are important, in relation for example to hygiene in kitchens, bakeries, airports, bathrooms, swimming pools, department stores, hotels, hospitals, stables, animal husbandries, etc. 
     The term “hygiene pest” is therefore understood to mean one or more animal pests whose presence in the hygiene sector is problematic, in particular for health reasons. It is therefore a primary objective to avoid or minimize the presence of hygiene pests, and/or exposure to them, in the hygiene sector. This can be achieved in particular through the application of a pesticide that can be used both to prevent infestation and to tackle an infestation which is already present. Preparations which avoid or reduce exposure to pests can also be used. Hygiene pests include, for example, the organisms mentioned below. 
     The term “hygiene protection” thus covers all actions to maintain and/or improve these hygiene measures, procedures and practices. 
     The compounds of the formula (I) can preferably be used as pesticides. They are active against normally sensitive and resistant species and against all or some stages of development. The abovementioned pests include: 
     pests from the phylum of the Arthropoda, in particular from the class of the Arachnida, for example  Acarus  spp., for example  Acarus siro, Aceria kuko, Aceria sheldoni, Aculops  spp.,  Aculus  spp., for example  Aculus fockeui, Aculus schlechtendali, Amblyomma  spp.,  Amphitetranychus viennensis, Argas  spp.,  Boophilus  spp.,  Brevipalpus  spp., for example  Brevipalpus phoenicis, Bryobia graminum, Bryobia praetiosa, Centruroides  spp.,  Chorioptes  spp.,  Dermanyssus gallinae, Dermatophagoides pteronyssinus, Dermatophagoides farinae, Dermacentor  spp.,  Eotetranychus  spp., for example  Eotetranychus hicoriae, Epitrimerus pyri, Eutetranychus  spp., for example  Eutetranychus banksi, Eriophyes  spp., for example  Eriophyes  pyri,  Glycyphagus domesticus, Halotydeus destructor, Hemitarsonemus  spp., for example  Hemitarsonemus latus  (= Polyphagotarsonemus latus ),  Hyalomma  spp.,  Ixodes  spp.,  Latrodectus  spp.,  Loxosceles  spp.,  Neutrombicula autumnalis, Nuphersa  spp.,  Oligonychus  spp., for example  Oligonychus coffeae, Oligonychus coniferarum, Oligonychus ilicis, Oligonychus indicus, Oligonychus mangiferus, Oligonychus pratensis, Oligonychus punicae, Oligonychus yothersi, Ornithodorus  spp.,  Ornithonyssus  spp.,  Panonychus  spp., for example  Panonychus citri  (= Metatetranychus citri ),  Panonychus ulmi  (= Metatetranychus ulmi ),  Phyllocoptruta oleivora, Platytetranychus multidigituli, Polyphagotarsonemus latus, Psoroptes  spp.,  Rhipicephalus  spp.,  Rhizoglyphus  spp.,  Sarcoptes  spp.,  Scorpio maurus, Steneotarsonemus  spp.,  Steneotarsonemus spinki, Tarsonemus  spp., for example  Tarsonemus confusus, Tarsonemus pallidus, Tetranychus  spp., for example  Tetranychus canadensis, Tetranychus cinnabarinus, Tetranychus turkestani, Tetranychus urticae, Trombicula alfreddugesi, Vaejovis  spp.,  Vasates lycopersici;    
     from the class of the Chilopoda, for example  Geophilus  spp.,  Scutigera  spp.; 
     from the order or the class of the Collembola, for example  Onychiurus armatus; Sminthurus viridis;    
     from the class of the Diplopoda, for example  Blaniulus guttulatus;    
     from the class of the Insecta, for example from the order of the Blattodea, for example  Blatta orientalis, Blattella asahinai, Blattella germanica, Leucophaea maderae, Loboptera decipiens, Neostylopyga rhombifolia, Panchlora  spp.,  Parcoblatta  spp.,  Periplaneta  spp., for example  Periplaneta americana, Periplaneta australasiae, Pycnoscelus surinamensis, Supella longipalpa;    
     from the order of the Coleoptera, for example  Acalymma vittatum, Acanthoscelides obtectus, Adoretus  spp.,  Aethina tumida, Agelastica alni, Agrilus  spp., for example  Agrilus planipennis, Agrilus coxalis, Agrilus bilineatus, Agrilus anxius, Agriotes  spp., for example  Agriotes linneatus, Agriotes mancus, Agriotes obscurus, Alphitobius diaperinus, Amphimallon solstitialis, Anobium punctatum, Anomala dubia, Anoplophora  spp., for example  Anoplophora glabripennis, Anthonomus  spp., for example  Anthonomus grandis, Anthrenus  spp.,  Apion  spp.,  Apogonia  spp.,  Athous haemorrhoidales, Atomaria  spp., for example  Atomaria linearis, Attagenus  spp.,  Baris caerulescens, Bruchidius obtectus, Bruchus  spp., for example  Bruchus pisorum, Bruchus rufimanus, Cassida  spp.,  Cerotoma trifurcata, Ceutorrhynchus  spp., for example  Ceutorrhynchus assimilis, Ceutorrhynchus quadridens, Ceutorrhynchus rapae, Chaetocnema  spp., for example  Chaetocnema confinis, Chaetocnema denticulata, Chaetocnema ectypa, Cleonus mendicus, Conoderus  spp.,  Cosmopolites  spp., for example  Cosmopolites sordidus, Costelytra zealandica, Ctenicera  spp.,  Curculio  spp., for example  Curculio caryae, Curculio caryatrypes, Curculio obtusus, Curculio sayi, Cryptolestes ferrugineus, Cryptolestes pusillus, Cryptorhynchus lapathi, Cryptorhynchus mangiferae, Cylindrocopturus  spp.,  Cylindrocopturus adspersus, Cylindrocopturus furnissi, Dendroctonus  spp., for example  Dendroctonus ponderosae, Dermestes  spp.,  Diabrotica  spp., for example  Diabrotica balteata, Diabrotica barberi, Diabrotica undecimpunctata  howardi,  Diabrotica undecimpunctata undecimpunctata, Diabrotica virgifera virgifera, Diabrotica virgifera zeae, Dichocrocis  spp.,  Dicladispa armigera, Diloboderus  spp.,  Epicaerus  spp.,  Epilachna  spp., for example  Epilachna borealis, Epilachna varivestis, Epitrix  spp., for example  Epitrix cucumeris, Epitrix fuscula, Epitrix hirtipennis, Epitrix subcrinita, Epitrix tuberis, Faustinus  spp.,  Gibbium psylloides, Gnathocerus cornutus, Hellula undalis, Heteronychus arator, Heteronyx  spp.,  Hoplia argentea, Hylamorpha elegans, Hylotrupes bajulus, Hypera postica, Hypomeces squamosus, Hypothenemus  spp., for example  Hypothenemus hampei, Hypothenemus obscurus, Hypothenemus pubescens, Lachnosterna consanguinea, Lasioderma serricorne, Latheticus oryzae, Lathridius  spp.,  Lema  spp.,  Leptinotarsa decemlineata, Leucoptera  spp., for example  Leucoptera coffeella, Limonius ectypus, Lissorhoptrus oryzophilus, Listronotus  (=Hyperodes) spp.,  Lixus  spp.,  Luperodes  spp.,  Luperomorpha xanthodera, Lyctus  spp.,  Megacyllene  spp., for example  Megacyllene robiniae, Megascelis  spp.,  Melanotus  spp., for example  Melanotus longulus oregonensis, Meligethes aeneus, Melolontha  spp., for example  Melolontha melolontha, Migdolus  spp.,  Monochamus  spp.,  Naupactus xanthographus, Necrobia  spp.,  Neogalerucella  spp.,  Niptus hololeucus, Oryctes rhinoceros, Oryzaephilus surinamensis, Oryzaphagus oryzae, Otiorhynchus  spp., for example  Otiorhynchus cribricollis, Otiorhynchus ligustici, Otiorhynchus ovatus, Otiorhynchus rugosostriarus, Otiorhynchus sulcatus, Oulema  spp., for example  Oulema melanopus, Oulema oryzae, Oxycetonia jucunda, Phaedon cochleariae, Phyllophaga  spp.,  Phyllophaga helleri, Phyllotreta  spp., for example  Phyllotreta armoraciae, Phyllotreta pusilla, Phyllotreta ramosa, Phyllotreta striolata, Popillia japonica, Premnotrypes  spp.,  Prostephanus truncatus, Psylliodes  spp., for example  Psylliodes affinis, Psylliodes chrysocephala, Psylliodes punctulata, Ptinus  spp.,  Rhizobius ventralis, Rhizopertha dominica, Rhynchophorus  spp.,  Rhynchophorus ferrugineus, Rhynchophorus palmarum, Scolytus  spp., for example  Scolytus multistriatus, Sinoxylon perforans, Sitophilus  spp., for example  Sitophilus granarius, Sitophilus linearis, Sitophilus oryzae, Sitophilus zeamais, Sphenophorus  spp.,  Stegobium paniceum, Sternechus  spp., for example  Sternechus paludatus, Symphyletes  spp.,  Tanymecus  spp., for example  Tanymecus dilaticollis, Tanymecus indicus, Tanymecus palliatus, Tenebrio molitor, Tenebrioides mauretanicus, Tribolium  spp., for example  Tribolium audax, Tribolium castaneum, Tribolium confusum, Trogoderma  spp.,  Tychius  spp.,  Xylotrechus  spp.,  Zabrus  spp., for example  Zabrus tenebrioides;    
     from the order of the Dermaptera, for example  Anisolabis maritime, Forficula auricularia, Labidura riparia;    
     from the order of the Diptera, for example  Aedes  spp., for example  Aedes aegypti, Aedes albopictus, Aedes sticticus, Aedes vexans, Agromyza  spp., for example  Agromyza frontella, Agromyza parvicornis, Anastrepha  spp.,  Anopheles  spp., for example  Anopheles quadrimaculatus, Anopheles gambiae, Asphondylia  spp.,  Bactrocera  spp., for example  Bactrocera cucurbitae, Bactrocera dorsalis, Bactrocera oleae, Bibio hortulanus, Calliphora erythrocephala, Calliphora vicina, Ceratitis capitata, Chironomus  spp.,  Chrysomya  spp.,  Chrysops  spp.,  Chrysozona pluvialis, Cochliomya  spp.,  Contarinia  spp., for example  Contarinia johnsoni, Contarinia nasturtii, Contarinia pyrivora, Contarinia schulzi, Contarinia sorghicola, Contarinia tritici, Cordylobia anthropophaga, Cricotopus sylvestris, Culex  spp., for example  Culex pipiens, Culex quinquefasciatus, Culicoides  spp.,  Culiseta  spp.,  Cuterebra  spp.,  Dacus oleae, Dasineura  spp., for example  Dasineura brassicae, Delia  spp., for example  Delia antiqua, Delia coarctata, Delia florilega, Delia platura, Delia radicum, Dermatobia hominis, Drosophila  spp., for example  Drosphila melanogaster, Drosophila suzukii, Echinocnemus  spp.,  Euleia heraclei, Fannia  spp.,  Gasterophilus  spp.,  Glossina  spp.,  Haematopota  spp.,  Hydrellia  spp.,  Hydrellia griseola, Hylemya  spp.,  Hippobosca  spp.,  Hypoderma  spp.,  Liriomyza  spp., for example  Liriomyza brassicae, Liriomyza huidobrensis, Liriomyza sativae, Lucilia  spp., for example  Lucilia cuprina, Lutzomyia  spp.,  Mansonia  spp.,  Musca  spp., for example  Musca domestica, Musca domestica vicina, Oestrus  spp.,  Oscinella frit, Paratanytarsus  spp.,  Paralauterborniella subcincta, Pegomya  or  Pegomyia  spp., for example  Pegomya betae, Pegomya hyoscyami, Pegomya rubivora, Phlebotomus  spp.,  Phorbia  spp.,  Phormia  spp.,  Piophila casei, Platyparea poeciloptera, Prodiplosis  spp.,  Psila rosae, Rhagoletis  spp., for example  Rhagoletis cingulata, Rhagoletis completa, Rhagoletis fausta, Rhagoletis indifferens, Rhagoletis mendax, Rhagoletis pomonella, Sarcophaga  spp.,  Simulium  spp., for example  Simulium meridionale, Stomoxys  spp.,  Tabanus  spp.,  Tetanops  spp.,  Tipula  spp., for example  Tipula paludosa, Tipula  simplex,  Toxotrypana curvicauda;    
     from the order of the Hemiptera, for example  Acizzia acaciaebaileyanae, Acizzia dodonaeae, Acizzia uncatoides, Acrida turrita, Acyrthosipon  spp., for example  Acyrthosiphon pisum, Acrogonia  spp.,  Aeneolamia  spp.,  Agonoscena  spp.,  Aleurocanthus  spp.,  Aleyrodes proletella, Aleurolobus barodensis, Aleurothrixus floccosus, Allocaridara malayensis, Amrasca  spp., for example  Amrasca bigutulla, Amrasca devastans, Anuraphis cardui, Aonidiella  spp., for example  Aonidiella aurantii, Aonidiella citrina, Aonidiella inornata, Aphanostigma piri, Aphis  spp., for example  Aphis citricola, Aphis craccivora, Aphis fabae, Aphis forbesi, Aphis glycines, Aphis gossypii, Aphis hederae, Aphis illinoisensis, Aphis middletoni, Aphis nasturtii, Aphis nerii, Aphis pomi, Aphis spiraecola, Aphis viburniphila, Arboridia apicalis, Arytainilla  spp.,  Aspidiella  spp.,  Aspidiotus  spp., for example  Aspidiotus nerii, Atanus  spp.,  Aulacorthum solani, Bemisia tabaci, Blastopsylla occidentalis, Boreioglycaspis melaleucae, Brachycaudus helichrysi, Brachycolus  spp.,  Brevicoryne brassicae, Cacopsylla  spp., for example  Cacopsylla pyricola, Calligypona marginata, Capulinia  spp.,  Carneocephala fulgida, Ceratovacuna lanigera, Cercopidae, Ceroplastes  spp.,  Chaetosiphon fragaefolii, Chionaspis tegalensis, Chlorita onukii, Chondracris rosea, Chromaphis juglandicola, Chrysomphalus aonidum, Chrysomphalus ficus, Cicadulina mbila, Coccomytilus halli, Coccus  spp., for example  Coccus hesperidum, Coccus longulus, Coccus pseudomagnoliarum, Coccus viridis, Cryptomyzus ribis, Cryptoneossa  spp.,  Ctenarytaina  spp.,  Dalbulus  spp.,  Dialeurodes chittendeni, Dialeurodes citri, Diaphorina citri, Diaspis  spp.,  Diuraphis  spp.,  Doralis  spp.,  Drosicha  spp.,  Dysaphis  spp., for example  Dysaphis apiifolia, Dysaphis plantaginea, Dysaphis tulipae, Dysmicoccus  spp.,  Empoasca  spp., for example  Empoasca abrupta, Empoasca fabae, Empoasca maligna, Empoasca solana, Empoasca stevensi, Eriosoma  spp., for example  Eriosoma americanum, Eriosoma lanigerum, Eriosoma pyricola, Erythroneura  spp.,  Eucalyptolyma  spp.,  Euphyllura  spp.,  Euscelis bilobatus, Ferrisia  spp.,  Fiorinia  spp.,  Furcaspis oceanica, Geococcus coffeae, Glycaspis  spp.,  Heteropsylla cubana, Heteropsylla spinulosa, Homalodisca coagulata, Hyalopterus arundinis, Hyalopterus pruni, Icerya  spp., for example  Icerya purchasi, Idiocerus  spp.,  Idioscopus  spp.,  Laodelphax striatellus, Lecanium  spp., for example  Lecanium corni  (= Parthenolecanium corni ),  Lepidosaphes  spp., for example  Lepidosaphes ulmi, Lipaphis erysimi, Lopholeucaspis japonica, Lycorma delicatula, Macrosiphum  spp., for example  Macrosiphum euphorbiae, Macrosiphum lilii, Macrosiphum rosae, Macrosteles facifrons, Mahanarva  spp.,  Melanaphis sacchari, Metcalfiella  spp.,  Metcalfa pruinosa, Metopolophium dirhodum, Monellia costalis, Monelliopsis pecanis, Myzus  spp., for example  Myzus ascalonicus, Myzus cerasi, Myzus ligustri, Myzus ornatus, Myzus persicae, Myzus nicotianae, Nasonovia ribisnigri, Neomaskellia  spp.,  Nephotettix  spp., for example  Nephotettix cincticeps Nephotettix nigropictus, Nettigoniclla spectra, Nilaparvata lugens, Oncometopia  spp.,  Orthezia praelonga, Oxya chinensis, Pachypsylla  spp.,  Parabemisia myricae, Paratrioza  spp., for example  Paratrioza cockerelli, Parlatoria  spp.,  Pemphigus  spp., for example  Pemphigus bursarius, Pemphigus populivenae, Peregrinus maidis, Perkinsiella  spp.,  Phenacoccus  spp., for example  Phenacoccus madeirensis, Phloeomyzus passerinii, Phorodon humuli, Phylloxera  spp., for example  Phylloxera devastatrix, Phylloxera notabilis, Pinnaspis aspidistrae, Planococcus  spp., for example  Planococcus citri, Prosopidopsylla flava, Protopulvinaria pyriformis, Pseudaulacaspis pentagona, Pseudococcus  spp., for example  Pseudococcus calceolariae, Pseudococcus comstocki, Pseudococcus longispinus, Pseudococcus maritimus, Pseudococcus viburni, Psyllopsis  spp.,  Psylla  spp., for example  Psylla buxi, Psylla mali, Psylla pyri, Pteromalus  spp.,  Pulvinaria  spp.,  Pyrilla  spp.,  Quadraspidiotus  spp., for example  Quadraspidiotus juglansregiae, Quadraspidiotus ostreaeformis, Quadraspidiotus perniciosus, Quesada gigas, Rastrococcus  spp.,  Rhopalosiphum  spp., for example  Rhopalosiphum maidis, Rhopalosiphum oxyacanthae, Rhopalosiphum padi, Rhopalosiphum rufiabdominale, Saissetia  spp., for example  Saissetia coffeae, Saissetia miranda, Saissetia neglecta, Saissetia oleae, Scaphoideus titanus, Schizaphis graminum, Selenaspidus articulatus, Sipha flava, Sitobion avenae, Sogata  spp.,  Sogatella furcifera, Sogatodes  spp.,  Stictocephala festina, Siphoninus phillyreae, Tenalaphara malayensis, Tetragonocephela  spp.,  Tinocallis caryaefoliae, Tomaspis  spp.,  Toxoptera  spp., for example  Toxoptera aurantii, Toxoptera citricidus, Trialeurodes vaporariorum, Trioza  spp., for example  Trioza diospyri, Typhlocyba  spp.,  Unaspis  spp.,  Viteus vitifolii, Zygina  spp.; 
     from the suborder of the Heteroptera, for example  Aelia  spp.,  Anasa tristis, Antestiopsis  spp.,  Boisea  spp.,  Blissus  spp.,  Calocoris  spp.,  Campylomma livida, Cavelerius  spp.,  Cimex  spp., for example  Cimex adjunctus, Cimex hemipterus, Cimex lectularius, Cimex pilosellus, Collaria  spp.,  Creontiades dilutus, Dasynus piperis, Dichelops furcatus, Diconocoris hewetti, Dysdercus  spp.,  Euschistus  spp., for example  Euschistus heros, Euschistus servus, Euschistus tristigmus, Euschistus variolarius, Eurydema  spp.,  Eurygaster  spp.,  Halyomorpha halys, Heliopeltis  spp.,  Horcias nobilellus, Leptocorisa  spp.,  Leptocorisa varicornis, Leptoglossus occidentalis, Leptoglossus phyllopus, Lygocoris  spp., for example  Lygocoris pabulinus, Lygus  spp., for example  Lygus elisus, Lygus hesperus, Lygus lineolaris, Macropes excavatus, Megacopta cribraria, Miridae, Monalonion atratum, Nezara  spp., for example  Nezara viridula, Nysius  spp.,  Oebalus  spp., Pentomidae,  Piesma quadrata, Piezodorus  spp., for example  Piezodorus guildinii, Psallus  spp.,  Pseudacysta persea, Rhodnius  spp.,  Sahlbergella singularis, Scaptocoris castanea, Scotinophora  spp.,  Stephanitis nashi, Tibraca  spp.,  Triatoma  spp.; 
     from the order of the Hymenoptera, for example  Acromyrmex  spp.,  Athalia  spp., for example  Athalia rosae, Atta  spp.,  Camponotus  spp.,  Dolichovespula  spp.,  Diprion  spp., for example  Diprion similis, Hoplocampa  spp., for example  Hoplocampa cookei, Hoplocampa testudinea, Lasius  spp.,  Linepithema  (Iridiomyrmex)  humile, Monomorium pharaonis, Paratrechina  spp.,  Paravespula  spp.,  Plagiolepis  spp.,  Sirex  spp., for example  Sirex noctilio, Solenopsis invicta, Tapinoma  spp.,  Technomyrmex albipes, Urocerus  spp.,  Vespa  spp., for example  Vespa crabro, Wasmannia auropunctata, Xeris  spp.; 
     from the order of the Isopoda, for example  Armadillidium vulgare, Oniscus asellus, Porcellio scaber;    
     from the order of the Isoptera, for example  Coptotermes  spp., for example  Coptotermes formosanus, Cornitermes cumulans, Cryptotermes  spp.,  Incisitermes  spp.,  Kalotermes  spp.,  Microtermes obesi, Nasutitermes  spp.,  Odontotermes  spp.,  Porotermes  spp.,  Reticulitermes  spp., for example  Reticulitermes flavipes, Reticulitermes hesperus;    
     from the order of the Lepidoptera, for example  Achroia grisella, Acronicta major, Adoxophyes  spp., for example  Adoxophyes orana, Aedia leucomelas, Agrotis  spp., for example  Agrotis segetum, Agrotis ipsilon, Alabama  spp., for example  Alabama argillacea, Amyelois transitella, Anarsia  spp.,  Anticarsia  spp., for example  Anticarsia gemmatalis, Argyroploce  spp.,  Autographa  spp.,  Barathra brassicae, Blastodacna atra, Borbo cinnara, Bucculatrix thurberiella, Bupalus piniarius, Busseola  spp.,  Cacoecia  spp.,  Caloptilia theivora, Capua reticulana, Carpocapsa pomonella, Carposina niponensis, Cheimatobia brumata, Chilo  spp., for example  Chilo plejadellus, Chilo suppressalis, Choreutis pariana, Choristoneura  spp.,  Chrysodeixis chalcites, Clysia ambiguella, Cnaphalocerus  spp.,  Cnaphalocrocis medinalis, Cnephasia  spp.,  Conopomorpha  spp.,  Conotrachelus  spp.,  Copitarsia  spp.,  Cydia  spp., for example  Cydia nigricana, Cydia pomonella, Dalaca noctuides, Diaphania  spp.,  Diparopsis  spp.,  Diatraea saccharalis, Dioryctria  spp., for example  Dioryctria zimmermani, Earias  spp.,  Ecdytolopha aurantium, Elasmopalpus lignosellus, Eldana saccharina, Ephestia  spp., for example  Ephestia elutella, Ephestia kuehniella, Epinotia  spp.,  Epiphyas postvittana, Erannis  spp.,  Erschoviella musculana, Etiella  spp.,  Eudocima  spp.,  Eulia  spp.,  Eupoecilia ambiguella, Euproctis  spp., for example  Euproctis chrysorrhoea, Euxoa  spp.,  Feltia  spp.,  Galleria mellonella, Gracillaria  spp.,  Grapholitha  spp., for example  Grapholita molesta, Grapholita prunivora, Hedylepta  spp.,  Helicoverpa  spp., for example  Helicoverpa armigera, Helicoverpa zea, Heliothis  spp., for example  Heliothis virescens, Hepialus  spp., for example  Hepialus humuli, Hofmannophila pseudospretella, Homoeosoma  spp.,  Homona  spp.,  Hyponomeuta padella, Kakivoria flavofasciata, Lampides  spp.,  Laphygma  spp.,  Laspeyresia molesta, Leucinodes orbonalis, Leucoptera  spp., for example  Leucoptera coffeella, Lithocolletis  spp., for example  Lithocolletis blancardella, Lithophane antennata, Lobesia  spp., for example  Lobesia botrana, Loxagrotis albicosta, Lymantria  spp., for example  Lymantria dispar, Lyonetia  spp., for example  Lyonetia clerkella, Malacosoma neustria, Maruca testulalis, Mamestra brassicae, Melanitis leda, Mocis  spp.,  Monopis obviella, Mythimna separata, Nemapogon cloacellus, Nymphula  spp.,  Oiketicus  spp.,  Omphisa  spp.,  Operophtera  spp.,  Oria  spp.,  Orthaga  spp.,  Ostrinia  spp., for example  Ostrinia nubilalis, Panolis flammea, Parnara  spp.,  Pectinophora  spp., for example  Pectinophora gossypiella, Perileucoptera  spp.,  Phthorimaea  spp., for example  Phthorimaea operculella, Phyllocnistis citrella, Phyllonorycter  spp., for example  Phyllonorycter blancardella, Phyllonorycter crataegella, Pieris  spp., for example  Pieris rapae, Platynota stultana, Plodia interpunctella, Plusia  spp.,  Plutella xylostella  (= Plutella maculipennis ),  Podesia  spp., for example  Podesia syringae, Prays  spp.,  Prodenia  spp.,  Protoparce  spp.,  Pseudaletia  spp., for example  Pseudaletia unipuncta, Pseudoplusia includens, Pyrausta nubilalis, Rachiplusia nu, Schoenobius  spp., for example  Schoenobius bipunctifer, Scirpophaga  spp., for example  Scirpophaga innotata, Scotia segetum, Sesamia  spp., for example  Sesamia inferens, Sparganothis  spp.,  Spodoptera  spp., for example  Spodoptera eradiana, Spodoptera exigua, Spodoptera frugiperda, Spodoptera praefica, Stathmopoda  spp.,  Stenoma  spp.,  Stomopteryx subsecivella, Synanthedon  spp.,  Tecia solanivora, Thaumetopoea  spp.,  Thermesia gemmatalis, Tinea cloacella, Tinea pellionella, Tineola bisselliella, Tortrix  spp.,  Trichophaga tapetzella, Trichoplusia  spp., for example  Trichoplusia ni, Tryporyza incertulas, Tuta absoluta, Virachola  spp.; 
     from the order of the Orthoptera or Saltatoria, for example  Acheta domesticus, Dichroplus  spp.,  Gryllotalpa  spp., for example  Gryllotalpa gryllotalpa, Hieroglyphus  spp.,  Locusta  spp., for example  Locusta migratoria, Melanoplus  spp., for example  Melanoplus devastator, Paratlanticus ussuriensis, Schistocerca gregaria;    
     from the order of the Phthiraptera, for example  Damalinia  spp.,  Haematopinus  spp.,  Linognathus  spp.,  Pediculus  spp.,  Phylloxera vastatrix, Phthirus pubis, Trichodectes  spp.; 
     from the order of the Psocoptera, for example  Lepinotus  spp.,  Liposcelis  spp.; 
     from the order of the Siphonaptera, for example,  Ceratophyllus  spp.,  Ctenocephalides  spp., for example  Ctenocephalides canis, Ctenocephalides felis, Pulex irritans, Tunga penetrans, Xenopsylla cheopis;    
     from the order of the Thysanoptera, for example  Anaphothrips obscurus, Baliothrips biformis, Chaetanaphothrips leeuweni, Drepanothrips reuteri, Enneothrips flavens, Frankliniella  spp., for example  Frankliniella fusca, Frankliniella occidentalis, Frankliniella schultzei, Frankliniella tritici, Frankliniella vaccinii, Frankliniella williamsi, Haplothrips  spp.,  Heliothrips  spp.,  Hercinothrips femoralis, Kakothrips  spp.,  Rhipiphorothrips cruentatus, Scirtothrips  spp.,  Taeniothrips cardamomi, Thrips  spp., for example  Thrips palmi, Thrips tabaci;    
     from the order of the Zygentoma (=Thysanura), for example  Ctenolepisma  spp.,  Lepisma saccharina, Lepismodes inquilinus, Thermobia domestica;    
     from the class of the Symphyla, for example  Scutigerella  spp., for example  Scutigerella immaculata; pests from the phylum of the Mollusca, for example from the class of the Bivalvia, for example Dreissena  spp., 
     and also from the class of the Gastropoda, for example  Arion  spp., for example  Arion ater rufus, Biomphalaria  spp.,  Bulinus  spp.,  Deroceras  spp., for example  Deroceras laeve, Galba  spp., Lymnaea spp.,  Oncomelania  spp.,  Pomacea  spp.,  Succinea  spp.; 
     plant pests from the phylum of the Nematoda, i.e. phytoparasitic nematodes, in particular  Aglenchus  spp., for example  Aglenchus agricola, Anguina  spp., for example  Anguina tritici, Aphelenchoides  spp., for example  Aphelenchoides arachidis, Aphelenchoides fragariae, Belonolaimus  spp., for example  Belonolaimus gracilis, Belonolaimus longicaudatus, Belonolaimus nortoni, Bursaphelenchus  spp., for example  Bursaphelenchus cocophilus, Bursaphelenchus eremus, Bursaphelenchus xylophilus, Cacopaurus  spp., for example  Cacopaurus pestis, Criconemella  spp., for example  Criconemella curvata, Criconemella onoensis, Criconemella ornata, Criconemella rusium, Criconemella xenoplax  (=Mesocriconema xenoplax),  Criconemoides  spp., for example  Criconemoides ferniae, Criconemoides onoense, Criconemoides ornatum, Ditylenchus  spp., for example  Ditylenchus dipsaci, Dolichodorus  spp.,  Globodera  spp., for example  Globodera pallida, Globodera rostochiensis, Helicotylenchus  spp., for example  Helicotylenchus dihystera, Hemicriconemoides  spp.,  Hemicycliophora  spp.,  Heterodera  spp., for example  Heterodera avenae, Heterodera glycines, Heterodera schachtii, Hirschmaniella  spp.,  Hoplolaimus  spp.,  Longidorus  spp., for example  Longidorus africanus, Meloidogyne  spp., for example  Meloidogyne chitwoodi, Meloidogyne fallax, Meloidogyne hapla, Meloidogyne incognita, Meloinema  spp.,  Nacobbus  spp.,  Neotylenchus  spp.,  Paralongidorus  spp.,  Paraphelenchus  spp.,  Paratrichodorus  spp., for example  Paratrichodorus minor, Paratylenchus  spp.,  Pratylenchus  spp., for example  Pratylenchus penetrans, Pseudohalenchus  spp.,  Psilenchus  spp.,  Punctodera  spp.,  Quinisulcius  spp.,  Radopholus  spp., for example  Radopholus citrophilus, Radopholus similis, Rotylenchulus  spp.,  Rotylenchus  spp.,  Scutellonema  spp.,  Subanguina  spp.,  Trichodorus  spp., for example  Trichodorus obtusus, Trichodorus primitivus, Tylenchorhynchus  spp., for example  Tylenchorhynchus annulatus, Tylenchulus  spp., for example  Tylenchulus semipenetrans, Xiphinema  spp., for example  Xiphinema index    
     The compounds of the formula (I) can optionally, at certain concentrations or application rates, also be used as herbicides, safeners, growth regulators or agents to improve plant properties, as microbicides or gametocides, for example as fungicides, antimycotics, bactericides, viricides (including agents against viroids) or as agents against MLO ( mycoplasma -like organisms) and RLO ( rickettsia -like organisms). If appropriate, they can also be used as intermediates or precursors for the synthesis of other active compounds. 
     Formulations/Use Forms 
     The present invention further relates to formulations, in particular formulations for controlling unwanted controlling animal pests. The formulation may be applied to the animal pest and/or in their habitat. 
     The formulation of the invention may be provided to the end user as “ready-for-use” use form, i.e. the formulations may be directly applied to the plants or seeds by a suitable device, such as a spraying or dusting device. Alternatively, the formulations may be provided to the end user in the form of concentrates which have to be diluted, preferably with water, prior to use. Unless otherwise indicated, the wording “formulation” therefore means such concentrate, whereas the wording “use form” means the end user as “ready-for-use” solution, i.e. usually such diluted formulation. 
     The formulation of the invention can be prepared in conventional manners, for example by mixing the compound of the invention with one or more suitable auxiliaries, such as disclosed herein. 
     The formulation comprises at least one compound of the invention and at least one agriculturally suitable auxiliary, e.g. carrier(s) and/or surfactant(s). 
     A carrier is a solid or liquid, natural or synthetic, organic or inorganic substance that is generally inert. The carrier generally improves the application of the compounds, for instance, to plants, plants parts or seeds. Examples of suitable solid carriers include, but are not limited to, ammonium salts, in particular ammonium sulfates, ammonium phosphates and ammonium nitrates, natural rock flours, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite and diatomaceous earth, silica gel and synthetic rock flours, such as finely divided silica, alumina and silicates. Examples of typically useful solid carriers for preparing granules include, but are not limited to crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite and dolomite, synthetic granules of inorganic and organic flours and granules of organic material such as paper, sawdust, coconut shells, maize cobs and tobacco stalks. Examples of suitable liquid carriers include, but are not limited to, water, organic solvents and combinations thereof. 
     Examples of suitable solvents include polar and nonpolar organic chemical liquids, for example from the classes of aromatic and nonaromatic hydrocarbons (such as cyclohexane, paraffins, alkylbenzenes, xylene, toluene, tetrahydronaphthalene, alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride), alcohols and polyols (which may optionally also be substituted, etherified and/or esterified, such as ethanol, propanol, butanol, benzylalcohol, cyclohexanol or glycol), ketones (such as acetone, methyl ethyl ketone, methyl isobutyl ketone, acetophenone, or cyclohexanone), esters (including fats and oils) and (poly)ethers, unsubstituted and substituted amines, amides (such as dimethylformamide or fatty acid amides) and esters thereof, lactams (such as N-alkylpyrrolidones, in particular N-methylpyrrolidone) and lactones, sulfones and sulfoxides (such as dimethyl sulfoxide), oils of vegetable or animal origin, nitriles (alkyl nitriles such as acetonitrile, propionotrilie, butyronitrile, or aromatic nitriles, such as benzonitrile), carbonic acid esters (cyclic carbonic acid esters, such as ethylene carbonate, propylene carbonate, butylene carbonate, or dialkyl carbonic acid esters, such as dimethyl carbonate, diethyl carbonate, dipropyl carbonate, dibutyl carbonate, dioctyl carbonate). The carrier may also be a liquefied gaseous extender, i.e. liquid which is gaseous at standard temperature and under standard pressure, for example aerosol propellants such as halohydrocarbons, butane, propane, nitrogen and carbon dioxide. 
     Preferred solid carriers are selected from clays, talc and silica. 
     Preferred liquid carriers are selected from water, fatty acid amides and esters thereof, aromatic and nonaromatic hydrocarbons, lactams, lactones, carbonic acid esters, ketones, (poly)ethers. 
     The amount of carrier typically ranges from 1 to 99.99%, preferably from 5 to 99.9%, more preferably from 10 to 99.5%, and most preferably from 20 to 99% by weight of the formulation. 
     Liquid carriers are typically present in a range of from 20 to 90%, for example 30 to 80% by weight of the formulation. 
     Solid carriers are typically present in a range of from 0 to 50%, preferably 5 to 45%, for example 10 to 30% by weight of the formulation. 
     If the formulation comprises two or more carriers, the outlined ranges refer to the total amount of carriers. 
     The surfactant can be an ionic (cationic or anionic), amphoteric or non-ionic surfactant, such as ionic or non-ionic emulsifier(s), foam former(s), dispersant(s), wetting agent(s), penetration enhancer(s) and any mixtures thereof. Examples of suitable surfactants include, but are not limited to, salts of polyacrylic acid, ethoxylated polya(alpha-substituted)acrylate derivatives, salts of lignosulfonic acid (such as sodium lignosulfonate), salts of phenolsulfonic acid or naphthalenesulfonic acid, polycondensates of ethylene oxide and/or propylene oxide with or without alcohols, fatty acids or fatty amines (for example, polyoxyethylene fatty acid esters such as castor oil ethoxylate, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers), substituted phenols (preferably alkylphenols or arylphenols), salts of sulfosuccinic esters, taurine derivatives (preferably alkyl taurates), phosphoric esters of polyethoxylated alcohols or phenols, fatty esters of polyols (such a fatty acid esters of glycerol, sorbitol or sucrose), sulfates (such as alkyl sulfates and alkyl ether sulfates), sulfonates (for example, alkylsulfonates, arylsulfonates and alkylbenzene sulfonates), sulfonated polymers of naphthalene/formaldehyde, phosphate esters, protein hydrolysates, lignosulfite waste liquors and methylcellulose. Any reference to salts in this paragraph refers preferably to the respective alkali, alkaline earth and ammonium salts. 
     Preferred surfactants are selected from ethoxylated polya(alpha-substituted)acrylate derivatives, polycondensates of ethylene oxide and/or propylene oxide with alcohols, polyoxyethylene fatty acid esters, alkylbenzene sulfonates, sulfonated polymers of naphthalene/formaldehyde, polyoxyethylene fatty acid esters such as castor oil ethoxylate, sodium lignosulfonate and arylphenol ethoxylate. 
     The amount of surfactants typically ranges from 5 to 40%, for example 10 to 20%, by weight of the formulation. 
     Further examples of suitable auxiliaries include water repellents, siccatives, binders (adhesive, tackifier, fixing agent, such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, natural phospholipids such as cephalins and lecithins and synthetic phospholipids, polyvinylpyrrolidone and tylose), thickeners and secondary thickeners (such as cellulose ethers, acrylic acid derivatives, xanthan gum, modified clays, e.g. the products available under the name Bentone, and finely divided silica), stabilizers (e.g. cold stabilizers, preservatives (e.g. dichlorophene, benzyl alcohol hemiformal, 1,2-Benzisothiazolin-3-on, 2-methyl-4-isothiazolin-3-one), antioxidants, light stabilizers, in particular UV stabilizers, or other agents which improve chemical and/or physical stability), dyes or pigments (such as inorganic pigments, e.g. iron oxide, titanium oxide and Prussian Blue; organic dyes, e.g. alizarin, azo and metal phthalocyanine dyes), antifoams (e.g. silicone antifoams and magnesium stearate), antifreezes, stickers, gibberellins and processing auxiliaries, mineral and vegetable oils, perfumes, waxes, nutrients (including trace nutrients, such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc), protective colloids, thixotropic substances, penetrants, sequestering agents and complex formers. 
     The choice of the auxiliaries depends on the intended mode of application of the compound of the invention and/or on the physical properties of the compound(s). Furthermore, the auxiliaries may be chosen to impart particular properties (technical, physical and/or biological properties) to the formulations or use forms prepared therefrom. The choice of auxiliaries may allow customizing the formulations to specific needs. 
     The formulation comprises an insecticidal/acaricidal/nematicidal effective amount of the compound(s) of the invention. The term “effective amount” denotes an amount, which is sufficient for controlling harmful insects/mites/nematodes on cultivated plants or in the protection of materials and which does not result in a substantial damage to the treated plants. Such an amount can vary in a broad range and is dependent on various factors, such as the insect/mite/nematode species to be controlled, the treated cultivated plant or material, the climatic conditions and the specific compound of the invention used. Usually, the formulation according to the invention contains from 0.01 to 99% by weight, preferably from 0.05 to 98% by weight, more preferred from 0.1 to 95% by weight, even more preferably from 0.5 to 90% by weight, most preferably from 1 to 80% by weight of the compound of the invention. It is possible that a formulation comprises two or more compounds of the invention. In such case the outlined ranges refer to the total amount of compounds of the present invention. 
     The formulation of the invention may be in any customary formulation type, such as solutions (e.g aqueous solutions), emulsions, water- and oil-based suspensions, powders (e.g. wettable powders, soluble powders), dusts, pastes, granules (e.g. soluble granules, granules for broadcasting), suspoemulsion concentrates, natural or synthetic products impregnated with the compound of the invention, fertilizers and also microencapsulations in polymeric substances. The compound of the invention may be present in a suspended, emulsified or dissolved form Examples of particular suitable formulation types are solutions, watersoluble concentrates (e.g. SL, LS), dispersible concentrates (DC), suspensions and suspension concentrates (e.g. SC, OD, OF, FS), emulsifiable concentrates (e.g. EC), emulsions (e.g. EW, EO, ES, ME, SE), capsules (e.g. CS, ZC), pastes, pastilles, wettable powders or dusts (e.g. WP, SP, WS, DP, DS), pressings (e.g. BR, TB, DT), granules (e.g. WG, SG, GR, FG, GG, MG), insecticidal articles (e.g. LN), as well as gel formulations for the treatment of plant propagation materials such as seeds (e.g. GW, GF). These and further formulations types are defined by the Food and Agriculture Organization of the United Nations (FAO). An overview is given in the “Catalogue of pesticide formulation types and international coding system”, Technical Monograph No. 2, 6th Ed. May 2008, Croplife International. 
     Preferably, the formulation of the invention is in form of one of the following types: EC, SC, FS, SE, OD, WG, WP, CS, more preferred EC, SC, OD, WG, CS. 
     Further details about examples of formulation types and their preparation are given below. If two or more compounds of the invention are present, the outlined amount of compound of the invention refers to the total amount of compounds of the present invention. This applies mutatis mutandis for any further component of the formulation, if two or more representatives of such component, e.g. wetting agent, binder, are present. 
     i) Water-Soluble Concentrates (SL, LS) 
     10-60% by weight of at least one compound of the invention and 5-15% by weight surfactant (e.g. polycondensates of ethylene oxide and/or propylene oxide with alcohols) are dissolved in such amount of water and/or water-soluble solvent (e.g. alcohols such as propylene glycol or carbonates such as propylene carbonate) to result in a total amount of 100% by weight. Before application the concentrate is diluted with water. 
     ii) Dispersible Concentrates (DC) 
     5-25% by weight of at least one compound of the invention and 1-10% by weight surfactant and/or binder (e.g. polyvinylpyrrolidone) are dissolved in such amount of organic solvent (e.g. cyclohexanone) to result in a total amount of 100% by weight. Dilution with water gives a dispersion. 
     iii) Emulsifiable Concentrates (EC) 
     15-70% by weight of at least one compound of the invention and 5-10% by weight surfactant (e.g. a mixture of calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in such amount of water-insoluble organic solvent (e.g. aromatic hydrocarbon or fatty acid amide) and if needed additional water-soluble solvent to result in a total amount of 100% by weight. Dilution with water gives an emulsion. 
     iv) Emulsions (EW, EO, ES) 
     5-40% by weight of at least one compound of the invention and 1-10% by weight surfactant (e.g. a mixture of calcium dodecylbenzenesulfonate and castor oil ethoxylate, or polycondensates of ethylene oxide and/or propylene oxide with or without alcohols) are dissolved in 20-40% by weight water-insoluble organic solvent (e.g. aromatic hydrocarbon). This mixture is added to such amount of water by means of an emulsifying machine to result in a total amount of 100% by weight. The resulting formulation is a homogeneous emulsion. Before application the emulsion may be further diluted with water. 
     v) Suspensions and Suspension Concentrates 
     v-1) Water-Based (SC, FS) 
     In a suitable grinding equipment, e.g. an agitated ball mill, 20-60% by weight of at least one compound of the invention are comminuted with addition of 2-10% by weight surfactant (e.g. sodium lignosulfonate and polyoxyethylene fatty alcohol ether), 0.1-2% by weight thickener (e.g. xanthan gum) and water to give a fine active substance suspension. The water is added in such amount to result in a total amount of 100% by weight. Dilution with water gives a stable suspension of the active substance. For FS type formulations up to 40% by weight binder (e.g. polyvinylalcohol) is added. 
     v-2) Oil-Based(OD, OF) 
     In a suitable grinding equipment, e.g. an agitated ball mill, 20-60% by weight of at least one compound of the invention are comminuted with addition of 2-10% by weight surfactant (e.g. sodium lignosulfonate and polyoxyethylene fatty alcohol ether), 0.1-2% by weight thickener (e.g. modified clay, in particular Bentone, or silica) and an organic carrier to give a fine active substance oil suspension. The organic carrier is added in such amount to result in a total amount of 100% by weight. Dilution with water gives a stable dispersion of the active substance. 
     vi) Water-Dispersible Granules and Water-Soluble Granules (WG, SG) 
     1-90% by weight, preferably 20-80%, most preferably 50-80% by weight of at least one compound of the invention are ground finely with addition of surfactant (e.g. sodium lignosulfonate and sodium alkylnaphthylsulfonates) and potentially carrier material and converted to water-dispersible or water-soluble granules by means of typical technical appliances like e. g. extrusion, spray drying, fluidized bed granulation. The surfactant and carrier material is used in such amount to result in a total amount of 100% by weight. Dilution with water gives a stable dispersion or solution of the active substance. 
     vii) Water-Dispersible Powders and Water-Soluble Powders (WP, SP, WS) 
     50-80% by weight of at least one compound of the invention are ground in a rotor-stator mill with addition of 1-20% by weight surfactant (e.g. sodium lignosulfonate, sodium alkylnaphthylsulfonates) and such amount of solid carrier, e.g. silica gel, to result in a total amount of 100% by weight. Dilution with water gives a stable dispersion or solution of the active substance. 
     viii) Gel (GW, GF) 
     In an agitated ball mill, 5-25% by weight of at least one compound of the invention are comminuted with addition of 3-10% by weight surfactant (e.g. sodium lignosulfonate), 1-5% by weight binder (e.g. carboxymethylcellulose) and such amount of water to result in a total amount of 100% by weight. This results in a fine suspension of the active substance. Dilution with water gives a stable suspension of the active substance. 
     ix) Microemulsion (ME) 
     5-20% by weight of at least one compound of the invention are added to 5-30% by weight organic solvent blend (e.g. fatty acid dimethylamide and cyclohexanone), 10-25% by weight surfactant blend (e.g. polyoxyethylene fatty alcohol ether and arylphenol ethoxylate), and such amount of water to result in a total amount of 100% by weight. This mixture is stirred for 1 h to produce spontaneously a thermodynamically stable microemulsion. 
     x) Microcapsules (CS) 
     An oil phase comprising 5-50% by weight of at least one compound of the invention, 0-40% by weight water-insoluble organic solvent (e.g. aromatic hydrocarbon), 2-15% by weight acrylic monomers (e.g. methylmethacrylate, methacrylic acid and a di- or triacrylate) are dispersed into an aqueous solution of a protective colloid (e.g. polyvinyl alcohol). Radical polymerization initiated by a radical initiator results in the formation of poly(meth)acrylate microcapsules. Alternatively, an oil phase comprising 5-50% by weight of at least one compound of the invention, 0-40% by weight water-insoluble organic solvent (e.g. aromatic hydrocarbon), and an isocyanate monomer (e.g. diphenylmethene-4,4′-diisocyanatae) are dispersed into an aqueous solution of a protective colloid (e.g. polyvinyl alcohol), this resulting in the formation of polyurea microcapsules. Optionally, the addition of a polyamine (e.g. hexamethylenediamine) is also used to result in the formation of polyurea microcapsules. The monomers amount to 1-10% by weight of the total CS formulation. 
     xi) Dustable powders (DP, DS) 
     1-10% by weight of at least one compound of the invention are ground finely and mixed intimately with such amount of solid carrier, e.g. finely divided kaolin, to result in a total amount of 100% by weight. 
     xii) Granules (GR, FG) 
     0.5-30% by weight of at least one compound of the invention are ground finely and associated with such amount of solid carrier (e.g. silicate) to result in a total amount of 100% by weight. 
     xiii) Ultra-low volume liquids (UL) 
     1-50% by weight of at least one compound of the invention are dissolved in such amount of organic solvent, e.g. aromatic hydrocarbon, to result in a total amount of 100% by weight. 
     The formulations types i) to xiii) may optionally comprise further auxiliaries, such as 0.1-1% by weight preservatives, 0.1-1% by weight antifoams, 0.1-1% by weight dyes and/or pigments, and 5-10% by weight antifreezes. 
     Mixtures 
     The compounds of the formula (I) may also be employed as a mixture with one or more suitable fungicides, bactericides, acaricides, molluscicides, nematicides, insecticides, microbiologicals, beneficial species, herbicides, fertilizers, bird repellents, phytotonics, sterilants, safeners, semiochemicals and/or plant growth regulators, in order thus, for example, to broaden the spectrum of action, to prolong the duration of action, to increase the rate of action, to prevent repulsion or prevent evolution of resistance. In addition, such active compound combinations may improve plant growth and/or tolerance to abiotic factors, for example high or low temperatures, to drought or to elevated water content or soil salinity. It is also possible to improve flowering and fruiting performance, optimize germination capacity and root development, facilitate harvesting and improve yields, influence maturation, improve the quality and/or the nutritional value of the harvested products, prolong storage life and/or improve the processability of the harvested products. 
     Furthermore, the compounds of the formula (I) can be present in a mixture with other active compounds or semiochemicals such as attractants and/or bird repellants and/or plant activators and/or growth regulators and/or fertilizers. Likewise, the compounds of the formula (I) can be used to improve plant properties such as, for example, growth, yield and quality of the harvested material. 
     In a particular embodiment according to the invention, the compounds of the formula (I) are present in formulations or the use forms prepared from these formulations in a mixture with further compounds, preferably those as described below. 
     If one of the compounds mentioned below can occur in different tautomeric forms, these forms are also included even if not explicitly mentioned in each case. Further, all named mixing partners can, if their functional groups enable this, optionally form salts with suitable bases or acids. 
     Insecticides/Acaricides/Nematicides 
     The active compounds identified here by their common names are known and are described, for example, in the pesticide handbook (“The Pesticide Manual” 16th Ed., British Crop Protection Council 2012) or can be found on the Internet (e.g. http://www.alanwood.net/pesticides). The classification is based on the current IRAC Mode of Action Classification Scheme at the time of filing of this patent application. 
     (1) Acetylcholinesterase (AChE) inhibitors, preferably carbamates selected from alanycarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimethacarb, XMC and xylylcarb, or organophosphates selected from acephate, azamethiphos, azinphos-ethyl, azinphos-methyl, cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos-methyl, coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos/DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, imicyafos, isofenphos, isopropyl O-(methoxyaminothiophosphoryl) salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, parathion-methyl, phenthoate, phorate, phosalone, phosmet, phosphamidon, phoxim, pirimiphos-methyl, profenofos, propetamphos, prothiofos, pyraclofos, pyridaphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, triclorfon and vamidothion. 
     (2) GABA-gated chloride channel blockers, preferably cyclodiene-organochlorines selected from chlordane and endosulfan, or phenylpyrazoles (fiproles) selected from ethiprole and fipronil. 
     (3) Sodium channel modulators, preferably pyrethroids selected from acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, bioallethrin s-cyclopentenyl isomer, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin [(1R)-trans-isomer], deltamethrin, empenthrin [(EZ)-(1R)-isomer], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadethrin, momfluorothrin, permethrin, phenothrin [(1R)-trans-isomer], prallethrin, pyrethrins (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethrin, tetramethrin [(1R)-isomer)], tralomethrin and transfluthrin, or DDT or methoxychlor. 
     (4) Nicotinic acetylcholine receptor (nAChR) competitive modulators, preferably neonicotinoids selected from acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam, or nicotine, or sulfoximines selected from sulfoxaflor, or butenolids selected from flupyradifurone, or mesoionics selected from triflumezopyrim. 
     (5) Nicotinic acetylcholine receptor (nAChR) allosteric modulators (Site I), preferably spinosyns selected from spinetoram and spinosad. 
     (6) Glutamate-gated chloride channel (GluCl) allosteric modulators, preferably avermectins/milbemycins selected from abamectin, emamectin benzoate, lepimectin and milbemectin. 
     (7) Juvenile hormone mimics, preferably juvenile hormone analogues selected from hydroprene, kinoprene and methoprene, or fenoxycarb or pyriproxyfen. 
     (8) Miscellaneous non-specific (multi-site) inhibitors, preferably alkyl halides selected from methyl bromide and other alkyl halides, or chloropicrine or sulphuryl fluoride or borax or tartar emetic or methyl isocyanate generators selected from diazomet and metam. 
     (9) Chordotonal organ TRPV channel modulators, preferably pyridine azomethanes selected from pymetrozine and pyrifluquinazone, or pyropenes selected from afidopyropen. 
     (10) Mite growth inhibitors affecting CHS1 selected from clofentezine, hexythiazox, diflovidazin and etoxazole. 
     (11) Microbial disruptors of the insect gut membranes selected from  Bacillus thuringiensis  subspecies  israelensis, Bacillus sphaericus, Bacillus thuringiensis  subspecies  aizawai, Bacillus thuringiensis  subspecies  kurstaki, Bacillus thuringiensis  subspecies  tenebrionis , and B.t. plant proteins selected from Cry1Ab, Cry1Ac, Cry1Fa, Cry1A.105, Cry2Ab, Vip3A, mCry3A, Cry3Ab, Cry3Bb and Cry34Ab1/35Ab1. 
     (12) Inhibitors of mitochondrial ATP synthase, preferably ATP disruptors selected from diafenthiuron, or organotin compounds selected from azocyclotin, cyhexatin and fenbutatin oxide, or propargite or tetradifon. 
     (13) Uncouplers of oxidative phosphorylation via disruption of the proton gradient selected from chlorfenapyr, DNOC and sulfluramid. 
     (14) Nicotinic acetylcholine receptor channel blockers selected from bensultap, cartap hydrochloride, thiocylam and thiosultap-sodium. 
     (15) Inhibitors of chitin biosynthesis affecting CHS1, preferably benzoylureas selected from bistrifluron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron. 
     (16) Inhibitors of chitin biosynthesis, type 1 selected from buprofezin. 
     (17) Moulting disruptor (in particular for Diptera, i.e. dipterans) selected from cyromazine. 
     (18) Ecdysone receptor agonists, preferably diacylhydrazines selected from chromafenozide, halofenozide, methoxyfenozide and tebufenozide. 
     (19) Octopamine receptor agonists selected from amitraz. 
     (20) Mitochondrial complex III electron transport inhibitors selected from hydramethylnone, acequinocyl, fluacrypyrim and bifenazate. 
     (21) Mitochondrial complex I electron transport inhibitors, preferably METI acaricides and insecticides selected from fenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad and tolfenpyrad, or rotenone (Derris). 
     (22) Voltage-dependent sodium channel blockers, preferably oxadiazines selected from indoxacarb, or semicarbazones selected from metaflumizone. 
     (23) Inhibitors of acetyl CoA carboxylase, preferably tetronic and tetramic acid derivatives selected from spirodiclofen, spiromesifen, spiropidion and spirotetramat. 
     (24) Mitochondrial complex IV electron transport inhibitors, preferably phosphides selected from aluminium phosphide, calcium phosphide, phosphine and zinc phosphide, or cyanides selected from calcium cyanide, potassium cyanide and sodium cyanide. 
     (25) Mitochondrial complex II electron transport inhibitors, preferably beta-ketonitrile derivatives selected from cyenopyrafen and cyflumetofen, or carboxanilides selected from pyflubumide. 
     (28) Ryanodine receptor modulators, preferably diamides selected from chlorantraniliprole, cyantraniliprole, cyclaniliprole, flubendiamide and tetraniliprole. 
     (29) Chordotonal organ Modulators (with undefined target site) selected from flonicamid. 
     (30) GABA-gated chlorid channel allosteric modulators, preferably meta-diamides selected from broflanilide, or isoxazoles selected from fluxametamide. 
     (31) Baculovisuses, preferably Granuloviruses (GVs) selected from  Cydia pomonella  GV and  Thaumatofibia leucotreta  (GV), or Nucleopolyhedroviruses (NPVs) selected from  Anficarsia gemmatalis  MNPV and  Helicoverpa armigera  NPV. 
     (32) Nicotinic acetylcholine receptor allosteric modulators (Site II) selected from GS-omega/kappa HXTX-Hv 1a peptide. 
     (33) further active compounds selected from Acynonapyr, Afoxolaner, Azadirachtin, Benclothiaz, Benzoximate, Benzpyrimoxan, Bromopropylate, Chinomethionat, Chloroprallethrin, Cryolite, Cyclobutrifluram or Cyclobutrifen (CAS 1460292-16-3), Cycloxaprid, Cyetpyrafen, Cyhalodiamide, Dicloromezotiaz, Dicofol, Dimpropyridaz, epsilon-Metofluthrin, epsilon-Momfluthrin, Flometoquin, Fluazaindolizine, Fluensulfone, Flufenerim, Flufenoxystrobin, Flufiprole, Fluhexafon, Fluopyram, Flupyrimin, Fluralaner, Fufenozide, Fupentiofenox (CAS 1472050-04-6), Guadipyr, Heptafluthrin, Imidaclothiz, Iprodione, Isocycloseram, kappa-Bifenthrin, kappa-Tefluthrin, Lotilaner, Meperfluthrin, Oxazosulfyl, Paichongding, Pyridalyl, Pyrifluquinazon, Pyriminostrobin, Spirobudiclofen, Tetramethylfluthrin, Tetrachlorantraniliprole, Tigolaner, Tioxazafen, Thiofluoximate, Iodomethane, Triflupentoxide (CAS 1472050-04-6); furthermore preparations based on  Bacillus firmus  (1-1582, BioNeem, Votivo), and also the following compounds: 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulphinyl]phenyl}-3-(trifluoromethyl)-1H-1,2,4-triazole-5-amine (known from WO2006/043635) (CAS 885026-50-6), {1′-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indol-3,4′-piperidin]-1(2H)-yl}(2-chloropyridin-4-yl)methanone (known from WO2003/106457) (CAS 637360-23-7), 2-chloro-N-[2-{1-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]piperidin-4-yl}-4-(trifluoromethyl)phenyl]isonicotinamide (known from WO2006/003494) (CAS 872999-66-1), 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4,5]dec-3-en-2-one (known from WO 2010052161) (CAS 1225292-17-0), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-yl ethyl carbonate (known from EP2647626) (CAS 1440516-42-6), 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from WO2004/099160) (CAS 792914-58-0), PF1364 (known from JP2010/018586) (CAS 1204776-60-2), (3E)-3-[1-[(6-chloro-3-pyridyl)methyl]-2-pyridylidene]-1,1,1-trifluoro-propan-2-one (known from WO2013/144213) (CAS 1461743-15-6), N-[3-(benzylcarbamoyl)-4-chlorophenyl]-1-methyl-3-(pentafluoroethyl)-4-(trifluoromethyl)-1H-pyrazole-5-carboxamide (known from WO2010/051926) (CAS 1226889-14-0), 5-bromo-4-chloro-N-[4-chloro-2-methyl-6-(methylcarbamoyl)phenyl]-2-(3-chloro-2-pyridyl)pyrazole-3-carboxamide (known from CN103232431) (CAS 1449220-44-3), 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(cis-1-oxido-3-thietanyl)-benzamide, 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(trans-1-oxido-3-thietanyl)-benzamide and 4-[(5S)-5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(cis-1-oxido-3-thietanyl)benzamide (known from WO 2013/050317 A1) (CAS 1332628-83-7), N-[3-chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl) sulfinyl]-propanamide, (+)-N-[3-chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)sulfinyl]-propanamide and (−)-N-[3-chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)sulfinyl]-propanamide (known from WO 2013/162715 A2, WO 2013/162716 A2, US 2014/0213448 A1) (CAS 1477923-37-7), 5-[[(2E)-3-chloro-2-propen-1-yl]amino]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile (known from CN 101337937 A) (CAS 1105672-77-2), 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)thioxomethyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, (Liudaibenjiaxuanan, known from CN 103109816 A) (CAS 1232543-85-9); N-[4-chloro-2-[[(1,1-dimethylethyl)amino]carbonyl]-6-methylphenyl]-1-(3-chloro-2-pyridinyl)-3-(fluoromethoxy)-1H-Pyrazole-5-carboxamide (known from WO 2012/034403 A1) (CAS 1268277-22-0), N-[2-(5-amino-1,3,4-thiadiazol-2-yl)-4-chloro-6-methylphenyl]-3-bromo-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide (known from WO 2011/085575 A1) (CAS 1233882-22-8), 4-[3-[2,6-dichloro-4-[(3,3-dichloro-2-propen-1-yl)oxy]phenoxy]propoxy]-2-methoxy-6-(trifluoromethyl)-pyrimidine (known from CN 101337940 A) (CAS 1108184-52-6); (2E)- and 2(Z)-2-[2-(4-cyanophenyl)-1-[3-(trifluoromethyl)phenyl]ethylidene]-N-[4-(difluoromethoxy)phenyl]-hydrazinecarboxamide (known from CN 101715774 A) (CAS 1232543-85-9); 3-(2,2-dichloroethenyl)-2,2-dimethyl-4-(1H-benzimidazol-2-yl)phenyl-cyclopropanecarboxylic acid ester (known from CN 103524422 A) (CAS 1542271-46-4); (4aS)-7-chloro-2,5-dihydro-2-[[(methoxycarbonyl) [4-[(trifluoromethyl)thio]phenyl]amino]carbonyl]-indeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylic acid methyl ester (known from CN 102391261 A) (CAS 1370358-69-2); 6-deoxy-3-O-ethyl-2,4-di-O-methyl-, 1-[N-[4-[1-[4-(1,1,2,2,2-pentafluoroethoxy)phenyl]-1H-1,2,4-triazol-3-yl]phenyl]carbamate]-α-L-mannopyranose (known from US 2014/0275503 A1) (CAS 1181213-14-8); 8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl)-3-aza-bicyclo[3.2.1]octane (CAS 1253850-56-4), (8-anti)-8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl)-3-aza-bicyclo[3.2.1]octane (CAS 933798-27-7), (8-syn)-8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl)-3-aza-bicyclo[3.2.1]octane (known from WO 2007040280 A1, WO 2007040282 A1) (CAS 934001-66-8), N-[3-chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)thio]-propanamide (known from WO 2015/058021 A1, WO 2015/058028 A1) (CAS 1477919-27-9) and N-[4-(aminothioxomethyl)-2-methyl-6-[(methylamino)carbonyl]phenyl]-3-bromo-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide (known from CN 103265527 A) (CAS 1452877-50-7), 5-(1,3-dioxan-2-yl)-4-[[4-(trifluoromethyl)phenyl]methoxy]-pyrimidine (known from WO 2013/115391 A1) (CAS 1449021-97-9), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-1-methyl-1,8-diazaspiro[4.5]decane-2,4-dione (known from WO 2014/187846 A1) (CAS 1638765-58-8), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-1-methyl-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-yl-carbonic acid ethyl ester (known from WO 2010/066780 A1, WO 2011151146 A1) (CAS 1229023-00-0), 4-[(5S)-5-(3,5-Dichloro-4-fluorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[(4R)-2-ethyl-3-oxo-4-isoxazolidinyl]-2-methyl-benzamide (bekannt aus WO 2011/067272, WO2013/050302) (CAS 1309959-62-3). 
     Fungicides 
     The active ingredients specified herein by their Common Name are known and described, for example, in The Pesticide Manual (16th Ed. British Crop Protection Council) or can be searched in the internet (e.g. (www.alanwood.net/pesticides). 
     All named fungicidal mixing partners of the classes (1) to (15) can, if their functional groups enable this, optionally form salts with suitable bases or acids. All named mixing partners of the classes (1) to (15) can include tautomeric forms, where applicable. 
     1) Inhibitors of the ergosterol biosynthesis, for example (1.001) cyproconazole, (1.002) difenoconazole, (1.003) epoxiconazole, (1.004) fenhexamid, (1.005) fenpropidin, (1.006) fenpropimorph, (1.007) fenpyrazamine, (1.008) fluquinconazole, (1.009) flutriafol, (1.010) imazalil, (1.011) imazalil sulfate, (1.012) ipconazole, (1.013) metconazole, (1.014) myclobutanil, (1.015) paclobutrazol, (1.016) prochloraz, (1.017) propiconazole, (1.018) prothioconazole, (1.019) pyrisoxazole, (1.020) spiroxamine, (1.021) tebuconazole, (1.022) tetraconazole, (1.023) triadimenol, (1.024) tridemorph, (1.025) triticonazole, (1.026) (1R,2S,5S)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol, (1.027) (1S,2R,5R)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol, (1.028) (2R)-2-(1-chlorocyclopropyl)-4-[(1R)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.029) (2R)-2-(1-chlorocyclopropyl)-4-[(1S)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.030) (2R)-2-[4-(4-chlorophenoxy) (trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1.031) (2S)-2-(1-chlorocyclopropyl) [(1R)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.032) (2S)-2-(1-chlorocyclopropyl)-4-[(1S)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.033) (2 S)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1.034) (R)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (1.035) (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (1.036) [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (1.037) 1-({(2R,4S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole, (1.038) 1-({(2S,4S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole, (1.039) 1-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate, (1.040) 1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate, (1.041) 1-{[rel(2R,3 S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate, (1.042) 2-[(2R,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.043) 2-[(2R,4R,5 S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.044) 2-[(2R,4 S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.045) 2-[(2R,4 S,5 S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.046) 2-[(2 S,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.047) 2-[(2 S,4R,5 S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.048) 2-[(2S,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.049) 2-[(2S,4S,5 S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.050) 2-[1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.051) 2-[2-chloro-4-(2,4-dichlorophenoxy)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1.052) 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.053) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.054) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)pentan-2-ol, (1.055) Mefentrifluconazole, (1.056) 2-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.057) 2-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.058) 2-{[rel(2R,3 S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.059) 5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol, (1.060) 5-(allylsulfanyl)-1-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (1.061) 5-(allylsulfanyl)-1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran yl]methyl}-1H-1,2,4-triazole, (1.062) 5-(allylsulfanyl)-1-{[rel(2R,3 S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (1.063) N′-(2,5-dimethyl-4-{[3-(1,1,2,2-tetrafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.064) N′-(2,5-dimethyl-4-{[3-(2,2,2-trifluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.065) N′-(2,5-dimethyl-4-{[3-(2,2,3,3-tetrafluoropropoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.066) N′-(2,5-dimethyl-4-{[3-(pentafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.067) N′-(2,5-dimethyl-4-{3-[(1,1,2,2-tetrafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.068) N′-(2,5-dimethyl-4-{3-[(2,2,2-trifluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.069) N′-(2,5-dimethyl-4-{3-[(2,2,3,3-tetrafluoropropyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.070) N′-(2,5-dimethyl-4-{3-[(pentafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.071) N′-(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N-methylimidoformamide, (1.072) N′-(4-{[3-(difluoromethoxy)phenyl]sulfanyl}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (1.073) N′-(4-{3-[(difluoromethyl)sulfanyl]phenoxy}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (1.074) N′-[5-bromo-6-(2,3-dihydro-1H-inden-2-yloxy)-2-methylpyridin-3-yl]-N-ethyl-N-methylimidoformamide, (1.075) N′-{4-[(4,5-dichloro-1,3-thiazol-2-yl)oxy]-2,5-dimethylphenyl}-N-ethyl-N-methylimidoformamide, (1.076) N′-{5-bromo-6-[(1R)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.077) N′-{5-bromo-6-[(1S)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.078) N′-{5-bromo-6-[(cis-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.079) N′-{5-bromo-6-[(trans-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.080) N′-{5-bromo-6-[1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.081) ipfentrifluconazole, (1.082) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1.083) 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, (1.084) 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, (1.085) 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile and (1.086) 4-[[6-[rac-(2R)-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4H-1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile. 
     2) Inhibitors of the respiratory chain at complex I or II, for example (2.001) benzovindiflupyr, (2.002) bixafen, (2.003) boscalid, (2.004) carboxin, (2.005) fluopyram, (2.006) flutolanil, (2.007) fluxapyroxad, (2.008) furametpyr, (2.009) Isofetamid, (2.010) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.011) isopyrazam (anti-epimeric enantiomer 1S,4R,9R), (2.012) isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), (2.013) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR), (2.014) isopyrazam (syn-epimeric enantiomer 1R,4S,9R), (2.015) isopyrazam (syn-epimeric enantiomer 1S,4R,9S), (2.016) isopyrazam (syn-epimeric racemate 1RS,4SR,9RS), (2.017) penflufen, (2.018) penthiopyrad, (2.019) pydiflumetofen, (2.020) Pyraziflumid, (2.021) sedaxane, (2.022) 1,3-dimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (2.023) 1,3-dimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.024) 1,3-dimethyl-N-[(3 S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.025) 1-methyl-3-(trifluoromethyl)-N-[2′-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2.026) 2-fluoro-6-(trifluoromethyl)-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)benzamide, (2.027) 3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (2.028)inpyrfluxam, (2.029) 3-(difluoromethyl)-1-methyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.030) fluindapyr, (2.031) 3-(difluoromethyl)-N-[(3R) fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazole-4-carboxamide, (2.032) 3-(difluoromethyl)-N-[(3 S)-7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazole carboxamide, (2.033) 5,8-difluoro-N-[2-(2-fluoro-4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)ethyl]quinazolin-4-amine, (2.034) N-(2-cyclopentyl-5-fluorobenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.035) N-(2-tert-butyl-5-methylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.036) N-(2-tert-butylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.037) N-(5-chloro-2-ethylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.038) N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.039) N-[(1R,4S)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.040) N-[(1S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.041) N-[1-(2,4-dichlorophenyl)-1-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.042) N-[2-chloro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.043) N-[3-chloro-2-fluoro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.044) N-[5-chloro-2-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.045) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-N-[5-methyl-2-(trifluoromethyl)benzyl]-1H-pyrazole-4-carboxamide, (2.046) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-fluoro-6-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.047) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropyl-5-methylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.048) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carbothioamide, (2.049) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.050) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(5-fluoro-2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.051) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-4,5-dimethylbenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.052) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-fluorobenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.053) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-methylbenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.054) N-cyclopropyl-N-(2-cyclopropyl-5-fluorobenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.055) N-cyclopropyl-N-(2-cyclopropyl-5-methylbenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.056) N-cyclopropyl-N-(2-cyclopropylbenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.057) pyrapropoyne. 
     3) Inhibitors of the respiratory chain at complex III, for example (3.001) ametoctradin, (3.002) amisulbrom, (3.003) azoxystrobin, (3.004) coumethoxystrobin, (3.005) coumoxystrobin, (3.006) cyazofamid, (3.007) dimoxystrobin, (3.008) enoxastrobin, (3.009) famoxadone, (3.010) fenamidone, (3.011) flufenoxystrobin, (3.012) fluoxastrobin, (3.013) kresoxim-methyl, (3.014) metominostrobin, (3.015) orysastrobin, (3.016) picoxystrobin, (3.017) pyraclostrobin, (3.018) pyrametostrobin, (3.019) pyraoxystrobin, (3.020) trifloxystrobin, (3.021) (2E)-2-{2-[({[(1E)-1-(3-{[(E)-1-fluoro-2-phenylvinyl]oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide, (3.022) (2E,3Z)-5-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}-2-(methoxyimino)-N,3-dimethylpent-3-enamide, (3.023) (2R)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (3.024) (2S)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (3.025)fenpicoxamid, (3.026) mandestrobin, (3.027) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-formamido-2-hydroxybenzamide, (3.028) (2E,3Z)-5-{[1-(4-chloro-2-fluorophenyl)-1H-pyrazol-3-yl]oxy}-2-(methoxyimino)-N,3-dimethylpent-3-enamide, (3.029) methyl {5-[3-(2,4-dimethylphenyl)-1H-pyrazol-1-yl]-2-methylbenzyl}carbamate, (3.030) metyltetraprole, (3.031) florylpicoxamid. 
     4) Inhibitors of the mitosis and cell division, for example (4.001) carbendazim, (4.002) diethofencarb, (4.003) ethaboxam, (4.004) fluopicolide, (4.005) pencycuron, (4.006) thiabendazole, (4.007) thiophanate-methyl, (4.008) zoxamide, (4.009) 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenylpyridazine, (4.010) 3-chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, (4.011) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine, (4.012) 4-(2-bromo-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.013) 4-(2-bromo-4-fluorophenyl)-N-(2-bromo-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.014) 4-(2-bromo-4-fluorophenyl)-N-(2-bromophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.015) 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.016) 4-(2-bromo-4-fluorophenyl)-N-(2-chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.017) 4-(2-bromo-4-fluorophenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.018) 4-(2-chloro-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.019) 4-(2-chloro-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.020) 4-(2-chloro-4-fluorophenyl)-N-(2-chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.021) 4-(2-chloro-4-fluorophenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.022) 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine, (4.023) N-(2-bromo-6-fluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.024) N-(2-bromophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.025) N-(4-chloro-2,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine. 
     5) Compounds capable to have a multisite action, for example (5.001) bordeaux mixture, (5.002) captafol, (5.003) captan, (5.004) chlorothalonil, (5.005) copper hydroxide, (5.006) copper naphthenate, (5.007) copper oxide, (5.008) copper oxychloride, (5.009) copper(2+) sulfate, (5.010) dithianon, (5.011) dodine, (5.012) folpet, (5.013) mancozeb, (5.014) maneb, (5.015) metiram, (5.016) metiram zinc, (5.017) oxine-copper, (5.018) propineb, (5.019) sulfur and sulfur preparations including calcium polysulfide, (5.020) thiram, (5.021) zineb, (5.022) ziram, (5.023) 6-ethyl-5,7-dioxo-6,7-dihydro-5H-pyrrolo[3′,4′:5,6][1,4]dithiino[2,3-c][1,2]thiazole-3-carbonitrile. 
     6) Compounds capable to induce a host defence, for example (6.001) acibenzolar-S-methyl, (6.002) isotianil, (6.003) probenazole, (6.004) tiadinil. 
     7) Inhibitors of the amino acid and/or protein biosynthesis, for example (7.001) cyprodinil, (7.002) kasugamycin, (7.003) kasugamycin hydrochloride hydrate, (7.004) oxytetracycline, (7.005) pyrimethanil, (7.006) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline. 
     8) Inhibitors of the ATP production, for example (8.001) silthiofam. 
     9) Inhibitors of the cell wall synthesis, for example (9.001) benthiavalicarb, (9.002) dimethomorph, (9.003) flumorph, (9.004) iprovalicarb, (9.005) mandipropamid, (9.006) pyrimorph, (9.007) valifenalate, (9.008) (2E)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one, (9.009) (2Z)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one. 
     10) Inhibitors of the lipid and membrane synthesis, for example (10.001) propamocarb, (10.002) propamocarb hydrochloride, (10.003) tolclofos-methyl. 
     11) Inhibitors of the melanin biosynthesis, for example (11.001) tricyclazole, (11.002) 2,2,2-trifluoroethyl {3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl}carbamate. 
     12) Inhibitors of the nucleic acid synthesis, for example (12.001) benalaxyl, (12.002) benalaxyl-M (kiralaxyl), (12.003) metalaxyl, (12.004) metalaxyl-M (mefenoxam). 
     13) Inhibitors of the signal transduction, for example (13.001) fludioxonil, (13.002) iprodione, (13.003) procymidone, (13.004) proquinazid, (13.005) quinoxyfen, (13.006) vinclozolin. 
     14) Compounds capable to act as an uncoupler, for example (14.001) fluazinam, (14.002) meptyldinocap. 
     15) Further fungicides selected from the group consisting of (15.001) abscisic acid, (15.002) benthiazole, (15.003) bethoxazin, (15.004) capsimycin, (15.005) carvone, (15.006) chinomethionat, (15.007) cufraneb, (15.008) cyflufenamid, (15.009) cymoxanil, (15.010) cyprosulfamide, (15.011) flutianil, (15.012) fosetyl-aluminium, (15.013) fosetyl-calcium, (15.014) fosetyl-sodium, (15.015) methyl isothiocyanate, (15.016) metrafenone, (15.017) mildiomycin, (15.018) natamycin, (15.019) nickel dimethyldithiocarbamate, (15.020) nitrothal-isopropyl, (15.021) oxamocarb, (15.022) Oxathiapiprolin, (15.023) oxyfenthiin, (15.024) pentachlorophenol and salts, (15.025) phosphorous acid and its salts, (15.026) propamocarb-fosetylate, (15.027) pyriofenone (chlazafenone), (15.028) tebufloquin, (15.029) tecloftalam, (15.030) tolnifanide, (15.031) 1-(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (15.032) 1-(4-{4-[(5 S) (2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl (trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (15.033) 2-(6-benzylpyridin-2-yl)quinazoline, (15.034) dipymetitrone, (15.035) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-(prop-2-yn yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.036) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.037) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-fluoro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.038) 2-[6-(3-fluoro-4-methoxyphenyl)-5-methylpyridin-2-yl]quinazoline, (15.039) 2-{(5R)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (15.040) 2-{(5S)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (15.041) Ipflufenoquin, (15.042) 2-{2-fluoro-6-[(8-fluoro-2-methylquinolin-3-yl)oxy)]phenyl}propan-2-ol, (15.043)fluoxapiprolin, (15.044) 2-{3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phenyl methanesulfonate, (15.045) 2-phenylphenol and salts, (15.046) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (15.047) quinofumelin, (15.048) 4-amino-5-fluoropyrimidin-2-ol (tautomeric form: 4-amino-5-fluoropyrimidin-2(1H)-one), (15.049) 4-oxo-4-[(2-phenylethyl)amino]butanoic acid, (15.050) 5-amino-1,3,4-thiadiazole-2-thiol, (15.051) 5-chloro-N′-phenyl-N′-(prop-2-yn-1-yl)thiophene-2-sulfonohydrazide, (15.052) 5-fluoro-2-[(4-fluorobenzyl)oxy]pyrimidin-4-amine, (15.053) 5-fluoro-2-[(4-methylbenzyl)oxy]pyrimidin-4-amine, (15.054) 9-fluoro-2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-1,4-benzoxazepine, (15.055) but-3-yn-1-yl {6-[({[(Z)-(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate, (15.056) ethyl (2Z)-3-amino-2-cyano-3-phenylacrylate, (15.057) phenazine-1-carboxylic acid, (15.058) propyl 3,4,5-trihydroxybenzoate, (15.059) quinolin-8-ol, (15.060) quinolin-8-ol sulfate (2:1), (15.061) tert-butyl {6-[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate, (15.062) 5-fluoro-4-imino-3-methyl-1-[(4-methylphenyl)sulfonyl]-3,4-dihydropyrimidin-2(1H)-one, (15.063) aminopyrifen, (15.064) (N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylimidoformamide), (15.065) (N′-(2-chloro-5-methyl-4-phenoxyphenyl)-N-ethyl-N-methylimido¬formamide), (15.066) (2-{2-[(7,8-difluoro-2-methylquinolin-3-yl)oxy]-6-fluorophenyl}propan-2-ol), (15.067) (5-bromo-1-(5,6-dimethylpyridin-3-yl)-3,3-dimethyl-3,4-dihydroisoquinoline), (15.068) (3-(4,4-difluoro-5,5-dimethyl-4,5-dihydrothieno[2,3-c]pyridin-7-yl)quinoline), (15.069) (1-(4,5-dimethyl-1H-benzimidazol-1-yl)-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline), (15.070) 8-fluoro-3-(5-fluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinolone, (15.071) 8-fluoro-3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinolone, (15.072) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)-8-fluoroquinoline, (15.073) (N-methyl-N-phenyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide), (15.074) (methyl{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}carbamate), (15.075) (N-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}¬cyclopropane¬carboxamide), (15.076) N-methyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]¬benzamide, (15.077) N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, (15.078) N—[(Z)-methoxy iminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, (15.079) N-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-cyclopropane¬carboxamide, (15.080) N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol yl]benzamide, (15.081) 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-acetamide, (15.082) N-allyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl]methyl]acetamide, (15.083) N-[(E)-N-methoxy-C-methyl-carbonimidoyl]-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-benzamide, (15.084) N—[(Z)—N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, (15.085) N-allyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-methyl¬-propanamide, (15.086) 4,4-dimethyl]-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]¬pyrrolidin-2-one, (15.087) N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-benzenecarbothioamide, (15.088) 5-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrrolidin-2-one, (15.089) N-((2,3-difluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-3,3,3-trifluoro-propanamide, (15.090) 1-methoxy-1-methyl-3-[[4-[5-(trifluoromethyl}-1,2,4-oxadiazol-3-yl]phenyl]¬methyl]urea, (15.091) 1,1-diethyl-3-[[4-[5-(trifluoromethyl}-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.092) N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phen¬yl]methyl]propanamide, (15.093) N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, (15.094) 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.095) N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]¬methyl)¬cyclopropane¬carboxamide, (15.096) N,2-dimethoxy-N-[[4-[5-(trifluoromethyl}-1,2,4-oxadiazol-3-yl]phenyl]¬methyl]¬propanamide, (15.097) N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]¬propanamide, (15.098) 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]¬methyl]¬urea, (15.099) 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.100) 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.101) 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidin-2-one, (15.102) 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isooxazolidin-3-one, (15.103) 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, (15.104) 3,3-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]¬phenyl]¬methyl]¬piperidin-2-one, (15.105) 1-[[3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]¬phenyl]¬methyl]¬azepan-2-one, (15.106) 4,4-dimethyl-2-[[4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]¬phenyl]¬methyl]isoxazolidin-3-one (15.107) 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]¬phenyl]methyl]isoxazolidin-3-one, (15.108) ethyl (1-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}-1H-pyrazol-4-yl)acetate, (15.109) N,N-dimethyl-1-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}-1H-1,2,4-triazol-3-amine and (15.110) N-{2,3-difluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}butanamide 
     Biological Pesticides as Mixing Components 
     The compounds of the formula (I) can be combined with biological pesticides. 
     Biological pesticides comprise in particular bacteria, fungi, yeasts, plant extracts and products formed by microorganisms, including proteins and secondary metabolites. 
     Biological pesticides comprise bacteria such as spore-forming bacteria, root-colonising bacteria and bacteria which act as biological insecticides, fungicides or nematicides. 
     Examples of such bacteria which are employed or can be used as biological pesticides are: 
       Bacillus amyloliquefaciens , strain FZB42 (DSM 231179), or  Bacillus cereus , in particular  B. cereus  strain CNCM 1-1562 or  Bacillus firmus , strain 1-1582 (Accession number CNCM 1-1582) or  Bacillus pumilus , in particular strain GB34 (Accession No. ATCC 700814) and strain QST2808 (Accession No. NRRL B-30087), or  Bacillus subtilis , in particular strain GB03 (Accession No. ATCC SD-1397), or  Bacillus subtilis  strain QST713 (Accession No. NRRL B-21661) or  Bacillus subtilis  strain OST 30002 (Accession No. NRRL B-50421)  Bacillus thuringiensis , in particular  B. thuringiensis  subspecies  israelensis  (serotype H-14), strain AM65-52 (Accession No. ATCC 1276 ), or  B. thuringiensis  subsp.  aizawai , in particular strain ABTS-1857 (SD-1372), or  B. thuringiensis  subsp.  kurstaki  strain HD-1, or  B. thuringiensis  subsp.  tenebrionis  strain NB 176 (SD-5428),  Pasteuria penetrans, Pasteuria  spp. ( Rotylenchulus reniformis  nematode)-PR3 (Accession Number ATCC SD-5834),  Streptomyces microflavus  strain AQ6121 (=QRD 31.013, NRRL B-50550),  Streptomyces galbus  strain AQ 6047 (Acession Number NRRL 30232). 
     Examples of fungi and yeasts which are employed or can be used as biological pesticides are: 
       Beauveria bassiana , in particular strain ATCC 74040,  Coniothyrium minitans , in particular strain CON/M/91-8 (Accession No. DSM-9660),  Lecanicillium  spp., in particular strain HRO LEC12 , Lecanicillium lecanii , (formerly known as  Verticillium lecanii ), in particular strain KV01 , Metarhizium anisopliae , in particular strain F52 (DSM3884/ATCC 90448),  Metschnikowia fructicola , in particular strain NRRL Y-30752,  Paecilomyces fumosoroseus  (now:  Isaria fumosorosea ), in particular strain IFPC 200613, or strain Apopka 97 (Accesion No. ATCC 20874),  Paecilomyces lilacinus , in particular  P. lilacinus  strain 251 (AGAL 89/030550),  Talaromyces flavus , in particular strain V117b,  Trichoderma atroviride , in particular strain SC1 (Accession Number CBS 122089),  Trichoderma harzianum , in particular  T. harzianum rifai  T39. (Accession Number CNCM 1-952). 
     Examples of viruses which are employed or can be used as biological pesticides are: 
       Adoxophyes orana  (summer fruit  tortrix ) granulosis virus (GV),  Cydia pomonella  (codling moth) granulosis virus (GV),  Helicoverpa armigera  (cotton bollworm) nuclear polyhedrosis virus (NPV),  Spodoptera exigua  (beet armyworm) mNPV,  Spodoptera frugiperda  (fall armyworm) mNPV,  Spodoptera littoralis  (African cotton leafworm) NPV. 
     Also included are bacteria and fungi which are added as ‘inoculant’ to plants or plant parts or plant organs and which, by virtue of their particular properties, promote plant growth and plant health Examples which may be mentioned are: 
       Agrobacterium  spp.,  Azorhizobium caulinodans, Azospirillum  spp.,  Azotobacter  spp.,  Bradyrhizobium  spp.,  Burkholderia  spp., in particular  Burkholderia cepacia  (formerly known as  Pseudomonas cepacia ),  Gigaspora  spp., or  Gigaspora monosporum, Glomus  spp.,  Laccaria  spp.,  Lactobacillus buchneri, Paraglomus  spp.,  Pisolithus tinctorus, Pseudomonas  spp.,  Rhizobium  spp., in particular  Rhizobium trifolii, Rhizopogon  spp.,  Scleroderma  spp.,  Suillus  spp.,  Streptomyces  spp. 
     Examples of plant extracts and products formed by microorganisms including proteins and secondary metabolites which are employed or can be used as biological pesticides are: 
       Allium sativum, Artemisia absinthium , azadirachtin, Biokeeper WP,  Cassia nigricans, Celastrus angulatus, Chenopodium anthelminticum , chitin, Armour-Zen, Dryopteris filix-mas,  Equisetum arvense, Fortune Aza , Fungastop, Heads Up ( Chenopodium quinoa  saponin extract), Pyrethrum/Pyrethrins,  Quassia amara, Quercus, Quillaja, Regalia , “Requiem™ Insecticide”, rotenone, ryania/ryanodine,  Symphytum officinale, Tanacetum vulgare , thymol, Triact 70, TriCon,  Tropaeulum majus, Urtica dioica, Veratrin, Viscum album , Brassicaceae extract, in particular oilseed rape powder or mustard powder, as well as bioinsecticidal/acaricidal active substances obtained from olive oil, in particular unsaturated fatty/carboxylic acids having carbon chain lengths C 16 -C 20  as active ingredients, such as, for example, contained in the product with the trade name FLiPPER®. 
     Safener as Mixing Components 
     The compounds of the formula (I) can be combined with safeners such as, for example, benoxacor, cloquintocet (-mexyl), cyometrinil, cyprosulfamide, dichlormid, fenchlorazole (-ethyl), fenclorim, flurazole, fluxofenim, furilazole, isoxadifen (-ethyl), mefenpyr (-diethyl), naphthalic anhydride, oxabetrinil, 2-methoxy-N-({4-[(methylcarbamoyl)amino]phenyl}sulphonyl)benzamide (CAS 129531-12-0), 4-(dichloroacetyp-1-oxa-4-azaspiro[4.5]decane (CAS 71526-07-3), 2,2,5-trimethyl-3-(dichloroacetyp-1,3-oxazolidine (CAS 52836-31-4). 
     Plants and Plant Parts 
     All plants and plant parts can be treated in accordance with the invention. Here, plants are to be understood to mean all plants and plant parts such as wanted and unwanted wild plants or crop plants (including naturally occurring crop plants), for example cereals (wheat, rice, triticale, barley, rye, oats), maize, soya bean, potato, sugar beet, sugar cane, tomatoes, pepper, cucumber, melon, carrot, watermelon, onion, lettuce, spinach, leek, beans,  Brassica oleracea  (e.g. cabbage) and other vegetable species, cotton, tobacco, oilseed rape, and also fruit plants (with the fruits apples, pears, citrus fruits and grapevines). Crop plants can be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant varieties which can or cannot be protected by varietal property rights. Plants should be understood to mean all developmental stages, such as seeds, seedlings, young (immature) plants up to mature plants. Plant parts should be understood to mean all parts and organs of the plants above and below ground, such as shoot, leaf, flower and root, examples given being leaves, needles, stalks, stems, flowers, fruit bodies, fruits and seeds, and also tubers, roots and rhizomes. Parts of plants also include harvested plants or harvested plant parts and vegetative and generative propagation material, for example seedlings, tubers, rhizomes, cuttings and seeds. 
     Treatment according to the invention of the plants and plant parts with the compounds of the formula (I) is carried out directly or by allowing the compounds to act on the surroundings, environment or storage space by the customary treatment methods, for example by immersion, spraying, evaporation, fogging, scattering, painting on, injection and, in the case of propagation material, in particular in the case of seeds, also by applying one or more coats. 
     As already mentioned above, it is possible to treat all plants and their parts according to the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding methods, such as crossing or protoplast fusion, and also parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering methods, if appropriate in combination with conventional methods (genetically modified organisms), and parts thereof are treated. The term “parts” or “parts of plants” or “plant parts” has been explained above. The invention is used with particular preference to treat plants of the respective commercially customary cultivars or those that are in use. Plant cultivars are to be understood as meaning plants having new properties (“traits”) and which have been obtained by conventional breeding, by mutagenesis or by recombinant DNA techniques. They can be cultivars, varieties, bio- or genotypes. 
     Transgenic Plant, Seed Treatment and Integration Events 
     According to the invention, the compounds of formula (I) can be advantageously used to treat transgenic plants, plant cultivars or plant parts that received genetic material which imparts advantageous and/or useful properties (traits) to these plants, plant cultivars or plant parts. Therefore, it is contemplated that the present invention may be combined with one or more recombinant traits or transgenic event(s) or a combination thereof. For the purposes of this application, a transgenic event is created by the insertion of a specific recombinant DNA molecule into a specific position (locus) within the chromosome of the plant genome. The insertion creates a novel DNA sequence referred to as an “event” and is characterized by the inserted recombinant DNA molecule and some amount of genomic DNA immediately adjacent to/flanking both ends of the inserted DNA. Such trait(s) or transgenic event(s) include, but are not limited to, pest resistance, water use efficiency, yield performance, drought tolerance, seed quality, improved nutritional quality, hybrid seed production, and herbicide tolerance, in which the trait is measured with respect to a plant lacking such trait or transgenic event. Concrete examples of such advantageous and/or useful properties (traits) are better plant growth, vigor, stress tolerance, standability, lodging resistance, nutrient uptake, plant nutrition, and/or yield, in particular improved growth, increased tolerance to high or low temperatures, increased tolerance to drought or to levels of water or soil salinity, enhanced flowering performance, easier harvesting, accelerated ripening, higher yields, higher quality and/or a higher nutritional value of the harvested products, better storage life and/or processability of the harvested products, and increased resistance or tolerance against animal and microbial pests, such as against insects, arachnids, nematodes, mites, slugs and snails. 
     Among DNA sequences encoding proteins which confer properties of resistance or tolerance to such animal and microbial pests, in particular insects, mention will particularly be made of the genetic material from  Bacillus thuringiensis  encoding the Bt proteins widely described in the literature and well known to those skilled in the art. Mention will also be made of proteins extracted from bacteria such as  Photorhabdus  (WO97/17432 and WO98/08932). In particular, mention will be made of the Bt Cry or VIP proteins which include the Cry1A, CryIAb, CryIAc, CryIIA, CryIIIA, CryIIIB2, Cry9c Cry2Ab, Cry3Bb and CryIF proteins or toxic fragments thereof and also hybrids or combinations thereof, especially the Cry1F protein or hybrids derived from a Cry1F protein (e.g. hybrid Cry1A-Cry1F proteins or toxic fragments thereof), the Cry1A-type proteins or toxic fragments thereof, preferably the Cry1Ac protein or hybrids derived from the Cry1Ac protein (e.g. hybrid Cry1Ab-Cry1Ac proteins) or the Cry1Ab or Bt2 protein or toxic fragments thereof, the Cry2Ae, Cry2Af or Cry2Ag proteins or toxic fragments thereof, the Cry1A.105 protein or a toxic fragment thereof, the VIP3Aa19 protein, the VIP3Aa20 protein, the VIP3A proteins produced in the COT202 or COT203 cotton events, the VIP3Aa protein or a toxic fragment thereof as described in Estruch et al. (1996), Proc Natl Acad Sci US A. 28; 93(11):5389-94, the Cry proteins as described in WO2001/47952, the insecticidal proteins from Xenorhabdus (as described in WO98/50427),  Serratia  (particularly from  S. entomophila ) or  Photorhabdus  species strains, such as Tc-proteins from  Photorhabdus  as described in WO98/08932. Also any variants or mutants of any one of these proteins differing in some amino acids (1-10, preferably 1-5) from any of the above named sequences, particularly the sequence of their toxic fragment, or which are fused to a transit peptide, such as a plastid transit peptide, or another protein or peptide, is included herein. 
     Another and particularly emphasized example of such properties is conferred tolerance to one or more herbicides, for example imidazolinones, sulphonylureas, glyphosate or phosphinothricin. Among DNA sequences encoding proteins which confer properties of tolerance to certain herbicides on the transformed plant cells and plants, mention will be particularly be made to the bar or PAT gene or the  Streptomyces coelicolor  gene described in WO2009/152359 which confers tolerance to glufosinate herbicides, a gene encoding a suitable EPSPS (5-Enolpyruvylshikimat-3-phosphat-synthase) which confers tolerance to herbicides having EPSPS as a target, especially herbicides such as glyphosate and its salts, a gene encoding glyphosate-n-acetyltransferase, or a gene encoding glyphosate oxidoreductase. Further suitable herbicide tolerance traits include at least one ALS (acetolactate synthase) inhibitor (e.g. WO2007/024782), a mutated  Arabidopsis  ALS/AHAS gene (e.g. U.S. Pat. No. 6,855,533), genes encoding 2,4-D-monooxygenases conferring tolerance to 2,4-D (2,4-dichlorophenoxyacetic acid) and genes encoding Dicamba monooxygenases conferring tolerance to dicamba (3,6-dichloro-2-methoxybenzoic acid). 
     Further and particularly emphasized examples of such properties are increased resistance against phytopathogenic fungi, bacteria and/or viruses owing, for example, to systemic acquired resistance (SAR), systemin, phytoalexins, elicitors and also resistance genes and correspondingly expressed proteins and toxins. 
     Particularly useful transgenic events in transgenic plants or plant cultivars which can be treated with preference in accordance with the invention include Event 531/PV-GHBK04 (cotton, insect control, described in WO2002/040677), Event 1143-14A (cotton, insect control, not deposited, described in WO2006/128569); Event 1143-51B (cotton, insect control, not deposited, described in WO2006/128570); Event 1445 (cotton, herbicide tolerance, not deposited, described in US-A 2002-120964 or WO2002/034946); Event 17053 (rice, herbicide tolerance, deposited as PTA-9843, described in WO2010/117737); Event 17314 (rice, herbicide tolerance, deposited as PTA-9844, described in WO2010/117735); Event 281-24-236 (cotton, insect control-herbicide tolerance, deposited as PTA-6233, described in WO2005/103266 or US-A 2005-216969); Event 3006-210-23 (cotton, insect control-herbicide tolerance, deposited as PTA-6233, described in US-A 2007-143876 or WO2005/103266); Event 3272 (corn, quality trait, deposited as PTA-9972, described in WO2006/098952 or US-A 2006-230473); Event 33391 (wheat, herbicide tolerance, deposited as PTA-2347, described in WO2002/027004), Event 40416 (corn, insect control-herbicide tolerance, deposited as ATCC PTA-11508, described in WO 11/075593); Event 43A47 (corn, insect control-herbicide tolerance, deposited as ATCC PTA-11509, described in WO2011/075595); Event 5307 (corn, insect control, deposited as ATCC PTA-9561, described in WO2010/077816); Event ASR-368 (bent grass, herbicide tolerance, deposited as ATCC PTA-4816, described in US-A 2006-162007 or WO2004/053062); Event B16 (corn, herbicide tolerance, not deposited, described in US-A 2003-126634); Event BPS-CV127-9 (soybean, herbicide tolerance, deposited as NCIMB No. 41603, described in WO2010/080829); Event BLR1 (oilseed rape, restoration of male sterility, deposited as NCIMB 41193, described in WO2005/074671), Event CE43-67B (cotton, insect control, deposited as DSM ACC2724, described in US-A 2009-217423 or WO2006/128573); Event CE44-69D (cotton, insect control, not deposited, described in US-A 2010-0024077); Event CE44-69D (cotton, insect control, not deposited, described in WO2006/128571); Event CE46-02A (cotton, insect control, not deposited, described in WO2006/128572); Event COT102 (cotton, insect control, not deposited, described in US-A 2006-130175 or WO2004/039986); Event COT202 (cotton, insect control, not deposited, described in US-A 2007-067868 or WO2005/054479); Event COT203 (cotton, insect control, not deposited, described in WO2005/054480);); Event DAS21606-3/1606 (soybean, herbicide tolerance, deposited as PTA-11028, described in WO2012/033794), Event DAS40278 (corn, herbicide tolerance, deposited as ATCC PTA-10244, described in WO2011/022469); Event DAS-44406-6/pDAB8264.44.06.1 (soybean, herbicide tolerance, deposited as PTA-11336, described in WO2012/075426), Event DAS-14536-7/pDAB8291.45.36.2 (soybean, herbicide tolerance, deposited as PTA-11335, described in WO2012/075429), Event DAS-59122-7 (corn, insect control-herbicide tolerance, deposited as ATCC PTA 11384, described in US-A 2006-070139); Event DAS-59132 (corn, insect control-herbicide tolerance, not deposited, described in WO2009/100188); Event DAS68416 (soybean, herbicide tolerance, deposited as ATCC PTA-10442, described in WO2011/066384 or WO2011/066360); Event DP-098140-6 (corn, herbicide tolerance, deposited as ATCC PTA-8296, described in US-A 2009-137395 or WO 08/112019); Event DP-305423-1 (soybean, quality trait, not deposited, described in US-A 2008-312082 or WO2008/054747); Event DP-32138-1 (corn, hybridization system, deposited as ATCC PTA-9158, described in US-A 2009-0210970 or WO2009/103049); Event DP-356043-5 (soybean, herbicide tolerance, deposited as ATCC PTA-8287, described in US-A 2010-0184079 or WO2008/002872); Event EE-I (brinjal, insect control, not deposited, described in WO 07/091277); Event FiI 17 (corn, herbicide tolerance, deposited as ATCC 209031, described in US-A 2006-059581 or WO 98/044140); Event FG72 (soybean, herbicide tolerance, deposited as PTA-11041, described in WO2011/063413), Event GA21 (corn, herbicide tolerance, deposited as ATCC 209033, described in US-A 2005-086719 or WO 98/044140); Event GG25 (corn, herbicide tolerance, deposited as ATCC 209032, described in US-A 2005-188434 or WO98/044140); Event GHB119 (cotton, insect control-herbicide tolerance, deposited as ATCC PTA-8398, described in WO2008/151780); Event GHB614 (cotton, herbicide tolerance, deposited as ATCC PTA-6878, described in US-A 2010-050282 or WO2007/017186); Event GJ11 (corn, herbicide tolerance, deposited as ATCC 209030, described in US-A 2005-188434 or WO98/044140); Event GM RZ13 (sugar beet, virus resistance, deposited as NCIMB-41601, described in WO2010/076212); Event H7-1 (sugar beet, herbicide tolerance, deposited as NCIMB 41158 or NCIMB 41159, described in US-A 2004-172669 or WO 2004/074492); Event JOPLIN1 (wheat, disease tolerance, not deposited, described in US-A 2008-064032); Event LL27 (soybean, herbicide tolerance, deposited as NCIMB41658, described in WO2006/108674 or US-A 2008-320616); Event LL55 (soybean, herbicide tolerance, deposited as NCIMB 41660, described in WO 2006/108675 or US-A 2008-196127); Event LLcotton25 (cotton, herbicide tolerance, deposited as ATCC PTA-3343, described in WO2003/013224 or US-A 2003-097687); Event LLRICE06 (rice, herbicide tolerance, deposited as ATCC 203353, described in U.S. Pat. No. 6,468,747 or WO2000/026345); Event LLRice62 (rice, herbicide tolerance, deposited as ATCC 203352, described in WO2000/026345), Event LLRICE601 (rice, herbicide tolerance, deposited as ATCC PTA-2600, described in US-A 2008-2289060 or WO2000/026356); Event LY038 (corn, quality trait, deposited as ATCC PTA-5623, described in US-A 2007-028322 or WO2005/061720); Event MIR162 (corn, insect control, deposited as PTA-8166, described in US-A 2009-300784 or WO2007/142840); Event MIR604 (corn, insect control, not deposited, described in US-A 2008-167456 or WO2005/103301); Event MON15985 (cotton, insect control, deposited as ATCC PTA-2516, described in US-A 2004-250317 or WO2002/100163); Event MON810 (corn, insect control, not deposited, described in US-A 2002-102582); Event MON863 (corn, insect control, deposited as ATCC PTA-2605, described in WO2004/011601 or US-A 2006-095986); Event MON87427 (corn, pollination control, deposited as ATCC PTA-7899, described in WO2011/062904); Event MON87460 (corn, stress tolerance, deposited as ATCC PTA-8910, described in WO2009/111263 or US-A 2011-0138504); Event MON87701 (soybean, insect control, deposited as ATCC PTA-8194, described in US-A 2009-130071 or WO2009/064652); Event MON87705 (soybean, quality trait-herbicide tolerance, deposited as ATCC PTA-9241, described in US-A 2010-0080887 or WO2010/037016); Event MON87708 (soybean, herbicide tolerance, deposited as ATCC PTA-9670, described in WO2011/034704); Event MON87712 (soybean, yield, deposited as PTA-10296, described in WO2012/051199), Event MON87754 (soybean, quality trait, deposited as ATCC PTA-9385, described in WO2010/024976); Event MON87769 (soybean, quality trait, deposited as ATCC PTA-8911, described in US-A 2011-0067141 or WO2009/102873); Event MON88017 (corn, insect control-herbicide tolerance, deposited as ATCC PTA-5582, described in US-A 2008-028482 or WO2005/059103); Event MON88913 (cotton, herbicide tolerance, deposited as ATCC PTA-4854, described in WO2004/072235 or US-A 2006-059590); Event MON88302 (oilseed rape, herbicide tolerance, deposited as PTA-10955, described in WO2011/153186), Event MON88701 (cotton, herbicide tolerance, deposited as PTA-11754, described in WO2012/134808), Event MON89034 (corn, insect control, deposited as ATCC PTA-7455, described in WO 07/140256 or US-A 2008-260932); Event MON89788 (soybean, herbicide tolerance, deposited as ATCC PTA-6708, described in US-A 2006-282915 or WO2006/130436); Event MSI 1 (oilseed rape, pollination control-herbicide tolerance, deposited as ATCC PTA-850 or PTA-2485, described in WO2001/031042); Event MS8 (oilseed rape, pollination control-herbicide tolerance, deposited as ATCC PTA-730, described in WO2001/041558 or US-A 2003-188347); Event NK603 (corn, herbicide tolerance, deposited as ATCC PTA-2478, described in US-A 2007-292854); Event PE-7 (rice, insect control, not deposited, described in WO2008/114282); Event RF3 (oilseed rape, pollination control—herbicide tolerance, deposited as ATCC PTA-730, described in WO2001/041558 or US-A 2003-188347); Event RT73 (oilseed rape, herbicide tolerance, not deposited, described in WO2002/036831 or US-A 2008-070260); Event SYHT0H2/SYN-000H2-5 (soybean, herbicide tolerance, deposited as PTA-11226, described in WO2012/082548), Event T227-1 (sugar beet, herbicide tolerance, not deposited, described in WO2002/44407 or US-A 2009-265817); Event T25 (corn, herbicide tolerance, not deposited, described in US-A 2001-029014 or WO2001/051654); Event T304-40 (cotton, insect control-herbicide tolerance, deposited as ATCC PTA-8171, described in US-A 2010-077501 or WO2008/122406); Event T342-142 (cotton, insect control, not deposited, described in WO2006/128568); Event TC1507 (corn, insect control-herbicide tolerance, not deposited, described in US-A 2005-039226 or WO2004/099447); Event VIP1034 (corn, insect control-herbicide tolerance, deposited as ATCC PTA-3925, described in WO2003/052073), Event 32316 (corn, insect control-herbicide tolerance, deposited as PTA-11507, described in WO2011/084632), Event 4114 (corn, insect control-herbicide tolerance, deposited as PTA-11506, described in WO2011/084621), event EE-GM3/FG72 (soybean, herbicide tolerance, ATCC Accession No PTA-11041) optionally stacked with event EE-GM1/LL27 or event EE-GM2/LL55 (WO2011/063413A2), event DAS-68416-4 (soybean, herbicide tolerance, ATCC Accession No PTA-10442, WO2011/066360A1), event DAS-68416-4 (soybean, herbicide tolerance, ATCC Accession No PTA-10442, WO2011/066384A1), event DP-040416-8 (corn, insect control, ATCC Accession No PTA-11508, WO2011/075593A1), event DP-043A47-3 (corn, insect control, ATCC Accession No PTA-11509, WO2011/075595A1), event DP-004114-3 (corn, insect control, ATCC Accession No PTA-11506, WO2011/084621A1), event DP-032316-8 (corn, insect control, ATCC Accession No PTA-11507, WO2011/084632A1), event MON-88302-9 (oilseed rape, herbicide tolerance, ATCC Accession No PTA-10955, WO2011/153186A1), event DAS-21606-3 (soybean, herbicide tolerance, ATCC Accession No. PTA-11028, WO2012/033794A2), event MON-87712-4 (soybean, quality trait, ATCC Accession No. PTA-10296, WO2012/051199A2), event DAS-44406-6 (soybean, stacked herbicide tolerance, ATCC Accession No. PTA-11336, WO2012/075426A1), event DAS-14536-7 (soybean, stacked herbicide tolerance, ATCC Accession No. PTA-11335, WO2012/075429A1), event SYN-000H2-5 (soybean, herbicide tolerance, ATCC Accession No. PTA-11226, WO2012/082548A2), event DP-061061-7 (oilseed rape, herbicide tolerance, no deposit No available, WO2012071039A1), event DP-073496-4 (oilseed rape, herbicide tolerance, no deposit No available, US2012131692), event 8264.44.06.1 (soybean, stacked herbicide tolerance, Accession No PTA-11336, WO2012075426A2), event 8291.45.36.2 (soybean, stacked herbicide tolerance, Accession No. PTA-11335, WO2012075429A2), event SYHT0H2 (soybean, ATCC Accession No. PTA-11226, WO2012/082548A2), event MON88701 (cotton, ATCC Accession N° PTA-11754, WO2012/134808A1), event KK179-2 (alfalfa, ATCC Accession No PTA-11833, 
     WO2013/003558A1), event pDAB8264.42.32.1 (soybean, stacked herbicide tolerance, ATCC Accession No PTA-11993, WO2013/010094A1), event MZDTO9Y (corn, ATCC Accession No PTA-13025, WO2013/012775A1). 
     Further, a list of such transgenic event(s) is provided by the United States Department of Agriculture&#39;s (USDA) Animal and Plant Health Inspection Service (APHIS) and can be found on their website on the world wide web at aphis.usda.gov. For this application, the status of such list as it is/was on the filing date of this application, is relevant. 
     The genes/events which impart the desired traits in question may also be present in combinations with one another in the transgenic plants. Examples of transgenic plants which may be mentioned are the important crop plants, such as cereals (wheat, rice, triticale, barley, rye, oats), maize, soya beans, potatoes, sugar beet, sugar cane, tomatoes, peas and other types of vegetable, cotton, tobacco, oilseed rape and also fruit plants (with the fruits apples, pears, citrus fruits and grapes), with particular emphasis being given to maize, soya beans, wheat, rice, potatoes, cotton, sugar cane, tobacco and oilseed rape. Traits which are particularly emphasized are the increased resistance of the plants to insects, arachnids, nematodes and slugs and snails, as well as the increased resistance of the plants to one or more herbicides. 
     Commercially available examples of such plants, plant parts or plant seeds that may be treated with preference in accordance with the invention include commercial products, such as plant seeds, sold or distributed under the GENUITY®, DROUGHTGARD®, SMARTSTAX®, RIB COMPLETE®, ROUNDUP READY®, VT DOUBLE PRO®, VT TRIPLE PRO®, BOLLGARD II®, ROUNDUP READY 2 YIELD®, YIELDGARD®, ROUNDUP READY® 2 XTEN D ™, INTACTA RR2 PRO®, VISTIVE GOLD®, and/or XTENDFLEX™ trade names. 
     Crop Protection—Types of Treatment 
     The treatment of the plants and plant parts with the compounds of the formula (I) is carried out directly or by action on their surroundings, habitat or storage space using customary treatment methods, for example by dipping, spraying, atomizing, irrigating, evaporating, dusting, fogging, broadcasting, foaming, painting, spreading-on, injecting, watering (drenching), drip irrigating and, in the case of propagation material, in particular in the case of seed, furthermore as a powder for dry seed treatment, a solution for liquid seed treatment, a water-soluble powder for slurry treatment, by incrusting, by coating with one or more coats, etc. It is furthermore possible to apply the compounds of the formula (I) by the ultra-low volume method or to inject the application form or the compound of the formula (I) itself into the soil. 
     A preferred direct treatment of the plants is foliar application, i.e. the compounds of the formula (I) are applied to the foliage, where treatment frequency and the application rate should be adjusted according to the level of infestation with the pest in question. 
     In the case of systemically active compounds, the compounds of the formula (I) also access the plants via the root system. The plants are then treated by the action of the compounds of the formula (I) on the habitat of the plant. This may be done, for example, by drenching, or by mixing into the soil or the nutrient solution, i.e. the locus of the plant (e.g. soil or hydroponic systems) is impregnated with a liquid form of the compounds of the formula (I), or by soil application, i.e. the compounds of the formula (I) according to the invention are introduced in solid form (e.g. in the form of granules) into the locus of the plants, or by drip application (often also referred to as “chemigation”), i.e. the liquid application of the compounds of the formula (I) according to the invention from surface or sub-surface driplines over a certain period of time together with varying amounts of water at defined locations in the vicinity of the plants. In the case of paddy rice crops, this can also be done by metering the compound of the formula (I) in a solid application form (for example as granules) into a flooded paddy field. 
     Digital Technologies 
     The compounds of the invention can be used in combination with models e.g. embedded in computer programs for site specific crop management, satellite farming, precision farming or precision agriculture. Such models support the site specific management of agricultural sites with data from various sources such as soils, weather, crops (e.g. type, growth stage, plant health), weeds (e.g. type, growth stage), diseases, pests, nutrients, water, moisture, biomass, satellite data, yield etc. with the purpose to optimize profitability, sustainability and protection of the environment. In particular, such models can help to optimize agronomical decisions, control the precision of pesticide applications and record the work performed. 
     As an example, the compounds of the invention can be applied to a crop plant according to an appropriate dose regime if a model models the development of a pest and calculates that a threshold has been reached for which it is recommendable to apply the compound of the invention to the crop plant. 
     Commercially available systems which include agronomic models are e.g. FieldScripts™ from The Climate Corporation, Xarvio™ from BASF, AGLogic™ from John Deere, etc. 
     The compounds of the invention can also be used in combination with smart spraying equipment such as e.g. spot spraying or precision spraying equipment attached to or housed within a farm vehicle such as a tractor, robot, helicopter, airplane, unmanned aerial vehicle (UAV) such as a drone, etc. Such an equipment usually includes input sensors (such as e.g. a camera) and a processing unit configured to analyze the input data and configured to provide a decision based on the analysis of the input data to apply the compound of the invention to the crop plants (respectively the weeds) in a specific and precise manner. The use of such smart spraying equipment usually also requires positions systems (e.g. GPS receivers) to localize recorded data and to guide or to control farm vehicles; geographic information systems (GIS) to represent the information on intelligible maps, and appropriate farm vehicles to perform the required farm action such as the spraying. 
     In an example, pests can be detected from imagery acquired by a camera. In an example the pests can be identified and/or classified based on that imagery. Such identification and/classification can make use of image processing algorithms. Such image processing algorithms can utilize machine learning algorithms, such as trained neutral networks, decision trees and utilize artificial intelligence algorithms. In this manner, the compounds described herein can be applied only where needed. 
     Treatment of Seed 
     The control of animal pests by treating the seed of plants has been known for a long time and is the subject of continuous improvements. However, the treatment of seed entails a series of problems which cannot always be solved in a satisfactory manner Thus, it is desirable to develop methods for protecting the seed and the germinating plant which dispense with, or at least reduce considerably, the additional application of pesticides during storage, after sowing or after emergence of the plants. It is furthermore desirable to optimize the amount of active compound employed in such a way as to provide optimum protection for the seed and the germinating plant from attack by animal pests, but without damaging the plant itself by the active compound employed. In particular, methods for the treatment of seed should also take into consideration the intrinsic insecticidal or nematicidal properties of pest-resistant or -tolerant transgenic plants in order to achieve optimum protection of the seed and also the germinating plant with a minimum of pesticides being employed. 
     The present invention therefore in particular also relates to a method for the protection of seed and germinating plants, from attack by pests, by treating the seed with one of the compounds of the formula (I). The method according to the invention for protecting seed and germinating plants against attack by pests furthermore comprises a method where the seed is treated simultaneously in one operation or sequentially with a compound of the formula (I) and a mixing component. It also comprises a method where the seed is treated at different times with a compound of the formula (I) and a mixing component. The invention likewise relates to the use of the compounds of the formula (I) for the treatment of seed for protecting the seed and the resulting plant from animal pests. 
     Furthermore, the invention relates to seed which has been treated with a compound of the formula (I) according to the invention so as to afford protection from animal pests. The invention also relates to seed which has been treated simultaneously with a compound of the formula (I) and a mixing component. The invention furthermore relates to seed which has been treated at different times with a compound of the formula (I) and a mixing component. In the case of seed which has been treated at different points in time with a compound of the formula (I) and a mixing component, the individual substances may be present on the seed in different layers. Here, the layers comprising a compound of the formula (I) and mixing components may optionally be separated by an intermediate layer. The invention also relates to seed where a compound of the formula (I) and a mixing component have been applied as component of a coating or as a further layer or further layers in addition to a coating. 
     Furthermore, the invention relates to seed which, after the treatment with a compound of the formula (I), is subjected to a film-coating process to prevent dust abrasion on the seed. 
     One of the advantages encountered with a systemically acting compound of the formula (I) is the fact that, by treating the seed, not only the seed itself but also the plants resulting therefrom are, after emergence, protected against animal pests. In this manner, the immediate treatment of the crop at the time of sowing or shortly thereafter can be dispensed with. 
     It has to be considered a further advantage that by treatment of the seed with a compound of the formula (I), germination and emergence of the treated seed may be enhanced. 
     It is likewise to be considered advantageous that compounds of the formula (I) can be used in particular also for transgenic seed. 
     Furthermore, compounds of the formula (I) can be employed in combination with compositions or compounds of signalling technology, leading to better colonization by symbionts such as, for example, rhizobia, mycorrhizae and/or endophytic bacteria or fungi, and/or to optimized nitrogen fixation. 
     The compounds of the formula (I) are suitable for protection of seed of any plant variety which is used in agriculture, in the greenhouse, in forests or in horticulture. In particular, this takes the form of seed of cereals (for example wheat, barley, rye, millet and oats), corn, cotton, soya beans, rice, potatoes, sunflowers, coffee, tobacco, canola, oilseed rape, beets (for example sugarbeets and fodder beets), peanuts, vegetables (for example tomatoes, cucumbers, bean, cruciferous vegetables, onions and lettuce), fruit plants, lawns and ornamental plants. The treatment of the seed of cereals (such as wheat, barley, rye and oats), maize, soya beans, cotton, canola, oilseed rape, vegetables and rice is of particular importance. 
     As already mentioned above, the treatment of transgenic seed with a compound of the formula (I) is also of particular importance. This takes the form of seed of plants which, as a rule, comprise at least one heterologous gene which governs the expression of a polyeptide with in particular insecticidal and/or nematicidal properties. The heterologous genes in transgenic seed can originate from microorganisms such as  Bacillus, Rhizobium, Pseudomonas, Serratia, Trichoderma, Clavibacter, Glomus  or  Gliocladium . The present invention is particularly suitable for the treatment of transgenic seed which comprises at least one heterologous gene originating from  Bacillus  sp. It is particularly preferably a heterologous gene derived from  Bacillus thuringiensis.    
     In the context of the present invention, the compound of the formula (I) is applied to the seed. Preferably, the seed is treated in a state in which it is stable enough to avoid damage during treatment. In general, the seed may be treated at any point in time between harvest and sowing. The seed usually used has been separated from the plant and freed from cobs, shells, stalks, coats, hairs or the flesh of the fruits. For example, it is possible to use seed which has been harvested, cleaned and dried down to a moisture content which allows storage. Alternatively, it is also possible to use seed which, after drying, has been treated with, for example, water and then dried again, for example priming. In the case of rice seed, it is also possible to use seed which has been soaked, for example in water to a certain stage of the rice embryo (‘pigeon breast stage’), stimulating the germination and a more uniform emergence. 
     When treating the seed, care must generally be taken that the amount of the compound of the formula (I) applied to the seed and/or the amount of further additives is chosen in such a way that the germination of the seed is not adversely affected, or that the resulting plant is not damaged. This must be ensured particularly in the case of active compounds which can exhibit phytotoxic effects at certain application rates. 
     In general, the compounds of the formula (I) are applied to the seed in a suitable formulation. Suitable formulations and processes for seed treatment are known to the person skilled in the art. 
     The compounds of the formula (I) can be converted to the customary seed dressing formulations, such as solutions, emulsions, suspensions, powders, foams, slurries or other coating compositions for seed, and also ULV formulations. 
     These formulations are prepared in a known manner, by mixing the compounds of the formula (I) with customary additives such as, for example, customary extenders and also solvents or diluents, colorants, wetting agents, dispersants, emulsifiers, antifoams, preservatives, secondary thickeners, adhesives, gibberellins and also water. 
     Colorants which may be present in the seed-dressing formulations which can be used in accordance with the invention are all colorants which are customary for such purposes. It is possible to use either pigments, which are sparingly soluble in water, or dyes, which are soluble in water. Examples include the dyes known by the names Rhodamine B, C.I. Pigment Red 112 and C.I. Solvent Red 1. 
     Useful wetting agents which may be present in the seed dressing formulations usable in accordance with the invention are all substances which promote wetting and which are conventionally used for the formulation of agrochemically active compounds. Preference is given to using alkylnaphthalenesulphonates, such as diisopropyl- or diisobutylnaphthalenesulphonates. 
     Useful dispersants and/or emulsifiers which may be present in the seed dressing formulations usable in accordance with the invention are all nonionic, anionic and cationic dispersants conventionally used for the formulation of active agrochemical ingredients. Preference is given to using nonionic or anionic dispersants or mixtures of nonionic or anionic dispersants. Suitable nonionic dispersants include in particular ethylene oxide/propylene oxide block polymers, alkylphenol polyglycol ethers and tristryrylphenol polyglycol ethers, and the phosphated or sulphated derivatives thereof. Suitable anionic dispersants are in particular lignosulphonates, polyacrylic acid salts and arylsulphonate/formaldehyde condensates. 
     Antifoams which may be present in the seed dressing formulations usable in accordance with the invention are all foam-inhibiting substances conventionally used for the formulation of active agrochemical ingredients. Preference is given to using silicone antifoams and magnesium stearate. 
     Preservatives which may be present in the seed dressing formulations usable in accordance with the invention are all substances usable for such purposes in agrochemical compositions. Examples include dichlorophene and benzyl alcohol hemiformal. 
     Secondary thickeners which may be present in the seed dressing formulations usable in accordance with the invention are all substances which can be used for such purposes in agrochemical compositions. 
     Cellulose derivatives, acrylic acid derivatives, xanthan, modified clays and finely divided silica are preferred. 
     Adhesives which may be present in the seed dressing formulations usable in accordance with the invention are all customary binders usable in seed dressing products. Polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose may be mentioned as being preferred. 
     Gibberellins which can be present in the seed-dressing formulations which can be used in accordance with the invention are preferably the gibberellins A1, A3 (=gibberellic acid), A4 and A7; gibberellic acid is especially preferably used. The gibberellins are known (cf. R. Wegler “Chemie der Pflanzenschutz- and Schadlingsbekampfungsmittel”, vol. 2, Springer Verlag, 1970, pp. 401-412). 
     The seed dressing formulations usable in accordance with the invention can be used to treat a wide variety of different kinds of seed either directly or after prior dilution with water. For instance, the concentrates or the preparations obtainable therefrom by dilution with water can be used to dress the seed of cereals, such as wheat, barley, rye, oats, and triticale, and also the seed of maize, rice, oilseed rape, peas, beans, cotton, sunflowers, soya beans and beets, or else a wide variety of different vegetable seed. The seed dressing formulations usable in accordance with the invention, or the dilute use forms thereof, can also be used to dress seed of transgenic plants. 
     For treatment of seed with the seed dressing formulations usable in accordance with the invention, or the use forms prepared therefrom by adding water, all mixing units usable customarily for the seed dressing are useful. Specifically, the procedure in the seed dressing is to place the seed into a mixer, operated batch-wise or continously, to add the particular desired amount of seed dressing formulations, either as such or after prior dilution with water, and to mix everything until the formulation is distributed homogeneously on the seed. If appropriate, this is followed by a drying operation. 
     The application rate of the seed dressing formulations usable in accordance with the invention can be varied within a relatively wide range. It is guided by the particular content of the compounds of the formula (I) in the formulations and by the seed. The application rates of the compound of the formula (I) are generally between 0.001 and 50 g per kilogram of seed, preferably between 0.01 and 15 g per kilogram of seed. 
     Animal Health 
     In the animal health field, i.e. in the field of veterinary medicine, the compounds of the formula (I) are active against animal parasites, in particular ectoparasites or endoparasites. The term endoparasite includes in particular helminths and protozoae, such as coccidia. Ectoparasites are typically and preferably arthropods, in particular insects or acarids. 
     In the field of veterinary medicine the compounds of the formula (I) are suitable, with favourable toxicity in warm blooded animals, for controlling parasites which occur in animal breeding and animal husbandry in livestock, breeding, zoo, laboratory, experimental and domestic animals They are active against all or specific stages of development of the parasites. 
     Agricultural livestock include, for example, mammals, such as, sheep, goats, horses, donkeys, camels, buffaloes, rabbits, reindeers, fallow deers, and in particular cattle and pigs; or poultry, such as turkeys, ducks, geese, and in particular chickens; or fish or crustaceans, e.g. in aquaculture; or, as the case may be, insects such as bees. 
     Domestic animals include, for example, mammals, such as hamsters, guinea pigs, rats, mice, chinchillas, ferrets or in particular dogs, cats; cage birds; reptiles; amphibians or aquarium fish. 
     According to a particular embodiment, the compounds of the formula (I) are administered to mammals. 
     According to another particular embodiment, the compounds of the formula (I) are administered to birds, namely cage birds or in particular poultry. 
     By using the compounds of the formula (I) to control animal parasites, it is intended to reduce or prevent illness, cases of deaths and performance reductions (in the case of meat, milk, wool, hides, eggs, honey and the like), so that more economical and simpler animal keeping is made possible and better animal well-being is achievable. 
     The term “control” or “controlling”, as used herein with regard to the animal health field, means that the compounds of the formula (I) are effective in reducing the incidence of the respective parasite in an animal infected with such parasites to innocuous levels. More specifically, “controlling”, as used herein, means that the compounds of the formula (I) are effective in killing the respective parasite, inhibiting its growth, or inhibiting its proliferation. 
     Exemplary arthropods include, without any limitation from the order of the Anoplurida, for example,  Haematopinus  spp.,  Linognathus  spp.,  Pediculus  spp.,  Phtirus  spp.,  Solenopotes  spp.; 
     from the order of the Mallophagida and the suborders Amblycerina and Ischnocerina, for example  Bovicola  spp.,  Damalina  spp.,  Felicola  spp.,  Lepikentron  spp.,  Menopon  spp.,  Trichodectes  spp.,  Trimenopon  spp.,  Trinoton  spp.,  Werneckiella  spp.; 
     from the order of the Diptera and the suborders Nematocerina and Brachycerina, for example  Aedes  spp.,  Anopheles  spp.,  Atylotus  spp.,  Braula  spp.,  Calliphora  spp.,  Chrysomyia  spp.,  Chrysops  spp.,  Culex  spp.,  Culicoides  spp.,  Eusimulium  spp.,  Fannia  spp.,  Gasterophilus  spp.,  Glossina  spp.,  Haematobia  spp.,  Haematopota  spp.,  Hippobosca  spp.,  Hybomitra  spp.,  Hydrotaea  spp.,  Hyl ) oderma  spp.,  Lipoptena  spp.,  Lucilia  spp.,  Lutzomyia  spp.,  Melophagus  spp.,  Morellia  spp.,  Musca  spp.,  Odagmia  spp.,  Oestrus  spp.,  Philipomyia  spp.,  Phlebotomus  spp.,  Rhinoestrus  spp.,  Sarcophaga  spp.,  Simulium  spp.,  Stomoxys  spp.,  Tabanus  spp.,  Tipula  spp.,  Wilhelmia  spp.,  Wohlfahrtia  spp. 
     from the order of the Siphonapterida, for example  Ceratophyllus  spp.;  Ctenocephalides  spp.,  Pulex  spp.,  Tunga  spp.,  Xenopsylla  spp.; 
     from the order of the Heteropterida, for example  Cimex  spp.,  Panstrongylus  spp.,  Rhodnius  spp.,  Triatoma  spp.; as well as nuisance and hygiene pests from the order of the Blattarida. 
     Further, among the arthropods, the following acari may be mentioned by way of example, without any limitation: 
     from the subclass of the Acari (Acarina) and the order of the Metastigmata, for example, from the family of argasidae like  Argas  spp.,  Ornithodorus  spp.,  Otobius  spp., from the family of Ixodidae like  Amblyomma  spp.,  Dermacentor  spp.,  Haemaphysalis  spp.,  Hyalomma  spp.,  Ixodes  spp.,  Rhipicephalus  ( Boophilus ) spp,  Rhipicephalus  spp. (the original genus of multi host ticks); from the order of mesostigmata like  Dermanyssus  spp.,  Ornithonyssus  spp.,  Pneumonyssus  spp.,  Raillietia  spp.,  Sternostoma  spp.,  Tropilaelaps  spp.,  Varroa  spp.; from the order of the Actinedida (Prostigmata), for example  Acarapis  spp.,  Cheyletiella  spp.,  Demodex  spp.,  Listrophorus  spp.,  Myobia  spp.,  Neotrombicula  spp.,  Ornithocheyletia  spp.,  Psorergates  spp.,  Trombicula  spp.; and from the order of the Acaridida (Astigmata), for example  Acarus  spp.,  Caloglyphus  spp.,  Chorioptes  spp.,  Cytodites  spp.,  Hypodectes  spp.,  Knemidocoptes  spp.,  Laminosioptes  spp.,  Notoedres  spp.,  Otodectes  spp.,  Psoroptes  spp.,  Pterolichus  spp.,  Sarcoptes  spp.,  Trixacarus  spp.,  Tyrophagus  spp. 
     Exemplary parasitic protozoa include, without any limitation: 
     Mastigophora ( Flagellata ) such as: 
     Metamonada: from the order Diplomonadida, for example,  Giardia  spp.,  Spironucleus  spp. 
     Parabasala: from the order Trichomonadida, for example,  Histomonas  spp.,  Pentatrichomonas  spp., Tetratrichomonas  spp.,  Trichomonas  spp.,  Tritrichomonas  spp. 
     Euglenozoa: from the order Trypanosomatida, for example,  Leishmania  spp.,  Trypanosoma  spp Sarcomastigophora ( Rhizopoda ), such as Entamoebidae, for example,  Entamoeba  spp., Centramoebidae, for example,  Acanthamoeba  sp., Euamoebidae, e.g.  Hartmanella  sp. 
     Alveolata such as Apicomplexa (Sporozoa): e.g.  Cryptosporidium  spp.; from the order Eimeriida, for example,  Besnoitia  spp.,  Cystoisospora  spp.,  Eimeria  spp.,  Hammondia  spp.,  Isospora  spp.,  Neospora  spp.,  Sarcocystis  spp.,  Toxoplasma  spp.; from the order Adeleida e.g.  Hepatozoon  spp., Klossiella spp.; from the order Haemosporida e.g. Leucocytozoon spp.,  Plasmodium  spp.; from the order Piroplasmida e.g.  Babesia  spp.,  Ciliophora  spp.,  Echinozoon  spp.,  Theileria  spp.; from the order Vesibuliferida e.g.  Balantidium  spp.,  Buxtonella  spp. 
       Microspora  such as  Encephalitozoon  spp.,  Enterocytozoon  spp.,  Globidium  spp.,  Nosema  spp., and furthermore, e.g.  Myxozoa  spp. 
     Helminths pathogenic for humans or animals include, for example, acanthocephala, nematodes, pentastoma and platyhelmintha (e.g. monogenea, cestodes and trematodes). 
     Exemplary helminths include, without any limitation: 
     Monogenea: e.g.:  Dactylogyrus  spp.,  Gyrodactylus  spp.,  Microbothrium  spp.,  Polystoma  spp.,  Troglocephalus  spp. 
     Cestodes: from the order of the Pseudophyllidea, for example:  Bothridium  spp.,  Diphyllobothrium  spp.,  Diplogonoporus  spp.,  Ichthyobothrium  spp.,  Ligula  spp.,  Schistocephalus  spp.,  Spirometra  spp. 
     from the order of the Cyclophyllida, for example:  Andyra  spp.,  Anoplocephala  spp.,  Avitellina  spp.,  Bertiella  spp.,  Cittotaenia  spp.,  Davainea  spp.,  Diorchis  spp.,  Diplopylidium  spp.,  Dipylidium  spp.,  Echinococcus  spp.,  Echinocotyle  spp.,  Echinolepis  spp.,  Hydatigera  spp.,  Hymenolepis  spp.,  Joyeuxiella  spp.,  Mesocestoides  spp.,  Moniezia  spp.,  Paranoplocephala  spp.,  Raillietina  spp.,  Stilesia  spp.,  Taenia  spp.,  Thysaniezia  spp.,  Thysanosoma  spp. 
     Trematodes: from the class of the Digenea, for example:  Austrobilharzia  spp.,  Brachylaima  spp.,  Calicophoron  spp.,  Catatropis  spp.,  Clonorchis  spp.  Collyriclum  spp.,  Cotylophoron  spp.,  Cyclocoelum  spp.,  Dicrocoelium  spp.,  Diplostomum  spp.,  Echinochasmus  spp.,  Echinoparyphium  spp.,  Echinostoma  spp.,  Eurytrema  spp.,  Fasciola  spp.,  Fasciolides  spp.,  Fasciolopsis  spp.,  Fischoederius  spp.,  Gastrothylacus  spp.,  Gigantobilharzia  spp.,  Gigantocotyle  spp.,  Heterophyes  spp.,  Hypoderaeum  spp.,  Leucochloridium  spp.,  Metagonimus  spp.,  Metorchis  spp.,  Nanophyetus  spp.,  Notocotylus  spp.,  Opisthorchis  spp.,  Ornithobilharzia  spp.,  Paragonimus  spp.,  Paramphistomum  spp.,  Plagiorchis  spp.,  Posthodiplostomum  spp.,  Prosthogonimus  spp.,  Schistosoma  spp.,  Trichobilharzia  spp.,  Troglotrema  spp.,  Typhlocoelum  spp. 
     Nematodes: from the order of the Trichinellida, for example:  Capillaria  spp.,  Eucoleus  spp.,  Paracapillaria  spp.,  Trichinella  spp.,  Trichomosoides  spp.,  Trichuris  spp. 
     from the order of the Tylenchida, for example: Micronema spp., Parastrongyloides spp.,  Strongyloides  spp. 
     from the order of the Rhabditina, for example:  Aelurostrongylus  spp.,  Amidostomum  spp.,  Ancylostoma  spp.,  Angiostrongylus  spp.,  Bronchonema  spp.,  Bunostomum  spp.,  Chabertia  spp.,  Cooperia  spp.,  Cooperioides  spp.,  Crenosoma  spp.,  Cyathostomum  spp.,  Cyclococercus  spp.,  Cyclodontostomum  spp.,  Cylicocyclus  spp.,  Cylicostephanus  spp.,  Cylindropharynx  spp.,  Cystocaulus  spp.,  Dictyocaulus  spp.,  Elaphostrongylus  spp.,  Filaroides  spp.,  Globocephalus  spp.,  Graphidium  spp.,  Gyalocephalus  spp.,  Haemonchus  spp.,  Heligmosomoides  spp.,  Hyostrongylus  spp.,  Marshallagia  spp.,  Metastrongylus  spp.,  Muellerius  spp.,  Necator  spp.,  Nematodirus  spp.,  Neostrongylus  spp.,  Nippostrongylus  spp.,  Obeliscoides  spp.,  Oesophagodontus  spp.,  Oesophagostomum  spp.,  Ollulanus  spp.;  Ornithostrongylus  spp.,  Oslerus  spp.,  Ostertagia  spp.,  Paracooperia  spp.,  Paracrenosoma  spp.,  Parafilaroides  spp.,  Parelaphostrongylus  spp.,  Pneumocaulus  spp.,  Pneumostrongylus  spp.,  Poteriostomum  spp.,  Protostrongylus  spp.,  Spicocaulus  spp.,  Stephanurus  spp.,  Strongylus  spp.,  Syngamus  spp.,  Teladorsagia  spp.,  Trichonema  spp.,  Trichostrongylus  spp.,  Triodontophorus  spp.,  Troglostrongylus  spp.,  Uncinaria  spp. 
     from the order of the Spirurida, for example  Acanthocheilonema  spp.,  Anisakis  spp.,  Ascaridia  spp.;  Ascaris  spp.,  Ascarops  spp.,  Aspiculuris  spp.,  Baylisascaris  spp.,  Brugia  spp.,  Cercopithifilaria  spp.,  Crassicauda  spp.,  Dipetalonema  spp.,  Dirofilaria  spp.,  Dracunculus  spp.;  Draschia  spp.,  Enterobius  spp.,  Filaria  spp.,  Gnathostoma  spp.,  Gongylonema  spp.,  Habronema  spp.,  Heterakis  spp.;  Litomosoides  spp.,  Loa  spp.,  Onchocerca  spp.,  Oxyuris  spp.,  Parabronema  spp.,  Parafilaria  spp.,  Parascaris  spp.,  Passalurus  spp.,  Physaloptera  spp.,  Probstmayria  spp.,  Pseudofilaria  spp.,  Setaria  spp.,  Skjrabinema  spp.,  Spirocerca  spp.,  Stephanofilaria  spp.,  Strongyluris  spp.,  Syphacia  spp.,  Thelazia  spp.,  Toxascaris  spp.,  Toxocara  spp.,  Wuchereria  spp. 
     Acantocephala: from the order of the Oligacanthorhynchida, for example:  Macracanthorhynchus  spp.,  Prosthenorchis  spp.; from the order of the Moniliformida, for example:  Moniliformis  spp. 
     from the order of the Polymorphida, for example:  Filicollis  spp.; from the order of the Echinorhynchida, for example:  Acanthocephalus  spp.,  Echinorhynchus  spp.,  Leptorhynchoides  spp. 
     Pentastoma: from the order of the Porocephalida, for example  Linguatula  spp. 
     In the veterinary field and in animal keeping, the administration of the compounds of the formula (I) is carried out by methods generally known in the art, such as enterally, parenterally, dermally or nasally, in the form of suitable preparations. Administration can be carried out prophylactically, methaphylactically or therapeutically. 
     Thus, one embodiment of the present invention refers to the compounds of the formula (I) for use as a medicament. 
     Another aspect refers to the compounds of the formula (I) for use as an antiendoparasitical agent. 
     Another particular aspect refers to the compounds of the formula (I) for use as a anthelmintic agent, more particular for use as a nematicidal agent, a platyhelminthicidal agent, an acanthocephalicidal agent, or a pentastomicidal agent. 
     Another particular aspect refers to the compounds of the formula (I) for use as an antiprotozoal agent. 
     Another aspect refers to the compounds of the formula (I) for use as an antiectoparasitical agent, in particular an arthropodicidal agent, more particular an insecticidal agent or acaricidal agent. 
     Further aspects of the invention are veterinary formulations, comprising an effective amount of at least one compound of the formula (I) and at least one of the following: pharmaceutically acceptable excipient (e.g. solid or liquid diluents), pharmaceutically acceptable auxiliary (e.g. surfactants), in particular a pharmaceutically acceptable excipient and/or pharmaceutically acceptable auxiliary which is normally used in veterinary formulations. 
     A related aspect of the invention is a method for preparing a veterinary formulation as described herein, comprising the step of mixing at least one compound of the formula (I) with pharmaceutically acceptable excipients and/or auxiliaries, in particular with pharmaceutically acceptable excipients and/or auxiliaries which are normally used in veterinary formulations. 
     Another particular aspect of the invention are veterinary formulations, selected from the group of ectoparasiticidal and endoparasiticidal formulations, more particular selected from the group of anthelmintic, antiprotozoal, and arthropodicidal formulations, even more particular selected from the group of nematicidal, platyhelminthicidal, acanthocephalicidal, pentastomicidal, insecticidal, and acaricidal formulations, in accordance with the mentioned aspects, as well as their methods for preparation. 
     Another aspect refers to a method for treatment of a parasitic infection, in particular an infection by a parasite selected from the group of ectoparasites and endoparasites mentioned herein, by applying an effective amount of a compound of the formula (I) to an animal, in particular a non-human animal, in need thereof. 
     Another aspect refers to a method for treatment of a parasitic infection, in particular an infection by a parasite selected from the group of ectoparasites and endoparasites mentioned herein, by applying a veterinary formulation as defined herein to an animal, in particular a non-human animal, in need thereof. 
     Another aspect refers to the use of the compounds of the formula (I) in the treatment of a parasitic infection, in particular an infection by a parasite selected from the group of ectoparasites and endoparasites mentioned herein, in an animal, in particular a non-human animal 
     In the present context of the animal health or veterinary field, the term “treatment” includes prophylactic, metaphylactic or therapeutical treatment. 
     In a particular embodiment, mixtures of at least one compound of the formula (I) with other active ingredients, particularly with endo- and ectoparasiticides, for the veterinary field are provided herewith. 
     In the field of animal health “mixture” not only means that two (or more) different active ingredients are formulated in a joint formulation and are accordingly applied together but also refers to products which comprise separate formulations for each active compound. Accordingly, if more than two active compounds are to be applied, all active compounds may be formulated in a joint formulation or all active compounds may be formulated in separate formulations; also feasible are mixed forms where some of the active compounds are formulated jointly and some of the active compounds are formulated separately. Separate formulations allow the separate or successive application of the active compounds in question. 
     The active compounds specified herein by their common names are known and described, for example, in the Pesticide Manual (see above) or can be searched in the internet (e.g. http://www.alanwood.net/pesticides). 
     Exemplary active ingredients from the group of ectoparasiticides, as mixing partners, include, without limitation insecticides and acaricides listed in detail above. Further active ingredients which may be used are listed below following the aforementioned classification which is based on the current IRAC Mode of Action Classification Scheme: (1) Acetylcholinesterase (AChE) inhibitors; (2) GABA-gated chloride channel blockers; (3) Sodium channel modulators; (4) Nicotinic acetylcholine receptor (nAChR) competitive modulators; (5) Nicotinic acetylcholine receptor (nAChR) allosteric modulators; (6) Glutamate-gated chloride channel (GluCl) allosteric modulators; (7) Juvenile hormone mimics; (8) Miscellaneous non-specific (multi-site) inhibitors; (9) Modulators of Chordotonal Organs; (10) Mite growth inhibitors; (12) Inhibitors of mitochondrial ATP synthase, such as, ATP disruptors; (13) Uncouplers of oxidative phosphorylation via disruption of the proton gradient; (14) Nicotinic acetylcholine receptor channel blockers; (15) Inhibitors of chitin biosynthesis, type 0; (16) Inhibitors of chitin biosynthesis, type 1; (17) Moulting disruptor (in particular for Diptera, i.e. dipterans); (18) Ecdysone receptor agonists; (19) Octopamine receptor agonists; (21) Mitochondrial complex I electron transport inhibitors; (25) Mitochondrial complex II electron transport inhibitors; (20) Mitochondrial complex III electron transport inhibitors; (22) Voltage-dependent sodium channel blockers; (23) Inhibitors of acetyl CoA carboxylase; (28) Ryanodine receptor modulators; (30) GABA-gated chloride channel allosteric modulators. 
     Active compounds with unknown or non-specific mode of action, e.g., fentrifanil, fenoxacrim, cycloprene, chlorobenzilate, chlordimeform, flubenzimine, dicyclanil, amidoflumet, quinomethionate, triarathene, clothiazoben, tetrasul, potassium oleate, petroleum, metoxadiazone, gossyplure, flutenzin, bromopropylate, cryolite; 
     Compounds from other classes, e.g. butacarb, dimetilan, cloethocarb, phosphocarb, pirimiphos (-ethyl), parathion (-ethyl), methacrifos, isopropyl o-salicylate, trichlorfon, tigolaner, sulprofos, propaphos, sebufos, pyridathion, prothoate, dichlofenthion, demeton-S-methylsulphone, isazofos, cyanofenphos, dialifos, carbophenothion, autathiofos, aromfenvinfos (-methyl), azinphos (-ethyl), chlorpyrifos (-ethyl), fosmethilan, iodofenphos, dioxabenzofos, formothion, fonofos, flupyrazofos, fensulfothion, etrimfos; 
     organochlorines, e.g. camphechlor, lindane, heptachlor; or phenylpyrazoles, e.g. acetoprole, pyrafluprole, pyriprole, vaniliprole, sisapronil; or isoxazolines, e.g. sarolaner, afoxolaner, lotilaner, fluralaner; 
     pyrethroids, e.g. (cis-, trans-), metofluthrin, profluthrin, flufenprox, flubrocythrinate, fubfenprox, fenfluthrin, protrifenbute, pyresmethrin, RU15525, terallethrin, cis-resmethrin, heptafluthrin bioethanomethrin, biopermethrin, fenpyrithrin, cis-cypermethrin, cis-permethrin, clocythrin, cyhalothrin (lambda-), chlovaporthrin, or halogenated carbonhydrogen compounds (HCHs), 
     neonicotinoids, e.g. nithiazine 
     dicloromezotiaz, triflumezopyrim 
     macrocyclic lactones, e.g. nemadectin, ivermectin, latidectin, moxidectin, selamectin, eprinomectin, doramectin, emamectin benzoate; milbemycin oxime 
     triprene, epofenonane, diofenolan; 
     Biologicals, hormones or pheromones, for example natural products, e.g. thuringiensin, codlemone or neem components 
     dinitrophenols, e.g. dinocap, dinobuton, binapacryl; 
     benzoylureas, e.g. fluazuron, penfluron, 
     amidine derivatives, e.g. chlormebuform, cymiazole, demiditraz 
     Bee hive  varroa  acaricides, for example organic acids, e.g. formic acid, oxalic acid. 
     Exemplary active ingredients from the group of endoparasiticides, as mixing partners, include, without limitation, anthelmintically active compounds and antiprotozoal active compounds. 
     Anthelmintically active compounds, including, without limitation, the following nematicidally, trematicidally and/or cestocidally active compounds: 
     from the class of macrocyclic lactones, for example; eprinomectin, abamectin, nemadectin, moxidectin, doramectin, selamectin, lepimectin, latidectin, milbemectin, ivermectin, emamectin, milbemycin; 
     from the class of benzimidazoles and probenzimidazoles, for example: oxibendazole, mebendazole, triclabendazole, thiophanate, parbendazole, oxfendazole, netobimin, fenbendazole, febantel, thiabendazole, cyclobendazole, cambendazole, albendazole-sulphoxide, albendazole, flubendazole; 
     from the class of depsipeptides, preferably cyclic depsipetides, in particular 24-membered cyclic depsipeptides, for example: emodepside, PF1022A; 
     from the class of tetrahydropyrimidines, for example: morantel, pyrantel, oxantel; 
     from the class of imidazothiazoles, for example: butamisole, levamisole, tetramisole; 
     from the class of aminophenylamidines, for example amidantel, deacylated amidantel (dAMD), tribendimidine; 
     from the class of aminoacetonitriles, for example: monepantel; 
     from the class of paraherquamides, for example: paraherquamide, derquantel; 
     from the class of salicylanilides, for example tribromsalan, bromoxanide, brotianide, clioxanide, closantel, niclosamide, oxyclozanide, rafoxanide; 
     from the class of substituted phenols, for example: nitroxynil, bithionol, disophenol, hexachlorophene, niclofolan, meniclopholan; 
     from the class of organophosphates, for example: trichlorfon, naphthalofos, dichlorvos/DDVP, crufomate, coumaphos, haloxon; 
     from the class of piperazinones/quinolines, for example: praziquantel, epsiprantel; 
     from the class of piperazines, for example: piperazine, hydroxyzine; 
     from the class of tetracyclines, for example tetracyclin, chlorotetracycline, doxycyclin, oxytetracyclin, rolitetracyclin; 
     from diverse other classes, for example: bunamidine, niridazole, resorantel, omphalotin, oltipraz, nitroscanate, nitroxynile, oxamniquine, mirasan, miracil, lucanthone, hycanthone, hetolin, emetine, diethylcarbamazine, dichlorophen, diamfenetide, clonazepam, bephenium, amoscanate, clorsulon. 
     Antiprotozoal active compounds, including, without limitation, the following active compounds: 
     from the class of triazines, for example: diclazuril, ponazuril, letrazuril, toltrazuril; 
     from the class of polylether ionophore, for example: monensin, salinomycin, maduramicin, narasin; 
     from the class of macrocyclic lactones, for example: milbemycin, erythromycin; 
     from the class of quinolones, for example: enrofloxacin, pradofloxacin; 
     from the class of quinines, for example: chloroquine; 
     from the class of pyrimidines, for example: pyrimethamine; 
     from the class of sulfonamides, for example sulfaquinoxaline, trimethoprim, sulfaclozin; 
     from the class of thiamines, for example: amprolium; 
     from the class of lincosamides, for example: clindamycin; 
     from the class of carbanilides, for example: imidocarb; 
     from the class of nitrofuranes, for example: nifurtimox; 
     from the class of quinazolinone alkaloids, for example: halofuginon; 
     from diverse other classes, for example oxamniquin, paromomycin; 
     from the class of vaccines or antigenes from microorganisms, for example:  Babesia canis  rossi,  Eimeria tenella, Eimeria praecox, Eimeria necatrix, Eimeria mitis, Eimeria maxima, Eimeria brunetti, Eimeria acervulina, Babesia canis vogeli, Leishmania infantum, Babesia canis canis, Dictyocaulus viviparus.    
     All named mixing partners can, if their functional groups enable this, optionally form salts with suitable bases or acids. 
     Vector Control 
     The compounds of the formula (I) can also be used in vector control. For the purpose of the present invention, a vector is an arthropod, in particular an insect or arachnid, capable of transmitting pathogens such as, for example, viruses, worms, single-cell organisms and bacteria from a reservoir (plant, animal, human, etc.) to a host. The pathogens can be transmitted either mechanically (for example trachoma by non-stinging flies) to a host, or by injection (for example malaria parasites by mosquitoes) into a host. 
     Examples of vectors and the diseases or pathogens they transmit are: 
     1) Mosquitoes
           Anopheles : malaria, filariasis;     Culex : Japanese encephalitis, other viral diseases, filariasis, transmission of other worms;     Aedes : yellow fever, dengue fever, other viral diseases, filariasis;   Simuliidae: transmission of worms, in particular  Onchocerca volvulus;      Psychodidae: transmission of leishmaniasis       

     2) Lice: skin infections, epidemic typhus; 
     3) Fleas: plague, endemic typhus, cestodes; 
     4) Flies: sleeping sickness (trypanosomiasis); cholera, other bacterial diseases; 
     5) Mites: acariosis, epidemic typhus, rickettsialpox, tularaemia, Saint Louis encephalitis, tick-borne encephalitis (TBE), Crimean-Congo haemorrhagic fever, borreliosis; 
     6) Ticks: borellioses such as  Borrelia burgdorferi  sensu lato.,  Borrelia  duttoni, tick-borne encephalitis, Q fever ( Coxiella burnetii ), babesioses ( Babesia canis canis ), ehrlichiosis. 
     Examples of vectors in the sense of the present invention are insects, for example aphids, flies, leafhoppers or  thrips , which are capable of transmitting plant viruses to plants. Other vectors capable of transmitting plant viruses are spider mites, lice, beetles and nematodes. 
     Further examples of vectors in the sense of the present invention are insects and arachnids such as mosquitoes, in particular of the genera  Aedes, Anopheles , for example  A. gambiae, A. arabiensis, A. funestus, A. dirus  (malaria) and  Culex , psychodids such as  Phlebotomus, Lutzomyia , lice, fleas, flies, mites and ticks capable of transmitting pathogens to animals and/or humans. 
     Vector control is also possible if the compounds of the formula (I) are resistance-breaking. 
     Compounds of the formula (I) are suitable for use in the prevention of diseases and/or pathogens transmitted by vectors. Thus, a further aspect of the present invention is the use of compounds of the formula (I) for vector control, for example in agriculture, in horticulture, in gardens and in leisure facilities, and also in the protection of materials and stored products. 
     Protection of Industrial Materials 
     The compounds of the formula (I) are suitable for protecting industrial materials against attack or destruction by insects, for example from the orders Coleoptera, Hymenoptera, Isoptera, Lepidoptera, Psocoptera and Zygentoma. 
     Industrial materials in the present context are understood to mean inanimate materials, such as preferably plastics, adhesives, sizes, papers and cards, leather, wood, processed wood products and coating compositions. The use of the invention for protecting wood is particularly preferred. 
     In a further embodiment, the compounds of the formula (I) are used together with at least one further insecticide and/or at least one fungicide. 
     In a further embodiment, the compounds of the formula (I) are present as a ready-to-use pesticide, i.e. they can be applied to the material in question without further modifications. Suitable further insecticides or fungicides are in particular those mentioned above. 
     Surprisingly, it has also been found that the compounds of the formula (I) can be employed for protecting objects which come into contact with saltwater or brackish water, in particular hulls, screens, nets, buildings, moorings and signalling systems, against fouling. Likewise, the compounds of the formula (I), alone or in combinations with other active compounds, can be used as antifouling agents. 
     Control of Animal Pests in the Hygiene Sector 
     The compounds of the formula (I) are suitable for controlling animal pests in the hygiene sector. In particular, the invention can be applied in the domestic sector, in the hygiene sector and in the protection of stored products, especially for controlling insects, arachnids, ticks and mites encountered in enclosed spaces such as dwellings, factory halls, offices, vehicle cabins, animal husbandries. For controlling animal pests, the compounds of the formula (I) are used alone or in combination with other active compounds and/or auxiliaries. They are preferably used in domestic insecticide products. The compounds of the formula (I) are effective against sensitive and resistant species, and against all developmental stages. 
     These pests include, for example, pests from the class Arachnida, from the orders Scorpiones, Araneae and Opiliones, from the classes Chilopoda and Diplopoda, from the class Insecta the order Blattodea, from the orders Coleoptera, Dermaptera, Diptera, Heteroptera, Hymenoptera, Isoptera, Lepidoptera, Phthiraptera, Psocoptera, Saltatoria or Orthoptera, Siphonaptera and Zygentoma and from the class Malacostraca the order Isopoda. 
     They are used, for example, in aerosols, pressure-free spray products, for example pump and atomizer sprays, automatic fogging systems, foggers, foams, gels, evaporator products with evaporator tablets made of cellulose or plastic, liquid evaporators, gel and membrane evaporators, propeller-driven evaporators, energy-free, or passive, evaporation systems, moth papers, moth bags and moth gels, as granules or dusts, in baits for spreading or in bait stations. 
     Abbreviations and Symbols 
     
         
         AcOH: acetic acid 
         ACN: acetonitrile 
         aq.: aqueous 
         br.: broad 
         d: doublet 
         DCC: N,N′-dicyclohexylcarbodiimide 
         DCM: dichloromethane 
         DIPEA: N,N-diisopropylethylamine 
         DMF: N,N-dimethylformamideDMSO: dimethylsulfoxide 
         ee: enantiomeric excess 
         eq.: equivalent 
         ESI: electrospray ionization 
         Et 3 N triethylamine 
         EtOAc: ethyl acetate 
         hr(s) hour(s) 
         HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate 
         HOBt: 1-hydroxybenzotriazole hydrate 
         HPLC: high performance liquid chromatography 
         iPrOH: isopropanol 
         J: coupling constant 
         LCMS: liquid chromatography-mass spectrometry 
         m/z: mass-to-charge ratio 
         M: molarity 
         m: multiplet 
         MeCN acetonitrile 
         MeOH: methanol 
         MTBE: methyl-tert.-butylether 
         n-BuLi n-butyllithium 
         NaH 2 PO 4  monosodium phosphate 
         NaOH sodium hydroxide 
         Na 2 SO 4  sodium sulfate 
         NH 4 Cl ammonium chloride 
         NMR: nuclear magnetic resonance 
         Pd(dppf)Cl 2  [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
         psi pound-force per square inch (pressure) 
         q: quartet 
         Rf: retention factor TLC 
         r. t.: room temperature 
         RT: room temperature 
         R t : retention time 
         s: singlet 
         sat.: saturated 
         T: temperature 
         t: triplet 
         T3P®: propylphosphonic anhydride 
         THF: tetrahydrofuran 
         TLC thin layer chromatography 
         TMSOK potassium trimethylsilanolate 
         wt.: weight 
         δ: chemical shift 
         λ: wavelength 
       
    
    
    
     DESCRIPTION OF THE PROCESSES AND INTERMEDIATES 
     Compounds of formula I′ may be prepared as illustrated in the following scheme 1 where R 1 , R 2 , R 3a , R 3b , R 4 , R 5  and Y are as previously defined and X 1  stands for OH or Cl. 
     
       
         
         
             
             
         
       
     
     X 1 ═OH: A triazole compound of formula (1) is reacted with a carboxylic acid of formula (2a) (X 1 ═OH) to form compounds of formula (I′). For example, a mixture of a triazole of formula (1), a carboxylic acid of formula (2a) (X 1 ═OH), a suitable coupling reagent, such as T3P®, HATU or DCC/HOBt, a suitable base such as triethylamine or DIPEA, in a suitable solvent, such as ethyl acetate or DMF are mixed at temperatures ranging from around 0 to 100° C. to provide compounds of formula (I′) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     X 1 ═Cl: A triazole compound of formula (1) is reacted with a carboxylic acid chloride of formula (2b) (X 1 ═Cl) to form compounds of formula (I′). For example, a mixture of a triazole of formula (1), a carboxylic acid chloride of formula (2b) (X 1 ═Cl), a suitable base such as triethylamine or DIPEA, in a suitable solvent, such as dichloromethane or THF are mixed at temperatures ranging from around 0 to 100° C. to provide compounds of formula (I′) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     Carboxylic acids of formula (2a) (X 1 ═OH) and carboxylic acid chlorides of formula (2b) (X 1 ═Cl) are commercially available or may be synthesized by or in analogy to literature reported syntheses (see, e.g. WO2020/002563) or by methods known to a person skilled in the state of the art. 
     For example 
     3-Chloro-5-[(methylsulfonyl)methyl]benzoic acid: Prepareded by saponification of methyl 3-chloro-5-[(methylsulfonyl)methyl]benzoate, the latter is yielded from methyl 3-(bromomethyl)-5-chlorobenzoate (see U.S. Pat. No. 5,254,584 or by NBS-bromination of methyl 3-chloro-5-methylbenzoate in analogy to CN104387332) by reaction with sodium methylsulfinate in analogy to US2012/10205. 
     The preparation of methyl 3-chloro-5-methylbenzoate is described in U.S. Pat. No. 5,254,584. 
     3-[(2,3,3-Trichloroprop-2-en-1-yl)oxy]-5-(trifluoromethyl)benzoic acid: From commercially available 3-hydroxy-5-(trifluoromethyl)benzoic acid and 1,1,1,2,3-pentachloropropane. The reaction (potassium carbonate, DMSO, 45° C.) yields 2,3,3-trichloroprop-2-en-1-yl 3-[(2,3,3-trichloroprop-2-en-1-yl)oxy]-5-(trifluoromethyl)benzoate which is then saponified to the acid. 
     3-Bromo-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzoic acid is prepared analogously starting from commercially available 3-bromo-5-hydroxybenzoic acid. 
     3-[(3,3-Dichloroprop-2-en-1-yl)oxy]-5-(trifluoromethyl)benzoic acid is prepared analogously starting from 3-hydroxy-5-(trifluoromethyl)benzoic acid and 1,1,1,3-tetrachloropropane. 
     3-[(2,2-Dichlorocyclopropyl)methoxy]-5-(trifluoromethyl)benzoic acid: Prepared analogously starting from commercially available 3-hydroxy-5-(trifluoromethyl)benzoic acid and 2-(bromomethyl)-1,1-dichlorocyclopropane, the latter is known e.g. from DE2804739. 
     3-Bromo-5-[(2,2-difluorocyclopropyl)methoxy]benzoic acid: Prepared analogously starting from commercially available 3-bromo-5-hydroxybenzoic acid and commercially available 2-(bromomethyl)-1,1-difluorocyclopropane. 
     3-Bromo-5[(2,2-dichlorocyclopropyl)methoxy]benzoic acid: Prepared starting from allyl 3-(allyloxy)-5-bromobenzoate (synthesis described in Angewandte Chemie-International Edition, 2012, vol. 51, #52, p. 13036-13040) followed by dichlorocarbene addition, e.g. in analogy to a procedure described in Russian Journal of General Chemistry, 2001, vol. 71, #4, p. 542-545, followed by hydrolysis of the remaining ester. 
     3-Bromo-5[(2,2-dichlorocyclopropyl)oxy]benzoic acid: Prepared starting from methyl 3-bromo-5-hydroxybenzoate (synthesis described in WO2015/66515, 2015, A1). Conversion to methyl 3-bromo-5-(2-hydroxyethoxy)benzoate is performed in analogy to the procedure described in US2016/244460 A1. The following chlorination with thionyl chloride in the presence of DMF is performed in analogy to the procedure described WO2004/16611, A1. Elimination to yield the vinyloxy ether is performed in analogy to the procedure described in WO2006/77364 A1, the conditions of the conversion simultaneously lead to hydrolysis of the ester function. The following addition of dichlorocarbene is performed in analogy to to a procedure described in Russian Journal of General Chemistry, 2001, vol. 71, #4, p. 542-545 and succeeds in the presence of an alcohol as EtOH. The conditions of the conversion simultaneously lead to esterification of the carboxylic acid function. To yield the acid, the ester function is hydrolysed. 
     3-[(Methylsulfinyl)methoxy]-5-(trifluoromethyl)benzoic acid: Prepared (potassium carbonate, DMSO, a similar conversion is described in CN106083539) from commercially available 3-hydroxy-5-(trifluoromethyl)benzoic acid and chloro(methylsulfinyl)methane, the latter is known from CN106083539. 
     The requisite triazole compounds of formula (1) may be prepared as illustrated in the following scheme 2, where R 1 , R 3a , R 3b , R 4 , R 5  and Y are as previously described and LG is a suitable leaving group such as bromine, chlorine or —OSO 2 Me (see also WO 2017192385). 
     
       
         
         
             
             
         
       
     
     An amine of formula (4) is reacted with a substituted azole of formula (3) to form compounds of formula (1b). For example, a mixture of an azole of formula (3), an amine of formula (4), a suitable base, such as K 2 CO 3 , NaH or DIPEA in a suitable solvent, such as acetonitrile or DMF are mixed at temperatures ranging from around 20 to 120° C. to provide compounds of formula (1b) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     Alternatively, a substituted azole of formula (3) is reacted with ammonia (5) to form compounds of formula (1a). For example, a solution of ammonia (5) in a suitable solvent, such as methanol, and a substituted azole of formula (3) are mixed in a sealed tube at temperatures ranging from around 0 to 25° C. to provide compounds of formula (1a) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as trituration. 
     A substituted azole of formula (1a), a compound of formula (6), a suitable base, such as K 2 CO 3  or DIPEA in a suitable solvent, such as acetonitrile or DMF are then mixed at temperatures ranging from around 20 to 120° C. to provide compounds of formula (1b) which may then be isolated and, if necessary and desired, purified using techniques well known in the art such as chromatography. 
     Amines of formula (4) and compounds of formula (6) are commercially available or may be synthesized by methods known to a person skilled in the state of the art. 
     The requisite triazole compounds of formula (3) may be prepared as illustrated in the following scheme 3, where R 3a , R 3b , R 4 , and Y are as previously described, LG is a suitable leaving group such as bromine, chlorine or —OSO 2 Me and R 5  is hydrogen or C 1 -C 3 alkyl (see also WO 2017192385). 
     
       
         
         
             
             
         
       
     
     An amide of formula (7) is reacted with an N,N-dimethylamide dimethyl acetal (8) to form compounds of formula (9) which are subsequently reacted with hydrazines (10) or their corresponding salts, e.g. hydrochloride salts, under acidic conditions to form compounds of formula (3). For example, a compound of formula (7) and an N,N-dimethylamide dimethyl acetal of formula (8) are reacted in a suitable solvent, such as CH 2 Cl 2  at reflux to provide compounds of formula (9). Upon removal of the solvent, compounds of formula (9) are reacted with a substituted hydrazine (10) in a suitable solvent such as 1,4-dioxane, acetic acid or a mixture of such solvents at temperatures ranging from around 20 to 100° C. to provide compounds of formula (3) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     N,N-dimethylamide acetals of formula (8), amides of formula (7) and hydrazines of formula (10) or their corresponding salts, e.g. hydrochloride salts, are commercially available or may be synthesized by methods known to a person skilled in the state of the art. 
     For example 
     6-hydrazinonicotinonitrile is described in US2010/305085. 
     Compounds of formula (I′) may be prepared as illustrated in the following scheme 4 where R 1 , R 2 , R 3a , R 3b , R 4  and Y are as previously defined and R 5  is hydrogen or C 1 -C 3 alkyl. 
     
       
         
         
             
             
         
       
     
     An amide of formula (11) is reacted with an N,N-dimethylamide dimethyl acetal of formula (8) to form compounds of formula (12) which are subsequently reacted with substituted hydrazines of formula (10) or their corresponding salts, e.g. hydrochloride salts, under acidic conditions to form compounds of formula (I′). For example, a compound of formula (11) and an N,N-dimethylamide dimethyl acetal of formula (8) are reacted in a suitable solvent, such as CH 2 Cl 2  at reflux to provide compounds of formula (12). Upon removal of the solvent, compounds of formula (12) are reacted with a substituted hydrazine of formula (10) in a suitable solvent such as 1,4-dioxane, acetic acid or a mixture of such solvents at temperatures ranging from around 20 to 100° C. The resulting compounds of formula (I′) may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     The requisite amides of formula (11) may be prepared as illustrated in the following scheme 5, where R 1 , R 2 , R 3a , R 3b , and Y are as previously described (see also WO 2017192385). 
     
       
         
         
             
             
         
       
     
     An amino amide of formula (13) is reacted with a carboxylic acid of formula (2a) to form compounds of formula (11). For example, a mixture of an amino amide of formula (13), a carboxylic acid (2a), a suitable coupling reagent, such as T3P®, HATU or DCC/HOBt, a suitable base such as triethylamine or DIPEA, in a suitable solvent such as ethyl acetate or DMF are mixed at temperatures ranging from around 0 to 100° C. to provide compounds of formula (11) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     Alternatively, an amino acid of formula (14) is reacted with thionyl chloride in a suitable solvent, such as MeOH, at r.t. to provide amino esters of formula (15). The resulting amino esters (15) may then be alkylated through reaction with an aldehyde or a ketone in the presence of a suitable reducing agent such as sodium triacetoxyborohydride, a dehydrating agent such as Na 2 SO 4 , in a suitable solvent such as acetic acid, at r.t. to provide compounds of formula (16). 
     Amino esters of formula (15) and (16) are reacted with a carboxylic acid of formula (2a), a suitable coupling reagent, such as T3P®, a suitable base such as DIPEA, in a suitable solvent, such as ethyl acetate at about 90° C. to provide amido esters of formula (17) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. The resulting amido esters of formula (17) are reacted with magnesium nitride in a suitable solvent, such as MeOH at about 80° C. in a sealed tube to provide compounds of formula (11) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography or extraction. Compounds of formula (2a) and (14) are commercially available or accessible by methods known to the skilled artist. 
     The requisite amino amide compounds of formula (13) are commercially available or may be prepared as illustrated in the following scheme 6, where R 1 , R 3a , R 3b , and Y are as previously described and LG is a suitable leaving group (see also WO 2017192385). 
     
       
         
         
             
             
         
       
     
     An amine of formula (4) is reacted with an amide of formula (7) to form compounds of formula (13). For example, a mixture of an amine of formula (4), an amide of formula (7), a suitable base, such as K 2 CO 3  or DIPEA in a suitable solvent, such as acetonitrile or DMF are mixed at 25-80° C. to provide compounds of formula (13) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     Compounds of formula (4) and (7) are commercially available, or may be synthesized by methods known to a person skilled in the state of the art. 
     In an alternative approach compounds of formula (I′) may be prepared as illustrated in the following scheme 7 where R 1 , R 2 , R 3a , R 3b , R 4  and Y are as previously defined and R 5  is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or C 3 -C 6 cycloalkyl. 
     
       
         
         
             
             
         
       
     
     An amidine or its suitable corresponding salt, e.g. hydrochloride salt, of formula (8) is reacted with an acid of formula (19). For example, an amidine hydrochloride of formula (18), a carboxylic acid (19), a suitable coupling reagent, such as HATU or DCC/HOBt, a suitable base such as triethylamine or DIPEA, in a suitable solvent such as acetonitrile or DMF are mixed at temperatures ranging from around 0 to 100° C., to form compounds of formula (20) which are subsequently reacted with substituted hydrazines of formula (10) or their corresponding salts, e.g. hydrochloride salts, under acidic conditions to form compounds of formula (I′) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     Amidine hydrochlorides of formula (18), carboxylic acid derivatives of formula (19) and hydrazines of formula (10) are commercially available or may be synthesized by methods known to the skilled artisan. 
     In an alternative approach compounds of formula (1) may be prepared as illustrated in the following scheme 8 where R 1 , R 3a , R 3b , R 4  and Y are as previously defined and R 5  is hydrogen or C 1 -C 3 alkyl. 
     
       
         
         
             
             
         
       
     
     An amide of formula (21) is reacted with an N,N-dimethylamide dimethyl acetal of formula (8) to form compounds of formula (22) which are subsequently reacted with substituted hydrazines of formula (10) or their corresponding salts, e.g. hydrochloride salts, under acidic conditions to form compounds of formula (23). For example, a compound of formula (21) and a N,N-dimethylamide dimethyl acetal of formula (8) are reacted in a suitable solvent, such as CH 2 Cl 2  at reflux to provide compounds of formula (22). After removal of the solvent, compounds of formula (22) are reacted with a substituted hydrazine of formula (10) in a suitable solvent such as 1,4-dioxane, acetic acid or a mixture of such solvents at temperatures ranging from around 20 to 80° C. The resulting compounds of formula (23) may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     A carbamate of formula (23) is treated with an acid to form amines of formula (1). For example, a carbamate of formula (23) and a suitable acid, such as hydrogen chloride or trifluoracetic acid, are reacted in a suitable solvent, such as dioxane or in the case of trifluoroacetic acid without an additional solvent at temperatures ranging from around 0 to 80° C. The resulting amines of formula (1) may then be isolated as their acid salts or after base treatment as free amines and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     The requisite amides of formula (21) and hydrazines of formula (10) or their corresponding salts, e.g. hydrochloride salts, are commercially available or may be synthesized by methods described in this application or methods known to the skilled artisan (e.g. amides of formula (21) may be synthesized by reacting amino amides for formula (13) with bis(1,1-dimethylethyl) dicarbonate). 
     Scheme 9 illustrates the preparation of 3-haloalkyl triazoles containing amines (1c) where R 4  is as previously defined, R 5  is C 1 -C 6 haloalkyl and alkyl is C 1 -C 6 alkyl. 
     
       
         
         
             
             
         
       
     
     In a first step, a hydrazone amide (25) is formed as described in EP 1099695. In a second step, 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl chloride (26), prepared from 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoic acid and oxalyl chloride according to  Tetrahedron: Asymmetry,  21(8), 936-942, 2010, reacts with the hydrazone amide (25) in the presence of a base, like pyridine, as described in EP 1099695 to form a triazole of formula (27). In a third step, the phthalimide protecting group is removed by reaction with hydrazine hydrate in a suitable solvent, like ethanol, as described in WO 2018086605. In a final step, the obtained amine (1c) is reacted with a carboxylic acid as described in scheme 1 to form the example compounds. 
     Scheme 10 illustrates the preparation of alkoxytriazole containing amines (1d) where R 4  is as previously defined and alkyl is optionally substituted C 1 -C 6 alkyl. 
     
       
         
         
             
             
         
       
     
     The synthesis starts with the reaction of 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl chloride (26) with potassium thiocyanate (KSCN) in acetone to yield the corresponding isothiocyanate intermediate (28) which is treated in the next step with the corresponding alcohol to afford the O-alkyl [2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl]carbamothioates (29). The reaction between intermediate (29) and a hydrazine of formula (10) in ethanol affords cyclized products of formula (30) as described in Bioorganic &amp; Medicinal Chemistry 26 (2018) 3321-3344. The deprotection of the amino group with hydrazine hydrate yields primary amines of formula (1d). In a final step, the obtained amine (1d) is reacted with a carboxylic acid as described in scheme 1 to form the example compounds. 
     Scheme 11 illustrates the preparation of alkyltriazole containing amines (1e) where R 5  is optionally substituted C 3 -C 6 cyloalkyl and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is substituted as previously described. Z is NH 2  or OC 1 -C 6 alkyl. R 4  is as previously defined. 
     
       
         
         
             
             
         
       
     
     N-(tert-butoxycarbonyl)-alanine (31) is reacted with a alkylamidine (18a, Z═NH 2 ) or an alkylimidate (24a, Z═OC 1 -C 6 alkyl) to form intermediates of formula (32) which are subsequently reacted with substituted hydrazines of formula (10) to form alkyltriazoles of formula (23a). For example in the case of (18a, Z═NH 2 ) (compare  J. Org. Chem.  2011, 76, 1177-1179) N-(tert-butoxycarbonyl)-alanine and an alkylamidine of formula (18a) are reacted in the presence of a suitable coupling reagent, such as HATU, a suitable base such as triethylamine or DIPEA, in a suitable solvent, such as DMF, at temperatures ranging from 0 to 50° C. to form acylamidine intermediate of formula (32). After removal of the solvent, the intermediates of formula (32) are reacted with a substituted hydrazine of formula (10) in a suitable solvent such as acetic acid at temperatures ranging from around 20 to 80° C. The resulting alkyltriazoles of formula (23a) may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     In the case of Z═OC 1 -C 6 alkyl N-(tert-butoxycarbonyl)-alanine and an alkylimidate of formula (24a) or a suitable salt thereof are reacted in the presence of a suitable coupling reagent, such as HATU, a suitable base such as triethylamine or DIPEA, in a suitable solvent, such as THF at temperatures ranging from around 0 to 25° C. to form acyl imidate intermediates of formula (32). Upon addition of a substituted hydrazine of formula (10) the intermediate of formula (32) reacts at temperatures ranging from around 20 to 80° C. to give alkyltriazoles of formula (23) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     Carbamates of formula (23a) are treated with an acid to form amines of formula (1e) as shown in scheme 8. 
     The requisite alkylamidines (18a) and alkylimidates (24a) or their suitable salts and hydrazines of formula (10) are commercially available or may be synthesized by methods described in this application or methods known to the skilled artisan (see for example WO 2011/133447 for the synthesis of methyl cyclopropanecarboximidate hydrochloride). 
     Compounds of formula (I′c) may be prepared as illustrated in the following scheme 12, where R 1 , R 2 , R 3a , R 3b , R 5 , R 41  and R 42  are as previously defined. T is pyridine, pyrimidine, pyrazine, pyridazine or thiazole substituted with one —CO 2 —C 1 -C 6 -alkyl group, —COOH, or —CON(R 41 )R 42  group respectively. Alk is C 1 -C 6 alkyl. 
     
       
         
         
             
             
         
       
     
     An ester compound of formula (I′a) is saponified to obtain the respective carboxylic acid compound of formula (I′b) followed by an amide coupling step with amines of formula (33) to obtain amides of formula (I′c) by methods known to a person skilled in the state of the art. 
     For example, an ester of formula (I′a) and a suitable base such as LiOH, NaOH or KOH, in a suitable solvent such as dioxane, methanol, water or THF or mixtures thereof, are mixed at temperatures ranging from around 0 to 100° C. to provide acids of formula (I′b) which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     For example, a mixture of an amine of formula (33), a carboxylic acid (I′b), a suitable coupling reagent, such as T3P HATU or DCC/HOBt, a suitable base such as triethylamine or DIPEA, in a suitable solvent such as ethyl acetate or DMF are mixed at temperatures ranging from around 0 to 100° C. to provide compounds of formula Ic which may then be isolated and, if necessary and desired, purified using techniques well known in the art, such as chromatography. 
     Amines of formula (33) are commercially available or may be synthesized by methods known to the skilled artisan. Compounds of formula (I′ a) and (I′b) may be prepared a described for example in scheme 4 using hydrazines of the general formula (10) in which R 4  is pyridine, pyrimidine, pyrazine, pyridazine or thiazole substituted with one —CO 2 —C 1 -C 6 -alkyl or —COOH group respectively. 
     The preparation and use examples which follow illustrate the invention without limiting it. 
     General Procedure 1: O-Alkylation of Phenols 
     To a solution of phenol (1 eq) in an appropriate solvent was added potassium carbonate (1-3 eq) freshly crushed and the corresponding alkylating reagent (1-3 eq) and the mixture was stirred till the reaction was complete. The mixture was diluted with water, extracted several times with ethyl acetate and then the combined organic layer was washed with brine and dried over Na 2 SO 4 . After evaporation of the solvent under vacuo the crude product was purified by reserved-phase chromatography (water/acetonitrile) or flash chromatography. 
     When acetonitrile was used as the solvent, the reaction was stirred at room temperature. When using DMF as the solvent, the mixture was stirred between 60-100° C. 
     STARTING COMPOUNDS AND INTERMEDIATES 
     Intermediate 1A 
     Methyl 3-chloro-5-(hydroxymethyl)benzoate 
     
       
         
         
             
             
         
       
     
     Dimethyl 5-chloroisophthalate (90.0 g, 394 mmol, 1.00 eq) was dissolved in MeOH (900 mL) and DCM (900 mL) and the solution was cooled to 0° C. NaBH 4  (59.6 g, 1.57 mol, 4.00 eq) was added in portions to the mixture. The reaction mixture was stirred at 25° C. for 16 hrs. TLC (petroleum ether/ethyl acetate=3:1, R f =0.17) indicated ca. 30% of the starting compound remained, and one new spot was formed. The reaction mixture was poured into aqueous saturated solution of NH 4 C 1  (500 mL) and extracted with DCM (2×200 mL). The combined organic phases were washed with brine (500 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO 2 , petroleum ether/ethyl acetate=50/1 to 3/1). Methyl 3-chloro-5-(hydroxymethyl)benzoate (52.8 g, 263 mmol, 66.9% yield) was obtained as colorless oil. 
     Intermediate 2A 
     Methyl 3-chloro-5-(chloromethyl)benzoate 
     
       
         
         
             
             
         
       
     
     Methyl 3-chloro-5-(hydroxymethyl)benzoate (52.0 g, 259 mmol, 1.00 eq) was dissolved in DCE (360 mL) and cooled to 0° C. and kept under inert atmosphere (N 2 ). SOCl 2  (123 g, 1.04 mol, 75.2 mL, 4.00 eq) was added dropwise to the mixture. The reaction mixture was stirred at 50° C. for 16 hrs. TLC (petroleum ether/ethyl acetate=5:1, R f =0.75) indicated the starting material was consumed completely and one new spot was formed. The reaction mixture was diluted with H 2 O (200 mL) and extracted with DCM (2×200 mL). The combined organic phases were washed with brine (200 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. Methyl 3-chloro-5-(chloromethyl)benzoate (54.5 g, crude) was obtained as off-white oil. 
     Intermediate 3A 
     Methyl 3-chloro-5-(cyanomethyl)benzoate 
     
       
         
         
             
             
         
       
     
     Methyl 3-chloro-5-(chloromethyl)benzoate (54.0 g, 246 mmol, 1.00 eq) and trimethylsilylcyanide (97.8 g, 986 mmol, 123 mL, 4.00 eq) were dissolved in DMF (380 mL). Cesium fluoride (74.9 g, 493 mmol, 18.2 mL, 2.00 eq) was added to the mixture at room temperature. The reaction mixture was stirred at 25° C. for 16 hrs. The reaction mixture was poured into a saturated aqueous solution of NH 4 Cl (500 mL) and extracted with ethyl acetate (2×200 mL). The combined organic phases were washed with brine (200 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO 2 , petroleum ether/ethyl acetate=50/1 to 3/1). Methyl 3-chloro (cyanomethyl)benzoate (42.0 g, 200 mmol, 81.3% yield) was obtained as off-white solid. 
     Intermediate 4A 
     Methyl 3-chloro-5-(2-cyanopropan-2-yl)benzoate 
     
       
         
         
             
             
         
       
     
     Methyl 3-chloro-5-(cyanomethyl)benzoate (20.0 g, 95.4 mmol, 1.00 eq) and methyl iodide (67.7 g, 477 mmol, 29.7 mL, 5.00 eq) were dissolved in THF (140 mL) and cooled to −65° C. under inert atmosphere (N 2 ). LDA (2.00 M, 143 mL, 3.00 eq) was added dropwise to the mixture. The reaction mixture was stirred at −65° C. for 2 hrs. TLC (petroleum ether/ethyl acetate=3:1, R f =0.43) indicated the starting material was consumed completely and many new spots formed. The mixture was allowed to warm to room temperature and was poured into ice water (200 mL) and then extracted with ethyl acetate (2×100 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO 2 , petroleum ether/ethyl acetate=50/1 to 3/1). The isolated major product was triturated with MTBE (40.0 mL) at 25° C. for 16 hrs. Methyl 3-chloro-5-(2-cyanopropan-2-yl)benzoate (10.0 g, 41.1 mmol, 43.1% yield, 97.7% purity) was obtained as colorless solid. 
     Intermediate 5A 
     3-Chloro-5-(2-cyanopropan-2-yl)benzoic acid 
     
       
         
         
             
             
         
       
     
     Methyl 3-chloro-5-(2-cyanopropan-2-yl)benzoate (9.50 g, 40.0 mmol, 1.00 eq) was dissolved in MeOH (40.0 mL) and H 2 O (30 mL) at 0° C. Lithium hydroxide (1.91 g, 79.9 mmol, 2.00 eq) was added portion wise to the mixture. The reaction mixture was stirred at 25° C. for 3 hrs. TLC (petroleum ether/ethyl acetate=1:1, R f =0.04) indicated the starting material was consumed completely and one new spot was formed. The reaction mixture was concentrated under vacuum. The remaining residue was diluted with water (50 mL) and then extracted with ethyl acetate (50 mL). The aqueous phase was adjusted to pH 4 with 3N HCl. The aqueous phase was then extracted with ethyl acetate (2×30 mL). The combined organic phases were washed with brine (30 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum. The crude product was triturated with MTBE (30 mL) at 25° C. for 16 hrs. The title compound, 3-chloro-5-(2-cyanopropan-2-yl)benzoic acid (5.00 g, 22.3 mmol, 55.7% yield, 99.6% purity), was obtained as colorless solid. 
       1 H NMR (400 MHz, CDCl 3 ): δ=1.79 (s, 6H) 7.76-7.77 (m, 1H), 8.06-8.07 (m, 1H), 8.09-8.10 (m, 1H). Measured using a Bruker 400 MHz spectrometer. 
     Intermediate 6A 
     3-Chloro-5-(methoxycarbonyl)benzoic acid 
     
       
         
         
             
             
         
       
     
     To a mixture of dimethyl 5-chloroisophthalate (5.00 g, 21.8 mmol) in MeOH/THF (250 mL/250 mL) was added 1 M NaOH (21.8 mL, 21.8 mmol) in portions, then the reaction was stirred at 25° C. for 16 hrs. 
     HPLC-UV indicated complete conversion of the starting material. The reaction was concentrated to remove the solvents, the residue was adjusted to pH=2 with 4 N HCl to give a precipitate. The solid was collected by filtration, washed with water, dried in vacuo to yield the desired product as colorless solid (3.75 g, 80% yield). 
       1 H NMR (600 MHz, CDCl 3 ): δ=8.64 (s, 1H), 8.27 (s, 2H), 3.98 (s, 3H). Measured using a Bruker Biospin GmbH 600 NMR spectrometer. 
     Intermediate 7A 
     Methyl 3-chloro-5-[methoxy(methyl)carbamoyl]benzoate 
     
       
         
         
             
             
         
       
     
     To a solution of N, O-dimethylhydroxylamine hydrochloride (2.73 g, 27.6 mmol) in DCM (200 mL) was added triethylamine (11.3 mL, 80.6 mmol) and the solution was stirred for 30 min at 25° C. Then, 3-chloro-5-(methoxycarbonyl)benzoic acid (5.00 g, 23.3 mmol) was added followed by EDCI (8.82 g, 45.9 mmol) and HOBt (5.99 g, 46.6 mmol) at 0° C. The reaction mixture was allowed to warm to 25° C. and stirred for another 4 hrs. The mixture was partitioned between DCM and water. The aqueous phase was extracted with DCM. The combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by silica gel column (EtOAc/petroleum ether=1/10 to 1/5) to give the pure desired product (4.33 g, 72%). 
       1 H NMR (600 MHz, CDCl 3 ): δ=8.24 (s, 1H), 8.11 (s, 1H), 7.86 (s, 1H), 3.95 (s, 3H), 3.56 (s, 3H), 3.38 (s, 3H). Measured using a Bruker Biospin GmbH 600 NMR spectrometer. 
     Intermediate 8A 
     Methyl 3-chloro-5-(cyclopropylcarbonyl)benzoate 
     
       
         
         
             
             
         
       
     
     A solution of methyl 3-chloro-5-[methoxy(methyl)carbamoyl]benzoate (5.00 g, 19.4 mmol) in dry THF (200 mL) was added dropwise cyclopropylmagnesium bromide (38.8 mL, 19.4 mmol) at 0° C. The reaction mixture was stirred at 25° C. for 0.5 hrs, followed by quenching at 0° C. with aqueous NH 4 Cl and extraction with EtOAc (3×50.0 mL). The organic layers were combined and washed with brine twice, dried over Na 2 SO 4  and concentrated. The residue was purified by silica gel column (EtOAc/petroleum ether=1/30) to give the pure desired product (1 g, 21%). 
       1 H NMR (600 MHz, CDCl 3 ): δ=8.55 (s, 1H), 8.20 (s, 1H), 8.14 (s, 1H), 3.96 (s, 3H), 2.69-2.65 (m, 1H), 1.31-1.25 (m, 2H), 1.14-1.11 (m, 2H). Measured using a Bruker Biospin GmbH 600 NMR spectrometer. 
     Intermediate 9A 
     3-Chloro-5-(cyclopropylcarbonyl)benzoic acid 
     
       
         
         
             
             
         
       
     
     To a mixture of methyl 3-chloro-5-(cyclopropylcarbonyl)benzoate (3.80 g, 15.9 mmol) in MeOH/THF (15.0 mL/15.0 mL) was added 1 M NaOH (31.8 mL, 31.8 mmol) in portions, then the reaction was stirred at 25° C. for 16 hrs. The reaction mixture was concentrated to remove the solvents and the residue was adjusted to pH=2 with 3 N HCl to give a precipitate. The solid was collected by filtration, washed with water, dried over vacuo to give pure target compound as colorless solid (3.1 g, 87%). 
       1 H NMR (600 MHz, CDCl 3 ): δ=13.56 (bs, 1H), 8.43 (s, 1H), 8.31 (s, 1H), 8.14 (s, 1H), 2.99-2.95 (m, 1H), 1.14-1.07 (m, 4H). Measured using a Bruker Biospin GmbH 600 NMR spectrometer. 
     Intermediate 10A 
     3-[(Methylsulfinyl)methoxy]-5-(trifluoromethyl)benzoic acid 
     
       
         
         
             
             
         
       
     
     4.85 g (23.5 mmol) 3-hydroxy-5-(trifluoromethyl)benzoic acid, 7.5 g (66.2 mmol) chloro(methylsulfinyl)methane and 19 g (137.5 mmol) K 2 CO 3  were stirred in DMSO. After evaporation of the volatiles under reduced pressure the residue was dissolved in EtOAc, aq. citric acid, aq. NaCl. The aquous layer was extracted three times with EtOAc, the combined organic phases were dried with Na 2 SO 4  and evaporated under reduced pressure. Chromatography of the residue (RP-18, Water-Acetone, 0.1% HCOOH) yielded 2.3 g (68%, yield corrected by purity). 
     ESI mass [m/z]: 280.9 [M−H] −   
     Intermediate 11A 
     N-[(2S)-1-Amino-1-oxopropan-2-yl]-3-[(methylsulfinyl)methoxy]-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     1.8 g (6.4 mmol) 3-[(methylsulfinyl)methoxy]-5-(trifluoromethyl)benzoic acid and 1.2 g (9.6 mmol) L-alaninamide-HCl were dispersed in 100 mL DMF with 10 mL Et 3 N. At ice-water cooling, 7 mL (10.2 mmol) T3P (Propylphosphonic anhydride) 50% in acetonitrile were added during 0.5 h. The mixture was stirred at RT over night. After addition of excess aquous citric acid, the mixture was evaporated under reduced pressure. The residue was dissolved in EtOAc/THF, aq. citric acid, aq. NaCl. The aquous phase was extracted three times with EtOAc, the combined organic phases were washed two times with aq. K 2 CO 3 , dried with aq. NaCl, then Na 2 SO 4  and evaporated under reduced pressure to yield 2.25 g (75%, yield corrected by purity). 
     ESI mass [m/z]: 353.1 [M+H] +   
     Intermediate 12A 
     N-[(2S)-1-{(E)-[(Dimethylamino)methylene]amino}-1-oxopropan-2-yl]-3-[(methylsulfinyl)methoxy](trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     A mixture of 0.7 g (2 mmol) N-[(2S)-1-amino-1-oxopropan-2-yl]-3-[(methylsulfinyl)methoxy]-5-(trifluoromethyl)benzamide and dimethylformamide dimethyl acetal (5 ml) in 80 mL THF was heated to reflux for 15 min. The mixture was evaporated under reduced pressure and directly used in the subsequent step. 
     Intermediate 13A 
     2,3,3-Trichloroprop-2-en-1-yl 3-bromo-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzoate 
     
       
         
         
             
             
         
       
     
     5.07 g (23.4 mmol) 3-bromo-5-hydroxybenzoic acid, 9.5 g (43.9 mmol) 1,1,1,2,3-pentachloropropane and 11.05 g (80 mmol) K 2 CO 3  were stirred in 200 mL DMSO at 45° C. for 1 d. After evaporation of the volatiles under reduced pressure the residue was dissolved in EtOAc, aq, citric acid, aq. NaCl. The aquous phase was extracted three times with EtOAc and the combined organic phases were dried with Na 2 SO 4  and evaporated under reduced pressure to yield 11 g (84%, yield corrected by purity). 
       1 H NMR (400 MHz, CDCl 3 ): δ=7.8 (m, 1H), 7.55 (m, 1H), 7.3 (m, 1H), 5.2 (s, 2H), 4.9 (s, 2H) 
     Intermediate 14A 
     3-Bromo-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzoic acid 
     
       
         
         
             
             
         
       
     
     11 g (21.8 mmol) 2,3,3-trichloroprop-2-en-1-yl 3-bromo-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzoate were stirred in water-THF with aq. NaOH. After completion of the reaction aq. citric acid was added and the organic solvent was evaporated under reduced pressure. The precipitate was filtered off, washed with water an dried to yield 10.7 g crude product. 
     ESI mass [m/z]: 358.9 [M−H] −   
     Intermediate 15A 
     N-[(2S)-1-Amino-1-oxopropan-2-yl]-3-bromo-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzamide 
     
       
         
         
             
             
         
       
     
     5.3 g (14.7 mmol) 3-bromo-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzoic acid and 2.7 g (21.7 mmol) L-alaninamide-HCl were dispersed in 100 mL DMF with 10 mL Et 3 N. At ice-water cooling, 7 mL (10.2 mmol) T3P (Propylphosphonic anhydride) 50% in acetonitrile were added during 0.5 h. The mixture was stirred at RT over night. A further lot of 6 mL T3P was added, now totalling 13 mL (19 mmol). The mixture was stirred at RT over night. After addition of excess aqueous citric acid, the mixture was evaporated under reduced pressure. The residue was dissolved in EtOAc/THF, aq. citric acid, aq. NaCl. The aquous phase was extracted three times with EtOAc, the combined organic phases were washed two times with aq. K 2 CO 3 , dried with aq. NaCl, than Na 2 SO 4  and evaporated under reduced pressure to yield 4.8 g (44%, yield corrected by purity). 
     ESI mass [m/z]: 431.0 [M+H] +   
     Intermediate 16A 
     3-Bromo-N-[(2S)-1-{(E)-[(dimethylamino)methylene]amino}-1-oxopropan-2-yl]-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzamide 
     
       
         
         
             
             
         
       
     
     4.75 g (11 mmol) N-[(2 S)-1-amino-1-oxopropan-2-yl]-3-bromo-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzamide were refluxed with 10 mL (75 mmol) dimethylformamide dimethyl acetal in THF for 0.5 h. The mixture was evaporated under reduced pressure and directly used in the next step. 
     Intermediate 17A 
     2-Hydrazino-1,3-thiazole-5-carbonitrile 
     
       
         
         
             
             
         
       
     
     A mixture of 9.00 g (62.2 mmol) 2-chloro-1,3-thiazole-5-carbonitrile and 124.5 mL (124.5 mmol) of a 1 M solution of hydrazine in THF was refluxed for 2 h. After cooling to room temperature, the mixture was evaporated and then the residue was suspended in 50 mL of hot water. The resulting precipitate was filtered, washed with water and dried under vacuo to yield the title compound (9.00 g). Further drying by co-evaporation with absolute toluene resulted in a decrease in mass and this material was used in the next step. 
       1 H NMR peak list (DMSO-d 6 , 400 MHz): δ=9.7694 (1.7); 7.8727 (13.8); 5.3331 (16.0); 3.3330 (6.9); 2.5083 (12.7); 2.5040 (16.5); 2.4997 (12.5) 
     ESI mass [m/z]: 141.0 [M+H] +   
     Intermediate 18A 
     tert-Butyl {(1S)-1-[1-(5-cyanopyridin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}carbamate 
     
       
         
         
             
             
         
       
     
     To a solution of 2.00 g (10.6 mmol) N 2 -(tert-butoxycarbonyl)-L-alaninamide in 40 mL dichloromethane was added 2.1 mL (16 mmol) N,N-dimethylformamide dimethylacetal. The solution was heated at reflux for 2 h after which the solvent was removed under reduced pressure. The residue was dissolved in a mixture of 20 mL 1,4-dioxane and 20 mL glacial acetic acid. 1.7 g (13 mmol) 6-hydrazinonicotinonitrile was added and the mixture stirred at 50° C. for 60 min. The solvents were removed under reduced pressure, a saturated aqueous solution of NaHCO 3  was added and the mixture repeatedly extracted with ethyl acetate. The combined organic layers were washed with brine, dried with Na 2 SO 4  and the solvent was removed under reduced pressure. The residue was purified by reversed phase chromatography (H 2 O/acetonitrile) to provide 3.0 g of tert-butyl {(1S)-1-[1-(5-cyanopyridin-2-yl)-1H-1,2,4-triazol yl]ethyl}carbamate. 
     [α] D   20 =+89 (c=1.0; ethanol) 
       1 H NMR (DMSO-d 6 , 400 MHz): 9.10 (s, 1H), 8.57 (dd, 1H), 8.21 (s, 1H), 8.05 (d, 1H), 7.52 (d, 1H), 5.63 (m, 1H), 1.43 (d, 3H), 1.31 (s, 9H). 
     ESI mass [m/z]: 259.2 [M-C 4 H 8 +H] +   
     Intermediate 19A 
     6-{5-[(1S)-1-Aminoethyl]-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride 
     
       
         
         
             
             
         
       
     
     To a solution of 2.9 g (9.2 mmol) tert-butyl {(1S)-1-[1-(5-cyanopyridin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}carbamate in 40 mL 1,4-dioxane were added 23 mL of a 4 M solution of HCl in 1,4-dioxane. The mixture was stirred for 4 h at 50° C. and overnight at room temperature. The solvent was removed under reduced pressure to provide 2.81 g of a residue containing 6-{5-[(1S)-1-aminoethyl]-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride. This was used without further purification. 
       1 H NMR (DMSO-d 6 , 400 MHz): 9.11 (d, 1H), 8.80 (br d, 3H), 8.61 (dd, 1H), 8.45 (s, 1H), 8.13 (d, 1H), 5.39 (m, 1H), 1.63 (d, 3H). 
     ESI mass [m/z]: 215.2 [amine+H] +   
     Intermediate 20A 
     O-Methyl [(2S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl]carbamothioate 
     
       
         
         
             
             
         
       
     
     To a solution of 1.0 g (4.6 mmol) (2S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) propanoic acid in toluene (15 ml) was added 0.80 mL (9.12 mmol) oxalyl chloride and one drop of N,N-dimethylformamide. The reaction mixture was stirred 3 h at room temperature and then hexane (15 ml) was added and the stirring was continued over night. After this time additional oxalyl chloride (0.5 ml) was added again and the reaction mixture was stirred 3 h and finally was evaporated. The crude residue was dissolved in acetone (15 ml) and then 0.44 g (4.56 mmol) KSCN were added as a solution in acetone (5 ml) and the mixture was stirred at 60° C. for 2 h. Then 0.46 mL (11.4 mmol) of methanol were added and the mixture was stirred at 60° C. over night, cooled to room temperature and evaporated under reduced pressure. The resulting residue was dissolved in EtOAc, washed with water and brine respectively and finally the organic layer was dried over anhydrous Na 2 SO 4 , and then concentrated under reduced pressure. The crude product was purified by silica gel chromatography to yield the tittle compound (0.82 g, 59%). 
     ESI mass [m/z]: 293.1 [M+H] +   
     Intermediate 21A 
     6-{5-[(1S)-1-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-methoxy-1H-1,2,4-triazol-1-yl}nicotinonitrile 
     
       
         
         
             
             
         
       
     
     To a solution of 1.5 g (5.1 mmol) O-methyl [(2S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl]carbamothioate in ethanol (30 ml) were added 0.69 g (5.1 mmol) 6-hydrazinonicotinonitrile and the reaction mixture was stirred at 90° C. over night. The mixture was cooled to room temperature, evaporated under reduced pressure and the resulting residue was dissolved in EtOAc, washed with water and brine respectively. The organic layer was dried over anhydrous Na 2 SO 4  and then concentrated under reduced pressure. The crude product was purified by silica gel chromatography to yield the tittle compound (1.23 g, 58%). 
     ESI mass [m/z]: 375.1 [M+H] +   
     Intermediate 22A 
     6-{5-[(1S)-1-Aminoethyl]-3-methoxy-1H-1,2,4-triazol-1-yl}nicotinonitrile 
     
       
         
         
             
             
         
       
     
     To a solution of 1.20 g (3.20 mmol) 6-{5-[(1S)-1-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-3-methoxy-1H-1,2,4-triazol-1-yl}nicotinonitrile in ethanol (30 ml) were added 0.39 mL (8.01 mmol) hydrazin hydrate and the reaction was heated to reflux temperature over night. After cooling the mixture to room temperature, acetone (10 ml) was added and it was heated again to reflux temperature for 3 h. The resulting precipitate was filtered and the filtrate evaporated under reduced pressure to yield a residue which was used in the next step without further purification (1.05 g, 44% purity, 59% yield). 
     ESI mass [m/z]: 245.1 [M+H] +   
     Intermediate 23A 
     tert-Butyl {(1S)-1-[1-(5-cyanopyridin-2-yl)-3-cyclopropyl-1H-1,2,4-triazol-5-yl]ethyl}carbamate 
     
       
         
         
             
             
         
       
     
     To a solution of 2.0 g (10.5 mmol) N-(tert-butoxycarbonyl)-L-alanine in N,N-dimethylformamide (37.5 ml) was added 1.91 g (15.9 mml) cyclopropylamidin followed by 4.42 g (11.63 mmol) of HATU and 5.52 mL (31.7 mmol) of N,N-diisopropylethylamin and the reaction mixture was stirred at room temperature for 3 h. Afterwards 6.05 mL (105.7 mmol) of acetic acid and 2.13 g (15.8 mmol) of 6-hydrazinonicotinonitrile were added and the reaction mixture was stirred 5 h at 80° C. and then at room temperature overnight. The reaction mixture was cooled to room temperature, a saturated aqueous solution of Na 2 CO 3  was added and then the mixture was extracted with EtOAc. The combined organic layers were washed with water, an aqueous solution of 5% NaH 2 PO 4 , brine and finally dried over Na 2 SO 4 . After filtration and evaporation of the solvent under vacuo the crude was purified by preparative HPLC (water/acetonitrile). The combined product fractions were evaporated to yield the title compound (0.77 g, 21%). 
     ESI mass [m/z]: 355.3 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, CD3CN): 
     δ=8.8116 (6.3); 8.8100 (6.6); 8.8062 (6.7); 8.8046 (5.9); 8.2628 (4.8); 8.2573 (4.6); 8.2412 (5.5); 8.2357 (5.4); 7.9980 (7.0); 7.9964 (6.6); 7.9764 (5.9); 7.9747 (5.6); 5.8766 (0.8); 5.7388 (0.5); 5.7213 (1.4); 5.7031 (1.9); 5.6849 (1.3); 5.6682 (0.4); 2.1614 (41.0); 2.0585 (1.0); 2.0462 (2.0); 2.0378 (2.2); 2.0344 (1.4); 2.0255 (3.5); 2.0194 (1.3); 2.0132 (2.1); 2.0049 (2.2); 1.9926 (1.1); 1.9648 (4.6); 1.9528 (18.4); 1.9467 (34.9); 1.9405 (49.0); 1.9343 (33.6); 1.9281 (17.1); 1.4498 (14.5); 1.4328 (14.5); 1.3608 (16.0); 1.2685 (1.1); 1.2388 (0.7); 1.1974 (0.7); 1.0334 (0.4); 1.0281 (0.4); 1.0173 (1.7); 1.0106 (5.0); 1.0083 (4.1); 1.0049 (6.3); 0.9990 (1.5); 0.9901 (6.0); 0.9848 (6.4); 0.9754 (1.5); 0.9669 (2.7); 0.9546 (1.2); 0.9464 (3.2); 0.9446 (3.1); 0.9403 (2.8); 0.9385 (2.8); 0.9342 (3.2); 0.9324 (3.0); 0.9274 (4.6); 0.9204 (2.9); 0.9154 (3.3); 0.9084 (2.6); 0.9047 (1.3); 0.9014 (1.4); 0.8974 (1.0); 0.8927 (0.8); 0.8872 (0.7); 0.8837 (0.6); 0.1459 (0.8); 0.0080 (6.7); −0.0002 (166.9); −0.0086 (6.2); −0.0171 (0.6); −0.1495 (0.8) 
     Intermediate 24A 
     6-{5-[(1S)-1-Aminoethyl]-3-cyclopropyl-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride (1:1) 
     
       
         
         
             
             
         
       
     
     A solution of 830 mg (2.34 mmol) tert-butyl {(1S)-1-[1-(5-cyanopyridin-2-yl)-3-cyclopropyl-1H-1,2,4-triazol-5-yl]ethyl}carbamate in dioxane (22 ml) was treated with HCl 4N in dioxane (10.9 ml). The reaction mixture was stirred at room temperature overnight. The resulting precipitate was separated by filtration and dried under air to yield the title compound (0.71, 100%). 
     ESI mass [m/z]: 255.1 [amine+H] +   
     Intermediate 25A 
     3-(Cyanomethyl)-5-(trifluoromethoxy)benzoic acid 
     
       
         
         
             
             
         
       
     
     A vial was charged with 3-bromo-5-(trifluoromethoxy)benzoic acid (500 mg, 1.75 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (418 mg, 2.10 mmol) and DMSO (17.5 mL). Then, potassium fluoride (306 mg, 5.26 mmol) and water (5.0 mL) were added and the mixture was degassed. [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (128 mg, 0.17 mmol) was added and the vial was sealed and heated to 130° C. for 16 h. After cooling to RT, the mixture was filtered over a plug of Celite and the filter cake was washed with ethyl acetate. Aqueous sodium hydroxide solution (1.0 M) was added and the layers were separated. The aqueous layer was acidified with hydrochloric acid (0.1 M) until pH 5 and extracted with ethyl acetate. All organic phases were combined, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by preparative HPLC to afford the title compound. Yield: 217 mg (50% of theory). 
     ESI mass [m/z]: 246.0 [M+H] +   
       1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm]=13.63 (br s, 1H), 7.99 (s, 1H), 7.77 (s, 1H), 7.66 (s, 1H), 4.23 (s, 2H). 
     Intermediate 26A 
     Sodium 3-(1-cyano-1-methyl-ethyl)-5-(trifluoromethoxy)benzoate 
     
       
         
         
             
             
         
       
     
     A flask was charged with a mixture of iodomethane (173 μL, 2.77 mmol) and sodium hydride (159 mg, 4.16 mmol, 63% dispersion in mineral oil) in DMF (1.0 ml). The mixture was cooled to 0° C. and a solution of 3-(cyanomethyl)-5-(trifluoromethoxy)benzoic acid (170 mg, 0.69 mmol) in DMF (2.0 ml) was added dropwise at this temperature. After complete addition, the mixture was allowed to warm to r.t. and stirred overnight. Water was added and the mixture was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to leave the crude title compound which was used in the next steps without further purification. Yield: 95.2 mg (47% of theory). 
       1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm]=8.07 (s, 1H), 7.77-7.73 (m, 1H), 7.57 (s, 1H), 1.72 (s, 6H). 
     Intermediate 27A 
     3-Bromo-5-(2,2-dichlorovinyl)benzonitrile 
     
       
         
         
             
             
         
       
     
     To a solution of 1.0 g (4.8 mmol) 3-bromo-5-formylbenzonitrile in 5 mL acetonitrile were added 1.89 g (9.52 mmol) bromo(trichloro)methane and 3.75 g (14.2 mmol) triphenylphosphine. The mixture was stirred overnight at ambient temperature after which the crude reaction mixture was purified by reversed phase chromatography (MeCN/H 2 O) to provide 1.06 g 3-bromo-5-(2,2-dichlorovinyl)benzonitrile. 
     EI mass [m/z]: 277 [M + ](EI=electron ionization) 
     Intermediate 28A 
     3-Bromo-5-(2,2-dichlorovinyl)benzoic acid 
     
       
         
         
             
             
         
       
     
     A mixture of 300 mg (1.1 mmol) 3-bromo-5-(2,2-dichlorovinyl)benzonitrile and 2.5 mL a 50% sulfuric acid was stirred for 6 h at 100° C. and overnight at room temperature. Water and ethyl acetate were then added and the reaction mixture repeatedly extracted with ethyl acetate. The combined organic layers were washed with brine and dried with Na 2 SO 4 . The solvent was removed under reduced pressure to provide 277 mg of 3-bromo-5-(2,2-dichlorovinyl)benzoic acid. 
       1 H-NMR (DMSO-d 6 , 400 MHz): δ=13.5 (brs, 1H), 8.20 (s, 1H), 8.01-8.02 (m, 2H), 7.38 (s, 1H). 
     ESI mass [m/z]: 294.8 [M−H] −   
     Intermediate 29A 
     3-Chloro-5-[(methylsulfonyl)oxy]benzoic acid 
     
       
         
         
             
             
         
       
     
     To a suspension of 250 mg (1.4 mmol) 3-chloro-5-hydroxybenzoic acid in 5.9 mL THF were added at 0° C. 0.22 mL (2.89 mmol) methanesulfonyl chloride and 0.81 mL (5.8 mmoL) triethylamine. The reaction mixture was stirred for 15 min and then diluted with ethyl acetate and washed with 1 M hydrochloric acid. The organic layer was dried with Na 2 SO 4  and the solvent was removed under reduced pressure to provide 365 mg of a residue containing 3-chloro-5-[(methylsulfonyl)oxy]benzoic acid. This was used without further purification. 
     ESI mass [m/z]: 249.0 [M−H] −   
     Intermediate 30A 
     3-Acetoxy-5-chlorobenzoic acid 
     
       
         
         
             
             
         
       
     
     250 mg (1.4 mmol) 3-chloro-5-hydroxybenzoic acid was dissolved in a mixture of 0.8 mL water and 64 mg (1.59 mmol) sodium hydroxide. 1 g of ice was added to this solution, followed of the addition of 0.18 mL (1.9 mmol) acetic acid anhydride. The reaction mixture was stirred overnight at room temperature. It was then acidified using 1 M hydrochloric acid and repeatedly extracted with ethyl acetate. The combined organic layers were dried with Na 2 SO 4  and the solvent was removed under reduced pressure to provide 233 mg of 3-acetoxy-5-chlorobenzoic acid. This was used without further purification. 
       1 H-NMR (DMSO-d 6 , 400 MHz): δ=13.5 (brs, 1H), 7.80 (m, 1H), 7.65 (m, 1H), 7.61 (m, 1H), 2.29 (s, 3H). 
     ESI mass [m/z]: 213.0 [M−H] −   
     Intermediate 31A 
     3,5-Dibromo-N-methoxy-N-methylbenzamide 
     
       
         
         
             
             
         
       
     
     To a mixture of 3,5-dibromobenzoic acid (40.0 g, 143 mmol, 1.00 eq) and N,O-dimethylhydroxylamine hydrochloride (18.1 g, 186 mmol, 1.30 eq) and N-ethyl-N-isopropylpropan-2-amine (55.4 g, 429 mmol, 74.7 mL, 3.00 eq) in acetonitrile (250 mL) was added HATU (81.5 g, 214 mmol, 1.50 eq). The mixture was stirred at 25° C. for 16 hrs. The mixture was then diluted with water (500 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated. The crude product was purified by silica gel chromatography (petroleum ether/EtOAc) to obtain 3,5-dibromo-N-methoxy-N-methylbenzamide (43.7 g, 135 mmol, 94.7% yield) as a yellow oil. 
     Intermediate 32A 
     (3,5-Dibromophenyl)(4-fluorophenyl)methanone 
     
       
         
         
             
             
         
       
     
     To a solution of 3,5-dibromo-N-methoxy-N-methylbenzamide (8.50 g, 26.3 mmol, 1.00 eq) in THF (60.0 mL) was added bromo(4-fluorophenyl)magnesium (1.00 M, 39.5 mL, 1.50 eq) at −10 to 0° C. The mixture was stirred at 25° C. for 12 hrs. The mixture was added into an aqueous solution of NH 4 Cl (50.0 mL). The mixture was extracted with ethyl acetate (2×30.0 mL). The combined organic layers were dried with anhydrous Na 2 SO 4  and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate) to obtain (3,5-dibromophenyl)(4-fluorophenyl)methanone (7.14 g, 19.9 mmol, 75.8% yield) as a white solid. 
     Intermediate 33A 
     1,3-Dibromo-5-[difluoro(4-fluorophenyl)methyl]benzene 
     
       
         
         
             
             
         
       
     
     Under a nitrogen atmosphere (3,5-dibromophenyl)(4-fluorophenyl)methanone (6.80 g, 19.0 mmol, 1.00 eq) was dissolved in Bis(2-methoxyethyl)aminosulfur trifluoride (45.0 mL). The mixture was stirred at 60° C. for 16 hrs. The mixture was then diluted with the CH 2 Cl 2  (30.0 mL) and added dropwise into water (50.0 mL). After phase separation the aqueous phase was extracted with CH 2 Cl 2  (2×20.0 mL). The combined organic phase was dried with anhydrous Na 2 SO 4  and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate) to obtain compound 1,3-dibromo-5-[difluoro(4-fluorophenyl)methyl]benzene (6.90 g, 18.2 mmol, 95.6% yield) as a white solid. 
     Intermediate 34A 
     1-Bromo-3-[difluoro(4-fluorophenyl)methyl]-5-vinylbenzene 
     
       
         
         
             
             
         
       
     
     To a mixture of 1,3-dibromo-5-[difluoro(4-fluorophenyl)methyl]benzene (6.10 g, 16.1 mmol, 1.00 eq), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (2.23 g, 14.5 mmol, 2.45 mL, 0.90 eq), Na 2 CO 3  (3.40 g, 32.1 mmol, 2.00 eq), dioxane (50.0 mL) and H 2 O (10.0 mL) was added [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl 2 dppf) (940 mg, 1.28 mmol, 0.08 eq) under a nitrogen atmosphere. The mixture was stirred at 80° C. for 16 h. Water (50.0 mL) was then added and the aqueous phase extracted with ethyl acetate (2×30.0 mL). The combined organic layers were dried with anhydrous Na 2 SO 4  and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate) to obtain 1-bromo-3-[difluoro(4-fluorophenyl)methyl]vinylbenzene (4.70 g, 14.4 mmol, 89.5% yield) as a white solid. 
     Intermediate 35A 
     3-Bromo-5-[difluoro(4-fluorophenyl)methyl]benzoic acid 
     
       
         
         
             
             
         
       
     
     KMnO 4  (1.16 g, 7.34 mmol, 0.50 eq) was added to a mixture of 1-bromo-3-[difluoro(4-fluorophenyl)methyl]-5-vinylbenzene (4.80, 14.7 mmol, 1.00 eq) and NaIO 4  (12.6 g, 58.7 mmol, 3.25 mL, 4.00 eq) in acetone (40 mL) and H 2 O (20 mL) at 30° C. The mixture was stirred at 30° C. for 0.5 hrs and then acidified by the addition of 2 N HCl until pH=3. The mixture was filtered and extracted with CH 2 Cl 2  (3×20 ml). The combined organic layers were dried with anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by prep-HPLC (water/acetonitrile/0.1% TFA) to 3-bromo-5-[difluoro(4-fluorophenyl)methyl]benzoic acid (1.10 g, 3.03 mmol, 20.6% yield, 95.2% purity) as a white solid. 
       1 H-NMR (DMSO-d 6 , 400 MHz): δ=8.14 (s, 1H), 8.03-7.99 (m, 1H), 7.94 (s, 1H), 7.69-7.61 (m, 2H), 7.39-7.27 (m, 2H). 
     ESI mass [m/z]: 344.9 [M−H] −   
     Intermediate 36A 
     tert-Butyl (1S)-1-[1-(5-cyano-1,3-thiazol-2-yl)-1H-1,2,4-triazol-5-yl]ethyl carbamate 
     
       
         
         
             
             
         
       
     
     To a solution of 0.500 g (2.65 mmol) N 2 -(tert-butoxycarbonyl)-L-alaninamide in 17 mL CH 2 Cl 2  were added 0.53 mL (4.0 mmol) N,N-dimethylformamide dimethylacetal. The solution was heated at reflux for 2 h after which the solvent was removed under reduced pressure. The residue was dissolved in a mixture of 10 mL glacial acetic acid and 10 mL 1,4-dioxane. 0.596 g (4.25 mmol) 2-hydrazino-1,3-thiazole carbonitrile were added and the mixture was stirred for 1 h at 50° C. The solvent was then removed under reduced pressure, a saturated aq. NaHCO 3  solution was added and the mixture repeatedly extracted with ethyl acetate. The combined organic layers were washed with brine, dried with Na 2 SO 4  and the solvent was removed under reduced pressure. The residue was purified by chromatography on silica (ethyl acetate/cyclohexane) to provide 356 mg of tert-butyl {(1S)-1-[1-(5-cyano-1,3-thiazol-2-yl)-1H-1,2,4-triazol yl]ethyl}carbamate. 
       1 H NMR peak list (DMSO-d 6 , 400 MHz): δ=8.6600 (4.0); 8.2923 (2.2); 7.6953 (0.8); 7.6777 (0.8); 5.5940 (0.6); 5.5771 (0.8); 5.5591 (0.6); 3.3345 (44.8); 2.8917 (0.5); 2.7322 (0.4); 2.6766 (0.4); 2.6721 (0.5); 2.6676 (0.4); 2.5253 (1.7); 2.5119 (31.6); 2.5076 (60.4); 2.5031 (78.1); 2.4986 (58.0); 2.4944 (28.8); 2.3345 (0.4); 2.3300 (0.5); 2.3255 (0.4); 1.9897 (0.7); 1.9092 (0.5); 1.4244 (7.1); 1.4069 (7.1); 1.3706 (0.6); 1.3363 (16.0); 1.1752 (0.5); 1.0697 (1.0); 0.0078 (2.3); −0.0002 (50.8); −0.0085 (2.0) 
     ESI mass [m/z]: 265.0 [M-C 4 H 8 +H] +   
     Intermediate 37A 
     Methyl 3-(cyclobutyloxy)-5-methylbenzoate 
     
       
         
         
             
             
         
       
     
     Intermediate 37A was synthesized under reaction conditions described in the general procedure 1 from 100 mg (0.60 mmol) methyl 3-hydroxy-5-methylbenzoate, 89 mg (0.66 mmol) bromocyclobutane and 166 mg (1.20 mmol) K 2 CO 3  in DMF at 85° C. to yield the title compound (75 mg, 57%). 
     ESI mass [m/z]: 221.3 [M+H] +   
     Intermediate 38A 
     3-(Cyclobutyloxy)-5-methylbenzoic acid 
     
       
         
         
             
             
         
       
     
     To a solution of 71 mg (0.32 mmol) methyl 3-(cyclobutyloxy)-5-methylbenzoate in 1 mL dioxane and 1 mL water was added 18 mg (0.80 mmol) LiOH and the mixture was stirred at room temperature overnight. After removing the dioxane under vacuo, water was added, and the solution was acidified with aq. 10% HCl till pH 3. Water was evaporated under vacuo and codestillated with toluene to give the title compound (66 mg, 95%) which was used in the next without further purification. 
     ESI mass [m/z]: 207.2 [M+H] +   
     Intermediate 39A 
     Methyl 3-(cyclopropylmethoxy)-5-methylbenzoate 
     
       
         
         
             
             
         
       
     
     Intermediate 39A was synthesized under reaction conditions described in the general procedure 1 from 300 mg (1.80 mmol) methyl 3-hydroxy-5-methylbenzoate, 268 mg (1.98 mmol) (bromomethyl)cyclopropane and 499 mg (3.61 mmol) K 2 CO 3  in DMF at room temperature to yield the title compound (329 mg, 82%). 
     ESI mass [m/z]: 221.1 [M+H] +   
     Intermediate 40A 
     3-(Cyclopropylmethoxy)-5-methylbenzoic acid 
     
       
         
         
             
             
         
       
     
     To a solution of 285 mg (1.29 mmol) methyl 3-(cyclopropylmethoxy)-5-methylbenzoate in 7 mL dioxane and 2.3 mL water was added 74 mg (3.23 mmol) LiOH and the mixture was stirred at room temperature overnight. After removing the dioxane under vacuo, water was added and the solution was acidified with aq. 10% HCl till pH 1. Water was evaporated under vacuo and codestillated with toluene to give the title compound (520 mg, 93%) which was used in the next without further purification. 
     ESI mass [m/z]: 207.2 [M+H] +   
     Intermediate 41A 
     Methyl 3-(cyclopentyloxy)-5-methylbenzoate 
     
       
         
         
             
             
         
       
     
     This intermediate was synthesized under reaction conditions described in the general procedure 1 from 100 mg (0.60 mmol) methyl 3-hydroxy-5-methylbenzoate, 99 mg (0.66 mmol) bromocyclopentane and 166 mg (1.20 mmol) K 2 CO 3  in DMF at 60° C. to yield the title compound (74 mg, 38%). 
     ESI mass [m/z]: 235.2 [M+H] +   
     Intermediate 42A 
     3-(Cyclopentyloxy)-5-methylbenzoic acid 
     
       
         
         
             
             
         
       
     
     To a solution of 79 mg (0.33 mmol) methyl 3-(cyclopentyloxy)-5-methylbenzoate 1.8 mL dioxane and 0.6 mL water was added 19 mg (0.84 mmol) LiOH and the mixture was stirred at room temperature overnight. After removing the dioxane under vacuo, water was added, and the solution was acidified with aq. 10% HCl till pH 1. Water was evaporated under vacuo and codestillated with toluene to give the title compound (73 mg, 97%) which was used in the next without further purification. 
     ESI mass [m/z]: 221.2 [M+H] +   
     Intermediate 43A 
     Methyl 3-methyl-5-(oxetan-3-yloxy)benzoate 
     
       
         
         
             
             
         
       
     
     Intermediate 43A was synthesized under reaction conditions described in the general procedure 1 from 100 mg (0.60 mmol) methyl 3-hydroxy-5-methylbenzoate, 91 mg (0.66 mmol) 3-bromooxetane and 166 mg (1.20 mmol) K 2 CO 3  in DMF at 85° C. to yield the title compound (85 mg, 60%). 
     ESI mass [m/z]: 223.1 [M+H] +   
     Intermediate 44A 
     3-Methyl-5-(oxetan-3-yloxy)benzoic acid 
     
       
         
         
             
             
         
       
     
     To a solution of 86 mg (0.38 mmol) methyl 3-methyl-5-(oxetan-3-yloxy)benzoate 2 mL dioxane and 0.7 mL water was added 22 mg (0.96 mmol) LiOH and the mixture was stirred at room temperature overnight. After removing the dioxane under vacuo, water was added, and the solution was acidified was acidified with aq. 10% HCl till pH 1. Water was evaporated under vacuo and codestillated with toluene to give the title compound (79 mg) which was used in the next without further purification. 
     ESI mass [m/z]: 209.1 [M+H] +   
     Intermediate 45A 
     Methyl 3-chloro-5-methylbenzoate 
     
       
         
         
             
             
         
       
     
     To 25.5 g (145 mmol) 3-chloro-5-methylbenzoic acid in 100 ml DCM containing 5 drops DMF were added 16 ml (0.22 mmol) thionyl chloride at reflux. The mixture was heated under reflux overnight and the volatiles were then removed under reduced pressure. The residue was dissolved in 100 ml DCM and at 0-5° C. a mixture of MeOH and Et 3 N was added. The mixture was stirred overnight. Aq. HCl was added and the organic layer was washed with water, dried and evaporated under reduced pressure to yield 24.4 g (72%, yield corrected by purity). 
     ESI mass [m/z]: 185.2 [M+H] +   
       1 H NMR (400 MHz, CDCl 3 ): δ=2.4 (s, 3H), 3.85 (s, 3H), 7.6 (s, 1H), 7.7 (m, 2H). 
     Intermediate 46A 
     Methyl 3-(bromomethyl)-5-chlorobenzoate 
     
       
         
         
             
             
         
       
     
     51.7 g (280 mmol) Methyl 3-chloro-5-methylbenzoate and 0.55 g AIBN were heated under reflux in 160 ml ACN. NBS was added in portions, the mixture was heated under reflux for 1 day, stirred at room temperature for 3 days and the volatiles were then removed under reduced pressure. The residue was dissolved in EtOAc and washed with aq. sodium bisulfite, dried and evaporated to yield 75.9 g (77%, yield corrected by purity). 
     ESI mass [m/z]: 262.9 [M+H] +   
     Intermediate 47A 
     Methyl 3-chloro-5-[(methylsulfonyl)methyl]benzoate 
     
       
         
         
             
             
         
       
     
     12.2 g (44 mmol) Methyl 3-(bromomethyl)-5-chlorobenzoate and 13.4 g (132 mmol) sodium sulfinate were stirred in 90 ml DMF at 80° C. for 1.5 d. 13 g sodium sulfinate were added and stirring at 80° C. was continued for 5 h. The volatiles were then removed under reduced pressure and the residue was taken up in DCM. Washing the DCM phase twice with water, drying and evaporation under reduced pressure yielded 12.6 g crude product. Reversed phase chromatography (acetonitrile/water, 0.1% HCOOH) gave 7.94 g (69%). 
     ESI mass [m/z]: 261.1 [M−H] −   
       1 H NMR (400 MHz, D6-DMSO): δ=2.95 (s, 3H), 3.9 (s, 3H), 4.15 (s, 2H), 7.75 (m, 1H), 7.95 (m, 1H), 8.0 (m, 1H). 
     Intermediate 48A 
     3-[(Methylsulfinyl)methoxy]-5-(trifluoromethyl)benzoic acid 
     
       
         
         
             
             
         
       
     
     4.67 g (26.8 mmol) Methyl 3-chloro-5-[(methylsulfonyl)methyl]benzoate was dissolved in 50 ml EtOH. 2.9 g (32 mmol) NaOH in 25 ml water were added. The mixture was stirred overnight and the volatiles were removed under reduced pressure. The residue was taken up in water and the pH was adjusted to pH=2 using aq. HCl. The mixture was stirred for 1 h, the precipitate filtered off, washed with water and dried. This yielded 4.45 g (quantitative yield corrected by purity) of the title compound. 
     ESI mass [m/z]: 247.1 [M−H] −   
       1 H NMR (400 MHz, D6-DMSO): δ=2.95 (s, 3H), 4.65 (m, 2H), 7.75 (m, 1H), 7.9 (m, 1H), 7.95 (m, 1H), 13.5 (br, 1H). 
     Intermediate 49A 
     3-Chloro-5-[(methylsulfonyl)methyl]benzoyl chloride 
     
       
         
         
             
             
         
       
     
     To 0.3 g (1.1 mmol) 3-[(methylsulfinyl)methoxy]-5-(trifluoromethyl)benzoic acid in 7.5 ml DCM were added two drops of DMF and 0.33 g (206 mmol) oxaxlyl chloride. The mixture was heated under reflux for 2 h and the volatiles were removed under reduced pressure. The crude product was directly used in the following step to synthesize the example compounds. 
     Intermediate 50A 
     3-(Cyclopropoxy)-5-(trifluoromethoxy)benzoic acid 
     Step 1: 1-Bromo-3-(cyclopropoxy)-5-(trifluoromethoxy)benzene 
     
       
         
         
             
             
         
       
     
     To a solution of 3-bromo-5-(trifluoromethoxy)phenol (1) (10 g, 38.9 mmol) in DMF (200 mL) cesium carbonate (25.35 g, 77.8 mmol) and bromocyclopropane (23.59 g, 195 mmol) were added. The mixture was stirred at 130° C. in sealed reactor for 48 hours, poured in water (300 mL) and extracted with EtOAc (5×100 mL). The organic phase was washed with brine (2×100 mL), dried over Na 2 SO 4 , concentrated under reduced pressure and purified by flash chromatography affording 1-bromo-3-(cyclopropoxy)-5-(trifluoromethoxy)benzene (2) (3.5 g, 11.78 mmol, 30.3% yield). 
     Step 2: 1-Methyl 3-(cyclopropoxy)-5-(trifluoromethoxy)benzoate 
     
       
         
         
             
             
         
       
     
     To a solution of 1-bromo-3-(cyclopropoxy)-5-(trifluoromethoxy)benzene (2) (3.5 g, 11.78 mmol) in MeOH (50 mL), triethylamine (2.38 g, 23.6 mmol) and Pd(dppf)Cl 2  (0.861 g, 1.178 mmol) were added. The mixture was stirred at 130° C. under pressure of CO (10 Torr) for 48 h, diluted with EtOAc (200 mL), filtered through a pad of celite and concentrated under reduced pressure. The residue was dissolved in EtOAc (100 mL) and washed with water (2×100 mL). The organic phase was dried over Na 2 SO 4  and concentrated under reduced pressure to afford methyl 3-(cyclopropoxy)-5-(trifluoromethoxy)benzoate (3) (3.1 g, 11.2 mmol, 95% yield, ˜90% purity). 
     Step 3: 3-(Cyclopropoxy)-5-(trifluoromethoxy)benzoic acid (50A) 
     
       
         
         
             
             
         
       
     
     To a solution of methyl 3-(cyclopropoxy)-5-(trifluoromethoxy)benzoate (3) (3.1 g, 11.2 mmol) in a mixture of THF and H 2 O (1:3, 50 mL) LiOH.H 2 O (0.6367 g, 15.17 mmol) was added at 0° C. The mixture was stirred for 8 h at r.t. THF was removed under reduced pressure, water phase was acidified to pH˜5 and extracted with EtOAc (2×50 mL). The organic phase was dried over Na 2 SO 4  and concentrated under reduced pressure. Purification by HPLC gave 3-(cyclopropoxy)-5-(trifluoromethoxy)benzoic acid (1.17 g, 4.47 mmol, 40% yield). 
     ESI mass [m/z]: 261.0 [M−H] −   
       1 H NMR (400 MHz, D6-DMSO): δ=0.65 (m, 2H), 0.83 (d, 2H), 3.99 (m, 1H), 7.27 (s, 1H), 7.41 (s, 1H), 7.58 (m, 1H), 13.51 (s, 1H). Measured with Bruker AVANCE III 400 MHz. 
     Intermediate 51A 
     3-Bromo-5-(1-cyano-1-methyl-ethoxy)benzoic acid 
     Step 1: Methyl 3-(2-amino-1,1-dimethyl-2-oxo-ethoxy)-5-bromo-benzoate 
     
       
         
         
             
             
         
       
     
     To a solution of methyl 3-bromo-5-hydroxy-benzoate (9.74 g, 42.2 mmol) in dry dioxane (100 mL) was added NaH (2.12 g, 88.62 mmol). The reaction mixture was stirred for 1 h and 2-bromo-2-methylpropanamide (14 g, 84.4 mmol) was added. The resulting mixture was stirred under reflux for 4 h. The mixture was filtrated, the filtrate was concentrated in vacuo to obtain 6 (8 g, 60% yield). 
     Step 2: Methyl 3-bromo-5-(1-cyano-1-methyl-ethoxy)benzoate 
     
       
         
         
             
             
         
       
     
     To a solution of methyl 3-(2-amino-1,1-dimethyl-2-oxo-ethoxy)-5-bromo-benzoate (8 g, 25.3 mmol) and triethylamine (10.22 g, 101 mmol) in dry dichloromethane (80 mL), cooled to 0° C., was added dropwise a solution of trifluoroacetic anhydride (15.9 g, 75.9 mmol) in dichloromethane. The reaction mixture was stirred overnight at r.t. and diluted with an aqueous NaHCO 3  solution. The water phase was extracted with dichloromethane three times and the combined organic layers were dried over anhydrous Na 2 SO 4  and evaporated under reduced pressure to obtain 5.67 g of compound 7 (75% yield). 
     Step 3: 3-Bromo-5-(1-cyano-1-methyl-ethoxy)benzoic acid (51A) 
     
       
         
         
             
             
         
       
     
     To a solution of methyl 3-bromo-5-(1-cyano-1-methyl-ethoxy)benzoate (5.67 g, 19 mmol) in a mixture of THF/H 2 O (15/1.3) was added in portions LiOH.H 2 O (2.4 g, 57 mmol) and the mixture was stirred overnight at r.t. The reaction mixture was acidified with 2 N solution of HCl to pH=2-3. The water phase was extracted with dichloromethane three times and the combined organic layers were dried over anhydrous Na 2 SO 4  and evaporated under reduced pressure to obtain 1.56 g of the title compound (28.9% yield). 
     ESI mass [m/z]: 283.9 [M−H] −   
       1 H NMR (400 MHz, D6-DMSO): δ=13.55 (bs, 1H, COOH), 7.88 (m, 1H), 7.73 (m, 1H), 7.64 (m, 1H), 1.72 (s, 6H). 
     Intermediate 52A 
     3-Chloro-5-(1-cyano-1-methyl-ethoxy)benzoic acid 
     
       
         
         
             
             
         
       
     
     3-Chloro-5-(1-cyano-1-methyl-ethoxy)benzoic acid was synthesized analoguously to intermediate 51A. 
     ESI mass [m/z]: 238.0 [M−H] −   
       1 H NMR (400 MHz, D6-DMSO): δ=13.55 (bs, 1H, COOH), 7.75 (m, 1H), 7.70 (m, 1H), 7.51 (m, 1H), 1.73 (s, 6H). 
     Intermediate 53A 
     tert-Butyl N-[(1S)-1-[2-(5-cyanopyrazin-2-yl)-1,2,4-triazol-3-yl]ethyl]carbamate 
     
       
         
         
             
             
         
       
     
     tert-Butyl N-[(1S)-1-[2-(5-cyanopyrazin-2-yl)-1,2,4-triazol-3-yl]ethyl]carbamate was synthesized analoguously to intermediate 18A. 
     Chiral purity: 100%—measured by SFC. Column. Chiralpak AD-3, 100×4.6 mm, I.D., 3 μm, mobile phase: A: CO 2 /B: isopropylamine (0.05% diethanolamine); gradient: from 5% to 40% in 2 min and hold 40% for 1 min, then from 40% to 5% of B for 1 min; Flow rate: 3.4 mL/min; column temp.: 35° C.; pressure 1800 psi. 
     ESI mass [m/z]: 260.1 [M-C 4 H 8 +H] +   
       1 H NMR (400 MHz, CDCl 3 ): δ=1.41 (s, 9H), 1.57 (d, J=6.8 Hz, 3H), 5.49 (d, J=7.2 Hz, 1H), 5.83-5.95 (m, 1H), 8.05 (s, 1H), 8.80 (d, J=1.2 Hz, 1H), 9.43 (d, J=0.8 Hz, 1H). Measured with Bruker AVANCE III 400 MHz. 
     Intermediate 54A 
     5-[5-[(1S)-1-Aminoethyl]-1,2,4-triazol-1-yl]pyrazine-2-carbonitrile hydrochloride 
     
       
         
         
             
             
         
       
     
     5-[5-[(1S)-1-Aminoethyl]-1,2,4-triazol-1-yl]pyrazine-2-carbonitrile hydrochloride was synthesized analoguously to intermediate 19A. 
       1 H NMR (DMSO-d 6 , 400 MHz): 9.40 (s, 1H), 9.29 (s, 1H), 8.55 (s, 1H), 6.55 (br s, 2H, NH 2 ), 5.34-5.28 (m, 1H), 1.66 (d, 3H). 
     ESI mass [m/z]: 216.1 [amine+H] +   
     Intermediate 55A 
     tert-Butyl N-[(1S)-1-[2-(6-cyanopyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]carbamate 
     
       
         
         
             
             
         
       
     
     tert-Butyl N-[(1S)-1-[2-(6-cyanopyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]carbamate was synthesized analoguously to intermediate 18A. 
     Chiral purity: 100%—measured by chiral HPLC. Method OD_RH (0.1% H 3 PO 4 /ACN). 
     ESI mass [m/z]: 260.0 [M-C 4 H 8 +H] +   
       1 H NMR (400 MHz, CDCl 3 ): δ=1.43 (s, 9H), 1.58 (d, J=6.8 Hz, 3H), 5.45-5.58 (m, 1H), 5.97-6.10 (m, 1H), 8.02 (s, 1H), 8.32 (d, J=0.8 Hz, 1H), 9.24 (d, J=1.2 Hz, 1H). Measured with Bruker AVANCE III 400 MHz. 
     Intermediate 56A 
     6-[5-[(1S)-1-Aminoethyl]-1,2,4-triazol-1-yl]pyrimidine-4-carbonitrile 2,2,2-trifluoroacetic acid salt 
     
       
         
         
             
             
         
       
     
     6-[5-[(1S)-1-Aminoethyl]-1,2,4-triazol-1-yl]pyrimidine-4-carbonitrile 2,2,2-trifluoroacetic acid salt was synthesized analoguously to intermediate 19A using trifluoroacetic acid in dichloromethane. 
     ESI mass [m/z]: 216.1 [amine+H] +   
     Intermediate 57A 
     tert-Butyl N-[(1S)-1-[2-(6-cyanopyrimidin-4-yl)-5-cyclopropyl-1,2,4-triazol-3-yl]ethyl]carbamate 
     
       
         
         
             
             
         
       
     
     tert-Butyl N-[(1S)-1-[2-(6-cyanopyrimidin-4-yl)-5-cyclopropyl-1,2,4-triazol-3-yl]ethyl]carbamate was synthesized analoguously to intermediate 23A. 
     Chiral purity: 96.2%—measured by chiral HPLC. Method OD_RH (0.1% H 3 PO 4 /ACN). 
     ESI mass [m/z]: 356.0 [M+H] +   
       1 H NMR (400 MHz, MeOD): δ=9.21 (s, 1H), 8.36 (s, 1H), 5.82 (q, J=6.8 Hz, 1H), 2.15-2.04 (m, 1H), 1.52 (d, J=6.8 Hz, 3H), 1.40 (br s, 9H), 1.09-0.98 (m, 4H). Measured with Bruker AVANCE III 400 MHz. 
     Intermediate 58A 
     6-[5-[(1S)-1-Aminoethyl]-3-cyclopropyl-1,2,4-triazol-1-yl]pyrimidine-4-carbonitrile hydrochloride 
     
       
         
         
             
             
         
       
     
     6-[5-[(1S)-1-Aminoethyl]-1,2,4-triazol-1-yl]pyrimidine-4-carbonitrile hydrochloride was synthesized analoguously to intermediate 24A. 
     ESI mass [m/z]: 256.2 [amine+H] +   
     Intermediate 59A 
     6-[5-[(1S)-1-Aminoethyl]-3-cyclopropyl-1,2,4-triazol-1-yl]pyrimidine-4-carboxamide hydrochloride 
     
       
         
         
             
             
         
       
     
     6-[5-[(1S)-1-Aminoethyl]-3-cyclopropyl-1,2,4-triazol-1-yl]pyrimidine-4-carboxamide hydrochloride was obtained as side hydrolysis product with intermediate 58A. 
     ESI mass [m/z]: 274.2 [amine+H] +   
     Intermediate 60A 
     3-Chloro-6-(1-cyano-1-methyl-ethyl)pyridine-4-carboxylic acid 
     Step 1: 2-Chloro-6-(cyanomethyl)pyridine-4-carboxylic acid 
     
       
         
         
             
             
         
       
     
     n-BuLi (91.14 mL, 2M, 183.3 mmol)) was diluted in anhydrous THF (150 mL) and cooled to −78° C. under argon. A solution of anhydrous acetonitrile (11.4 mL, 218.8 mmol) in anhydrous THF (30 mL) was added dropwise and the reaction mixture was maintained at −78° C. for 30 min. A solution of 2,6-dichloropyridine-4-carboxylic acid (7 g, 36.5 mmol) in THF (200 mL) was added dropwise over one hour and the reaction mixture was stirred at −78° C. for 45 min and then 1 h at room temperature. Then the reaction mixture was quenched with saturated aqueous citric acid solution (200 mL) and extracted with EtOAc (3×250 mL). The organic layer was washed with water (3×300 mL) followed by brine solution (200 mL) and dried over anhydrous Na 2 SO 4 , solvents were removed under reduced pressure. The residue was purified by flash silica gel chromatography using a gradient of 0% to 10% acetone in DCM. The obtained solid was triturated with 50% diethyl ether in n-pentane to obtained 4.2 g (58% yield) of 2-chloro-6-(cyanomethyl)pyridine-4-carboxylic acid as an off-white solid. 
     ESI mass [m/z]: 195.0 [M−H] −   
       1 H NMR (400 MHz, D6-DMSO): δ=7.87 (s, 1H), 7.82 (s, 1H), 4.27 (s, 2H). COOH not detected. 
     Step 2: 3-Chloro-6-(1-cyano-1-methyl-ethyl)pyridine-4-carboxylic acid 
     
       
         
         
             
             
         
       
     
     To a stirred solution of 2-chloro-6-(cyanomethyl)pyridine-4-carboxylic acid (4 g, 20.3 mmol) in acetonitrile (60 mL) under nitrogen, tetrabutylammonium bromide (6.56 g, 20.3 mmol) was added. Then methyl iodide (2.78 mL, 44.8 mmol) was added dropwise at room temperature, and then the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was cooled to 0° C., 8 mL of an aqueous NaOH solution (50%) was slowly added dropwise over 20 min. Then the reaction mixture was allowed to warm to room temperature and stirred for further 48 h. The reaction mixture was concentrated under vacuum at room temperature. The remaining residue was diluted with water and acidified with citric acid (pH˜5) and extracted with EtOAc (3×150 mL). The combined organic layers were washed with water (3×100 mL) and sodium thiosulfate solution (100 mL) followed by brine solution (150 mL). The organic layer was dried over anhydrous Na 2 SO 4 , solvents were removed under vacuum. The crude material was purified by by flash silica gel chromatography using a gradient 0% to 10% acetone in DCM. The resulting solid was washed with n-pentane to obtain 2.1 g (45% yield) of the title compounds as off-white solid. 
     ESI mass [m/z]: 223.1 [M−H] −   
       1 H NMR (400 MHz, D6-DMSO): δ=14.20 (bs, 1H, COOH), 7.96 (s, 1H), 7.85 (s, 1H), 1.74 (s, 6H). 
     Intermediate 61A 
     Step 1: 6-(5-{(1S)-1-[(tert-butoxycarbonyl)amino]ethyl}-3-methyl-1H-1,2,4-triazol-1-yl)nicotinic acid 
     
       
         
         
             
             
         
       
     
     To solution of 2.5 g (13.2 mmol) of N-(tert-butoxycarbonyl)-L-alaninamide in 15.7 ml dry dichloromethane was added 2.65 g (19.9 mmol) 1,1-dimethoxy-N,N-dimethylethanamine and the mixture was refluxed for 60 minutes. After cooling to room temperature, the mixture was evaporated under vacuo and the residue was dissolved in 30 ml acetic acid. Then 2.48 g (16.2 mmol) methyl 6-hydrazinonicotinate was added to the solution and the reaction mixture was stirred at 80° C. overnight. After cooling to room temperature the reaction mixture was poured into water and the corresponding precipitate was filtered and dried under vacuo to provide the title compound (1.99 g). 
     ESI mass [m/z]: 348.2 [M+H] +   
     Step 2: tert-Butyl [(1S)-1-(1-{5-[ethyl(methyl)carbamoyl]pyridin-2-yl}-3-methyl-1H-1,2,4-triazol-5-yl)ethyl]carbamate 
     
       
         
         
             
             
         
       
     
     To a solution of 1.85 g (5.32 mmol) 6-(5-{(1S)-1-[(tert-butoxycarbonyl)amino]ethyl}-3-methyl-1H-1,2,4-triazol-1-yl)nicotinic acid in 45 ml of dry dichloromethane were added 2.43 g (6.39 mmol) HATU and 1.86 ml (10.6 mmol) N,N-diisopropylethylamine After stirring for 60 minutes at room temperature a solution of 0.69 mg (7.99 mmol) ethylmethylamine in 7.0 ml dry dichloromethane was added slowly and the reaction mixture was stirred 16 h at room temperature. The mixture was then diluted with a 5% aq. solution of NaH 2 PO 4  and extracted with dichloromethane. Finally, the combine organic layers were concentrated and the residue was purified by preparative chromatography to yield the title compound (1.42 g). 
     ESI mass [m/z]: 389.3 [M+H] +   
       1 H NMR (400 MHz, D6-DMSO, peaklist): δ=8.5766 (0.6); 8.5465 (0.5); 8.3152 (0.4); 8.0715 (0.6); 8.0482 (0.4); 7.8590 (2.0); 7.8380 (1.7); 7.4108 (0.7); 7.3909 (0.7); 5.6124 (0.8); 5.5940 (1.2); 5.5760 (0.8); 3.5054 (0.6); 3.4891 (0.6); 3.3250 (138.0); 3.2915 (0.4); 3.2749 (0.5); 3.2710 (0.5); 2.9851 (2.4); 2.9738 (1.9); 2.9608 (1.9); 2.6899 (6.4); 2.6803 (0.4); 2.6757 (0.7); 2.6711 (0.9); 2.6666 (0.7); 2.6619 (0.3); 2.5245 (3.0); 2.5196 (5.1); 2.5112 (55.1); 2.5067 (110.6); 2.5022 (144.3); 2.4976 (102.2); 2.4930 (48.4); 2.3274 (16.0); 2.0862 (9.0); 1.9533 (0.4); 1.4300 (3.6); 1.4128 (3.3); 1.3811 (0.6); 1.3519 (0.3); 1.3096 (14.5); 1.2731 (0.6); 1.2565 (0.5); 1.1749 (0.9); 1.1577 (1.4); 1.1386 (1.3); 1.1348 (1.3); 1.1187 (1.7); 1.1077 (1.4); 1.0405 (0.9); 0.1459 (0.4); 0.0080 (4.1); −0.0002 (107.0); −0.0085 (3.7); −0.1497 (0.4). 
     Step 3: 6-{5-[(1S)-1-Aminoethyl]-3-methyl-1H-1,2,4-triazol-1-yl}-N-ethyl-N-methylnicotinamide hydrochloride (61A) 
     
       
         
         
             
             
         
       
     
     To 1.42 g (3.65 mmol) of tert-butyl [(1S)-1-(1-{5-[ethyl(methyl)carbamoyl]pyridin-2-yl}-3-methyl-1H-1,2,4-triazol-5-yl)ethyl]carbamate were added 17.1 mL of a 4 M solution of HCl in 1,4-dioxane. The mixture was stirred at room temperature until starting material disappeared. The solvent was removed under reduced pressure and the residue was used without further purification to yield 1.41 g of the title compound which was used without further purification (82% purity). 
     ESI mass [m/z]: 289.2 [amine+H] +   
       1 H NMR (400 MHz, D6-DMSO, peaklist): δ=8.7292 (0.9); 7.9513 (1.1); 7.9302 (0.9); 5.3597 (0.4); 3.7138 (1.1); 3.7099 (1.1); 3.6997 (1.2); 3.6788 (1.3); 3.6667 (1.3); 3.6227 (1.6); 3.5686 (16.0); 3.4928 (0.4); 2.9946 (1.0); 2.9600 (1.0); 2.6904 (1.6); 2.5264 (0.5); 2.5088 (19.3); 2.5045 (24.0); 2.5000 (17.4); 2.4177 (6.5); 1.6326 (2.7); 1.6158 (2.6); 1.1647 (0.6); 1.1475 (0.4); 1.1358 (0.4); 1.1212 (0.5); 1.1081 (0.6); −0.0002 (0.9). 
     Intermediate 62A 
     Step 1: (2,2-Difluorocyclopropyl)methyl 3-bromo-5[(2,2-difluorocyclopropyl)methoxy]benzoate 
     
       
         
         
             
             
         
       
     
     A mixture of 3-bromo-5-hydroxybenzoic acid (1.841 g, 6.49 mmol), 2-(bromomethyl)-1,1-difluorocyclopropane (2.99 mg, 17.5 mmol) and potassium carbonate (2.42, 17.5 mmol) in acetonitrile (16 ml) was stirred at 60° C. over night and concentrated under reduced pressure. After addition of aq. HCl and ethyl acetate, the organic layer was washed with water, dried with Na 2 SO 4  and evaporated under reduced pressure. Chromatography (silica, cyclohexane/ethyl acetate) yielded 0.657 g (25% of theory, 98% purity). 
     ESI mass [m/z]: 399.1 [M+H] +   
       1 H-NMR (400 MHz, D6-DMSO): δ=1.5 (m, 2H), 1.7 (m, 2H), 2.3 (m, 2H), 4.1 (m, 1H), 4.3 (m, 2H), 4.4 (m, 1H), 7.45 (s, 1H), 7.55 (s, 1H), 7.65 (s, 1H). 
     Step 2: 3-Bromo-5-[(2,2-difluorocyclopropyl)methoxy]benzoic acid 
     
       
         
         
             
             
         
       
     
     A mixture of (2,2-difluorocyclopropyl)methyl 3-bromo-5[(2,2-difluorocyclopropyl)methoxy]benzoate (0.657 g, 1.63 mmol) and sodium hydroxide (0.290 g, 3.26 mmol) in a mixture of ethanol (12 mL) and water (12 mL) was stirred at 40° C. for 2 hours and concentrated under reduced pressure. The residue was dissolved in aq. HCl/EtOAc, the organic layer was washed with water, dried with Na 2 SO 4  and concentrated under reduced pressure to yield 469 mg (97% of theory, 100% purity). 
     ESI mass [m/z]: 309.0 [M+H] +   
       1 H-NMR (400 MHz, D6-DMSO): δ=1.5 (m, 1H), 1.7 (m, 1H), 2.3 (m, 1H), 4.1 (m, 1H), 4.3 (m, 1H), 7.45 (s, 1H), 7.5 (s, 1H), 7.65 (s, 1H), 13.4 (br, 1H). 
     Intermediate 63A 
     Step 1: Allyl 3-bromo-5-[(2,2-dichlorocyclopropyl)methoxy]benzoate 
     
       
         
         
             
             
         
       
     
     A mixture of 17 g (55.4 mmol) allyl 3-(allyloxy)-5-bromobenzoate (synthesis described in Angewandte Chemie-International Edition, 2012, vol. 51, #52, p. 13036-13040), 205 mL CHCl 3 , 2.74 g (12 mmol) triethylbenzylammonium chloride, 0.5 g (5.7 mmol) lithium bromide and 0.6 mL EtOH was heated under reflux with vigorous stirring. 88.6 g (996 mmol) aq. NaOH (45%) were added dropwise. After 4.5 h, stirring was continued at RT for 3 days. The mixture was acidified with aq. HCl, the aqueous layer extracted with DCM, the combined organic layers were washed with water, dried with Na 2 SO 4  and evaporated under reduced pressure to yield a crude product of 18 g (85% of theory). Chromatography (silica, cyclohexane-EtOAc, then RP (ACN, water, 0.1% HCOOH) yielded 10.6 g of an enriched mixture, that was directly used in the subsequent step. 
     ESI mass [m/z]: 380.9 [M+H] +   
     Step 2: 3-Bromo-5-[(2,2-dichlorocyclopropyl)methoxy]benzoic acid 
     
       
         
         
             
             
         
       
     
     10.67 g of the material from the previous step and 4.5 g (56 mmol) aq. NaOH (45%) were stirred in EtOH 0.5 days at 40° C., 0.5 days at reflux and 5 days at RT. The organic solvent was removed under reduced pressure. The residue was dissolved in aq. HCl and EtOAc, the organic layer was washed with water, dried with Na 2 SO 4  and evaporated under reduced pressure. Repeated RP-chromatography (RP-18, ACN-water, 0.1% HCOOH, 0.05% HCOOH) yielded 0.6 g. 
     ESI mass [m/z]: 340.9 [M+H] +   
       1 H-NMR (400 MHz, D6-DMSO): δ=1.6 (m, 1H), 1.9 (m, 1H), 2.3 (m, 1H), 4 (m, 1H), 4.4 (m, 1H), 7.45 (s, 1H), 7.5 (s, 1H), 7.65 (s, 1H), 13.4 (br, 1H). 
     Intermediate 64A 
     Step 1: Methyl 3-bromo-5-(2-hydroxyethoxy)benzoate 
     
       
         
         
             
             
         
       
     
     To a stirred mixture of 14.8 g (64.4 mmol) methyl 3-bromo-5-hydroxybenzoate (synthesis described in WO2015/66515, 2015, A1) and 10.7 g (77.3 mmol) potassium carbonate in 200 mL ACN were added after 1 h 40.2 g (322 mmol) 2-bromoethanol. Stirring was continued at 60° C. for 0.5 days and the volatiles were removed under reduced pressure. EtOAc and water were added to the residue, the organic layer was washed with water, dried with Na 2 SO 4  and concentrated under reduced pressure. Chromatography of the crude product (silica, cyclohexane/EtOAc) yielded 9.7 g (53% of theory, corrected by purity). 
     ESI mass [m/z]: 275.1 [M+H] +   
     Step 2: Methyl 3-bromo-5-(2-chloroethoxy)benzoate 
     
       
         
         
             
             
         
       
     
     To a stirred mixture of 9.7 g (34.6 mmol) methyl 3-bromo-5-(2-hydroxyethoxy)benzoate in DCM with five drops of DMF were added 100 ml (1370 mmol) thionyl chloride. The mixture was heated under reflux for 0.5 days and the volatiles evaporated under reduced pressure. DCM was added, the insolubles removed by filtration and the remaining solution concentrated under reduced pressure. Chromatography of the crude product (silica, cyclohexane/EtOAc) yielded 7.3 g (70% of theory, yield corrected by purity). 
     ESI mass [m/z]: 295.0 [M+H] +   
       1 H-NMR (400 MHz, D6-DMSO): δ=3.9 (s, 3H), 4 (m, 2H), 4.4 (m, 2H), 7.45 (s, 1H), 7.5 (s, 1H), 7.7 (s, 1H). 
     Step 3: 3-Bromo-5-(vinyloxy)benzoic acid 
     
       
         
         
             
             
         
       
     
     To 6.45 g (21.4 mmol) methyl 3-bromo-5-(2-chloroethoxy)benzoate in 100 mL THF were added at 0-5° C. 6 g (53 mmol) potassium t.-butanolate. The mixture was stirred at RT for 0.5 days. The volatiles were removed under reduced pressure and the residue was dissolved in water/EtOAc. The mixture was acidified with aq. HCl, the organic layer was washed with water, dried with Na 2 SO 4  and evaporated to yield 5 g (88% of theory, corrected by purity). 
     ESI mass [m/z]: 245.0 [M+H] +   
       1 H-NMR (400 MHz, D6-DMSO): δ=4.65 (m, 1H), 4.85 (m, 1H), 7 (m, 1H), 7.55 (s, 1H), 7.6 (m, 1H), 7.75 (s, 1H), 13.5 (br, 1H). 
     Step 4: Ethyl 3-bromo-5-[(2,2-dichlorocyclopropyl)oxy]benzoate 
     
       
         
         
             
             
         
       
     
     5 g (18.8 mmol) 3-bromo-5-(vinyloxy)benzoic acid, 200 mL CHCl (ABCR, Art.-Nr. AB139647, Lot-Nr. 1362314, contains EtOH according to declaration) and 0.8 g (2.9 mmol) tetrabutylammonium chloride were stirred and 30 g (340 mmol) aq. NaOH 45% were added slowly. After 1 day, the addition of NaOH was repeated. The mixture was stirred for 2 days, water and DCM were added and the mixture was acidified with aq. HCl., the organic layer was washed with water, dried with Na 2 SO 4  and evaporated under reduced pressure to yield 6.8 g crude product. Repeated RP-chromatography (RP-18, ACN-water, 0.1% HCOOH, 0.05% HCOOH) yielded 2.21 g (33% of theory). 
     ESI mass [m/z]: 355.0 [M+H] +   
       1 H-NMR (400 MHz, D6-DMSO): δ=1.3 (m, 3H), 2 (m, 1H), 2.2 (m, 1H), 4.3 (m, 2H), 4.7 (m, 1H), 7.55 (s, 1H), 7.6 (s, 1H), 7.75 (s, 1H). 
     Step 5: 3-Bromo-5[(2,2-dichlorocyclopropyl)oxy]benzoic acid 
     
       
         
         
             
             
         
       
     
     0.97 g (2.7 mmol) ethyl 3-bromo-5[(2,2-dichlorocyclopropyl)oxy]benzoate and 0.5 g (5.5 mmol) aq. NaOH (45%) were stirred in 40 mL of a 1:1 mixture of EtOH and water for 4 h at 40° C. The organic solvent was removed under reduced pressure. Aq. HCl and DCM were added, the organic layer was washed with aq. NaCl, dried with Na 2 SO 4  and evaporated under reduced pressure to yield 0.78 g. 
     ESI mass [m/z]: 327.0 [M+H] +   
       1 H-NMR (400 MHz, D6-DMSO): δ=2 (m, 1H), 2.2 (m, 1H), 4.65 (m, 1H), 7.5 (s, 1H), 7.6 (s, 1H), 7.75 (s, 1H), 13.5 (br, 1H). 
     Intermediate 65A 
     Dimethyl 5-(methylsulfonyl)isophthalate 
     
       
         
         
             
             
         
       
     
     Dimethyl 5-bromoisophthalate (230 g, 842 mmol), potassium carbonate (233 g, 1.68 mol), L-proline (48.5 g, 421 mmol), sodium methanesulfinate (172 g, 1.68 mol) and CuI (160 g, 842 mmol) were added into DMSO (1.15 L). The reaction mixture was stirred at 80° C. for 16 h. After cooling to RT, the reaction mixture was partitioned between ethyl acetate (2.50 L) and water (800 mL). The organic phase was separated, washed with water (2×500 mL) and brine (2×500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=50/1 to 5/1) to afford the title compound. Yield: 80.0 g (294 mmol, 35% of theory). 
     Intermediate 66A 
     Methyl 3-(hydroxymethyl)-5-(methylsulfonyl)benzoate 
     
       
         
         
             
             
         
       
     
     Dimethyl 5-(methylsulfonyl)isophthalate (50.0 g, 184 mmol) was dissolved in THF (500 mL). Lithium borohydride (10.0 g, 459 mmol) was added in portions slowly at 0° C. The mixture was stirred at 0° C. for 4 h. The mixture was slowly added into ice water (500 mL) and stirred thoroughly. Then, the mixture was extracted with ethyl acetate (2×1.50 L). The combined organic layers were washed with water (2×500 mL) and brine (2×500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The obtained residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=50/1 to 5/1) to afford the title compound. Yield: 26.0 g (106 mmol, 58% of theory). 
     Intermediate 67A 
     Methyl 3-(chloromethyl)-5-(methylsulfonyl)benzoate 
     
       
         
         
             
             
         
       
     
     Methyl 3-(hydroxymethyl)-5-(methylsulfonyl)benzoate (77.0 g, 315 mmol) was dissolved in 1,2-dichloroethane (540 mL) at 0° C. under a nitrogen atmosphere. Thionyl chloride (150 g, 1.26 mol) was dropped into the mixture at 0° C. After complete addition, the reaction mixture was stirred at 50° C. for 16 h. Then, the reaction mixture was quenched by addition of water (100 mL) at 0° C., and then extracted with DCM (2×100 mL). The combined organic layers were washed with brine (2×50 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue which was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=50/1 to 1/1) to afford the title compound. Yield: 55.0 g (210 mmol, 67% of theory). 
     Intermediate 68A 
     Methyl 3-(cyanomethyl)-5-(methylsulfonyl)benzoate 
     
       
         
         
             
             
         
       
     
     Methyl 3-(chloromethyl)-5-(methylsulfonyl)benzoate (50.0 g, 190 mmol) and trimethylsilyl cyanide (28.3 g, 285 mmol, 35.7 mL) were dissolved in DMF (400 mL). Caesium fluoride (57.8 g, 381 mmol) was added into the mixture. The reaction mixture was stirred at 25° C. for 8 h. The reaction mixture was poured into saturated aqueous ammonium chloride solution (300 mL) and extracted with ethyl acetate (2×400 mL). The combined organic phases were washed with brine (80.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=10/1 to 1/1) to afford the title compound. Yield: 20.0 g (79.0 mmol, 42% of theory). 
     Intermediate 69A 
     3-(Cyanomethyl)-5-(methylsulfonyl)benzoic acid 
     
       
         
         
             
             
         
       
     
     Methyl 3-(cyanomethyl)-5-(methylsulfonyl)benzoate (10.0 g, 39.5 mmol) and lithium hydroxide monohydrate (1.99 g, 47.4 mmol) were dissolved in THF (50.0 mL) and water (10.0 mL). The reaction mixture was stirred at 0° C. for 2 h. The reaction mixture was concentrated under reduced pressure to remove the THF. Then, 1.0 M aqueous hydrochloric acid was added dropwise to the reaction mixture slowly at 0° C. until pH=4. After 5 min, a solid precipitated which was collected by filtration an dried to afford the crude title compound. The crude product was purified by reversed-phase HPLC (0.1% TFA condition) to afford the title compound. Yield: 5.20 g (21.7 mmol, 55% of theory). 
     ESI mass [m/z]: 238.0 [M−H] − . 
       1 H-NMR (400 MHz, MeOD): δ [ppm]=68.51 (s, 1H), 8.37 (s, 1H), 8.21 (s, 1H), 4.17 (s, 2H), 3.21 (s, 3H). 
     Intermediate 70A 
     3-(2-Cyanopropan-2-yl)-5-(methylsulfonyl)benzoic acid 
     
       
         
         
             
             
         
       
     
     Under an argon atmosphere, a solution of 3-(cyanomethyl)-5-(methylsulfonyl)benzoic acid (250 mg, 1.04 mmol) in dry DMF (2.50 mL) was treated with sodium hydride (238 mg, 6.27 mmol, 63% dispersion in mineral oil) followed by iodomethane (593 mg, 260 μL, 4.18 mmol) and the resulting mixture was stirred at RT overnight. After careful addition of water, the mixture was extacted with ethyl acetate. The combined organic layers were discarded. The aqeous layer was acidified by addition of hydrochloric acid follwoed by extraction with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was dried to afford the title compound along with some remaining DMF. The product was used in the next step without further purififcation. 
     ESI mass [m/z]: 268.1 [M+H] +   
       1 H NMR (DMSO-d 6 ) δ [ppm]=8.38-8.40 (m, 1H), 8.36-8.38 (m, 1H), 8.26-8.28 (m, 1H), 1.91 (s, 3H), 1.79 (s, 6H). 
     Intermediate 71A 
     Step 1: tert-Butyl N-[(1S)-2-[(E)-dimethylaminomethyleneamino]-1-methyl-2-oxo-ethyl]carbamate 
     
       
         
         
             
             
         
       
     
     tert-Butyl N-[(1S)-2-amino-1-methyl-2-oxo-ethyl]carbamate (150 g, 797 mmol, 1.00 eq) was dissolved in dioxane (1.50 L). N,N-Dimetyhlformamide dimethylacetal (142 g, 1.20 mol, 159 mL, 1.50 eq) was added into the mixture. The reaction mixture was stirred at 25° C. for 3 hrs. TLC (dichloromethane:methanol=10:1, Rf=0.67) indicated the starting material was consumed. The crude product (193 g, calculated) in dioxane was used in the next step without further purification. 
     Step 2: tert-Butyl N-[(1S)-1-[2-(6-chloropyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]carbamate 
     
       
         
         
             
             
         
       
     
     The reaction mixture of tert-Butyl N-[(1S)-2-[(E)-dimethylaminomethyleneamino]-1-methyl-2-oxo-ethyl]carbamate (193 g, 793 mmol, 1.00 eq) was added dropwise to a mixture of (6-chloropyrimidin-4-yl)hydrazine (126 g, 873 mmol, 1.10 eq) dissolved in AcOH (1900 mL). The reaction mixture was stirred at 25° C. for 16 hrs. TLC (petroleum ether:ethyl acetate=3:1, Rf=0.22) indicated the starting material was consumed completely. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate=50/1 to 3/1). tert-Butyl N-[(1S)-1-[2-(6-chloropyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]carbamate (160 g, 493 mmol, 62.1% yield) was obtained as a white solid. 
     Step 3: Methyl 6-[5-[(1S)-1-(tert-butoxycarbonylamino)ethyl]-1,2,4-triazol-1-yl]pyrimidine-4-carboxylate 
     
       
         
         
             
             
         
       
     
     To a solution of tert-butyl N-[(1S)-1-[2-(6-chloropyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]carbamate (80.0 g, 246 mmol, 1.00 eq) in MeOH (1.50 L) was added triethylamine (49.9 g, 493 mmol, 68.6 mL, 2.00 eq) and Pd(dppf)Cl 2  (18.0 g, 24.6 mmol, 0.100 eq) under nitrogen. The suspension was degassed under vacuum and purged with CO (carbon monoxide) several times. The mixture was stirred under CO (246 mmol, 1.00 eq) (50.0 psi) at 40° C. for 16 hrs. TLC (petroleum ether:ethyl acetate=1:1, Rf=0.27) indicated the starting material was consumed. The reaction mixture was filtered and the filter liquor was concentrated under vacuum. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate=50/1 to 1/1). Methyl 6-[5-[(1S)-1-(tert-butoxy carbonylamino)ethyl]-1,2,4-triazol-1-yl]pyrimidine-4-carboxylate (80.0 g, 230 mmol, 46.6% yield) was obtained as a white solid. 
       1 H NMR (DMSO-d 6 ) δ [ppm]=9.29 (s, 1H), 8.63 (s, 1H), 8.02 (s, 1H), 7.27 (s, 1H), 6.09-6.06 (m. 1H), 5.58-5.56 (d, 1H), 1.60-1.58 (d, 3H), 1.42 (s, 9H). 
     Step 4: tert-Butyl N-[(1S)-1-[2-(6-carbamoylpyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]carbamate 
     
       
         
         
             
             
         
       
     
     Methyl 6-[5-[(1S)-1-(tert-butoxycarbonylamino)ethyl]-1,2,4-triazol-1-yl]pyrimidine-4-carboxylate (40.0 g, 115 mmol, 1.00 eq) was dissolved in THF (240 mL) and MeOH (80.0 mL). NH 4 OH (96.6 g, 689 mmol, 106 mL, 25.0% purity, 6.00 eq) was added into the mixture. The reaction mixture was stirred at 25° C. for 6 hrs. TLC (petroleum ether:ethyl acetate=3:1, Rf=0.1) indicated the starting material was consumed completely. The reaction mixture was concentrated. The crude product was triturated with MTBE (300 mL) at 25° C. for 30 minutes. tert-Butyl N-[(1S)-1-[2-(6-carbamoylpyrimidin-4-yl)-1,2,4-triazol yl]ethyl]carbamate (64.0 g, 189 mmol, 82.1% yield, 98.2% purity) was obtained as a white solid. 
       1 H NMR (DMSO-d 6 ) δ [ppm]=9.30 (s, 1H), 8.47 (s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.12 (s, 1H), 5.80-5.76 (m. 1H), 1.46-1.44 (d, 3H), 1.32 (s, 9H). 
     Step 5: 6-[5-[(1S)-1-Aminoethyl]-1,2,4-triazol-1-yl]pyrimidine-4-carboxamide; hydrochloride 
     
       
         
         
             
             
         
       
     
     tert-Butyl N-[(1S)-1-[2-(6-carbamoylpyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]carbamate (1 g, 3 mmol) was dissolved in 30 mL dioxane, then 4 M HCl/dioxane (7.5 mL) was added and the mixture was stirred at 50° C. for 7 hrs and additional 4 days at r.t. The mixture was evaporated under reduced pressure to obtain 1.02 g of the crude product. 
     ESI mass [m/z]: 234.2 [amine+H] +   
       1 H NMR (DMSO-d 6 ) δ [ppm]=9.36 (s, 1H), 8.78 (s, 2H, NH 2 ), 8.52 (s, 1H), 8.50 (bs, 1H), 8.39 (s, 1H), 8.17 (bs, 1H), 5.07-5.45 (m, 1H), 1.67-1.65 (d, 3H). 
     Intermediate 72A 
     3-(1-Cyano-1-methyl-ethoxy)-5-cyclopropyl-benzoic acid 
     
       
         
         
             
             
         
       
     
     3-Bromo-5-(1-cyano-1-methyl-ethoxy)benzoic acid (1 g, 4 mmol) and cyclopropylboronic acid (0.6 g, 7 mmol) were dissolved in a mixture of 12 mL dioxane and 5 mL water under nitrogen, then subsequently K 2 CO 3  (1.7 g, 12 mmol) and Pd(dppf)Cl 2  (129 mg, 0.176 mmol) were added and the mixture was stirred under nitrogen at 100° C. for 2 hrs. The reaction mixture was evaporated under vacuum, the residue was quenched with water and acidified with 1M HCl to pH 4-5 and extracted with ethyl acetate three times. The combined organic layers were washed with brine and evaporated under vacuum. The residue was taken up with dichlormethane, the organic phase was extracted with a saturated aqueous solution of NaHCO 3 , the aqueous phase was separated and acidified with 2M HCl until pH 2, and again extracted with dichloromethane. The organic layers were collected and dried over Na s SO 4 , filtered, and evaporated in vacuum to obtain 3-(1-cyano-1-methyl-ethoxy)-5-cyclopropyl-benzoic acid as colorless solid (554 mg, yield 62.9%). 
       1 H NMR (DMSO-d 6 ) δ [ppm]=13.20 (bs, 1H, COOH), 7.49 (s, 2H), 7.06 (s, 1H), 2.05-2.01 (m, 1H), 1.69 (s, 6H), 1.03-0.99 (m, 2H), 0.73-0.69 (m, 2H). 
     EXAMPLES 
     Example I-3 
     N-{(1S)-1-[1-(5-Cyanopyridin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}-3-(cyclopropylmethoxy)-5-methylbenzamide 
     
       
         
         
             
             
         
       
     
     To a solution of 100 mg (0.39 mmol) 6-{5-[(1S)-1-aminoethyl]-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride (1:1) in 2 mL DCM was added 0.14 mL (0.79 mmol) DIPEA and the solution was stirred 30 minutes at room temperature. Then 173 mg (0.41 mmol, 50% pure) 3-(cyclopropylmethoxy)-5-methylbenzoic acid, 182 mg (0.47 mmol) HATU and 0.10 mL DIPEA (0.55 mmol) were added into the mixture and further stirred for 16 h. The reaction mixture was quenched with an aqueous solution of 5% NaH 2 PO 4  and then was extracted with dichloromethane. The organic phase was dried over Na 2 SO 4 , filtered and after evaporation of the solvent under vacuo the crude was purified by flash chromatography. The combined product fractions were evaporated to yield the title compound (120 mg, 75%). 
     ESI mass [m/z]: 403.3 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.0615 (3.4); 9.0597 (3.7); 9.0560 (3.8); 9.0542 (3.6); 8.9222 (2.0); 8.9047 (2.0); 8.5765 (3.2); 8.5709 (3.0); 8.5550 (3.4); 8.5494 (3.3); 8.3142 (0.9); 8.2169 (9.6); 8.0658 (3.8); 8.0640 (3.8); 8.0443 (3.6); 8.0425 (3.6); 7.1671 (3.7); 7.1090 (2.9); 6.8856 (3.0); 6.0463 (1.4); 6.0289 (2.2); 6.0114 (1.4); 5.7545 (6.8); 4.0380 (0.6); 4.0203 (0.6); 3.8173 (6.1); 3.7999 (6.2); 3.3213 (139.9); 2.6800 (0.3); 2.6753 (0.7); 2.6708 (0.9); 2.6661 (0.7); 2.6620 (0.3); 2.5243 (3.0); 2.5195 (4.4); 2.5109 (52.5); 2.5064 (106.2); 2.5018 (140.5); 2.4972 (101.8); 2.4927 (48.7); 2.3332 (0.6); 2.3286 (0.9); 2.3241 (0.6); 2.2819 (16.0); 1.9886 (2.8); 1.6176 (8.6); 1.6002 (8.5); 1.2394 (0.4); 1.2341 (0.5); 1.2200 (0.7); 1.2140 (0.7); 1.2103 (0.6); 1.2022 (1.2); 1.1929 (1.3); 1.1821 (0.8); 1.1751 (1.8); 1.1573 (0.8); 0.5856 (1.0); 0.5747 (3.1); 0.5704 (3.2); 0.5658 (1.5); 0.5600 (1.5); 0.5546 (3.2); 0.5502 (3.0); 0.5400 (1.1); 0.3300 (1.2); 0.3195 (3.5); 0.3160 (3.5); 0.3078 (3.1); 0.3040 (3.7); 0.2929 (0.9); 0.1460 (0.4); 0.0080 (2.8); −0.0002 (88.0); −0.0085 (2.7); −0.1495 (0.3) 
     Example I-4 
     N-{(1S)-1-[1-(5-Cyanopyridin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}-3-(cyclopentyloxy)-5-methylbenzamide 
     
       
         
         
             
             
         
       
     
     To a solution of 85 mg (0.33 mmol) 6-{5-[(1S)-1-aminoethyl]-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride (1:1) in 2 mL DCM was added 0.12 mL (0.67 mmol) DIPEA and the solution was stirred 30 minutes at room temperature. Then 78 mg (0.35 mmol) 3-(cyclopentyloxy)-5-methylbenzoic acid, 155 mg (0.40 mmol) HATU and 0.08 mL DIPEA (0.47 mmol) were added into the mixture and further stirred for 16 h. The reaction mixture was quenched with an aqueous solution of 5% NaH 2 PO 4  and then was extracted with dichloromethane. The organic phase was dried over Na 2 SO 4 , filtered and after evaporation of the solvent under vacuo the crude was purified by flash chromatography. The combined product fractions were evaporated to yield the title compound (84 mg, 60%). 
     ESI mass [m/z]: 417.3 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.0598 (3.4); 9.0581 (3.6); 9.0543 (3.7); 9.0525 (3.4); 8.9215 (1.9); 8.9039 (2.0); 8.5770 (3.0); 8.5715 (2.9); 8.5556 (3.2); 8.5500 (3.2); 8.2184 (9.4); 8.0683 (3.8); 8.0666 (3.8); 8.0468 (3.5); 8.0451 (3.6); 7.1565 (3.6); 7.1553 (3.6); 7.0677 (2.9); 6.8560 (2.9); 6.0436 (1.4); 6.0261 (2.2); 6.0086 (1.4); 5.7552 (5.9); 4.8379 (0.4); 4.8318 (0.9); 4.8230 (1.0); 4.8173 (1.6); 4.8028 (0.8); 4.0384 (0.6); 4.0206 (0.6); 3.3251 (74.8); 2.6762 (0.3); 2.6717 (0.5); 2.6670 (0.3); 2.5252 (1.4); 2.5205 (2.1); 2.5118 (27.3); 2.5073 (55.7); 2.5027 (73.5); 2.4981 (52.6); 2.4935 (25.0); 2.3342 (0.3); 2.3295 (0.5); 2.3248 (0.3); 2.2836 (16.0); 1.9892 (2.6); 1.8961 (1.4); 1.8822 (1.2); 1.8699 (0.9); 1.8641 (0.9); 1.7247 (0.4); 1.6904 (4.7); 1.6817 (2.5); 1.6758 (2.1); 1.6705 (2.0); 1.6609 (1.7); 1.6504 (1.1); 1.6445 (1.2); 1.6163 (9.1); 1.5988 (9.6); 1.5817 (1.9); 1.5726 (1.5); 1.1932 (0.8); 1.1754 (1.5); 1.1576 (0.7); 0.0080 (1.4); −0.0002 (46.5); −0.0086 (1.3) 
     Example I-5 
     N-{(1S)-1-[1-(5-Cyanopyridin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}-3-(cyclobutyloxy)-5-methylbenzamide 
     
       
         
         
             
             
         
       
     
     To a solution of 85 mg (0.33 mmol) 6-{5-[(1S)-1-aminoethyl]-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride (1:1) in 2 mL DCM was added 0.12 mL (0.67 mmol) DIPEA and the solution was stirred 30 minutes at room temperature. Then 73 mg (0.35 mmol) 3-(cyclobutyloxy)-5-methylbenzoic acid, 155 mg (0.40 mmol) HATU and 0.08 mL DIPEA (0.47 mmol) were added into the mixture and further stirred for 16 h. The reaction mixture was quenched with an aqueous solution of 5% NaH 2 PO 4  and then was extracted with dichloromethane. The organic phase was dried over Na 2 SO 4 , filtered and after evaporation of the solvent under vacuo the crude was purified by flash chromatography. The combined product fractions were evaporated to yield the title compound (74 mg, 53%). 
     ESI mass [m/z]: 403.3 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.0612 (3.2); 9.0597 (3.6); 9.0559 (3.5); 9.0542 (3.4); 8.9249 (1.9); 8.9073 (2.0); 8.5793 (2.6); 8.5738 (2.5); 8.5579 (2.8); 8.5523 (2.8); 8.3149 (0.8); 8.2184 (8.6); 8.0688 (3.4); 8.0673 (3.6); 8.0473 (3.2); 8.0458 (3.3); 7.1772 (3.6); 7.0035 (3.0); 6.7972 (3.0); 6.0434 (1.4); 6.0257 (2.2); 6.0082 (1.4); 4.7176 (0.3); 4.6993 (1.2); 4.6816 (1.9); 4.6637 (1.3); 4.6462 (0.3); 3.3192 (84.0); 2.6749 (1.5); 2.6704 (2.1); 2.6660 (1.6); 2.5239 (6.5); 2.5190 (9.8); 2.5103 (127.4); 2.5060 (254.4); 2.5015 (332.3); 2.4969 (241.0); 2.4925 (117.1); 2.4392 (0.8); 2.4326 (0.8); 2.4100 (1.5); 2.4022 (1.5); 2.3938 (1.5); 2.3718 (0.8); 2.3653 (0.6); 2.3329 (1.5); 2.3283 (2.1); 2.3238 (1.5); 2.2835 (16.0); 2.0738 (0.4); 2.0516 (0.4); 2.0263 (1.4); 2.0212 (0.9); 2.0070 (1.4); 2.0017 (1.7); 1.9965 (1.4); 1.9826 (1.1); 1.9773 (1.4); 1.9527 (0.4); 1.8114 (0.4); 1.7855 (1.0); 1.7607 (1.0); 1.7354 (0.4); 1.6714 (0.6); 1.6674 (0.7); 1.6463 (1.3); 1.6143 (8.5); 1.5969 (8.5); 0.1458 (0.6); 0.0080 (4.9); −0.0001 (151.7); −0.0084 (5.3); −0.1497 (0.6) 
     Example I-6 
     N-{(1S)-1-[1-(5-Cyanopyridin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}-3-methyl-5-(oxetan-3-yloxy)benzamide 
     
       
         
         
             
             
         
       
     
     To a solution of 85 mg (0.33 mmol) 6-{5-[(1S)-1-aminoethyl]-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride (1:1) in 2 mL DCM was added 0.12 mL (0.67 mmol) DIPEA and the solution was stirred 30 minutes at room temperature. Then 74 mg (0.35 mmol) 3-methyl-5-(oxetan-3-yloxy)benzoic acid, 155 mg (0.40 mmol) HATU and 0.08 mL DIPEA (0.47 mmol) were added into the mixture and further stirred for 16 h. The reaction mixture was quenched with an aqueous solution of 5% NaH 2 PO 4  and then was extracted with dichloromethane. The organic phase was dried over Na 2 SO 4 , filtered and after evaporation of the solvent under vacuo the crude was purified by flash chromatography. The combined product fractions were evaporated to yield the title compound (73 mg, 53%). 
     ESI mass [m/z]: 405.3 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.0613 (0.5); 9.0594 (0.5); 9.0558 (0.5); 9.0539 (0.5); 8.5807 (0.4); 8.5752 (0.4); 8.5593 (0.4); 8.5537 (0.4); 8.2218 (1.3); 8.0713 (0.5); 8.0694 (0.5); 8.0498 (0.5); 8.0479 (0.5); 7.2397 (0.5); 6.9486 (0.4); 6.7691 (0.4); 4.9083 (0.4); 4.5298 (0.4); 4.5165 (0.4); 4.5119 (0.4); 4.4984 (0.4); 3.3214 (26.8); 2.6897 (16.0); 2.5242 (0.8); 2.5195 (1.2); 2.5108 (15.5); 2.5063 (31.8); 2.5017 (42.0); 2.4970 (30.0); 2.4924 (14.2); 2.2950 (2.1); 1.6174 (1.2); 1.6000 (1.2); 0.0080 (0.8); 0.0057 (0.4); −0.0002 (25.2); −0.0086 (0.7) 
     Example I-12 
     3-[1-(3-Chlorophenyl)ethoxy]-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     Example I-12 was synthesized under the same reaction conditions described in the general procedure 1 from 150 mg (0.36 mmol) N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide, 50 mg (0.36 mmol) potassium carbonate and 79 mg (0.36 mmol) 1-(1-bromoethyl)-3-chlorobenzene in acetonitrile at room temperature to yield the title compound (36 mg, 18%). 
     ESI mass [m/z]: 555.3 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.2736 (1.4); 9.2612 (1.8); 9.2561 (1.8); 9.2441 (1.5); 9.0145 (4.4); 9.0095 (4.4); 8.5374 (1.9); 8.5345 (2.2); 8.5320 (2.2); 8.5291 (2.0); 8.5159 (2.1); 8.5130 (2.4); 8.5105 (2.4); 8.5076 (2.1); 8.3167 (0.4); 8.0179 (4.6); 7.9964 (4.2); 7.7298 (2.4); 7.6923 (2.4); 7.6515 (1.9); 7.6320 (1.9); 7.5205 (2.3); 7.4997 (2.3); 7.4066 (6.9); 7.3958 (4.6); 7.3933 (4.0); 7.3904 (3.8); 7.3835 (2.4); 7.3806 (3.0); 7.3717 (0.8); 7.3620 (0.7); 7.3576 (0.6); 7.3521 (1.5); 7.3468 (2.6); 7.3416 (1.6); 7.3390 (1.8); 7.3321 (1.8); 7.3290 (1.3); 7.3240 (1.1); 7.3187 (0.6); 6.0867 (0.3); 6.0693 (1.4); 6.0521 (2.1); 6.0355 (1.4); 6.0182 (0.3); 5.7569 (5.1); 5.7476 (1.6); 5.7369 (1.6); 5.7317 (1.6); 5.7214 (0.5); 5.7162 (0.5); 3.3261 (124.6); 2.6760 (1.0); 2.6716 (1.4); 2.6671 (1.1); 2.5250 (4.7); 2.5115 (86.5); 2.5072 (171.5); 2.5027 (225.8); 2.4981 (168.0); 2.4938 (84.8); 2.3374 (15.2); 2.3300 (16.0); 2.2436 (0.5); 1.6057 (8.5); 1.5884 (9.0); 1.5793 (6.7); 1.5716 (6.6); 1.5635 (6.3); 1.5558 (5.7); 0.1460 (0.3); 0.0079 (3.0); −0.0002 (77.7); −0.0085 (3.1); −0.1495 (0.3) 
     Example I-13 
     3-[(3-Chlorobenzyl)oxy]-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     Example I-13 was synthesized under the same reaction conditions described in general procedure 1 from 150 mg (0.36 mmol) N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide, 50 mg (0.36 mmol) potassium carbonate and 0.05 mL (0.36 mmol) 1-(bromomethyl)-3-chlorobenzene in acetonitrile at room temperature to yield the title compound (27 mg, 14%). 
     ESI mass [m/z]: 541.1 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d6-DMSO): δ=9.3095 (1.4); 9.2919 (1.4); 9.0299 (2.5); 9.0251 (2.5); 8.5402 (1.8); 8.5347 (1.7); 8.5188 (1.9); 8.5132 (1.9); 8.0226 (2.6); 8.0010 (2.4); 7.7723 (3.7); 7.7661 (2.4); 7.5618 (2.6); 7.5316 (2.2); 7.4513 (1.4); 7.4469 (1.0); 7.4376 (6.3); 7.4303 (2.5); 7.4255 (1.8); 7.4188 (0.8); 7.4156 (0.8); 6.1051 (1.0); 6.0876 (1.6); 6.0700 (1.1); 5.7564 (3.7); 5.2517 (7.1); 3.3287 (70.6); 2.6764 (0.4); 2.6720 (0.5); 2.6675 (0.4); 2.5252 (1.4); 2.5118 (28.1); 2.5075 (56.8); 2.5030 (75.4); 2.4984 (55.8); 2.4940 (27.7); 2.3406 (16.0); 1.6272 (5.7); 1.6098 (5.7); 0.0079 (0.9); −0.0002 (32.0); −0.0084 (1.3) 
     Example I-14 
     3-[1-(2-Chlorophenyl)ethoxy]-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     Example I-14 was synthesized under the same reaction conditions described in the general procedure 1 from 150 mg (0.36 mmol) N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide, 50 mg (0.36 mmol) potassium carbonate and 79 mg (0.36 mmol) 1-(1-bromoethyl)-2-chlorobenzene in acetonitrile at room temperature to yield the title compound (21 mg, 10%). 
     ESI mass [m/z]: 555.4 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.2743 (1.4); 9.2639 (1.6); 9.2568 (1.7); 9.2463 (1.5); 8.9982 (2.3); 8.9924 (4.3); 8.9868 (2.5); 8.5358 (3.2); 8.5303 (3.1); 8.5143 (3.4); 8.5087 (3.4); 8.3164 (0.4); 8.0178 (2.9); 8.0158 (2.9); 7.9963 (2.7); 7.9943 (2.7); 7.7510 (2.4); 7.7232 (2.4); 7.5822 (2.0); 7.5601 (2.0); 7.5110 (1.3); 7.5049 (1.4); 7.4958 (2.5); 7.4921 (3.6); 7.4878 (2.4); 7.4840 (2.5); 7.4791 (3.4); 7.4751 (3.1); 7.4667 (1.5); 7.4608 (1.9); 7.3638 (0.4); 7.3591 (0.6); 7.3550 (0.4); 7.3498 (0.7); 7.3452 (1.6); 7.3407 (1.7); 7.3353 (2.7); 7.3284 (4.5); 7.3208 (3.8); 7.3160 (2.0); 7.3106 (2.8); 7.3048 (1.4); 7.2977 (0.6); 7.2920 (0.8); 7.2768 (3.5); 6.0788 (0.3); 6.0620 (1.5); 6.0447 (2.3); 6.0279 (1.5); 6.0102 (0.4); 5.8845 (0.4); 5.8691 (1.6); 5.8592 (1.7); 5.8534 (1.7); 5.8435 (1.6); 5.8276 (0.4); 5.7565 (3.5); 3.3250 (93.1); 2.6804 (0.5); 2.6761 (1.1); 2.6715 (1.5); 2.6671 (1.1); 2.6629 (0.6); 2.5250 (4.6); 2.5202 (6.9); 2.5115 (87.7); 2.5071 (177.9); 2.5026 (235.7); 2.4981 (174.8); 2.4937 (87.7); 2.3391 (15.5); 2.3264 (16.0); 2.2423 (0.5); 1.6155 (6.7); 1.6097 (7.2); 1.5938 (13.4); 1.5791 (7.2); 1.5760 (7.1); 0.1461 (0.4); 0.0080 (2.8); −0.0002 (87.9); −0.0084 (3.4); −0.1494 (0.4) 
     Example I-15 
     3-[1-(4-Chlorophenyl)ethoxy]-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     Example I-15 was synthesized under the same reaction conditions described in general procedure 1 from 150 mg (0.36 mmol) N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide, 50 mg (0.36 mmol) potassium carbonate and 79 mg (0.36 mmol) 1-(1-bromoethyl)-4-chlorobenzene in acetonitrile at room temperature to yield the title compound (21 mg, 11%). 
     ESI mass [m/z]: 555.4 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d6-DMSO): δ=9.2635 (1.6); 9.2548 (1.8); 9.2458 (1.8); 9.2370 (1.7); 9.0172 (2.7); 9.0127 (4.7); 9.0077 (2.7); 8.5405 (1.9); 8.5362 (2.7); 8.5314 (1.8); 8.5190 (2.0); 8.5147 (2.9); 8.5098 (1.9); 8.3168 (0.3); 8.0200 (4.8); 7.9985 (4.4); 7.7236 (2.6); 7.6839 (2.6); 7.6315 (2.2); 7.6143 (2.2); 7.4732 (2.2); 7.4580 (3.1); 7.4517 (6.2); 7.4373 (6.2); 7.4264 (6.3); 7.4202 (2.8); 7.4153 (6.5); 7.4100 (2.5); 7.4052 (2.6); 7.3988 (1.3); 7.3936 (2.4); 7.3818 (4.1); 6.0823 (0.3); 6.0647 (1.3); 6.0500 (2.0); 6.0472 (2.0); 6.0323 (1.3); 6.0152 (0.3); 5.7570 (5.0); 5.7510 (1.6); 5.7403 (1.7); 5.7353 (1.7); 5.7248 (1.5); 5.7101 (0.4); 3.3257 (111.7); 2.6762 (1.1); 2.6718 (1.5); 2.6674 (1.1); 2.5072 (184.3); 2.5028 (236.4); 2.4984 (175.3); 2.3378 (15.4); 2.3298 (16.0); 1.6034 (10.5); 1.5860 (10.6); 1.5663 (6.6); 1.5607 (6.9); 1.5506 (6.8); 1.5450 (6.4); 1.4358 (0.4); 0.1463 (0.4); 0.0080 (4.2); 0.0000 (92.0); −0.0082 (3.9); −0.1493 (0.4) 
     Example I-16 
     3-[(2-Chlorobenzyl)oxy]-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     Example I-16 was synthesized under the same reaction conditions described in general procedure 1 from 150 mg (0.36 mmol) N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide, 50 mg (0.36 mmol) potassium carbonate and 74 mg (0.36 mmol) 1-(bromomethyl)-2-chlorobenzene in acetonitrile at room temperature to yield the title compound (12 mg, 6%). 
     ESI mass [m/z]: 541.4 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.3220 (1.4); 9.3043 (1.4); 9.0308 (2.2); 9.0290 (2.5); 9.0253 (2.4); 9.0235 (2.4); 8.5406 (2.0); 8.5350 (1.9); 8.5191 (2.2); 8.5135 (2.2); 8.0251 (2.5); 8.0234 (2.6); 8.0036 (2.3); 8.0018 (2.4); 7.7878 (2.5); 7.7701 (1.9); 7.6549 (1.2); 7.6496 (0.8); 7.6458 (0.7); 7.6395 (1.1); 7.6317 (1.4); 7.5538 (2.1); 7.5489 (2.6); 7.5434 (1.2); 7.5337 (0.8); 7.5298 (1.1); 7.5256 (1.9); 7.4490 (0.3); 7.4432 (0.6); 7.4305 (1.8); 7.4230 (2.3); 7.4150 (3.6); 7.4057 (2.4); 7.4005 (1.5); 7.3867 (0.4); 6.1064 (1.0); 6.0890 (1.6); 6.0714 (1.0); 5.7565 (3.2); 5.2883 (6.9); 3.3529 (0.3); 3.3276 (153.2); 2.6760 (0.6); 2.6714 (0.9); 2.6669 (0.6); 2.5250 (2.4); 2.5203 (3.6); 2.5116 (49.6); 2.5071 (102.6); 2.5025 (137.2); 2.4979 (100.6); 2.4934 (48.8); 2.3405 (16.0); 2.3295 (1.2); 2.3248 (0.8); 2.3206 (0.4); 1.6270 (5.4); 1.6096 (5.4); 0.0080 (2.1); −0.0002 (69.5); −0.0085 (2.3) 
     Example I-17 
     3-chloro-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}-5-[(methylsulfonyl)methyl]benzamide 
     
       
         
         
             
             
         
       
     
     To 0.23 g (0.9 mmol) 6-{5-[(1S)-1-aminoethyl]-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride (WO2019206799) and 0.37 ml Et 3 N in 10 ml DCM were added 0.27 g (0.9 mmol) 3-chloro[(methylsulfonyl)methyl]benzoyl chloride in 5 ml DCM at ice-water cooling. The mixture was stirred overnight at room temperature. Water was added, the organic layer was dried and evaporated under reduced pressure. Reversed phase chromatography of the residue (acetonitrile/water) yielded 6 mg (1.5%) of the title compound. 
     ESI mass [m/z]: 445.2 [M+H] +   
       1 H NMR (400 MHz, D6-DMSO): δ=1.6 (d, 3H), 2.9 (s, 3H), 4.55 (s, 2H), 6.1 (m, 1H), 7.65 (s, 1H), 7.8 (s, 1H), 7.9 (s, 1H), 8.1 (d, 1H), 8.3 (s, 1H), 8.55 (m, 1H), 9.05 (m, 1H), 9.25 (m, 1H). 
     Example I-18 
     3-(Benzyloxy)-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     Example I-18 was synthesized under the same reaction conditions described in general procedure 1 from 300 mg (0.19 mmol, 27% purity) N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide, 27 mg (0.19 mmol) potassium carbonate and 32 mg (0.19 mmol) benzyl bromide in acetonitrile at room temperature to yield the title compound (23 mg, 23%). 
     ESI mass [m/z]: 507.5 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.3008 (1.4); 9.2832 (1.5); 9.0287 (2.4); 9.0270 (2.6); 9.0232 (2.6); 9.0215 (2.4); 8.5397 (1.9); 8.5341 (1.9); 8.5182 (2.1); 8.5126 (2.1); 8.3161 (0.5); 8.0225 (2.6); 8.0209 (2.6); 8.0009 (2.4); 7.9993 (2.4); 7.7597 (4.7); 7.7558 (5.0); 7.5074 (2.3); 7.4865 (1.6); 7.4828 (2.2); 7.4653 (3.6); 7.4290 (1.4); 7.4261 (1.9); 7.4214 (0.7); 7.4085 (3.8); 7.4046 (1.7); 7.3899 (2.0); 7.3670 (1.5); 7.3556 (0.5); 7.3492 (1.6); 7.3423 (0.3); 7.3313 (0.4); 6.1004 (1.0); 6.0828 (1.6); 6.0654 (1.0); 5.2354 (7.0); 3.3261 (212.6); 2.6756 (1.2); 2.6710 (1.6); 2.6666 (1.2); 2.5245 (5.4); 2.5110 (98.2); 2.5066 (194.8); 2.5021 (255.0); 2.4976 (188.2); 2.4932 (93.4); 2.3397 (16.0); 2.3291 (2.0); 2.3246 (1.4); 2.2461 (0.4); 1.6238 (5.6); 1.6064 (5.6); 0.1459 (0.4); 0.0080 (3.0); −0.0001 (87.3); −0.0084 (3.3); −0.1496 (0.4). 
     Example I-19 
     N-{(1S)-1-[1-(5-Cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-(tetrahydro-2H-pyran-4-ylmethoxy)-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     Example I-19 was synthesized under the same reaction conditions described in general procedure 1 from 200 mg (0.48 mmol) N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide, 66 mg (0.48 mmol) potassium carbonate and 86 mg (0.48 mmol) 1 4-(bromomethyl)tetrahydro-2H-pyran in acetonitrile at room temperature to yield the title compound (43 mg, 17%). 
     ESI mass [m/z]: 515.2 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.2934 (1.4); 9.2756 (1.4); 9.0304 (2.4); 9.0289 (2.5); 9.0250 (2.6); 8.5400 (1.8); 8.5345 (1.8); 8.5185 (2.0); 8.5129 (2.0); 8.3160 (0.4); 8.0198 (2.6); 8.0184 (2.5); 7.9983 (2.4); 7.9968 (2.3); 7.7255 (2.6); 7.6509 (2.1); 7.4017 (2.2); 6.0962 (1.0); 6.0786 (1.6); 6.0611 (1.0); 3.9646 (3.4); 3.9486 (3.5); 3.9003 (1.2); 3.8927 (1.3); 3.8723 (1.4); 3.8648 (1.4); 3.3648 (1.4); 3.3260 (132.6); 2.6756 (0.9); 2.6711 (1.2); 2.6666 (0.9); 2.5246 (3.6); 2.5198 (5.4); 2.5111 (74.7); 2.5067 (152.9); 2.5022 (202.5); 2.4977 (150.1); 2.4933 (75.5); 2.3399 (16.0); 2.3292 (1.7); 2.3246 (1.1); 2.0267 (0.4); 2.0178 (0.6); 2.0090 (0.4); 1.9901 (0.4); 1.6993 (1.2); 1.6711 (1.5); 1.6667 (1.5); 1.6256 (5.7); 1.6082 (5.6); 1.4028 (0.4); 1.3916 (0.5); 1.3725 (1.0); 1.3613 (1.2); 1.3401 (1.1); 1.3297 (1.0); 1.3102 (0.4); 1.2995 (0.4); 0.1460 (0.4); 0.0079 (2.9); −0.0002 (94.9); −0.0084 (4.0); −0.1497 (0.4) 
     Example I-20 
     3-[(4-Chlorobenzyl)oxy]-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     Example I-20 was synthesized under the same reaction conditions described in general procedure 1 from 200 mg (0.48 mmol) N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide, 66 mg (0.48 mmol) potassium carbonate and 99 mg (0.48 mmol) 1-(bromomethyl)-4-chlorobenzene in acetonitrile at room temperature to yield the title compound (48 mg, 19%). 
     ESI mass [m/z]: 541.4 [M+1-1] +   
       1 H-NMR peaklist (400.2 MHz, d6-DMSO): δ=9.3032 (1.4); 9.2855 (1.5); 9.0278 (2.6); 9.0236 (2.5); 8.5404 (1.8); 8.5348 (1.7); 8.5189 (1.9); 8.5133 (1.8); 8.3153 (1.0); 8.0214 (2.6); 8.0000 (2.4); 7.7672 (2.7); 7.7471 (2.2); 7.5156 (2.8); 7.5103 (2.9); 7.4952 (6.6); 7.4806 (7.3); 7.4646 (0.8); 7.4589 (1.8); 6.0994 (1.0); 6.0821 (1.6); 6.0646 (1.0); 5.2365 (7.0); 3.3983 (0.4); 3.3287 (761.0); 2.6756 (2.4); 2.6711 (3.3); 2.6667 (2.5); 2.5244 (11.0); 2.5066 (406.8); 2.5022 (531.9); 2.4977 (395.5); 2.3389 (16.0); 2.3292 (3.9); 2.3245 (2.7); 2.0743 (0.6); 1.6231 (5.6); 1.6058 (5.6); 0.1459 (1.2); 0.0079 (9.9); −0.0001 (267.9); −0.0084 (11.5); −0.1498 (1.2) 
     Example I-21 
     N-{(1S)-1-[1-(5-Cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-(tetrahydro-2H-pyran-4-yloxy)-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     To a solution of 252 mg (0.961 mmol) triphenylphosphine in 4 mL THF under argon was added 221 mg (0.961 mmol) di-tert-butyl azodicarboxylate and the mixture was stirred for 15 minutes. Then 245 mg (2.40 mmol) tetrahydro-4-pyranol were added and after 15 minutes finally a solution of 200 mg (0.48 mmol) N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide in 2 mL THF was added and the reaction mixture was stirred at room temperature for 16 h. After evaporation of the solvent under vacuo the crude was purified by flash chromatography to yield the title compound (32 mg, 13%). 
     ESI mass [m/z]: 501.4 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d 6 -DMSO): δ=9.2882 (1.4); 9.2705 (1.5); 9.0292 (2.4); 9.0277 (2.4); 9.0238 (2.6); 8.5415 (1.8); 8.5360 (1.8); 8.5200 (2.0); 8.5144 (2.0); 8.0222 (2.6); 8.0208 (2.5); 8.0007 (2.4); 7.9992 (2.3); 7.7254 (2.6); 7.6610 (2.1); 7.4683 (2.2); 6.0904 (1.0); 6.0730 (1.6); 6.0554 (1.0); 4.7990 (0.5); 4.7879 (0.7); 4.7778 (1.0); 4.7674 (0.7); 4.7565 (0.5); 3.8734 (0.8); 3.8628 (1.5); 3.8501 (1.0); 3.8449 (1.1); 3.8331 (1.8); 3.8220 (0.9); 3.5337 (1.0); 3.5269 (1.2); 3.5105 (1.3); 3.5041 (2.0); 3.4817 (1.1); 3.4751 (1.0); 3.3354 (257.8); 2.6765 (0.7); 2.6722 (1.0); 2.6676 (0.7); 2.5255 (3.2); 2.5206 (5.1); 2.5120 (58.5); 2.5076 (116.8); 2.5031 (153.3); 2.4986 (114.2); 2.4942 (57.7); 2.3403 (16.0); 2.3304 (1.5); 2.3255 (0.9); 1.9860 (0.9); 1.9765 (1.0); 1.9645 (0.8); 1.9530 (1.2); 1.9442 (1.1); 1.6236 (6.2); 1.6061 (6.4); 1.5915 (1.1); 1.5801 (1.4); 1.5701 (0.9); 1.5577 (0.5); 1.5478 (0.4); 0.1460 (0.8); 0.0080 (6.3); −0.0002 (171.7); −0.0083 (7.6); −0.1496 (0.8) 
     Example I-27 
     N-{(1S)-1-[1-(5-Cyanopyridin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}-3-[(methylsulfinyl)methoxy]-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     0.82 g (2.0 mmol) N-[(2S)-1-{(E)-[(dimethylamino)methylene]amino}-1-oxopropan-2-yl]-3-[(methylsulfinyl)methoxy]-5-(trifluoromethyl)benzamide and 0.3 g (2.2 mmol) 6-hydrazono-1,6-dihydropyridine-3-carbonitrile were stirred in AcOH at 75° C. for 20 min. The mixture was evaporated under reduced pressure. The residue was dissolved in EtOAc aq. K 2 CO 3 , aq. NaCl. The aquous phase was extracted two times with EtOAc, the combined organic phases were dried with Na 2 SO 4  and evaporated under reduced pressure. Chromatography of the residue (silica, i-hexane-acetone) yielded 0.41 g (40%, yield corrected by purity). 
       1 H NMR: see peak list in table 1 
     ESI mass [m/z]: 479.2 [M+H] +   
     Example I-31 
     3-Bromo-N-{(1S)-1-[1-(5-cyano-1,3-thiazol-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzamide 
     
       
         
         
             
             
         
       
     
     0.7 g (1.4 mmol) 3-bromo-N-[(2S)-1-{(E)-[(dimethylamino)methylene]amino}-1-oxopropan-2-yl]-5-[(2,3,3-trichloroprop-2-en-1-yl)oxy]benzamide and 0.3 g (2.14 mmol) (2E)-2-hydrazono-2,3-dihydro-1,3-thiazole-5-carbonitrile were stirred in AcOH at 85° C. for 20 min. The mixture was evaporated under reduced pressure. The residue was dissolved in EtOAc, aq. K 2 CO 3 , aq. NaCl. The aquous phase was extracted two times with EtOAc, the combined organic phases were dried with Na 2 SO 4  and evaporated under reduced pressure. Chromatography of the residue (silica, petrol ether-acetone), trituration of the material with MTBE and drying yielded 0.35 g (40%, yield corrected by purity). 
       1 H NMR: see peak list in table 1 
     ESI mass [m/z]: 562.9 [M+H] +   
     Example I-33 
     3-Chloro-5-(2-cyanopropan-2-yl)-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}benzamide 
     
       
         
         
             
             
         
       
     
     A mixture of 98 mg (0.43 mmol) 3-chloro-5-(2-cyanopropan-2-yl)benzoic acid, 303 mg (0.79 mmol) 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), 0.24 mL (1.4 mmol) N-ethyldiisopropylamine and 3 mL DMF was stirred for 60 min at room temperature. 100 mg of 6-{5-[(1S)-1-aminoethyl]-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride were added and the mixture was stirred overnight at room temperature. The mixture was diluted with water and extracted with DCM, the DCM phase was separated, washed with brine, concentrated under reduced pressure and purified by preparative HPLC chromatography to provide 65 mg of the title compound. 
       1 H NMR (DMSO-d 6 , 400 MHz): δ [ppm]=9.30-9.29 (d, 1H), 9.06 (dd, 1H), 8.59-8.56 (dd, 1H), 8.25 (s, 1H), 8.07-8.06 (d, 1H), 7.81-7.87 (m, 2H), 7.75-7.74 (m, 1H), 6.09-6.06 (quint, 1H), 1.71 (s, 6H), 1.65-1.62 (d, 3H). 
     ESI mass [m/z]: 420.2 [M+H] +   
     Example I-40 
     2-(5-{(1S)-1-[3-Chloro-5-(1,1,1-trichloro-2-cyanopropan-2-yl)benzamido]ethyl}-3-methyl-1H-1,2,4-triazol-1-yl)-N,N-dimethyl-1,3-thiazole-5-carboxamide 
     
       
         
         
             
             
         
       
     
     To a solution of 109 mg (0.34 mmol) 2-{5-[(1S)-1-aminoethyl]-3-methyl-1H-1,2,4-triazol-1-yl}-N,N-dimethyl-1,3-thiazole-5-carboxamide hydrochloride (1:1) in 2 mL DCM was added 0.08 mL (0.4 mmol) DIPEA and the solution was stirred 30 minutes at room temperature. Then a solution of 73 mg (0.32 mmol) 3-chloro-5-(2-cyanopropan-2-yl)benzoic acid, 149 mg (0.39 mmol) HATU and 0.08 mL DIPEA (0.4 mmol) was added into the mixture and further stirred for 16 h. The reaction mixture was quenched with an aqueous solution of 5% NaH 2 PO 4  and then was extracted with dichloromethane. The organic phase was washed sodium bicarbonate, brine, dried over Na 2 SO 4  and after evaporation of the solvent under vacuo the crude was purified by reserved-phase chromatography. The combined product fractions were evaporated to yield the title compound (139 mg, 87%). 
       1 H-NMR peaklist (600.1 MHz, CD3CN 260 K): δ=8.0493 (0.5); 8.0375 (0.5); 7.9051 (4.0); 7.8297 (1.1); 7.8271 (1.8); 7.8244 (1.2); 7.7982 (1.2); 7.7954 (1.8); 7.7927 (1.0); 7.6978 (1.1); 7.6947 (1.9); 7.6917 (1.0); 6.1026 (0.6); 6.0907 (1.0); 6.0789 (0.6); 4.0563 (0.5); 4.0443 (0.5); 3.2669 (8.0); 3.0484 (7.3); 2.3379 (10.5); 2.3336 (1.0); 2.3078 (17.9); 2.2774 (0.5); 1.9846 (2.2); 1.9778 (0.6); 1.9700 (14.6); 1.9659 (28.1); 1.9617 (40.8); 1.9576 (28.1); 1.9535 (14.3); 1.7297 (1.3); 1.7244 (16.0); 1.6456 (3.6); 1.6339 (3.6); 1.2179 (0.5); 1.2059 (1.1); 1.1940 (0.5); 0.0054 (0.8); −0.0001 (21.6); −0.0057 (0.7) 
     ESI mass [m/z]: 486.1 [M+H] +   
     Example I-41 
     2-(5-{(1S)-1-[3-Chloro-5-(cyanomethyl)benzamido]ethyl}-3-methyl-1H-1,2,4-triazol-1-yl)-N,N-dimethyl-1,3-thiazole-5-carboxamide 
     
       
         
         
             
             
         
       
     
     To a solution of 109 mg (0.34 mmol) 2-{5-[(1S)-1-aminoethyl]-3-methyl-1H-1,2,4-triazol-1-yl}-N,N-dimethyl-1,3-thiazole-5-carboxamide hydrochloride (1:1) in 2 mL DCM was added 0.08 mL (0.4 mmol) DIPEA and the solution was stirred 30 minutes at room temperature. Then a solution of 64 mg (0.32 mmol) 3-chloro-5-(cyanomethyl)benzoic acid, 149 mg (0.39 mmol) HATU and 0.08 mL DIPEA (0.4 mmol) was added into the mixture and further stirred for 16 h. The reaction mixture was quenched with an aqueous solution of 5% NaH 2 PO 4  and then was extracted with dichloromethane. The organic phase was washed sodium bicarbonate, brine, dried over Na 2 SO 4  and after evaporation of the solvent under vacuo the crude was purified by reserved-phase chromatography. The combined product fractions were evaporated to yield the title compound (112 mg, 75%). 
       1 H-NMR peaklist (600.1 MHz, CD3CN 260 K): δ=7.9965 (1.0); 7.9846 (1.1); 7.9095 (8.5); 7.7882 (1.7); 7.7855 (2.9); 7.7827 (1.8); 7.7237 (3.0); 7.5548 (2.6); 6.0924 (1.2); 6.0806 (1.9); 6.0687 (1.3); 4.0561 (0.4); 4.0443 (0.4); 3.9086 (9.2); 3.2720 (16.0); 3.0501 (14.6); 2.3358 (21.9); 2.3214 (0.5); 2.3040 (276.6); 2.2711 (5.2); 2.0806 (0.4); 2.0765 (0.7); 2.0724 (1.0); 2.0682 (0.8); 2.0639 (0.5); 2.0026 (0.4); 1.9928 (0.4); 1.9845 (2.3); 1.9776 (2.2); 1.9732 (3.9); 1.9697 (59.5); 1.9656 (115.0); 1.9615 (167.7); 1.9574 (115.1); 1.9533 (58.2); 1.9446 (0.7); 1.8546 (0.3); 1.8505 (0.6); 1.8464 (1.0); 1.8423 (0.6); 1.6314 (7.2); 1.6197 (7.2); 1.2178 (0.5); 1.2059 (1.0); 1.1940 (0.5); 0.9167 (0.4); 0.9055 (0.4); 0.0968 (0.4); 0.0054 (3.4); −0.0001 (98.0); −0.0057 (2.7); −0.1001 (0.4) 
     ESI mass [m/z]: 458.1 [M+H] +   
     Example I-42 
     3-(1-Cyano-1-methyl-ethyl)-N-[(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl](trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     A solution of 3-(1-cyano-1-methyl-ethyl)-5-(trifluoromethyl)benzoic acid (102 mg, 0.39 mmol) in DMF (1.0 mL) was treated with HATU (265 mg, 0.69 mmol) and a solution of 6-[5-[(1S)-1-aminoethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile hydrochloride (100 mg, 0.39 mmol) in DMF (1.0 mL) was treated with DIPEA (125 μL, 1.03 mmol). After stirring at RT for 1 h, the two solutions were combined and the mixture was stirred at RT overnight. The reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by preparative HPLC to afford the title compound. Yield: 108 mg (56% of theory). 
       1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm]=9.45 (d, 1H), 9.07 (d, 1H), 8.57 (dd, 1H), 8.25 (s, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 8.08 (d, 1H), 7.99 (s, 1H), 6.15-6.07 (m, 1H), 1.75 (s, 6H), 1.67 (d, 3H). 
     ESI mass [m/z]: 454.2 [M+H] +   
     Example I-43 
     3-(1-Cyano-1-methyl-ethyl)-N-[(1S)-1-[2-(5-cyanothiazol-2-yl)-1,2,4-triazol-3-yl]ethyl]-5-(trifluoromethoxy)benzamide 
     
       
         
         
             
             
         
       
     
     A solution of sodium 3-(1-cyano-1-methyl-ethyl)-5-(trifluoromethoxy)benzoate (79.8 mg, 0.27 mmol) in DMF (1.0 mL) was treated with HATU (194 mg, 0.51 mmol) and a solution of 2-[5-[(1S)-1-aminoethyl]-1,2,4-triazol-1-yl]thiazole-5-carbonitrile hydrochloride (75.0 mg, 0.29 mmol) in DMF (1.0 mL) was treated with DIPEA (75 μL, 0.43 mmol). After stirring at RT for 1 h, the two solutions were combined and the mixture was stirred at RT overnight. The reaction mixture was directly purified by preparative HPLC to afford the title compound. Yield: 39.2 mg (28% of theory). 
       1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm]=9.44 (d, 1H), 8.67 (s, 1H), 8.32 (s, 1H), 8.04-8.02 (m, 1H), 7.83 (s, 1H), 7.69 (s, 1H), 6.08-6.01 (m, 1H), 1.74 (s, 6H), 1.64 (d, 3H). 
     ESI mass [m/z]: 476.1 [M+H] +   
     Example I-44 
     3-(1-Cyano-1-methyl-ethyl)-N-[(1S)-1-[2-(5-cyanothiazol-2-yl)-1,2,4-triazol-3-yl]ethyl]-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     A solution of 3-(1-cyano-1-methyl-ethyl)-5-(trifluoromethyl)benzoic acid (100 mg, 0.39 mmol) in DMF (1.0 mL) was treated with HATU (258 mg, 0.69 mmol) and a solution of 2-[5-[(1S)-1-aminoethyl]-1,2,4-triazol-1-yl]thiazole-5-carbonitrile hydrochloride (100 mg, 0.39 mmol) in DMF (1.0 mL) was treated with DIPEA (125 μL, 1.01 mmol). After stirring at RT for 1 h, the two solutions were combined and the mixture was stirred at RT overnight. The reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by preparative HPLC to afford the title compound. Yield: 109 mg (57% of theory). 
       1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm]=9.54 (d, 1H), 8.68 (s, 1H), 8.33 (s, 1H), 8.26 (s, 1H), 8.24 (s, 1H), 8.01 (s, 1H), 6.11-6.03 (m, 1H), 1.77 (s, 6H), 1.65 (d, 3H). 
     ESI mass [m/z]: 460.1 [M+H] +   
     Example I-45 
     3-(1-Cyano-1-methyl-ethyl)-N-[(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl](trifluoromethoxy)benzamide 
     
       
         
         
             
             
         
       
     
     A solution of sodium 3-(1-cyano-1-methyl-ethyl)-5-(trifluoromethoxy)benzoate (81.7 mg, 0.28 mmol) in DMF (1.0 mL) was treated with HATU (199 mg, 0.52 mmol) and a solution of 6-[5-[(1S)-1-aminoethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile hydrochloride (75.0 mg, 0.29 mmol) in DMF (1.0 mL) was treated with DIPEA (76 μL, 0.44 mmol). After stirring at RT for 1 h, the two solutions were combined and the mixture was stirred at RT overnight. The reaction mixture was directly purified by preparative HPLC to afford the title compound. Yield: 55.8 mg (40% of theory). 
       1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm]=9.36 (d, 1H), 9.07-9.04 (m, 1H), 8.57 (dd, 1H), 8.25 (s, 1H), 8.07 (d, 1H), 7.99-7.96 (m, 1H), 7.76 (s, 1H), 7.67 (s, 1H), 6.12-6.05 (m, 1H), 1.73 (s, 6H), 1.66 (d, 3H). 
     ESI mass [m/z]: 470.2 [M+H] +   
     Example I-47 
     N-{(1S)-1-[1-(5-Cyanopyridin-2-yl)-3-methyl-1H-1,2,4-triazol-5-yl]ethyl}-3-hydroxy-5-(trifluoromethyl)benzamide 
     
       
         
         
             
             
         
       
     
     A solution of 82 mg (0.39 mmol) 3-hydroxy-5-(trifluoromethyl)benzoic acid, 172 mg (0.45 mmol) HATU and 0.09 mL DIPEA (0.52 mmol) was stirred for 30 minutes at room temperature. A second solution of 100 mg (0.37 mmol) 6-{5-[(1S)-1-aminoethyl]-3-methyl-1H-1,2,4-triazol-1-yl}nicotinonitrile hydrochloride (1:1) and 0.13 mL (0.75 mmol) DIPEA in 3 mL DCM previously stirred for 30 minutes was added into the mixture and further stirred for 16 h. The reaction mixture was quenched with an aqueous solution of 5% NaH 2 PO 4  and was extracted with dichloromethane. The organic phase was washed sodium bicarbonate, brine, dried over Na 2 SO 4  and finally, after evaporation of the solvent under vacuo, the crude was purified by flash chromatography. The combined product fractions were evaporated to yield the title compound (29 mg, 19%). 
     ESI mass [m/z]: 417.4 [M+H] +   
       1 H-NMR peaklist (400.2 MHz, d6-DMSO): δ=10.3838 (0.4); 9.2349 (1.5); 9.2172 (1.5); 9.0264 (2.5); 9.0213 (2.5); 8.5412 (1.8); 8.5357 (1.7); 8.5197 (1.9); 8.5141 (1.9); 8.0221 (2.7); 8.0005 (2.5); 7.6049 (2.6); 7.4725 (2.3); 7.1749 (2.4); 6.0744 (1.1); 6.0570 (1.7); 6.0394 (1.1); 5.7565 (0.8); 3.3280 (41.9); 2.6763 (0.4); 2.6718 (0.5); 2.6672 (0.4); 2.5251 (1.4); 2.5115 (30.1); 2.5072 (60.2); 2.5027 (79.8); 2.4983 (59.5); 2.4940 (29.9); 2.3395 (16.0); 2.3300 (1.0); 1.6054 (5.9); 1.5880 (5.9); 0.0079 (1.7); −0.0002 (47.4); −0.0085 (1.7) 
     Example I-52 
     6-[5-[(1S)-1-[[3-chloro-5-(1-cyano-1-methyl-ethyl)benzoyl]amino]ethyl]-3-methyl-1,2,4-triazol-1-yl]-N-ethyl-N-methyl-pyridine-3-carboxamide 
     
       
         
         
             
             
         
       
     
     To a solution of 69 mg (0.30 mmol) 3-chloro-5-(2-cyanopropan-2-yl)benzoic acid in 3.0 ml of dry dichloromethane were added 140 mg (0.36 mmol) HATU and 0.075 ml (0.43 mmol) N,N-diisopropylethylamine. After stirring 60 minutes at room temperature a solution of 100 mg (0.30 mmol) 6-{5-[(1S)-1-aminoethyl]-3-methyl-1H-1,2,4-triazol-1-yl}-N-ethyl-N-methylnicotin-amide hydrochloride (1:1) in 2.0 ml dry and dichloromethane together with 0.11 ml (0.61 mmol) N,N-diisopropylethylamine were added and the mixture was stirred for 16 h at room temperature. The reaction mixture was diluted with a 5% aq. sol. of NaH 2 PO 4  and extracted several times with dichloromethane. Finally, the combine organic layers were concentrated and the residue was purified by preparative chromatography to provide the title compound (78 mg). 
     ESI mass [m/z]: 494.3 [M+H] +   
       1 H NMR (DMSO-d6, 400 MHz): see NMR peak list in table 1 
     Analytical Data of the Compounds 
     The determination of [M+H] +  or [M−H] −  by LC-MS under acidic chromatographic conditions was done with 1 mL formic acid per liter acetonitrile and 0.9 mL formic acid per liter Millipore water as eluents. The column Zorbax Eclipse Plus C18 50 mm*2.1 mm was used. The temperature of the column oven was 55° C. 
     The determination of the  1 H NMR data was effected with a Bruker Avance III 400 MHz equipped with a 1.7 mm TCI cryo probe, a Bruker Avance III 600 MHz equipped with a 5 mm multi-nuclear cryo probe or a Bruker Avance NEO 600 MHz equipped with a 5 mm TCI cryo probe with tetramethylsilane as reference (0.0) and the solvents CD 3 CN, CDCl 3  or D 6 -DMSO. 
     The NMR data of selected examples are listed either in conventional form (8 values, multiplet splitting, number of hydrogen atoms) or as NMR peak lists. 
     NMR Peak List Method 
     The  1 H NMR data of selected examples are stated in the form of  1 H NMR peak lists. For each signal peak, first the δ value in ppm and then the signal intensity in round brackets are listed. The pairs of δ value-signal intensity numbers for different signal peaks are listed with separation from one another by semicolons. 
     The peak list for one example therefore takes the form of: 
     δ 1  (intensity 1 ); δ 2  (intensity 2 ); . . . ; δ i  (intensity i ); . . . ; δ n  (intensity n ) 
     The intensity of sharp signals correlates with the height of the signals in a printed example of an NMR spectrum in cm and shows the true ratios of the signal intensities. In the case of broad signals, several peaks or the middle of the signal and the relative intensity thereof may be shown in comparison to the most intense signal in the spectrum. 
     For calibration of the chemical shift of  1 H NMR spectra, we use tetramethylsilane and/or the chemical shift of the solvent, particularly in the case of spectra which are measured in DMSO. Therefore, the tetramethylsilane peak may but need not occur in NMR peak lists. 
     The lists of the  1 H NMR peaks are similar to the conventional  1 H NMR printouts and thus usually contain all peaks listed in a conventional NMR interpretation. 
     In addition, like conventional  1 H NMR printouts, they may show solvent signals, signals of stereoisomers of the target compounds which are likewise provided by the invention, and/or peaks of impurities. 
     In the reporting of compound signals within the delta range of solvents and/or water, our lists of  1 H NMR peaks show the standard solvent peaks, for example peaks of DMSO in DMSO-D 6  and the peak of water, which usually have a high intensity on average. 
     The peaks of stereoisomers of the target compounds and/or peaks of impurities usually have a lower intensity on average than the peaks of the target compounds (for example with a purity of &gt;90%). 
     Such stereoisomers and/or impurities may be typical of the particular preparation process. Their peaks can thus help in identifying reproduction of our preparation process with reference to “by-product fingerprints”. 
     A person skilled in the art calculating the peaks of the target compounds by known methods (MestreC, ACD simulation, but also with empirically evaluated expected values) can, if required, isolate the peaks of the target compounds, optionally using additional intensity filters. This isolation would be similar to the peak picking in question in conventional  1 H NMR interpretation. 
     Further details of  1 H NMR peak lists can be found in the Research Disclosure Database Number 564025. 
     The compounds according to the invention described in table 1 below are likewise preferred compounds of the formula (I), wherein R 1  is hydrogen, R 3b  is methyl, R 3a  is hydrogen, X is oxygen and Y is a direct bond which are obtained according to or analogously to the preparation examples described above. 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                 TABLE 1 
               
               
                   
               
               
                   
                   
                   
                 ESI 
               
               
                   
                   
                   
                 Mass 
               
               
                 Example 
                 Structure 1)   
                 NMR Peak List 2)   
                 (m/z) 3)   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 1-1  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.1398 (1.3); 9.1223 (1.3); 9.0698 (2.4); 9.0680 (2.8); 9.0643 (2.8); 9.0624 (2.7); 8.5848 (1.2); 8.5817 (1.4); 8.5793 (1.4); 8.5762 (1.3); 8.5633 (1.3); 8.5603 (1.5); 8.5578 (1.5); 8.5547 (1.4); 8.2355 (3.7); 8.2318 (3.8); 8.0825 (2.6); 8.0610 (2.4); 7.8235 (1.6); 7.8195 (1.7); 7.8158 (1.6); 7.7839 (1.4); 7.7646 (1.6); 7.5683 (1.0); 7.5521 (1.5); 7.5491 (1.5); 7.5012 (1.6); 7.4820 (2.3); 7.4629 (0.9); 6.0937 (0.8); 6.0766 (1.3); 6.0590 (0.8); 4.3771 (0.5); 4.3591 (1.7); 4.3411 (1.7); 4.3231 (0.5); 4.0559 (1.1); 4.0381 (3.5); 4.0203 (3.6); 4.0026 (1.2); 3.3270 (22.5); 2.5252 (0.9); 2.5118 (17.4); 2.5074 (35.5); 2.5028 (46.8); 2.4982 (33.8); 2.4937 (16.3); 2.0866 (1.8); 2.0753 (1.8); 1.9894 (16.0); 1.6427 (5.8); 1.6253 (5.8); 1.5664 (8.2); 1.5483 (8.1); 1.3973 (0.4); 1.1931 (4.3); 1.1753 (8.5); 1.1575 (4.2); −0.0002 (8.6) 
                 372.3 
               
               
                   
               
               
                 1-2  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.1350 (1.6); 9.1176 (1.6); 9.0703 (2.8); 9.0687 (3.2); 9.0649 (3.1); 9.0631 (3.1); 8.5845 (2.5); 8.5790 (2.5); 8.5631 (2.7); 8.5575 (2.7); 8.2282 (8.2); 8.0850 (3.2); 8.0832 (3.4); 8.0635 (3.0); 8.0617 (3.2); 7.7752 (4.2); 7.7714 (5.0); 7.7587 (1.3); 7.7548 (1.9); 7.5118 (0.8); 7.5076 (0.6); 7.4926 (2.9); 7.4859 (2.8); 7.4824 (1.6); 7.4659 (2.2); 7.4465 (0.7); 6.0883 (1.3); 6.0708 (2.0); 6.0533 (1.3); 4.0825 (10.4); 4.0555 (0.6); 4.0377 (1.9); 4.0199 (1.9); 4.0022 (0.6); 3.3245 (39.3); 2.6895 (16.0); 2.6800 (0.4); 2.6756 (0.6); 2.6710 (0.9); 2.6665 (0.6); 2.5245 (2.8); 2.5197 (4.5); 2.5111 (51.6); 2.5066 (104.7); 2.5020 (137.0); 2.4974 (97.6); 2.4929 (46.1); 2.3333 (0.6); 2.3289 (0.8); 2.3242 (0.6); 2.0747 (0.8); 1.9889 (8.4); 1.6313 (7.9); 1.6139 (7.8); 1.1927 (2.3); 1.1749 (4.7); 1.1571 (2.3); 0.1458 (0.7); 0.0165 (0.3); 0.0079 (6.4); −0.0002 (174.1); −0.0086 
                 358.3 
               
               
                   
                   
                 (5.8); −0.1498 (0.7) 
                   
               
               
                   
               
               
                 1-3  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.0615 (3.4); 9.0597 (3.7); 9.0560 (3.8); 9.0542 (3.6); 8.9222 (2.0); 8.9047 (2.0); 8.5765 (3.2); 8.5709 (3.0); 8.5550 (3.4); 8.5494 (3.3); 8.3142 (0.9); 8.2169 (9.6); 8.0658 (3.8); 8.0640 (3.8); 8.0443 (3.6); 8.0425 (3.6); 7.1671 (3.7); 7.1090 (2.9); 6.8856 (3.0); 6.0463 (1.4); 6.0289 (2.2); 6.0114 (1.4); 5.7545 (6.8); 4.0380 (0.6); 4.0203 (0.6); 3.8173 (6.1); 3.7999 (6.2); 3.3213 (139.9); 2.6800 (0.3); 2.6753 (0.7); 2.6708 (0.9); 2.6661 (0.7); 2.6620 (0.3); 2.5243 (3.0); 2.5195 (4.4); 2.5109 (52.5); 2.5064 (106.2); 2.5018 (140.5); 2.4972 (101.8); 2.4927 (48.7); 2.3332 (0.6); 2.3286 (0.9); 2.3241 (0.6); 2.2819 (16.0); 1.9886 (2.8); 1.6176 (8.6); 1.6002 (8.5); 1.2394 (0.4); 1.2341 (0.5); 1.2200 (0.7); 1.2140 (0.7); 1.2103 (0.6); 1.2022 (1.2); 1.1929 (1.3); 1.1821 (0.8); 1.1751 (1.8); 1.1573 (0.8); 0.5856 (1.0); 0.5747 (3.1); 0.5704 (3.2); 0.5658 (1.5); 0.5600 (1.5); 0.5546 (3.2); 0.5502 (3.0); 0.5400 (1.1); 0.3300 (1.2); 0.3195 (3.5); 0.3160 (3.5); 0.3078 
                 403.3 
               
               
                   
                   
                 (3.1); 0.3040 (3.7); 0.2929 (0.9); 0.1460 
                   
               
               
                   
                   
                 (0.4); 0.0080 (2.8); −0.0002 (88.0); −0.0085 
                   
               
               
                   
                   
                 (2.7); −0.1495 (0.3) 
                   
               
               
                   
               
               
                 1-4  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.0598 (3.4); 9.0581 (3.6); 9.0543 (3.7); 9.0525 (3.4); 8.9215 (1.9); 8.9039 (2.0); 8.5770 (3.0); 8.5715 (2.9); 8.5556 (3.2); 8.5500 (3.2); 8.2184 (9.4); 8.0683 (3.8); 8.0666 (3.8); 8.0468 (3.5); 8.0451 (3.6); 7.1565 (3.6); 7.1553 (3.6); 7.0677 (2.9); 6.8560 (2.9); 6.0436 (1.4); 6.0261 (2.2); 6.0086 (1.4); 5.7552 (5.9); 4.8379 (0.4); 4.8318 (0.9); 4.8230 (1.0); 4.8173 (1.6); 4.8028 (0.8); 4.0384 (0.6); 4.0206 (0.6); 3.3251 (74.8); 2.6762 (0.3); 2.6717 (0.5); 2.6670 (0.3); 2.5252 (1.4); 2.5205 (2.1); 2.5118 (27.3); 2.5073 (55.7); 2.5027 (73.5); 2.4981 (52.6); 2.4935 (25.0); 2.3342 (0.3); 2.3295 (0.5); 2.3248 (0.3); 2.2836 (16.0); 1.9892 (2.6); 1.8961 (1.4); 1.8822 (1.2); 1.8699 (0.9); 1.8641 (0.9); 1.7247 (0.4); 1.6904 (4.7); 1.6817 (2.5); 1.6758 (2.1); 1.6705 (2.0); 1.6609 (1.7); 1.6504 (1.1); 1.6445 (1.2); 1.6163 (9.1); 1.5988 (9.6); 1.5817 (1.9); 1.5726 (1.5); 1.1932 (0.8); 1.1754 (1.5); 1.1576 (0.7); 0.0080 (1.4); 
                 417.3 
               
               
                   
                   
                 −0.0002 (46.5); −0.0086 (1.3) 
                   
               
               
                   
               
               
                 1-5  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.0612 (3.2); 9.0597 (3.6); 9.0559 (3.5); 9.0542 (3.4); 8.9249 (1.9); 8.9073 (2.0); 8.5793 (2.6); 8.5738 (2.5); 8.5579 (2.8); 8.5523 (2.8); 8.3149 (0.8); 8.2184 (8.6); 8.0688 (3.4); 8.0673 (3.6); 8.0473 (3.2); 8.0458 (3.3); 7.1772 (3.6); 7.0035 (3.0); 6.7972 (3.0); 6.0434 (1.4); 6.0257 (2.2); 6.0082 (1.4); 4.7176 (0.3); 4.6993 (1.2); 4.6816 (1.9); 4.6637 (1.3); 4.6462 (0.3); 3.3192 (84.0); 2.6749 (1.5); 2.6704 (2.1); 2.6660 (1.6); 2.5239 (6.5); 2.5190 (9.8); 2.5103 (127.4); 2.5060 (254.4); 2.5015 (332.3); 2.4969 (241.0); 2.4925 (117.1); 2.4392 (0.8); 2.4326 (0.8); 2.4100 (1.5); 2.4022 (1.5); 2.3938 (1.5); 2.3718 (0.8); 2.3653 (0.6); 2.3329 (1.5); 2.3283 (2.1); 2.3238 (1.5); 2.2835 (16.0); 2.0738 (0.4); 2.0516 (0.4); 2.0263 (1.4); 2.0212 (0.9); 2.0070 (1.4); 2.0017 (1.7); 1.9965 (1.4); 1.9826 (1.1); 1.9773 (1.4); 1.9527 (0.4); 1.8114 (0.4); 1.7855 (1.0); 1.7607 (1.0); 
                 403.3 
               
               
                   
                   
                 1.7354 (0.4); 1.6714 (0.6); 1.6674 (0.7); 
                   
               
               
                   
                   
                 1.6463 (1.3); 1.6143 (8.5); 1.5969 (8.5); 
                   
               
               
                   
                   
                 0.1458 (0.6); 0.0080 (4.9); −0.0001 (151.7); 
                   
               
               
                   
                   
                 −0.0084 (5.3); −0.1497 (0.6) 
                   
               
               
                   
               
               
                 1-6  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.0613 (0.5); 9.0594 (0.5); 9.0558 (0.5); 9.0539 (0.5); 8.5807 (0.4); 8.5752 (0.4); 8.5593 (0.4); 8.5537 (0.4); 8.2218 (1.3); 8.0713 (0.5); 8.0694 (0.5); 8.0498 (0.5); 8.0479 (0.5); 7.2397 (0.5); 6.9486 (0.4); 6.7691 (0.4); 4.9083 (0.4); 4.5298 (0.4); 4.5165 (0.4); 4.5119 (0.4); 4.4984 (0.4); 3.3214 (26.8); 2.6897 (16.0); 2.5242 (0.8); 2.5195 (1.2); 2.5108 (15.5); 2.5063 (31.8); 2.5017 (42.0); 2.4970 (30.0); 2.4924 (14.2); 2.2950 (2.1); 1.6174 (1.2); 1.6000 (1.2); 0.0080 (0.8); 0.0057 (0.4); −0.0002 (25.2); −0.0086 (0.7) 
                 405.3 
               
               
                   
               
               
                 1-7  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2257 (3.2); 9.2084 (3.3); 9.0393 (5.6); 9.0374 (6.3); 9.0338 (6.3); 9.0319 (6.0); 8.5700 (5.2); 8.5645 (5.0); 8.5486 (5.6); 8.5430 (5.6); 8.3142 (0.4); 8.2223 (16.0); 8.0629 (6.2); 8.0611 (6.4); 8.0415 (5.8); 8.0396 (6.0); 7.6660 (4.9); 7.6618 (7.6); 7.6579 (5.3); 7.4668 (0.7); 7.4610 (4.9); 7.4558 (2.0); 7.4486 (1.0); 7.4424 (7.6); 7.4397 (7.4); 7.4340 (1.2); 7.4260 (2.4); 7.4210 (6.8); 7.4151 (0.9); 7.3307 (4.5); 7.3271 (5.2); 7.3251 (6.0); 7.3215 (5.2); 7.2514 (5.4); 7.2460 (8.0); 7.2412 (7.2); 7.2231 (5.2); 7.2073 (1.3); 7.2046 (2.3); 7.2020 (1.4); 7.0932 (6.8); 7.0904 (9.0); 7.0852 (2.4); 7.0740 (4.1); 7.0714 (7.6); 7.0690 (6.7); 7.0625 (0.8); 6.0584 (0.5); 
                 445.1 
               
               
                   
                   
                 6.0411 (2.4); 6.0238 (3.7); 6.0064 (2.4); 
                   
               
               
                   
                   
                 5.9891 (0.5); 5.7545 (2.2); 3.3182 (75.3); 
                   
               
               
                   
                   
                 2.6803 (0.4); 2.6756 (0.8); 2.6711 (1.1); 
                   
               
               
                   
                   
                 2.6665 (0.8); 2.6618 (0.4); 2.5246 (3.4); 
                   
               
               
                   
                   
                 2.5199 (5.0); 2.5112 (64.7); 2.5067 (133.6); 
                   
               
               
                   
                   
                 2.5021 (177.4); 2.4975 (126.9); 2.4929 
                   
               
               
                   
                   
                 (60.6); 2.3380 (0.4); 2.3335 (0.8); 2.3289 
                   
               
               
                   
                   
                 (1.1); 2.3244 (0.8); 2.3197 (0.4); 1.6071 
                   
               
               
                   
                   
                 (14.3); 1.5896 (14.2); 1.2342 (0.4); 0.0080 
                   
               
               
                   
                   
                 (2.7); −0.0001 (84.2); −0.0085 (2.6); −0.1496 
                   
               
               
                   
                   
                 (0.3) 
                   
               
               
                   
               
               
                 1-8  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2346 (3.4); 9.2172 (3.4); 9.0463 (5.5); 9.0449 (6.1); 9.0411 (6.0); 9.0394 (5.8); 8.5743 (4.8); 8.5687 (4.6); 8.5528 (5.2); 8.5473 (5.1); 8.2250 (16.0); 8.0677 (6.2); 8.0661 (6.3); 8.0462 (5.7); 8.0446 (5.8); 7.6957 (5.0); 7.6917 (7.8); 7.6877 (5.1); 7.4962 (1.1); 7.4875 (12.2); 7.4819 (3.9); 7.4707 (4.0); 7.4651 (14.2); 7.4565 (1.3); 7.3623 (4.4); 7.3586 (5.4); 7.3567 (6.3); 7.3531 (5.4); 7.3171 (5.2); 7.3119 (7.6); 7.3068 (4.0); 7.1329 (1.3); 7.1242 (13.8); 7.1187 (4.1); 7.1074 (3.8); 7.1019 (12.4); 7.0932 (1.1); 6.0673 (0.5); 6.0500 (2.4); 6.0327 (3.8); 6.0153 (2.4); 5.9978 (0.5); 5.7548 (4.0); 3.3197 (56.3); 2.6764 (0.6); 2.6718 (0.8); 2.6670 (0.6); 2.5253 (2.5); 
                 479.1 
               
               
                   
                   
                 2.5205 (3.9); 2.5118 (49.0); 2.5074 (98.3); 
                   
               
               
                   
                   
                 2.5028 (128.0); 2.4982 (91.0); 2.4937 
                   
               
               
                   
                   
                 (43.0); 2.3342 (0.5); 2.3296 (0.7); 2.3252 
                   
               
               
                   
                   
                 (0.5); 1.6103 (14.5); 1.5929 (14.4); 1.2346 
                   
               
               
                   
                   
                 (0.4); 0.0081 (2.1); −0.0001 (61.7); −0.0084 
                   
               
               
                   
                   
                 (1.9) 
                   
               
               
                   
               
               
                 1-9  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2320 (3.8); 9.2148 (3.9); 9.0442 (6.8); 9.0392 (7.0); 8.5758 (4.2); 8.5704 (4.1); 8.5543 (4.5); 8.5489 (4.5); 8.2251 (14.9); 8.0669 (6.9); 8.0454 (6.4); 7.6600 (8.3); 7.3035 (5.6); 7.2952 (10.1); 7.2732 (10.0); 7.2572 (2.4); 7.2516 (7.0); 7.2399 (5.5); 7.2350 (7.8); 7.2300 (4.2); 7.1777 (0.8); 7.1684 (7.1); 7.1572 (7.4); 7.1513 (3.9); 7.1458 (5.1); 7.1401 (2.4); 7.1346 (4.8); 6.0609 (0.6); 6.0439 (2.7); 6.0266 (4.2); 6.0093 (2.7); 5.9919 (0.6); 3.3237 (39.1); 2.6719 (1.0); 2.6681 (0.7); 2.5073 (127.9); 2.5032 (156.3); 2.4989 (114.1); 2.3343 (0.7); 2.3299 (0.9); 1.6090 (16.0); 1.5916 (15.9); 1.2338 (0.6); 0.1461 (0.6); 0.0074 (6.1); −0.0002 (118.4); −0.0077 (7.4); 
                 463.1 
               
               
                   
                   
                 −0.1495 (0.6) 
                   
               
               
                   
               
               
                 1-10 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (600.1 MHz, d 6 -DMSO): δ = 9.2234 (3.5); 9.2118 (3.6); 9.0549 (5.0); 9.0539 (5.2); 9.0514 (5.3); 9.0503 (4.8); 8.5773 (4.2); 8.5736 (4.1); 8.5630 (4.4); 8.5593 (4.4); 8.5484 (7.4); 8.2250 (12.3); 8.0770 (5.6); 8.0761 (5.4); 8.0628 (5.2); 8.0617 (5.1); 7.9286 (7.9); 7.8529 (3.9); 7.8502 (6.3); 7.8475 (4.0); 7.6758 (6.6); 7.5263 (6.0); 6.0721 (0.5); 6.0605 (2.3); 6.0489 (3.6); 6.0373 (2.4); 6.0256 (0.5); 5.7537 (10.0); 5.4264 (16.0); 4.0244 (0.3); 3.3226 (128.4); 2.6183 (0.5); 2.6154 (0.7); 2.6124 (0.5); 2.5242 (1.6); 2.5212 (2.0); 2.5181 (2.0); 2.5091 (34.8); 2.5063 (73.6); 2.5033 (100.9); 2.5003 (74.1); 2.4974 (35.4); 2.3901 (0.5); 2.3872 (0.6); 2.3841 (0.4); 1.9893 (1.4); 1.6181 (13.8); 1.6065 (13.9); 1.1879 (0.4); 1.1761 (0.8); 1.1641 (0.4); 0.0053 (2.8); −0.0001 (77.5); −0.0056 
                 501.4 
               
               
                   
                   
                 (3.1); −0.1002 (0.3) 
                   
               
               
                   
               
               
                 1-11 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2572 (1.2); 9.2399 (1.3); 9.0649 (2.0); 9.0636 (2.1); 9.0596 (2.2); 9.0582 (2.0); 8.5825 (1.7); 8.5769 (1.6); 8.5610 (1.8); 8.5554 (1.8); 8.2322 (5.5); 8.0819 (2.2); 8.0804 (2.2); 8.0604 (2.0); 8.0589 (2.1); 7.7859 (1.7); 7.7817 (2.8); 7.7776 (1.8); 7.5480 (1.6); 7.5431 (2.6); 7.5393 (2.0); 7.5134 (1.9); 7.5084 (3.0); 7.5034 (1.4); 6.0744 (0.9); 6.0570 (1.4); 6.0396 (0.9); 3.3289 (70.6); 2.6719 (0.4); 2.5253 (1.4); 2.5204 (2.1); 2.5119 (22.7); 2.5075 (44.8); 2.5029 (59.1); 2.4983 (44.2); 2.4939 (22.1); 
                 411.3 
               
               
                   
                   
                 2.3298 (0.4); 2.2853 (16.0); 2.0748 (2.7); 
                   
               
               
                   
                   
                 1.6240 (5.2); 1.6066 (5.2); 0.0080 (0.7); 
                   
               
               
                   
                   
                 −0.0002 (21.9); −0.0084 (0.8) 
                   
               
               
                   
               
               
                 1-12 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2736 (1.4); 9.2612 (1.8); 9.2561 (1.8); 9.2441 (1.5); 9.0145 (4.4); 9.0095 (4.4); 8.5374 (1.9); 8.5345 (2.2); 8.5320 (2.2); 8.5291 (2.0); 8.5159 (2.1); 8.5130 (2.4); 8.5105 (2.4); 8.5076 (2.1); 8.3167 (0.4); 8.0179 (4.6); 7.9964 (4.2); 7.7298 (2.4); 7.6923 (2.4); 7.6515 (1.9); 7.6320 (1.9); 7.5205 (2.3); 7.4997 (2.3); 7.4066 (6.9); 7.3958 (4.6); 7.3933 (4.0); 7.3904 (3.8); 7.3835 (2.4); 7.3806 (3.0); 7.3717 (0.8); 7.3620 (0.7); 7.3576 (0.6); 7.3521 (1.5); 7.3468 (2.6); 7.3416 (1.6); 7.3390 (1.8); 7.3321 (1.8); 7.3290 (1.3); 7.3240 (1.1); 7.3187 (0.6); 6.0867 (0.3); 6.0693 (1.4); 6.0521 (2.1); 6.0355 (1.4); 6.0182 (0.3); 5.7569 (5.1); 5.7476 (1.6); 5.7369 (1.6); 5.7317 (1.6); 5.7214 (0.5); 5.7162 (0.5); 3.3261 (124.6); 2.6760 (1.0); 2.6716 (1.4); 2.6671 (1.1); 2.5250 (4.7); 2.5115 (86.5); 2.5072 (171.5); 2.5027 (225.8); 2.4981 (168.0); 2.4938 (84.8); 2.3374 (15.2); 
                 555.3 
               
               
                   
                   
                 2.3300 (16.0); 2.2436 (0.5); 1.6057 (8.5); 
                   
               
               
                   
                   
                 1.5884 (9.0); 1.5793 (6.7); 1.5716 (6.6); 
                   
               
               
                   
                   
                 1.5635 (6.3); 1.5558 (5.7); 0.1460 (0.3); 
                   
               
               
                   
                   
                 0.0079 (3.0); −0.0002 (77.7); −0.0085 (3.1); 
                   
               
               
                   
                   
                 −0.1495 (0.3) 
                   
               
               
                   
               
               
                 1-13 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.3095 (1.4); 9.2919 (1.4); 9.0299 (2.5); 9.0251 (2.5); 8.5402 (1.8); 8.5347 (1.7); 8.5188 (1.9); 8.5132 (1.9); 8.0226 (2.6); 8.0010 (2.4); 7.7723 (3.7); 7.7661 (2.4); 7.5618 (2.6); 7.5316 (2.2); 7.4513 (1.4); 7.4469 (1.0); 7.4376 (6.3); 7.4303 (2.5); 7.4255 (1.8); 7.4188 (0.8); 7.4156 (0.8); 6.1051 (1.0); 6.0876 (1.6); 6.0700 (1.1); 5.7564 (3.7); 5.2517 (7.1); 3.3287 (70.6); 2.6764 (0.4); 2.6720 (0.5); 2.6675 (0.4); 2.5252 (1.4); 2.5118 (28.1); 2.5075 (56.8); 2.5030 (75.4); 2.4984 (55.8); 2.4940 (27.7); 2.3406 (16.0); 1.6272 (5.7); 1.6098 (5.7); 0.0079 (0.9); −0.0002 (32.0); −0.0084 (1.3) 
                 541.1 
               
               
                   
               
               
                 1-14 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2743 (1.4); 9.2639 (1.6); 9.2568 (1.7); 9.2463 (1.5); 8.9982 (2.3); 8.9924 (4.3); 8.9868 (2.5); 8.5358 (3.2); 8.5303 (3.1); 8.5143 (3.4); 8.5087 (3.4); 8.3164 (0.4); 8.0178 (2.9); 8.0158 (2.9); 7.9963 (2.7); 7.9943 (2.7); 7.7510 (2.4); 7.7232 (2.4); 7.5822 (2.0); 7.5601 (2.0); 7.5110 (1.3); 7.5049 (1.4); 7.4958 (2.5); 7.4921 (3.6); 7.4878 (2.4); 7.4840 (2.5); 7.4791 (3.4); 7.4751 (3.1); 7.4667 (1.5); 7.4608 (1.9); 7.3638 (0.4); 7.3591 (0.6); 7.3550 (0.4); 7.3498 (0.7); 7.3452 (1.6); 7.3407 (1.7); 7.3353 (2.7); 7.3284 (4.5); 7.3208 (3.8); 7.3160 (2.0); 7.3106 (2.8); 7.3048 (1.4); 7.2977 (0.6); 7.2920 (0.8); 7.2768 (3.5); 6.0788 (0.3); 6.0620 (1.5); 6.0447 (2.3); 6.0279 (1.5); 6.0102 (0.4); 5.8845 (0.4); 5.8691 (1.6); 5.8592 (1.7); 5.8534 (1.7); 5.8435 (1.6); 5.8276 (0.4); 5.7565 (3.5); 
                 555.4 
               
               
                   
                   
                 3.3250 (93.1); 2.6804 (0.5); 2.6761 (1.1); 
                   
               
               
                   
                   
                 2.6715 (1.5); 2.6671 (1.1); 2.6629 (0.6); 
                   
               
               
                   
                   
                 2.5250 (4.6); 2.5202 (6.9); 2.5115 (87.7); 
                   
               
               
                   
                   
                 2.5071 (177.9); 2.5026 (235.7); 2.4981 
                   
               
               
                   
                   
                 (174.8); 2.4937 (87.7); 2.3391 (15.5); 
                   
               
               
                   
                   
                 2.3264 (16.0); 2.2423 (0.5); 1.6155 (6.7); 
                   
               
               
                   
                   
                 1.6097 (7.2); 1.5938 (13.4); 1.5791 (7.2); 
                   
               
               
                   
                   
                 1.5760 (7.1); 0.1461 (0.4); 0.0080 (2.8); 
                   
               
               
                   
                   
                 −0.0002 (87.9); −0.0084 (3.4); −0.1494 (0.4) 
                   
               
               
                   
               
               
                 1-15 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2635 (1.6); 9.2548 (1.8); 9.2458 (1.8); 9.2370 (1.7); 9.0172 (2.7); 9.0127 (4.7); 9.0077 (2.7); 8.5405 (1.9); 8.5362 (2.7); 8.5314 (1.8); 8.5190 (2.0); 8.5147 (2.9); 8.5098 (1.9); 8.3168 (0.3); 8.0200 (4.8); 7.9985 (4.4); 7.7236 (2.6); 7.6839 (2.6); 7.6315 (2.2); 7.6143 (2.2); 7.4732 (2.2); 7.4580 (3.1); 7.4517 (6.2); 7.4373 (6.2); 7.4264 (6.3); 7.4202 (2.8); 7.4153 (6.5); 7.4100 (2.5); 7.4052 (2.6); 7.3988 (1.3); 7.3936 (2.4); 7.3818 (4.1); 6.0823 (0.3); 6.0647 (1.3); 6.0500 (2.0); 6.0472 (2.0); 6.0323 (1.3); 6.0152 (0.3); 5.7570 (5.0); 5.7510 (1.6); 5.7403 (1.7); 5.7353 (1.7); 5.7248 (1.5); 5.7101 (0.4); 3.3257 (111.7); 2.6762 (1.1); 2.6718 (1.5); 2.6674 (1.1); 2.5072 (184.3); 2.5028 (236.4); 2.4984 (175.3); 2.3378 (15.4); 2.3298 (16.0); 1.6034 (10.5); 1.5860 (10.6); 1.5663 (6.6); 1.5607 (6.9); 1.5506 (6.8); 1.5450 (6.4); 1.4358 (0.4); 0.1463 (0.4); 0.0080 (4.2); 
                 555.4 
               
               
                   
                   
                 0.0000 (92.0); −0.0082 (3.9); −0.1493 (0.4) 
                   
               
               
                   
               
               
                 1-16 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.3220 (1.4); 9.3043 (1.4); 9.0308 (2.2); 9.0290 (2.5); 9.0253 (2.4); 9.0235 (2.4); 8.5406 (2.0); 8.5350 (1.9); 8.5191 (2.2); 8.5135 (2.2); 8.0251 (2.5); 8.0234 (2.6); 8.0036 (2.3); 8.0018 (2.4); 7.7878 (2.5); 7.7701 (1.9); 7.6549 (1.2); 7.6496 (0.8); 7.6458 (0.7); 7.6395 (1.1); 7.6317 (1.4); 7.5538 (2.1); 7.5489 (2.6); 7.5434 (1.2); 7.5337 (0.8); 7.5298 (1.1); 7.5256 (1.9); 7.4490 (0.3); 7.4432 (0.6); 7.4305 (1.8); 7.4230 (2.3); 7.4150 (3.6); 7.4057 (2.4); 7.4005 (1.5); 7.3867 (0.4); 6.1064 (1.0); 6.0890 (1.6); 6.0714 (1.0); 5.7565 (3.2); 5.2883 (6.9); 3.3529 (0.3); 3.3276 (153.2); 2.6760 (0.6); 2.6714 (0.9); 2.6669 (0.6); 2.5250 (2.4); 2.5203 (3.6); 2.5116 (49.6); 2.5071 (102.6); 2.5025 (137.2); 2.4979 (100.6); 2.4934 (48.8); 2.3405 (16.0); 2.3295 (1.2); 2.3248 (0.8); 2.3206 (0.4); 
                 541.4 
               
               
                   
                   
                 1.6270 (5.4); 1.6096 (5.4); 0.0080 (2.1); 
                   
               
               
                   
                   
                 −0.0002 (69.5); −0.0085 (2.3) 
                   
               
               
                   
               
               
                 1-17 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2516 (1.7); 9.2341 (1.8); 9.0658 (3.1); 9.0605 (3.2); 8.5855 (2.0); 8.5801 (1.9); 8.5641 (2.2); 8.5586 (2.1); 8.2368 (7.0); 8.0845 (3.3); 8.0630 (3.0); 7.9201 (3.4); 7.7869 (3.6); 7.6325 (3.4); 6.0822 (1.2); 6.0648 (1.8); 6.0473 (1.2); 4.5643 (6.8); 3.3230 (77.5); 2.9410 (16.0); 2.6752 (1.0); 2.6709 (1.4); 2.5241 (4.4); 2.5063 (180.2); 2.5020 (225.5); 2.4977 (161.9); 2.3330 (1.0); 2.3286 (1.3); 2.3244 (1.0); 1.6346 (7.0); 1.6172 (6.9); 0.0078 (2.2); −0.0002 (58.2) 
                 445.2 
               
               
                   
               
               
                 1-18 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.3008 (1.4); 9.2832 (1.5); 9.0287 (2.4); 9.0270 (2.6); 9.0232 (2.6); 9.0215 (2.4); 8.5397 (1.9); 8.5341 (1.9); 8.5182 (2.1); 8.5126 (2.1); 8.3161 (0.5); 8.0225 (2.6); 8.0209 (2.6); 8.0009 (2.4); 7.9993 (2.4); 7.7597 (4.7); 7.7558 (5.0); 7.5074 (2.3); 7.4865 (1.6); 7.4828 (2.2); 7.4653 (3.6); 7.4290 (1.4); 7.4261 (1.9); 7.4214 (0.7); 7.4085 (3.8); 7.4046 (1.7); 7.3899 (2.0); 7.3670 (1.5); 7.3556 (0.5); 7.3492 (1.6); 7.3423 (0.3); 7.3313 (0.4); 6.1004 (1.0); 6.0828 (1.6); 6.0654 (1.0); 5.2354 (7.0); 3.3261 (212.6); 2.6756 (1.2); 2.6710 (1.6); 2.6666 (1.2); 2.5245 (5.4); 2.5110 (98.2); 2.5066 (194.8); 2.5021 (255.0); 2.4976 (188.2); 2.4932 (93.4); 2.3397 (16.0); 2.3291 (2.0); 2.3246 (1.4); 2.2461 (0.4); 1.6238 (5.6); 1.6064 (5.6); 0.1459 (0.4); 0.0080 (3.0); −0.0001 (87.3); −0.0084 (3.3); 
                 507.5 
               
               
                   
                   
                 −0.1496 (0.4) 
                   
               
               
                   
               
               
                 1-19 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2934 (1.4); 9.2756 (1.4); 9.0304 (2.4); 9.0289 (2.5); 9.0250 (2.6); 8.5400 (1.8); 8.5345 (1.8); 8.5185 (2.0); 8.5129 (2.0); 8.3160 (0.4); 8.0198 (2.6); 8.0184 (2.5); 7.9983 (2.4); 7.9968 (2.3); 7.7255 (2.6); 7.6509 (2.1); 7.4017 (2.2); 6.0962 (1.0); 6.0786 (1.6); 6.0611 (1.0); 3.9646 (3.4); 3.9486 (3.5); 3.9003 (1.2); 3.8927 (1.3); 3.8723 (1.4); 3.8648 (1.4); 3.3648 (1.4); 3.3260 (132.6); 2.6756 (0.9); 2.6711 (1.2); 2.6666 (0.9); 2.5246 (3.6); 2.5198 (5.4); 2.5111 (74.7); 2.5067 (152.9); 2.5022 (202.5); 2.4977 (150.1); 2.4933 (75.5); 2.3399 (16.0); 2.3292 (1.7); 2.3246 (1.1); 2.0267 (0.4); 2.0178 (0.6); 2.0090 (0.4); 1.9901 (0.4); 1.6993 (1.2); 1.6711 (1.5); 1.6667 (1.5); 1.6256 (5.7); 1.6082 (5.6); 1.4028 (0.4); 1.3916 (0.5); 1.3725 (1.0); 1.3613 (1.2); 1.3401 (1.1); 1.3297 (1.0); 
                 515.2 
               
               
                   
                   
                 1.3102 (0.4); 1.2995 (0.4); 0.1460 (0.4); 
                   
               
               
                   
                   
                 0.0079 (2.9); −0.0002 (94.9); −0.0084 (4.0); 
                   
               
               
                   
                   
                 −0.1497 (0.4) 
                   
               
               
                   
               
               
                 1-20 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.3032 (1.4); 9.2855 (1.5); 9.0278 (2.6); 9.0236 (2.5); 8.5404 (1.8); 8.5348 (1.7); 8.5189 (1.9); 8.5133 (1.8); 8.3153 (1.0); 8.0214 (2.6); 8.0000 (2.4); 7.7672 (2.7); 7.7471 (2.2); 7.5156 (2.8); 7.5103 (2.9); 7.4952 (6.6); 7.4806 (7.3); 7.4646 (0.8); 7.4589 (1.8); 6.0994 (1.0); 6.0821 (1.6); 6.0646 (1.0); 5.2365 (7.0); 3.3983 (0.4); 3.3287 (761.0); 2.6756 (2.4); 2.6711 (3.3); 2.6667 (2.5); 2.5244 (11.0); 2.5066 (406.8); 2.5022 (531.9); 2.4977 (395.5); 2.3389 (16.0); 2.3292 (3.9); 2.3245 (2.7); 2.0743 (0.6); 1.6231 (5.6); 1.6058 (5.6); 0.1459 (1.2); 0.0079 (9.9); −0.0001 (267.9); −0.0084 (11.5); −0.1498 (1.2) 
                 541.4 
               
               
                   
               
               
                 1-21 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2882 (1.4); 9.2705 (1.5); 9.0292 (2.4); 9.0277 (2.4); 9.0238 (2.6); 8.5415 (1.8); 8.5360 (1.8); 8.5200 (2.0); 8.5144 (2.0); 8.0222 (2.6); 8.0208 (2.5); 8.0007 (2.4); 7.9992 (2.3); 7.7254 (2.6); 7.6610 (2.1); 7.4683 (2.2); 6.0904 (1.0); 6.0730 (1.6); 6.0554 (1.0); 4.7990 (0.5); 4.7879 (0.7); 4.7778 (1.0); 4.7674 (0.7); 4.7565 (0.5); 3.8734 (0.8); 3.8628 (1.5); 3.8501 (1.0); 3.8449 (1.1); 3.8331 (1.8); 3.8220 (0.9); 3.5337 (1.0); 3.5269 (1.2); 3.5105 (1.3); 3.5041 (2.0); 3.4817 (1.1); 3.4751 (1.0); 3.3354 (257.8); 2.6765 (0.7); 2.6722 (1.0); 2.6676 (0.7); 2.5255 (3.2); 2.5206 (5.1); 2.5120 (58.5); 2.5076 (116.8); 2.5031 (153.3); 2.4986 (114.2); 2.4942 (57.7); 2.3403 (16.0); 2.3304 (1.5); 2.3255 (0.9); 
                 501.4 
               
               
                   
                   
                 1.9860 (0.9); 1.9765 (1.0); 1.9645 (0.8); 
                   
               
               
                   
                   
                 1.9530 (1.2); 1.9442 (1.1); 1.6236 (6.2); 
                   
               
               
                   
                   
                 1.6061 (6.4); 1.5915 (1.1); 1.5801 (1.4); 
                   
               
               
                   
                   
                 1.5701 (0.9); 1.5577 (0.5); 1.5478 (0.4); 
                   
               
               
                   
                   
                 0.1460 (0.8); 0.0080 (6.3); −0.0002 (171.7); 
                   
               
               
                   
                   
                 −0.0083 (7.6); −0.1496 (0.8) 
                   
               
               
                   
               
               
                 1-22 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2407 (1.1); 9.2235 (1.1); 9.0652 (2.0); 9.0635 (2.0); 9.0598 (2.1); 9.0580 (1.8); 8.5877 (1.6); 8.5822 (1.5); 8.5662 (1.7); 8.5607 (1.7); 8.2277 (5.1); 8.0840 (2.1); 8.0823 (1.9); 8.0625 (2.0); 8.0607 (1.8); 7.8072 (1.3); 7.8030 (2.1); 7.7988 (1.3); 7.6263 (2.2); 7.4603 (1.3); 7.4564 (2.0); 6.0601 (0.8); 6.0428 (1.2); 6.0254 (0.7); 4.8564 (5.4); 3.3301 (74.4); 3.1268 (16.0); 2.6762 (0.5); 2.6715 (0.6); 2.6669 (0.4); 2.5250 (2.1); 2.5202 (3.4); 2.5116 (38.3); 2.5071 (76.2); 2.5026 (98.8); 2.4980 (70.7); 2.4935 (33.7); 2.3340 (0.4); 2.3294 (0.6); 2.3247 (0.4); 2.1435 (15.3); 1.6191 (4.5); 1.6017 (4.4); 0.1461 (0.4); 0.0080 (3.6); −0.0002 (89.6); −0.0085 (3.0); −0.1495 (0.4) 
                 478.0 
               
               
                   
               
               
                 1-23 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2526 (3.9); 9.2352 (4.0); 9.0590 (7.2); 9.0551 (6.8); 8.5846 (4.8); 8.5791 (4.5); 8.5632 (5.2); 8.5576 (4.9); 8.3160 (0.5); 8.2379 (16.0); 8.0824 (7.0); 8.0609 (6.5); 8.0080 (8.8); 8.0040 (7.5); 7.9952 (8.5); 7.9099 (8.0); 7.3086 (13.0); 6.0947 (0.6); 6.0775 (2.7); 6.0602 (4.2); 6.0428 (2.7); 6.0256 (0.6); 3.3253 (52.7); 2.6762 (1.2); 2.6715 (1.6); 2.6671 (1.2); 2.5071 (205.0); 2.5027 (255.2); 2.4983 (184.1); 2.3340 (1.2); 2.3296 (1.5); 2.3251 (1.1); 2.0751 (0.5); 1.6271 (16.0); 1.6097 (15.8); 0.1458 (0.9); −0.0002 (191.9); −0.0084 (7.8); −0.1497 (0.9) 
                 492.9 
               
               
                   
               
               
                 1-24 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 10.6331 (0.4); 9.3436 (2.4); 9.3261 (2.5); 9.0659 (4.1); 9.0645 (4.6); 9.0607 (4.5); 9.0590 (4.3); 8.5849 (3.2); 8.5794 (3.1); 8.5634 (3.5); 8.5579 (3.5); 8.2456 (10.9); 8.0886 (4.5); 8.0870 (4.6); 8.0671 (4.2); 8.0655 (4.3); 7.7992 (4.7); 7.7172 (3.7); 7.5258 (3.8); 6.1272 (0.4); 6.1100 (1.7); 6.0927 (2.7); 6.0752 (1.8); 6.0579 (0.4); 5.7576 (0.7); 5.1451 (16.0); 3.3345 (42.8); 2.5281 (1.0); 2.5147 (19.9); 2.5104 (40.1); 2.5058 (52.0); 2.5013 (37.6); 2.4970 (18.3); 1.6500 (10.2); 1.6326 (10.2); 1.0886 (2.9); 1.0389 (1.9); 1.0104 (0.4); 0.8839 (0.4); 0.8656 (0.7); 0.8478 (0.3); 0.8401 (0.9); 0.8228 (0.9); 0.7989 (0.4); 0.0080 (0.5); −0.0002 (13.7); −0.0085 (0.5) 
                 547.0 
               
               
                   
               
               
                 1-25 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.3913 (3.6); 9.3739 (3.7); 9.0551 (5.9); 9.0536 (6.6); 9.0498 (6.6); 9.0481 (6.2); 8.5784 (4.8); 8.5729 (4.6); 8.5569 (5.1); 8.5514 (5.1); 8.3171 (0.4); 8.2382 (16.0); 8.1623 (7.0); 8.0794 (6.4); 8.0778 (6.4); 8.0580 (6.0); 8.0563 (6.0); 7.9356 (7.1); 7.9077 (7.0); 7.6504 (4.2); 7.6372 (4.8); 7.6283 (5.3); 7.6153 (4.9); 7.3723 (4.7); 7.3502 (8.6); 7.3281 (4.0); 6.0980 (0.5); 6.0808 (2.5); 6.0635 (3.9); 6.0461 (2.5); 6.0287 (0.5); 3.3292 (113.3); 2.6772 (1.0); 2.6727 (1.3); 2.6682 (1.0); 2.5260 (3.9); 2.5125 (84.0); 2.5082 (167.5); 2.5037 (216.5); 2.4991 (155.8); 2.4948 (75.7); 2.3349 (1.0); 2.3305 (1.3); 2.3260 (0.9); 
                 543.1 
               
               
                   
                   
                 2.0763 (1.2); 1.6339 (14.8); 1.6165 (14.8); 
                   
               
               
                   
                   
                 −0.0002 (3.8) 
                   
               
               
                   
               
               
                 1-26 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.3321 (3.7); 9.3147 (3.8); 9.0652 (6.3); 9.0634 (6.9); 9.0597 (7.0); 9.0579 (6.4); 8.5839 (5.0); 8.5784 (4.9); 8.5625 (5.4); 8.5569 (5.4); 8.3167 (0.5); 8.2433 (16.0); 8.0845 (6.8); 8.0828 (6.7); 8.0630 (6.3); 8.0613 (6.2); 7.7592 (7.0); 7.6586 (5.6); 7.4603 (5.7); 6.5245 (3.7); 6.5080 (8.9); 6.4916 (3.8); 6.1204 (0.6); 6.1031 (2.6); 6.0857 (4.0); 6.0683 (2.6); 6.0512 (0.5); 4.8457 (0.3); 4.8288 (0.5); 4.8139 (12.5); 4.7974 (12.3); 4.0380 (0.4); 4.0200 (0.4); 3.3270 (125.3); 2.6762 (1.2); 2.6716 (1.6); 2.6671 (1.3); 2.5251 (5.2); 2.5115 (100.2); 2.5072 (195.9); 2.5027 (254.1); 2.4981 (187.8); 2.4938 (93.5); 2.3341 (1.1); 2.3295 (1.5); 2.3249 (1.1); 1.9894 (1.8); 1.9086 (1.1); 1.6482 (15.1); 1.6308 (15.1); 1.4261 (0.4); 1.3976 (7.3); 1.1931 (0.5); 1.1754 
                 511.2 
               
               
                   
                   
                 (1.0); 1.1575 (0.5); 0.8886 (0.4); 0.8716 
                   
               
               
                   
                   
                 (0.3); 0.0079 (2.0); −0.0002 (49.1); −0.0084 
                   
               
               
                   
                   
                 (2.0) 
                   
               
               
                   
               
               
                 1-27 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 10.6313 (1.3); 10.5673 (0.7); 9.3581 (1.7); 9.3410 (1.7); 9.0683 (3.1); 9.0644 (3.1); 8.5856 (2.2); 8.5800 (2.0); 8.5641 (2.3); 8.5585 (2.3); 8.2442 (7.3); 8.0871 (3.1); 8.0856 (3.1); 8.0656 (2.9); 8.0640 (2.9); 7.8231 (2.2); 7.8094 (3.1); 7.6919 (2.6); 6.1059 (1.2); 6.0885 (1.8); 6.0712 (1.2); 5.4597 (1.6); 5.4548 (1.5); 5.4328 (1.9); 5.4279 (1.9); 5.2171 (2.7); 5.1903 (2.2); 5.1887 (2.2); 3.3312 (32.5); 2.6776 (0.3); 2.6726 (0.5); 2.6560 (16.0); 2.5261 (0.9); 2.5128 (19.6); 2.5085 (38.5); 2.5040 (49.9); 2.4994 (36.3); 2.4950 (17.7); 2.4816 (0.7); 2.1189 (0.6); 2.0873 (1.2); 1.6533 (7.0); 1.6359 (7.0); 1.4383 (0.3); 1.4250 (0.6); 1.4199 (0.4); 1.4152 (0.4); 1.4053 (0.4); 1.3958 (0.8); 1.3074 (0.4); 1.2896 (0.5); 1.2615 (0.3); 1.2321 (0.4); 1.1414 
                 479.2 
               
               
                   
                   
                 (1.3); 1.0876 (9.2); 1.0378 (6.0); 1.0094 
                   
               
               
                   
                   
                 (1.1); 0.8833 (1.1); 0.8651 (2.3); 0.8582 
                   
               
               
                   
                   
                 (0.3); 0.8471 (1.1); 0.8394 (3.0); 0.8221 
                   
               
               
                   
                   
                 (2.8); 0.8169 (0.8); 0.7980 (1.2); 0.7792 
                   
               
               
                   
                   
                 (0.5); −0.0002 (1.6) 
                   
               
               
                   
               
               
                 1-28 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 11.6398 (0.5); 10.6341 (1.1); 10.5702 (0.6); 9.4255 (2.7); 9.4091 (2.8); 8.6725 (11.8); 8.3188 (10.5); 8.0742 (3.2); 7.8705 (5.1); 7.7638 (4.2); 7.5497 (4.3); 6.0724 (0.4); 6.0553 (1.8); 6.0382 (2.7); 6.0211 (1.8); 6.0040 (0.4); 5.7581 (0.7); 5.1559 (16.0); 3.3317 (43.0); 2.6770 (0.6); 2.6725 (0.7); 2.6680 (0.5); 2.5079 (97.0); 2.5035 (122.3); 2.4991 (92.3); 2.3348 (0.6); 2.3304 (0.8); 2.3259 (0.6); 2.0872 (7.2); 1.9757 (11.6); 1.9587 (12.1); 1.6348 (10.4); 1.6174 (10.3); 1.4469 (0.4); 1.4377 (0.4); 1.4244 (0.6); 1.4199 (0.4); 1.4148 (0.4); 1.4053 (0.4); 1.3954 (0.7); 1.3069 (0.5); 1.2969 (0.4); 1.2889 (0.7); 1.2792 (0.6); 1.2683 (0.6); 1.2608 (0.7); 1.2371 (2.9); 1.1722 (0.6); 1.1568 (0.6); 1.1461 (1.0); 1.1406 (0.7); 1.1352 (0.8); 1.1047 (0.4); 1.0870 
                 553.0 
               
               
                   
                   
                 (7.0); 1.0523 (0.4); 1.0373 (4.4); 1.0089 
                   
               
               
                   
                   
                 (0.9); 0.8832 (1.1); 0.8649 (2.3); 0.8541 
                   
               
               
                   
                   
                 (1.7); 0.8471 (1.6); 0.8391 (3.0); 0.8218 
                   
               
               
                   
                   
                 (2.5); 0.8166 (1.1); 0.7976 (1.0); 0.7789 
                   
               
               
                   
                   
                 (0.5); 0.1459 (0.4); 0.0075 (5.3); −0.0002 
                   
               
               
                   
                   
                 (97.4); −0.0083 (5.1); −0.1496 (0.4) 
                   
               
               
                   
               
               
                 1-29 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 10.6351 (0.5); 9.3402 (2.4); 9.3340 (2.5); 9.3232 (2.6); 9.3169 (2.4); 9.0677 (6.9); 9.0627 (6.9); 8.5839 (4.7); 8.5784 (4.5); 8.5625 (5.0); 8.5570 (5.0); 8.2427 (15.8); 8.0848 (7.1); 8.0633 (6.6); 7.7353 (7.7); 7.7219 (3.4); 7.7074 (3.2); 7.4842 (6.2); 6.1221 (0.6); 6.1048 (2.6); 6.0874 (4.0); 6.0701 (2.6); 6.0528 (0.6); 5.7582 (0.7); 4.4671 (2.8); 4.4547 (2.9); 4.4402 (3.2); 4.4276 (3.1); 4.0518 (3.2); 4.0285 (4.0); 4.0251 (3.8); 4.0017 (3.0); 3.3342 (35.6); 2.6785 (0.4); 2.6739 (0.6); 2.6697 (0.4); 2.5136 (35.9); 2.5095 (69.7); 2.5051 (90.6); 2.5006 (67.5); 2.3363 (0.4); 2.3318 (0.6); 2.3275 (0.4); 2.3053 (0.7); 2.2928 (0.8); 2.2830 (1.3); 2.2787 (1.2); 2.2731 (1.4); 2.2643 (1.6); 2.2560 (1.5); 2.2458 (1.4); 2.2363 (0.9); 2.2233 (0.8); 2.0882 
                 525.2 
               
               
                   
                   
                 (3.0); 1.9099 (3.6); 1.8913 (4.4); 1.8827 
                   
               
               
                   
                   
                 (3.5); 1.8642 (3.4); 1.6512 (15.9); 1.6338 
                   
               
               
                   
                   
                 (16.0); 1.6241 (4.6); 1.6048 (6.4); 1.5858 
                   
               
               
                   
                   
                 (3.0); 1.4282 (0.6); 1.4098 (0.6); 1.3957 
                   
               
               
                   
                   
                 (0.4); 1.2358 (0.6); 1.0879 (3.6); 1.0381 
                   
               
               
                   
                   
                 (2.5); 1.0096 (0.5); 0.8836 (0.5); 0.8654 
                   
               
               
                   
                   
                 (1.0); 0.8537 (0.5); 0.8474 (0.6); 0.8396 
                   
               
               
                   
                   
                 (1.4); 0.8224 (1.3); 0.8171 (0.4); 0.7984 
                   
               
               
                   
                   
                 (0.5); 0.0078 (1.4); −0.0002 (35.1); −0.0084 
                   
               
               
                   
                   
                 (1.4) 
                   
               
               
                   
               
               
                 1-30 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.4193 (2.6); 9.4144 (2.7); 9.4033 (2.8); 9.3980 (2.6); 8.6730 (14.5); 8.3162 (15.3); 7.8065 (7.4); 7.7684 (4.2); 7.5082 (6.2); 6.0736 (0.6); 6.0562 (2.5); 6.0392 (3.9); 6.0221 (2.5); 6.0049 (0.6); 4.4806 (2.9); 4.4681 (3.1); 4.4535 (3.4); 4.4410 (3.2); 4.0629 (3.1); 4.0396 (4.0); 4.0363 (3.7); 4.0128 (2.9); 3.3326 (45.5); 2.6773 (0.6); 2.6728 (0.8); 2.6685 (0.6); 2.5261 (2.8); 2.5083 (101.3); 2.5039 (129.9); 2.4994 (95.6); 2.4954 (47.3); 2.3350 (0.6); 2.3308 (0.8); 2.3263 (0.6); 2.3112 (0.6); 2.2982 (0.7); 2.2896 (1.2); 2.2780 (1.4); 2.2701 (1.6); 2.2625 (1.5); 2.2509 (1.4); 2.2422 (0.9); 2.2293 (0.7); 2.0875 (1.0); 1.9118 (3.6); 1.8933 (4.5); 1.8847 (3.6); 1.8749 (0.5); 1.8662 (3.5); 1.6372 (15.8); 1.6197 (16.0); 1.6072 (6.5); 1.5881 (2.8); 1.4245 (0.5); 1.4198 (0.3); 1.4051 (0.4); 1.3953 
                 531.1 
               
               
                   
                   
                 (0.6); 1.3071 (0.4); 1.2890 (0.5); 1.2798 
                   
               
               
                   
                   
                 (0.3); 1.2609 (0.4); 1.2367 (1.0); 1.1406 
                   
               
               
                   
                   
                 (0.3); 1.1047 (0.4); 1.0872 (6.4); 1.0375 
                   
               
               
                   
                   
                 (4.0); 1.0091 (0.8); 0.8832 (0.9); 0.8651 
                   
               
               
                   
                   
                 (1.8); 0.8545 (0.7); 0.8472 (1.0); 0.8392 
                   
               
               
                   
                   
                 (2.3); 0.8219 (2.0); 0.8167 (0.7); 0.7978 
                   
               
               
                   
                   
                 (0.9); 0.7789 (0.4); 0.0079 (2.2); −0.0001 
                   
               
               
                   
                   
                 (50.5); −0.0084 (1.9) 
                   
               
               
                   
               
               
                 1-31 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2703 (2.7); 9.2538 (2.7); 8.6676 (11.8); 8.3089 (10.2); 7.7123 (6.0); 7.4681 (4.8); 7.4651 (4.0); 7.4465 (4.1); 7.4424 (4.9); 7.4369 (2.7); 6.0346 (0.4); 6.0172 (1.8); 6.0002 (2.7); 5.9831 (1.8); 5.9662 (0.4); 5.7563 (1.6); 5.0966 (0.4); 5.0700 (16.0); 3.3276 (33.4); 2.6767 (0.4); 2.6723 (0.5); 2.6682 (0.4); 2.5077 (60.6); 2.5034 (76.2); 2.4990 (56.3); 2.3303 (0.5); 2.3256 (0.3); 1.9758 (0.4); 1.9590 (0.4); 1.6123 (10.2); 1.5949 (10.1); 0.0078 (2.5); −0.0002 (58.4); −0.0082 (2.8) 
                 562.9 
               
               
                   
               
               
                 1-32 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.1884 (2.4); 9.1706 (2.4); 9.0621 (4.2); 9.0568 (4.3); 8.5841 (3.3); 8.5787 (2.9); 8.5627 (3.3); 8.5571 (3.3); 8.3155 (2.5); 8.2340 (10.5); 8.0830 (4.4); 8.0615 (4.1); 7.6436 (5.8); 7.4198 (12.3); 7.4161 (11.6); 6.0887 (0.4); 6.0718 (1.7); 6.0543 (2.6); 6.0369 (1.7); 6.0186 (0.4); 5.0880 (0.5); 5.0571 (16.0); 3.4182 (0.4); 3.3258 (732.1); 2.6756 (5.2); 2.6710 (6.9); 2.6665 (5.0); 2.6359 (0.4); 2.6132 (0.5); 2.5243 (24.0); 2.5108 (433.4); 2.5065 (840.8); 2.5021 (1085.4); 2.4975 (782.6); 2.4933 (379.2); 2.3332 (4.8); 2.3289 (6.6); 2.3245 (4.8); 1.6217 (10.0); 1.6043 (9.9); 1.3851 (0.3); 1.2374 (0.6); 1.0866 (1.8); 1.0369 (1.4); 0.8653 (0.4); 0.8389 (0.8); 0.8219 (0.6); 0.1460 (3.5); 0.0402 (0.4); 0.0079 (32.4); −0.0002 (798.8); −0.0085 (29.5); −0.0358 (0.6); −0.1496 (3.6) 
                 557.0 
               
               
                   
               
               
                 I-33 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.3030 (0.9); 9.2858 (0.9); 9.0686 (1.6); 9.0644 (1.6); 8.5869 (1.0); 8.5814 (1.0); 8.5654 (1.1); 8.5599 (1.1); 8.2470 (3.7); 8.1981 (0.5); 8.0857 (1.6); 8.0643 (1.4); 8.0632 (1.4); 7.8709 (3.7); 7.8665 (4.0); 7.7466 (1.2); 7.7421 (2.0); 7.7377 (1.1); 6.0944 (0.6); 6.0771 (1.0); 6.0597 (0.6); 5.7574 (1.8); 2.5099 (11.1); 2.5054 (14.3); 2.5010 (10.6); 1.7103 (16.0); 1.6513 (3.6); 1.6339 (3.6); 0.0078 (0.5); −0.0002 (10.8); −0.0084 (0.4) 
                 419.9 
               
               
                   
               
               
                 1-34 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.4555 (2.5); 9.4392 (2.6); 8.8822 (10.7); 8.3571 (10.3); 7.8892 (4.8); 7.7813 (3.8); 7.5532 (3.8); 6.0839 (0.4); 6.0667 (1.7); 6.0498 (2.7); 6.0326 (1.7); 6.0154 (0.4); 5.7561 (5.7); 5.1591 (16.0); 3.3319 (13.3); 2.5265 (0.9); 2.5130 (19.7); 2.5088 (38.2); 2.5043 (49.3); 2.4998 (35.7); 2.4955 (17.2); 1.6472 (10.2); 1.6297 (10.2); 1.2361 (1.5); 1.1738 (0.5); 1.1584 (0.5); 1.1479 (0.8); 1.1370 (0.7); 1.0879 (3.0); 1.0382 (2.0); 1.0098 (0.4); 0.8837 (0.5); 0.8655 (1.0); 0.8535 (0.8); 0.8478 (0.7); 0.8397 (1.3); 0.8225 (1.1); 0.8171 (0.4); 0.7984 (0.5); 0.0079 (1.3); −0.0002 (32.4); −0.0085 (1.1) 
                 573.0 
               
               
                   
               
               
                 1-35 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.4243 (3.6); 9.4072 (3.6); 9.0703 (7.0); 9.0664 (6.7); 9.0649 (6.6); 8.5856 (4.8); 8.5800 (4.6); 8.5641 (5.1); 8.5586 (5.0); 8.3626 (8.6); 8.3592 (5.2); 8.3158 (0.7); 8.2472 (16.0); 8.2386 (0.7); 8.1851 (4.9); 8.1805 (7.7); 8.1766 (5.2); 8.1068 (5.4); 8.1026 (7.8); 8.0983 (4.8); 8.0872 (6.7); 8.0859 (6.9); 8.0657 (6.1); 8.0643 (6.4); 6.1301 (0.6); 6.1129 (2.6); 6.0955 (4.2); 6.0782 (2.8); 6.0603 (0.6); 3.4488 (0.4); 3.3280 (263.7); 2.9852 (0.7); 2.9732 (1.6); 2.9665 (1.8); 2.9543 (3.0); 2.9428 (1.8); 2.9358 (1.6); 2.9239 (0.8); 2.6761 (1.7); 2.6715 (2.3); 2.6670 (1.7); 2.5247 (8.2); 2.5112 (148.0); 2.5070 (293.5); 2.5025 (381.9); 2.4980 (275.6); 2.4937 (133.9); 2.3338 (1.6); 2.3293 (2.2); 2.3248 (1.6); 2.0749 (3.5); 1.6530 (15.8); 1.6356 (15.8); 1.2310 (0.5); 1.2153 (0.8); 1.1999 (0.5); 1.1390 (0.9); 1.1265 (2.8); 1.1184 (7.0); 1.1132 (4.1); 1.1068 (3.0); 1.0991 (8.1); 
                 421.1 
               
               
                   
                   
                 1.0946 (7.0); 1.0896 (7.3); 1.0780 (8.2); 
                   
               
               
                   
                   
                 1.0695 (3.1); 1.0570 (0.8); 0.0080 (1.6); 
                   
               
               
                   
                   
                 −0.0001 (46.1); −0.0084 (1.7) 
                   
               
               
                   
               
               
                 I-36 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2381 (3.0); 9.2207 (3.1); 9.0700 (4.9); 9.0685 (5.1); 9.0647 (5.3); 9.0631 (4.8); 8.5867 (4.0); 8.5811 (3.9); 8.5652 (4.3); 8.5596 (4.3); 8.2389 (12.5); 8.0896 (5.3); 8.0880 (5.2); 8.0681 (5.0); 8.0665 (4.9); 7.6696 (6.0); 7.6359 (1.8); 7.6306 (2.2); 7.6119 (1.8); 7.6080 (2.2); 7.4066 (2.2); 7.3837 (2.3); 6.1124 (0.5); 6.0952 (2.1); 6.0778 (3.3); 6.0604 (2.1); 6.0430 (0.5); 4.1239 (16.0); 3.3466 (1.8); 2.5304 (0.4); 2.5168 (7.2); 2.5124 (14.5); 2.5078 (19.7); 2.5033 (14.9); 2.4990 (7.4); 2.0796 (0.8); 1.6401 (11.9); 1.6227 (12.0); −0.0002 (0.9) 
                 376.1 
               
               
                   
               
               
                 1-37 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.3788 (0.9); 9.3625 (0.9); 8.6717 (3.7); 8.3184 (3.4); 7.9355 (1.9); 7.9315 (1.4); 7.9219 (1.4); 7.9181 (1.9); 7.7686 (1.2); 7.7642 (2.0); 7.7597 (1.1); 6.0468 (0.6); 6.0299 (0.9); 6.0128 (0.6); 5.7560 (7.9); 3.3242 (16.1); 2.5072 (32.1); 2.5029 (41.0); 2.4985 (30.4); 1.7190 (16.0); 1.6354 (3.5); 1.6180 (3.5) 
                 426.1 
               
               
                   
               
               
                 1-38 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2467 (1.0); 9.2289 (1.0); 9.0117 (1.7); 9.0069 (1.6); 8.5319 (1.1); 8.5264 (1.0); 8.5104 (1.2); 8.5049 (1.2); 8.0079 (1.7); 7.9862 (1.5); 7.8506 (3.9); 7.8463 (4.1); 7.7422 (1.3); 7.7379 (2.1); 7.7335 (1.1); 6.0478 (0.7); 6.0303 (1.0); 6.0130 (0.7); 5.7557 (5.0); 3.3236 (32.2); 2.6713 (0.4); 2.5068 (50.4); 2.5025 (63.2); 2.4981 (46.1); 2.3292 (0.4); 2.0746 (0.5); 2.0658 (0.5); 2.0536 (0.8); 2.0416 (0.5); 2.0331 (0.4); 1.7299 (2.4); 1.7086 (16.0); 1.6092 (3.7); 1.5918 (3.7); 1.2317 (0.8); 1.2213 (0.9); 1.2161 (0.9); 1.2055 (0.8); 1.0006 (1.3); 0.9952 (1.7); 0.9798 (1.2); 0.9743 (1.6); 0.9037 (0.3); 0.8925 (1.0); 0.8867 (0.6); 0.8801 (1.0); 0.8749 (0.9); 0.8683 (0.8); 0.8562 (0.7); −0.0002 (8.2); −0.0083 (0.4) 
                 460.3 
               
               
                   
               
               
                 1-39 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2959 (0.9); 9.2789 (0.9); 9.0192 (1.5); 9.0139 (1.6); 8.5447 (1.0); 8.5392 (1.0); 8.5231 (1.1); 8.5176 (1.1); 7.9820 (1.6); 7.9603 (1.5); 7.9010 (2.0); 7.8968 (1.7); 7.8920 (1.6); 7.8880 (2.0); 7.7538 (1.2); 7.7494 (2.0); 7.7451 (1.1); 6.0706 (0.6); 6.0534 (1.0); 6.0359 (0.6); 5.7558 (1.2); 3.9641 (9.6); 3.3242 (23.5); 2.5072 (33.9); 2.5028 (42.8); 2.4984 (31.3); 1.7124 (16.0); 1.6256 (3.5); 1.6082 (3.5); −0.0002 (4.9) 
                 450.2 
               
               
                   
               
               
                 1-40 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (600.1 MHz, CD3CN lowT): δ = 8.0493 (0.5); 8.0375 (0.5); 7.9051 (4.0); 7.8297 (1.1); 7.8271 (1.8); 7.8244 (1.2); 7.7982 (1.2); 7.7954 (1.8); 7.7927 (1.0); 7.6978 (1.1); 7.6947 (1.9); 7.6917 (1.0); 6.1026 (0.6); 6.0907 (1.0); 6.0789 (0.6); 4.0563 (0.5); 4.0443 (0.5); 3.2669 (8.0); 3.0484 (7.3); 2.3379 (10.5); 2.3336 (1.0); 2.3078 (17.9); 2.2774 (0.5); 1.9846 (2.2); 1.9778 (0.6); 1.9700 (14.6); 1.9659 (28.1); 1.9617 (40.8); 1.9576 (28.1); 1.9535 (14.3); 1.7297 (1.3); 1.7244 (16.0); 1.6456 (3.6); 1.6339 (3.6); 1.2179 (0.5); 1.2059 (1.1); 1.1940 (0.5); 0.0054 (0.8); −0.0001 (21.6); −0.0057 (0.7) 
                 486.1 
               
               
                   
               
               
                 1-41 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (600.1 MHz, CD3CN lowT): δ = 7.9965 (1.0); 7.9846 (1.1); 7.9095 (8.5); 7.7882 (1.7); 7.7855 (2.9); 7.7827 (1.8); 7.7237 (3.0); 7.5548 (2.6); 6.0924 (1.2); 6.0806 (1.9); 6.0687 (1.3); 4.0561 (0.4); 4.0443 (0.4); 3.9086 (9.2); 3.2720 (16.0); 3.0501 (14.6); 2.3358 (21.9); 2.3214 (0.5); 2.3040 (276.6); 2.2711 (5.2); 2.0806 (0.4); 2.0765 (0.7); 2.0724 (1.0); 2.0682 (0.8); 2.0639 (0.5); 2.0026 (0.4); 1.9928 (0.4); 1.9845 (2.3); 1.9776 (2.2); 1.9732 (3.9); 1.9697 (59.5); 1.9656 (115.0); 1.9615 (167.7); 1.9574 (115.1); 1.9533 (58.2); 1.9446 (0.7); 1.8546 (0.3); 1.8505 (0.6); 1.8464 (1.0); 1.8423 (0.6); 1.6314 (7.2); 
                 458.1 
               
               
                   
                   
                 1.6197 (7.2); 1.2178 (0.5); 1.2059 (1.0); 
                   
               
               
                   
                   
                 1.1940 (0.5); 0.9167 (0.4); 0.9055 (0.4); 
                   
               
               
                   
                   
                 0.0968 (0.4); 0.0054 (3.4); −0.0001 (98.0); 
                   
               
               
                   
                   
                 −0.0057 (2.7); −0.1001 (0.4) 
                   
               
               
                   
               
               
                 1-42 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm] = 9.45 (d, 1H), 9.07 (d, 1H), 8.57 (dd, 1H), 8.25 (s, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 8.08 (d, 1H), 7.99 (s, 1H), 6.15-6.07 (m, 1H), 1.75 (s, 6H), 1.67 (d, 3H). 
                 454.2 
               
               
                   
               
               
                 1-43 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm] = 9.44 (d, 1H), 8.67 (s, 1H), 8.32 (s, 1H), 8.04− 8.02 (m, 1H), 7.83 (s, 1H), 7.69 (s, 1H), 6.08−6.01 (m, 1H), 1.74 (s, 6H), 1.64 (d, 3H). 
                 476.1 
               
               
                   
               
               
                 1-44 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm] = 9.54 (d, 1H), 8.68 (s, 1H), 8.33 (s, 1H), 8.26 (s, 1H), 8.24 (s, 1H), 8.01 (s, 1H), 6.11-6.03 (m, 1H), 1.77 (s, 6H), 1.65 (d, 3H). 
                 460.1 
               
               
                   
               
               
                 1-45 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm] = 9.36 (d, 1H), 9.07-9.04 (m, 1H), 8.57 (dd, 1H), 8.25 (s, 1H), 8.07 (d, 1H), 7.99-7.96 (m, 1H), 7.76 (s, 1H), 7.67 (s, 1H), 6.12-6.05 (m, 1H), 1.73 (s, 6H), 1.66 (d, 3H). 
                 470.2 
               
               
                   
               
               
                 1-46 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.3539 (3.5); 9.3366 (3.6); 9.0684 (5.8); 9.0667 (6.3); 9.0630 (6.2); 9.0612 (6.0); 8.5866 (5.0); 8.5811 (4.8); 8.5652 (5.4); 8.5596 (5.4); 8.2450 (16.0); 8.0905 (6.3); 8.0888 (6.4); 8.0691 (6.0); 8.0673 (6.1); 7.9300 (5.1); 7.9258 (8.0); 7.9218 (5.4); 7.7401 (4.3); 7.7347 (7.1); 7.7311 (6.0); 7.7139 (6.1); 7.7089 (8.4); 7.7037 (3.9); 6.1140 (0.5); 6.0969 (2.5); 6.0795 (3.9); 6.0622 (2.5); 6.0449 (0.5); 3.4768 (46.5); 3.4684 (3.1); 3.3336 (21.8); 2.5289 (0.8); 2.5241 (1.3); 2.5154 (15.6); 2.5110 (31.0); 2.5064 (40.7); 2.5018 (30.1); 2.4974 (14.8); 2.0782 (7.0); 1.6427 (14.2); 1.6253 (14.2); 0.9036 (0.4); 0.0080 (0.5); −0.0002 (16.7); −0.0085 (0.5) 
                 447.3 
               
               
                   
               
               
                 1-47 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d6-DMSO): δ = 10.3838 (0.4); 9.2349 (1.5); 9.2172 (1.5); 9.0264 (2.5); 9.0213 (2.5); 8.5412 (1.8); 8.5357 (1.7); 8.5197 (1.9); 8.5141 (1.9); 8.0221 (2.7); 8.0005 (2.5); 7.6049 (2.6); 7.4725 (2.3); 7.1749 (2.4); 6.0744 (1.1); 6.0570 (1.7); 6.0394 (1.1); 5.7565 (0.8); 3.3280 (41.9); 2.6763 (0.4); 2.6718 (0.5); 2.6672 (0.4); 2.5251 (1.4); 2.5115 (30.1); 2.5072 (60.2); 2.5027 (79.8); 2.4983 (59.5); 2.4940 (29.9); 2.3395 (16.0); 2.3300 (1.0); 1.6054 (5.9); 1.5880 (5.9); 0.0079 (1.7); −0.0002 (47.4); −0.0085 (1.7) 
                 417.4 
               
               
                   
               
               
                 1-48 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.1127 (0.9); 9.0950 (0.9); 9.0605 (1.6); 9.0555 (1.5); 8.5805 (1.1); 8.5749 (1.0); 8.5591 (1.2); 8.5536 (1.1); 8.2387 (3.6); 8.0741 (1.6); 8.0526 (1.5); 7.8931 (0.4); 7.7893 (0.4); 7.6946 (1.8); 7.6279 (2.0); 7.5063 (1.8); 6.0818 (0.6); 6.0644 (1.0); 6.0469 (0.6); 5.7549 (0.9); 3.3235 (46.6); 2.9760 (0.6); 2.9588 (0.8); 2.9416 (0.6); 2.6756 (0.4); 2.6713 (0.5); 2.6664 (0.4); 2.5065 (57.0); 2.5021 (73.2); 2.4977 (53.1); 2.3333 (0.3); 2.3290 (0.4); 2.3246 (0.3); 2.0112 (0.4); 1.9887 (0.4); 1.9087 (0.4); 1.7141 (4.3); 1.6896 (16.0); 1.6610 (3.8); 1.6436 (3.7); 1.2583 (0.4); 1.2471 (2.6); 1.2329 (10.4); 1.2157 (9.1); 0.8886 (0.5); 0.8718 (0.5); 0.1457 (0.5); 0.0078 (4.9); 0.0069 (4.9); −0.0002 (110.4); −0.0085 (4.8); −0.1498 (0.5) 
                 428.3 
               
               
                   
               
               
                 1-49 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO): δ = 9.2535 (2.7); 9.2370 (2.7); 8.6671 (16.0); 8.3156 (0.5); 8.3043 (11.5); 7.6842 (3.8); 7.6803 (6.4); 7.6765 (4.0); 7.4836 (3.4); 7.4799 (4.1); 7.4779 (4.8); 7.4743 (4.0); 7.4315 (4.2); 7.4269 (5.2); 7.4214 (3.2); 6.0253 (0.4); 6.0081 (1.8); 5.9911 (2.8); 5.9741 (1.8); 5.9568 (0.4); 5.7556 (6.5); 3.9728 (0.6); 3.9656 (1.3); 3.9580 (1.9); 3.9505 (2.6); 3.9432 (1.9); 3.9355 (1.3); 3.9282 (0.6); 3.3244 (113.0); 2.6801 (0.4); 2.6756 (0.8); 2.6711 (1.1); 2.6665 (0.8); 2.6620 (0.4); 2.5245 (3.5); 2.5111 (69.0); 2.5067 (136.6); 2.5022 (176.3); 
                 461.0 
               
               
                   
                   
                 2.4976 (125.5); 2.4930 (59.9); 2.3336 (0.8); 
                   
               
               
                   
                   
                 2.3290 (1.1); 2.3244 (0.8); 2.3199 (0.4); 
                   
               
               
                   
                   
                 1.6067 (11.0); 1.5892 (11.0); 0.8293 (0.8); 
                   
               
               
                   
                   
                 0.8135 (3.4); 0.8104 (3.3); 0.7958 (4.1); 
                   
               
               
                   
                   
                 0.7814 (1.2); 0.6833 (1.5); 0.6706 (3.5); 
                   
               
               
                   
                   
                 0.6652 (5.0); 0.6529 (1.3); 0.6453 (1.0); 
                   
               
               
                   
                   
                 0.1457 (1.2); 0.0079 (12.8); −0.0002 
                   
               
               
                   
                   
                 (290.0); −0.0086 (11.1); −0.0216 (0.6); 
                   
               
               
                   
                   
                 −0.0268 (0.4); −0.1497 (1.2) 
                   
               
               
                   
               
               
                 1-50 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.3595 (2.9); 9.3430 (2.9); 8.6679 (12.8); 8.3149 (2.0); 8.3102 (11.6); 7.9117 (5.4); 7.7920 (5.4); 7.6200 (5.0); 6.0421 (0.4); 6.0253 (2.0); 6.0084 (2.9); 5.9912 (1.9); 5.9739 (0.4); 4.1290 (16.0); 3.3233 (310.9); 2.6755 (3.4); 2.6711 (4.7); 2.6667 (3.5); 2.5796 (0.5); 2.5242 (16.1); 2.5108 (298.6); 2.5066 (581.1); 2.5022 (747.3); 2.4977 (543.5); 2.4935 (272.8); 2.3333 (3.4); 2.3289 (4.6); 2.3245 (3.4); 2.0741 (2.1); 1.6204 (11.4); 1.6029 (11.5); 0.1460 (1.7); 0.0237 (0.4); 0.0076 (16.2); −0.0001 (349.4); −0.0076 (15.5); −0.1495 (1.7) 
                 398.1 
               
               
                   
               
               
                 1-51 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.2466 (1.4); 9.2298 (1.4); 8.6315 (8.0); 7.7492 (2.0); 7.7455 (3.3); 7.7419 (2.0); 7.5529 (1.4); 7.5469 (2.4); 7.5436 (2.2); 7.5295 (2.3); 7.5253 (2.5); 7.5195 (1.3); 6.0042 (1.0); 5.9872 (1.5); 5.9700 (1.0); 4.9073 (0.8); 4.8854 (2.8); 4.8634 (2.9); 4.8412 (1.0); 3.3257 (82.0); 2.6758 (0.5); 2.6713 (0.7); 2.6668 (0.5); 2.5247 (2.4); 2.5199 (3.8); 2.5113 (43.6); 2.5069 (86.2); 2.5024 (110.3); 2.4978 (77.2); 2.4932 (36.3); 2.3405 (16.0); 2.3294 (1.0); 2.3247 (0.6); 2.0746 (3.0); 1.5949 (5.4); 1.5774 (5.4); 0.0079 (0.4); −0.0002 (12.1); −0.0085 (0.4) 
                 490.2 
               
               
                   
               
               
                 1-52 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.2133 (0.6); 9.1962 (0.6); 8.5516 (0.3); 8.5079 (0.4); 8.0656 (0.4); 8.0223 (0.3); 7.8824 (0.4); 7.8789 (0.3); 7.8653 (1.9); 7.8509 (2.5); 7.8462 (2.5); 7.7286 (1.2); 7.7240 (2.1); 7.7195 (1.1); 6.0676 (0.6); 6.0499 (0.9); 6.0322 (0.6); 5.7559 (0.7); 3.4837 (0.3); 3.4690 (0.3); 3.3266 (29.1); 3.1512 (0.3); 3.1367 (0.3); 2.9648 (1.1); 2.8544 (1.0); 2.6717 (0.4); 2.5250 (1.1); 2.5113 (22.7); 2.5072 (43.6); 2.5028 (55.2); 2.4982 (39.6); 2.4940 (19.3); 2.3418 (8.9); 1.7299 (3.0); 1.6986 (16.0); 1.6276 (3.3); 1.6102 (3.3); 1.1612 (0.4); 1.1447 (0.7); 1.0235 (0.7); −0.0002 (0.8) 
                 494.3 
               
               
                   
               
               
                 1-53 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.4556 (2.8); 9.4393 (2.8); 8.6727 (12.2); 8.3200 (10.7); 8.2017 (5.3); 8.1432 (0.9); 8.0174 (5.3); 7.9233 (5.1); 6.0642 (0.4); 6.0473 (1.9); 6.0302 (2.9); 6.0131 (1.9); 5.9957 (0.4); 3.3322 (240.9); 2.6762 (1.4); 2.6717 (1.9); 2.6672 (1.5); 2.6628 (0.8); 2.5250 (8.3); 2.5116 (112.4); 2.5072 (216.8); 2.5027 (282.2); 2.4982 (214.1); 2.4938 (112.2); 2.3386 (0.7); 2.3340 (1.4); 2.3295 (1.9); 2.3250 (1.4); 2.0752 (12.7); 1.8036 (0.7); 1.7880 (0.9); 1.7780 (0.6); 1.7718 (1.3); 1.7655 (0.6); 1.7559 (0.9); 1.7390 (0.7); 1.7235 (0.4); 1.6312 (11.2); 1.6137 (11.1); 0.7129 (6.0); 0.7071 (6.7); 
                 495.1 495.1 
               
               
                   
                   
                 0.6934 (16.0); 0.1458 (1.0); 0.0078 (10.9); 
                   
               
               
                   
                   
                 −0.0003 (232.1); −0.0084 (11.4); −0.1497 
                   
               
               
                   
                   
                 (1.0) 
                   
               
               
                   
               
               
                 1-54 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.4279 (2.9); 9.4115 (2.9); 8.6682 (15.9); 8.3171 (13.3); 7.9017 (5.7); 7.8107 (4.0); 7.5736 (3.8); 6.0574 (0.4); 6.0402 (1.9); 6.0232 (3.0); 6.0062 (2.0); 5.9889 (0.4); 4.1890 (16.0); 3.3718 (0.4); 3.3331 (418.8); 2.8913 (0.7); 2.7317 (0.6); 2.6807 (0.8); 2.6762 (1.6); 2.6717 (2.2); 2.6672 (1.6); 2.6628 (0.8); 2.5252 (7.3); 2.5204 (11.5); 2.5118 (129.3); 2.5073 (254.7); 2.5027 (330.6); 2.4982 (242.2); 2.4936 (118.9); 2.3386 (0.7); 2.3341 (1.5); 2.3296 (2.1); 2.3250 (1.6); 2.3205 (0.7); 2.0751 (0.9); 1.6322 (11.7); 1.6148 (11.7); 0.1460 (1.0); 0.0080 (9.1); −0.0002 (247.0); −0.0085 (8.6); −0.0234 (0.3); −0.1495 (1.1) 
                 448.2 
               
               
                   
               
               
                 I-55 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.5944 (0.9); 9.5780 (1.0); 8.6803 (4.8); 8.4158 (1.2); 8.4122 (2.1); 8.4086 (1.3); 8.3340 (4.1); 8.2863 (1.2); 8.2822 (1.9); 8.2782 (1.2); 8.1796 (1.3); 8.1754 (2.1); 8.1711 (1.1); 6.1034 (0.6); 6.0863 (0.9); 6.0693 (0.6); 3.3330 (29.6); 3.3207 (9.8); 2.5257 (1.0); 2.5123 (15.2); 2.5079 (29.1); 2.5034 (36.7); 2.4989 (26.4); 2.4945 (12.8); 2.0759 (4.5); 1.7746 (16.0); 1.6646 (3.6); 1.6472 (3.6); 0.0079 (0.9); −0.0002 (20.5); −0.0085 (0.7) 
                 470.2 
               
               
                   
               
               
                 1-56 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.3967 (0.9); 9.3792 (1.0); 9.3742 (2.9); 9.3707 (2.9); 9.2515 (2.8); 9.2481 (2.6); 8.3678 (4.1); 8.0014 (1.2); 7.9976 (2.0); 7.9937 (1.2); 7.7857 (1.3); 7.6814 (1.3); 6.0657 (0.6); 6.0484 (1.0); 6.0310 (0.6); 3.3279 (18.6); 2.5263 (0.5); 2.5215 (0.8); 2.5129 (11.3); 2.5084 (22.9); 2.5039 (29.6); 2.4993 (20.5); 2.4948 (9.4); 2.0757 (1.5); 1.7322 (16.0); 1.6563 (3.7); 1.6389 (3.7); 0.0079 (1.1); −0.0002 (32.6); −0.0086 (1.0) 
                 471.3 
               
               
                   
               
               
                 1-57 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.3735 (11.0); 9.3702 (11.1); 9.3550 (2.9); 9.2487 (8.8); 9.2452 (8.3); 8.3575 (13.3); 7.8794 (5.6); 7.7714 (4.0); 7.5605 (3.9); 6.0698 (0.4); 6.0524 (2.0); 6.0351 (3.2); 6.0178 (2.1); 6.0003 (0.5); 5.7551 (10.4); 4.1903 (0.8); 4.1787 (16.0); 3.3407 (16.0); 2.6766 (0.6); 2.6721 (0.8); 2.6676 (0.6); 2.5256 (2.3); 2.5209 (3.4); 2.5122 (48.8); 2.5077 (101.4); 2.5032 (132.8); 2.4986 (92.8); 2.4940 (43.0); 2.3345 (0.6); 2.3300 (0.8); 2.3254 (0.6); 1.6377 (12.4); 1.6203 (12.3); 0.1459 (0.7); 0.0079 (5.9); −0.0002 (178.7); −0.0086 (5.9); −0.0166 (0.4); −0.1496 (0.7) 
                 443.2 
               
               
                   
               
               
                 1-58 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.4907 (0.8); 9.4735 (0.8); 9.3775 (2.5); 9.3741 (2.6); 9.2596 (2.6); 9.2561 (2.4); 8.3697 (4.0); 8.2318 (1.5); 8.1859 (1.4); 7.9970 (1.4); 6.0884 (0.6); 6.0711 (0.9); 6.0538 (0.6); 3.3279 (18.4); 2.5262 (0.6); 2.5214 (0.8); 2.5129 (10.6); 2.5084 (21.8); 2.5039 (28.5); 2.4993 (20.0); 2.4947 (9.3); 2.0758 (2.0); 1.7579 (16.0); 1.6638 (3.5); 1.6464 (3.5); 0.0079 (1.3); −0.0002 (37.2); −0.0086 (1.3) 
                 455.2 
               
               
                   
               
               
                 1-59 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.4006 (4.4); 9.3833 (4.6); 9.3737 (9.1); 9.3705 (11.4); 9.2538 (7.9); 9.2504 (9.2); 8.7856 (1.0); 8.4239 (0.4); 8.4143 (0.4); 8.4115 (0.4); 8.3647 (12.1); 8.3618 (7.3); 8.1624 (7.3); 8.0955 (0.7); 8.0518 (0.6); 7.9950 (0.8); 7.9783 (7.4); 7.9137 (7.4); 6.0721 (0.6); 6.0555 (2.3); 6.0382 (3.6); 6.0209 (2.4); 6.0039 (0.6); 3.3646 (358.8); 3.3467 (270.7); 3.0337 (1.0); 2.7149 (0.7); 2.6790 (1.2); 2.6750 (1.6); 2.6706 (1.2); 2.5487 (53.3); 2.5454 (161.0); 2.5283 (10.9); 2.5101 (206.6); 2.5059 (254.4); 2.5015 (195.9); 2.3713 (0.8); 2.3371 (1.3); 2.3328 (1.6); 2.3284 (1.3); 2.0778 (0.6); 1.9037 (0.8); 1.8889 (0.9); 1.8799 (0.7); 1.8129 (0.8); 1.7981 (1.3); 1.7821 (1.6); 
                 490.3 490.3 
               
               
                   
                   
                 1.7672 (1.8); 1.7489 (1.5); 1.7356 (1.0); 
                   
               
               
                   
                   
                 1.7172 (0.6); 1.6375 (14.5); 1.6202 (14.6); 
                   
               
               
                   
                   
                 1.5168 (1.1); 1.4994 (1.1); 0.7145 (9.1); 
                   
               
               
                   
                   
                 0.6915 (16.0) 
                   
               
               
                   
               
               
                 1-60 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.3432 (0.6); 9.3269 (0.6); 8.6610 (4.0); 8.3123 (3.0); 7.9606 (0.9); 7.9567 (1.6); 7.9528 (0.9); 7.6269 (0.9); 7.6233 (1.0); 7.6213 (1.2); 7.6178 (1.0); 7.5673 (1.0); 7.5628 (1.3); 7.5574 (0.8); 6.0248 (0.4); 6.0078 (0.6); 5.9907 (0.4); 3.3264 (25.1); 2.5254 (0.4); 2.5207 (0.6); 2.5120 (9.2); 2.5075 (19.1); 2.5029 (25.2); 2.4983 (17.8); 2.4937 (8.2); 2.0749 (2.7); 1.7172 (16.0); 1.6183 (2.6); 1.6008 (2.6); −0.0002 (1.7) 
                 488.1 
               
               
                   
               
               
                 1-61 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.3399 (0.7); 9.3235 (0.7); 8.6615 (3.9); 8.3127 (3.0); 7.8260 (1.0); 7.8219 (1.5); 7.8180 (1.0); 7.5954 (0.9); 7.5917 (1.1); 7.5898 (1.2); 7.5862 (1.0); 7.4465 (1.0); 7.4413 (1.5); 7.4362 (0.9); 6.0259 (0.4); 6.0089 (0.7); 5.9919 (0.4); 3.3269 (20.8); 2.5256 (0.4); 2.5208 (0.5); 2.5121 (8.1); 2.5077 (16.5); 2.5031 (21.7); 2.4985 (15.4); 2.4940 (7.3); 2.0752 (1.1); 1.7234 (16.0); 1.7057 (0.4); 1.6201 (2.7); 1.6027 (2.7); −0.0002 (1.3) 
                 442.2 
               
               
                   
               
               
                 1-62 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.2637 (2.1); 9.2583 (2.2); 9.2474 (2.2); 9.2420 (2.1); 8.6670 (15.0); 8.3147 (0.6); 8.3054 (14.6); 7.6461 (6.4); 7.4800 (2.1); 7.4742 (3.0); 7.4707 (4.1); 7.4669 (2.7); 7.4647 (3.0); 7.4612 (2.5); 7.4120 (4.6); 7.4075 (6.2); 7.4020 (3.7); 6.0338 (0.5); 6.0167 (2.1); 5.9997 (3.2); 5.9827 (2.1); 5.9649 (0.5); 5.7552 (7.8); 4.3983 (2.6); 4.3856 (2.7); 4.3711 (3.0); 4.3585 (2.9); 3.9933 (2.4); 3.9700 (2.9); 3.9667 (2.8); 3.9432 (2.2); 3.3285 (190.5); 2.6765 (0.6); 2.6721 (0.9); 2.6675 (0.6); 2.5255 (2.5); 2.5208 (3.7); 2.5121 (52.7); 2.5076 (108.7); 2.5031 (142.7); 2.4984 (101.2); 2.4939 (47.6); 2.3345 (0.6); 2.3299 (0.9); 2.3253 (0.6); 2.2833 (0.6); 2.2703 (0.6); 2.2623 (1.0); 2.2504 (1.1); 2.2426 (1.3); 2.2351 (1.2); 2.2228 (1.1); 2.2148 (0.8); 2.2021 (0.6); 1.8950 (3.3); 1.8765 (4.0); 1.8678 (3.3); 1.8494 (3.2); 1.6137 (13.3); 1.5964 (16.0); 1.5782 (5.6); 1.5593 (2.5); 1.2343 (1.9); 0.8540 (0.4); −0.0001 (3.7) 
                 543.0 
               
               
                   
               
               
                 1-63 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.2492 (2.3); 9.2355 (2.3); 8.6669 (16.0); 8.3147 (0.4); 8.3051 (13.6); 7.6402 (6.2); 7.4375 (4.0); 7.4349 (4.4); 7.4320 (4.7); 7.3853 (4.3); 7.3805 (5.8); 7.3754 (3.5); 6.0338 (0.5); 6.0166 (2.1); 5.9996 (3.2); 5.9825 (2.1); 5.9655 (0.5); 5.7556 (2.7); 4.2604 (0.9); 4.2531 (0.9); 4.2439 (1.0); 4.2350 (1.7); 4.2268 (1.2); 4.2173 (1.3); 4.2106 (1.1); 4.0620 (1.5); 4.0368 (2.4); 4.0141 (1.2); 3.3300 (97.8); 2.6771 (0.4); 2.6727 (0.5); 2.6679 (0.4); 2.5259 (1.6); 2.5211 (2.5); 2.5125 (30.6); 2.5081 (62.3); 2.5036 (81.8); 2.4990 (58.5); 2.4945 (28.0); 2.3350 (0.4); 2.3304 (0.5); 2.3258 (0.4); 2.2704 (0.6); 2.2539 (0.7); 2.2389 (1.1); 2.2210 (1.1); 2.2059 (0.7); 2.1894 (0.6); 1.7840 (0.5); 1.7719 (0.6); 1.7640 (0.7); 1.7529 (1.5); 1.7417 (1.1); 1.7340 (1.2); 1.7231 (1.4); 1.7121 (0.6); 1.7044 (0.6); 1.6925 (0.6); 1.6122 (12.5); 1.5947 (12.4); 1.5300 (0.6); 1.5198 (0.7); 1.5109 (1.0); 1.5004 (1.2); 1.4853 (1.0); 1.4773 
                 511.1 
               
               
                   
                   
                 (1.2); 1.4666 (1.1); 1.4579 (0.6); 1.4475 
                   
               
               
                   
                   
                 (0.6); 1.2341 (0.6); −0.0002 (2.6) 
                   
               
               
                   
               
               
                 1-64 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.3085 (2.4); 9.2923 (2.4); 8.7046 (0.6); 8.6663 (16.0); 8.4149 (0.5); 8.3154 (1.2); 8.3099 (11.6); 7.8071 (0.4); 7.5762 (3.2); 7.5726 (3.9); 7.5706 (3.9); 7.5671 (3.4); 7.5540 (0.5); 7.5507 (0.5); 7.4441 (3.5); 7.4416 (3.2); 7.4277 (0.4); 7.2193 (3.3); 7.2174 (3.3); 7.1462 (0.4); 6.0404 (0.4); 6.0227 (1.8); 6.0057 (2.5); 5.9888 (1.7); 5.9713 (0.4); 5.8824 (0.3); 3.9995 (0.7); 3.9926 (1.3); 3.9850 (1.9); 3.9776 (2.6); 3.9703 (1.9); 3.9627 (1.3); 3.9554 (0.7); 3.3278 (498.0); 2.9760 (0.3); 2.8903 (0.3); 2.6805 (1.0); 2.6758 (2.1); 2.6712 (2.8); 2.6666 (2.0); 2.6620 (1.0); 2.5248 (9.1); 2.5201 (13.2); 2.5114 (164.9); 2.5069 (339.2); 2.5023 (443.4); 2.4977 (309.5); 
                 465.2 
               
               
                   
                   
                 2.4931 (142.5); 2.3383 (0.9); 2.3337 (2.0); 
                   
               
               
                   
                   
                 2.3291 (2.7); 2.3245 (1.9); 2.3201 (0.8); 
                   
               
               
                   
                   
                 2.1355 (0.9); 1.9889 (0.4); 1.6442 (0.5); 
                   
               
               
                   
                   
                 1.6206 (10.2); 1.6031 (10.1); 1.2981 (0.3); 
                   
               
               
                   
                   
                 1.2589 (0.6); 1.2347 (1.2); 1.2253 (1.8); 
                   
               
               
                   
                   
                 1.2088 (2.6); 1.1927 (1.5); 1.1751 (0.3); 
                   
               
               
                   
                   
                 1.0484 (0.3); 1.0331 (0.3); 0.8732 (0.4); 
                   
               
               
                   
                   
                 0.8540 (0.4); 0.8470 (1.0); 0.8303 (3.5); 
                   
               
               
                   
                   
                 0.8272 (3.4); 0.8128 (4.0); 0.7984 (1.2); 
                   
               
               
                   
                   
                 0.7145 (0.4); 0.7044 (1.8); 0.6962 (3.1); 
                   
               
               
                   
                   
                 0.6919 (3.4); 0.6861 (4.5); 0.6740 (1.2); 
                   
               
               
                   
                   
                 0.6663 (0.8); −0.0002 (2.0) 
                   
               
               
                   
               
               
                 1-65 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.2577 (3.1); 9.2413 (3.1); 8.6122 (16.0); 8.3158 (0.8); 7.5555 (4.0); 7.5518 (5.1); 7.5468 (4.1); 7.4169 (4.7); 7.2145 (4.5); 5.9777 (0.5); 5.9601 (2.3); 5.9429 (3.4); 5.9258 (2.2); 5.9084 (0.5); 3.9983 (0.7); 3.9910 (1.5); 3.9834 (2.2); 3.9760 (3.0); 3.9686 (2.2); 3.9611 (1.4); 3.9536 (0.7); 3.3255 (226.0); 2.6798 (1.0); 2.6758 (1.9); 2.6712 (2.5); 2.6668 (1.9); 2.5245 (9.8); 2.5111 (160.4); 2.5068 (314.7); 2.5023 (405.2); 2.4978 (287.0); 2.4934 (136.3); 2.3336 (1.7); 2.3291 (2.4); 2.3247 (1.8); 2.1074 (0.6); 2.0950 (1.4); 2.0862 (1.6); 2.0744 (2.9); 2.0624 (1.7); 2.0537 (1.5); 2.0414 (0.7); 1.5797 (12.4); 1.5622 (12.3); 1.3978 (0.7); 1.2352 (0.7); 1.0347 
                 505.3 
               
               
                   
                   
                 (3.8); 1.0293 (4.8); 1.0140 (3.6); 1.0084 
                   
               
               
                   
                   
                 (5.1); 0.9876 (0.4); 0.9814 (0.4); 0.9040 
                   
               
               
                   
                   
                 (0.8); 0.8961 (0.9); 0.8918 (0.9); 0.8791 
                   
               
               
                   
                   
                 (2.6); 0.8674 (2.6); 0.8506 (2.8); 0.8337 
                   
               
               
                   
                   
                 (4.7); 0.8293 (4.4); 0.8143 (5.3); 0.8006 
                   
               
               
                   
                   
                 (1.5); 0.7079 (1.8); 0.6898 (5.9); 0.6778 
                   
               
               
                   
                   
                 (1.6); 0.6699 (1.1); −0.0001 (1.4) 
                   
               
               
                   
               
               
                 1-66 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.4311 (0.8); 9.4139 (0.8); 9.3891 (2.7); 9.3861 (2.7); 8.6143 (2.7); 8.6112 (2.6); 8.3658 (4.0); 8.0200 (1.1); 8.0162 (1.8); 8.0123 (1.1); 7.8109 (1.3); 7.8085 (1.2); 7.6853 (1.2); 6.2181 (0.6); 6.2007 (0.9); 6.1834 (0.6); 3.8924 (0.5); 3.3326 (21.3); 3.2418 (0.5); 3.2247 (0.5); 2.5266 (0.7); 2.5219 (1.1); 2.5132 (11.5); 2.5087 (22.7); 2.5041 (29.5); 2.4995 (21.4); 2.4950 (10.2); 2.0762 (0.7); 1.7455 (2.2); 1.7343 (16.0); 1.6683 (3.4); 1.6509 (3.4); 0.0080 (0.4); −0.0002 (10.2) 
                 471.4 
               
               
                   
               
               
                 1-67 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.4000 (1.2); 9.3835 (1.2); 8.6148 (6.8); 8.0054 (1.6); 8.0016 (2.6); 7.9979 (1.6); 7.7968 (1.7); 7.6926 (1.8); 5.9978 (0.8); 5.9807 (1.3); 5.9635 (0.9); 3.3322 (129.8); 2.6766 (0.5); 2.6721 (0.6); 2.6675 (0.5); 2.6535 (0.5); 2.5255 (2.2); 2.5207 (3.4); 2.5121 (39.9); 2.5077 (79.3); 2.5031 (103.1); 2.4985 (74.4); 2.4940 (35.9); 2.3345 (0.5); 2.3299 (0.6); 2.3253 (0.4); 2.1003 (0.5); 2.0916 (0.6); 2.0796 (1.1); 2.0675 (0.6); 2.0589 (0.6); 1.7387 (16.0); 1.6066 (4.6); 1.5891 (4.6); 1.3977 (3.0); 1.2003 (0.4); 1.1896 (0.3); 1.1837 (0.4); 1.0364 (1.5); 1.0319 (1.9); 1.0156 (1.5); 1.0110 (1.9); 0.8869 (1.0); 0.8801 (0.7); 0.8744 (1.2); 0.8678 (1.0); 0.8629 (1.0); 0.8510 (0.8); 0.0079 (2.1); −0.0002 (57.3); 
                 516.2 
               
               
                   
                   
                 −0.0086 (1.7) 
                   
               
               
                   
               
               
                 1-68 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (DMSO-d 6 ) δ: 9.36 (d, 1H), 9.24 (d, 1H), 8.44 (s, 1H), 8.32 (d, 1H), 8.10 (s, 1H), 7.98 (s, 1H), 7.78 (s, 1H), 7.68 (s, 1H), 6.17-6.25 (m, 1H), 2.06-2.14 (m, 1H), 1.73 (s, 6H), 1.63 (d, 3H), 0.97-1.06 (m, 2H), 0.85-0.96 (m, 2H) ppm. 
                 529.4 
               
               
                   
               
               
                 1-69 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.5669 (1.3); 9.5503 (1.4); 8.6146 (9.2); 7.8882 (15.3); 5.9937 (1.0); 5.9766 (1.5); 5.9596 (1.0); 3.3331 (12.8); 2.5262 (0.8); 2.5214 (1.1); 2.5128 (15.8); 2.5083 (32.2); 2.5037 (42.4); 2.4991 (30.3); 2.4945 (14.4); 2.1064 (0.6); 2.0977 (0.6); 2.0947 (0.5); 2.0858 (1.3); 2.0768 (0.7); 2.0737 (0.7); 2.0650 (0.7); 2.0529 (0.3); 1.7249 (16.0); 1.7220 (15.9); 1.6012 (5.1); 1.5837 (5.2); 1.0595 (0.3); 1.0458 (1.5); 1.0402 (2.1); 1.0283 (1.2); 1.0251 (1.4); 1.0195 (2.1); 1.0081 (0.4); 0.8994 (0.6); 0.8904 (1.4); 0.8874 (1.5); 0.8833 (1.4); 0.8788 (1.8); 0.8727 (1.5); 0.8607 (0.4); −0.0002 (6.0) 
                 467.1 
               
               
                   
               
               
                 1-70 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.6064 (1.1); 9.5896 (1.1); 8.6349 (7.3); 7.9533 (0.6); 7.9187 (12.8); 6.0356 (0.8); 6.0186 (1.3); 6.0014 (0.8); 5.7588 (4.4); 3.3453 (0.6); 3.3325 (68.4); 2.8915 (5.1); 2.7323 (4.2); 2.7311 (4.1); 2.5256 (1.0); 2.5209 (1.5); 2.5122 (19.2); 2.5077 (39.0); 2.5031 (50.9); 2.4985 (36.3); 2.4940 (17.0); 2.3539 (13.4); 2.3300 (0.4); 1.7246 (16.0); 1.6217 (4.5); 1.6043 (4.5); −0.0002 (6.3) 
                 441.1 
               
               
                   
               
               
                 1-71 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.6274 (1.0); 9.6111 (1.0); 8.6713 (6.5); 8.3411 (4.6); 7.9041 (11.4); 6.0539 (0.7); 6.0369 (1.0); 6.0199 (0.7); 3.3307 (38.4); 2.5256 (0.8); 2.5208 (1.2); 2.5122 (15.4); 2.5077 (30.9); 2.5031 (40.2); 2.4984 (28.4); 2.4939 (13.2); 2.0763 (0.7); 1.7224 (16.0); 1.6425 (4.1); 1.6250 (4.0); −0.0002 (7.9) 
                 427.1 
               
               
                   
               
               
                 1-72 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.3225 (1.6); 9.3188 (1.6); 9.3059 (1.8); 9.3027 (1.6); 8.6682 (16.0); 8.3127 (8.9); 7.8354 (1.8); 7.8317 (3.0); 7.8280 (1.8); 7.8129 (1.9); 7.8091 (3.1); 7.8054 (1.9); 7.5358 (1.8); 7.5323 (2.1); 7.5298 (2.4); 7.5265 (3.5); 7.5231 (2.0); 7.5206 (2.2); 7.5171 (1.8); 7.4477 (3.3); 7.4429 (4.4); 7.4378 (2.7); 6.0256 (1.0); 6.0215 (1.0); 6.0085 (1.6); 6.0045 (1.5); 5.9914 (1.1); 5.9875 (1.0); 5.7586 (15.7); 4.6451 (1.3); 4.6372 (1.4); 4.6326 (1.6); 4.6245 (2.8); 4.6164 (1.5); 4.6117 (1.4); 4.6038 (1.2); 3.3326 (76.1); 2.6724 (0.4); 2.5258 (1.4); 2.5211 (2.2); 2.5124 (24.9); 2.5080 (49.5); 2.5034 (64.1); 2.4988 (45.5); 2.4942 (21.3); 2.3301 (0.4); 2.2075 (1.2); 2.2025 (1.1); 2.1863 (1.9); 2.1842 (2.1); 2.1816 (2.0); 2.1794 (1.8); 2.1633 (1.4); 2.1584 (1.3); 
                 429.1 
               
               
                   
                   
                 1.9683 (1.6); 1.9642 (1.5); 1.9557 (1.6); 
                   
               
               
                   
                   
                 1.9515 (1.5); 1.9451 (1.4); 1.9409 (1.3); 
                   
               
               
                   
                   
                 1.9325 (1.3); 1.9283 (1.2); 1.6166 (6.8); 
                   
               
               
                   
                   
                 1.6144 (6.8); 1.5991 (6.7); 1.5969 (6.6); 
                   
               
               
                   
                   
                 −0.0002 (9.2) 
                   
               
               
                   
               
               
                 1-73 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.4499 (0.8); 9.4333 (0.8); 8.2576 (3.9); 8.1614 (4.4); 8.0450 (1.1); 8.0411 (1.8); 8.0373 (1.1); 7.8420 (1.2); 7.8395 (1.0); 7.6949 (1.2); 6.0932 (0.5); 6.0760 (0.9); 6.0588 (0.6); 5.7586 (1.8); 4.0381 (0.8); 4.0203 (0.8); 3.7938 (0.4); 3.7771 (0.4); 3.3338 (56.0); 3.2403 (0.7); 3.0256 (0.7); 2.6897 (1.1); 2.5256 (0.9); 2.5209 (1.2); 2.5121 (17.1); 2.5076 (34.9); 2.5030 (45.8); 2.4984 (32.7); 2.4939 (15.5); 2.0123 (1.3); 2.0008 (0.5); 1.9897 (3.6); 1.7375 (16.0); 1.6570 (3.2); 1.6395 (3.2); 1.1928 (1.0); 1.1750 (2.0); 1.1572 (1.0); 0.8881 (1.4); 0.8714 (1.3); −0.0002 (6.2) 
                 522.2 
               
               
                   
               
               
                 1-74 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.4386 (0.8); 9.4219 (0.8); 8.7805 (0.6); 8.7690 (0.6); 8.2560 (3.9); 8.2452 (4.8); 8.0285 (1.1); 8.0246 (1.8); 8.0208 (1.1); 7.8286 (1.0); 7.8261 (1.2); 7.8235 (1.1); 7.6923 (1.2); 6.0770 (0.5); 6.0600 (0.8); 6.0428 (0.5); 3.3310 (67.1); 3.3170 (0.4); 2.8060 (4.1); 2.7945 (4.0); 2.6717 (0.4); 2.5252 (1.3); 2.5204 (2.0); 2.5118 (24.7); 2.5073 (49.6); 2.5027 (64.1); 2.4981 (45.3); 2.4935 (21.0); 2.3296 (0.4); 2.0760 (2.5); 1.7349 (16.0); 1.6468 (3.1); 1.6293 (3.1); −0.0002 (5.5) 
                 508.3 
               
               
                   
               
               
                 1-75 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.6072 (0.9); 9.5899 (1.0); 9.3902 (3.5); 9.3871 (3.4); 8.6136 (3.4); 8.6106 (3.4); 8.3807 (4.8); 7.8963 (10.3); 6.2127 (0.7); 6.1954 (1.1); 6.1781 (0.7); 3.3623 (0.4); 3.3403 (111.1); 3.3217 (0.4); 2.6898 (0.7); 2.5260 (0.8); 2.5213 (1.1); 2.5127 (15.0); 2.5082 (31.3); 2.5036 (41.5); 2.4989 (29.7); 2.4944 (13.9); 2.0759 (2.0); 1.7191 (16.0); 1.6580 (4.1); 1.6406 (4.0); 1.4332 (0.8); −0.0002 (0.5) 
                 422.0 
               
               
                   
               
               
                 1-76 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400.2 MHz, d 6 -DMSO) δ = 9.3833 (1.1); 9.3658 (1.1); 9.3224 (2.9); 9.3195 (2.8); 8.5090 (3.0); 8.5061 (2.9); 7.9870 (2.2); 7.9836 (1.4); 7.7819 (1.6); 7.6883 (1.6); 6.1569 (0.7); 6.1395 (1.1); 6.1221 (0.7); 5.7607 (0.4); 3.3335 (17.6); 2.5266 (0.6); 2.5129 (10.7); 2.5087 (20.9); 2.5043 (27.1); 2.4998 (20.0); 2.4958 (10.1); 2.0984 (0.4); 2.0896 (0.5); 2.0777 (0.9); 2.0656 (0.5); 2.0570 (0.5); 1.9906 (1.3); 1.7349 (16.0); 1.6272 (3.9); 1.6098 (3.9); 1.1934 (0.3); 1.1756 (0.7); 1.1578 (0.3); 1.0385 (1.2); 1.0324 (1.7); 1.0178 (1.1); 1.0117 (1.8); 0.9302 (0.8); 0.9183 (0.8); 0.9125 (0.6); 0.9091 (0.6); 0.9034 (0.8); 0.8967 (0.6); 0.8915 (0.7); −0.0002 (3.6) 
                 511.4 
               
               
                   
               
               
                 1-77 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.4185 (4.1); 9.4012 (4.2); 9.3659 (10.3); 9.3628 (10.7); 9.2422 (10.8); 9.2390 (10.3); 8.3558 (16.0); 8.1854 (7.8); 7.9647 (7.9); 7.9197 (7.8); 7.6560 (4.8); 7.6428 (5.4); 7.6341 (5.9); 7.6210 (5.2); 7.3743 (5.2); 7.3523 (9.4); 7.3302 (4.4); 6.0559 (0.6); 6.0392 (2.7); 6.0219 (4.1); 6.0046 (2.7); 5.9873 (0.6); 3.3306 (141.6); 2.6761 (1.6); 2.6718 (2.1); 2.5072 (279.4); 2.5028 (348.8); 2.4986 (259.9); 2.3337 (1.6); 2.3297 (2.1); 2.3253 (1.6); 2.0765 (3.4); 1.6230 (15.6); 1.6057 (15.3); −0.0002 (2.0) 
                 544.0 
               
               
                   
               
               
                 1-78 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.4718 (2.7); 9.4554 (2.8); 8.6624 (16.0); 8.3148 (12.6); 8.2254 (5.1); 7.9972 (5.2); 7.9387 (5.1); 7.6661 (3.2); 7.6530 (3.5); 7.6440 (3.8); 7.6309 (3.6); 7.3786 (3.5); 7.3566 (6.4); 7.3345 (3.0); 6.0497 (0.4); 6.0324 (1.8); 6.0155 (2.7); 5.9984 (1.8); 5.9811 (0.4); 3.3793 (0.4); 3.3436 (297.1); 2.6796 (0.7); 2.6750 (0.9); 2.6705 (0.7); 2.5286 (3.0); 2.5238 (4.6); 2.5151 (58.9); 2.5107 (118.2); 2.5061 (152.7); 2.5016 (109.2); 2.4971 (52.1); 2.3375 (0.7); 2.3329 (0.9); 2.3283 (0.6); 2.0789 (1.0); 1.6228 (10.7); 1.6053 (10.6) 
                 549.0 
               
               
                   
               
               
                 1-79 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.4450 (1.4); 9.4285 (1.4); 8.6254 (8.6); 8.2411 (2.6); 8.0117 (2.6); 7.9390 (2.6); 7.6666 (1.6); 7.6534 (1.8); 7.6444 (2.0); 7.6313 (1.8); 7.3777 (1.8); 7.3557 (3.3); 7.3335 (1.5); 6.0124 (1.0); 5.9954 (1.5); 5.9782 (1.0); 3.3318 (81.7); 2.6764 (0.6); 2.6718 (0.8); 2.6674 (0.6); 2.5254 (2.6); 2.5207 (3.9); 2.5119 (48.7); 2.5075 (97.2); 2.5030 (125.0); 2.4984 (88.8); 2.4939 (42.0); 2.3371 (16.0); 2.0766 (0.8); 1.5994 (5.3); 1.5820 (5.3); −0.0002 (0.7) 
                 563.0 
               
               
                   
               
               
                 1-80 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.4494 (3.5); 9.4323 (3.6); 9.3800 (10.6); 9.3770 (9.9); 8.6075 (10.5); 8.6046 (9.8); 8.3525 (16.0); 8.2111 (6.6); 7.9865 (6.7); 7.9245 (6.5); 7.6596 (4.1); 7.6464 (4.6); 7.6376 (4.9); 7.6245 (4.5); 7.3756 (4.5); 7.3535 (8.2); 7.3315 (3.9); 6.2071 (0.5); 6.1899 (2.4); 6.1726 (3.7); 6.1553 (2.4); 6.1380 (0.5); 5.7603 (7.2); 3.3345 (156.7); 2.6770 (0.9); 2.6726 (1.2); 2.6681 (0.8); 2.5260 (4.1); 2.5125 (81.8); 2.5081 (156.3); 2.5036 (195.3); 2.4991 (136.9); 2.4947 (64.0); 2.3349 (0.9); 2.3304 (1.2); 2.3259 (0.8); 1.6375 (14.0); 1.6201 (13.9); 1.6004 (0.4); −0.0003 (0.4) 
                 544.0 
               
               
                   
               
               
                 1-81 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.4842 (3.6); 9.4669 (3.9); 9.3929 (10.3); 9.3900 (10.3); 8.6174 (10.5); 8.6145 (10.7); 8.4036 (8.4); 8.3640 (16.0); 8.3196 (0.4); 8.2076 (4.6); 8.2033 (7.6); 8.1991 (5.4); 8.1553 (5.4); 8.1511 (7.6); 8.1467 (4.4); 6.2371 (0.6); 6.2203 (2.5); 6.2030 (4.0); 6.1857 (2.5); 6.1685 (0.6); 3.4584 (0.3); 3.4230 (0.4); 3.4130 (0.4); 3.4019 (0.5); 3.3311 (1076.8); 2.9969 (0.7); 2.9852 (1.6); 2.9779 (1.8); 2.9662 (3.0); 2.9544 (1.8); 2.9476 (1.7); 2.9356 (0.8); 2.7836 (0.3); 2.6902 (0.7); 2.6758 (8.1); 2.6713 (10.8); 2.6669 (8.3); 2.5246 (38.1); 2.5109 (685.9); 2.5068 (1334.6); 2.5023 (1732.0); 
                 422.2 
               
               
                   
                   
                 2.4978 (1295.8); 2.3929 (0.3); 2.3474 (0.5); 
                   
               
               
                   
                   
                 2.3336 (7.8); 2.3291 (10.6); 2.3247 (8.0); 
                   
               
               
                   
                   
                 1.6563 (14.5); 1.6389 (14.4); 1.6144 (0.6); 
                   
               
               
                   
                   
                 1.4328 (2.2); 1.2335 (0.3); 1.1412 (0.8); 
                   
               
               
                   
                   
                 1.1290 (2.5); 1.1205 (6.5); 1.1095 (2.9); 
                   
               
               
                   
                   
                 1.1014 (7.4); 1.0967 (6.3); 1.0913 (6.8); 
                   
               
               
                   
                   
                 1.0795 (7.8); 1.0709 (3.1); 0.0080 (1.4); 
                   
               
               
                   
                   
                 0.0001 (41.3) 
                   
               
               
                   
               
               
                 1-82 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.4872 (1.6); 9.4704 (1.6); 8.6401 (7.6); 8.6343 (0.5); 8.4394 (2.1); 8.4359 (3.6); 8.4324 (2.1); 8.2146 (1.8); 8.2103 (3.1); 8.2063 (2.1); 8.1823 (2.4); 8.1782 (3.1); 8.1738 (1.6); 6.0434 (1.1); 6.0263 (1.6); 6.0091 (1.1); 3.3309 (103.9); 2.9917 (0.6); 2.9847 (0.7); 2.9728 (1.2); 2.9614 (0.7); 2.9542 (0.7); 2.9421 (0.3); 2.6761 (0.8); 2.6717 (1.0); 2.6671 (0.7); 2.5249 (3.2); 2.5113 (65.5); 2.5071 (127.0); 2.5027 (161.3); 2.4982 (114.9); 2.4938 (54.6); 2.3461 (16.0); 2.3382 (1.7); 2.3295 (1.1); 2.3249 (0.8); 1.6206 (5.8); 1.6031 (5.9); 
                 441.3 
               
               
                   
                   
                 1.5819 (0.4); 1.1438 (0.3); 1.1312 (1.1); 
                   
               
               
                   
                   
                 1.1231 (2.7); 1.1177 (1.6); 1.1118 (1.2); 
                   
               
               
                   
                   
                 1.1038 (3.2); 1.0995 (2.8); 1.0948 (3.1); 
                   
               
               
                   
                   
                 1.0832 (3.3); 1.0747 (1.2); 0.0079 (1.5); 
                   
               
               
                   
                   
                 −0.0001 (40.1); −0.0084 (1.3) 
                   
               
               
                   
               
               
                 1-83 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.5078 (2.6); 9.4914 (2.6); 8.6747 (16.0); 8.6675 (0.6); 8.4325 (0.5); 8.4222 (3.5); 8.4186 (6.3); 8.4149 (3.6); 8.3228 (12.5); 8.3181 (1.1); 8.3138 (0.5); 8.3082 (0.5); 8.2128 (3.4); 8.2081 (5.5); 8.2041 (3.9); 8.1651 (4.1); 8.1608 (5.4); 8.1563 (3.2); 8.1495 (0.5); 8.1447 (0.4); 6.0788 (0.4); 6.0614 (1.8); 6.0444 (2.7); 6.0273 (1.8); 6.0098 (0.4); 5.7587 (0.7); 3.3328 (106.9); 2.9989 (0.5); 2.9868 (1.1); 2.9801 (1.3); 2.9681 (2.2); 2.9624 (1.0); 2.9563 (1.3); 2.9495 (1.2); 2.9374 (0.6); 2.8910 (0.9); 2.7310 (0.8); 2.6804 (0.6); 2.6761 
                 427.1 
               
               
                   
                   
                 (1.2); 2.6715 (1.6); 2.6670 (1.2); 2.6625 
                   
               
               
                   
                   
                 (0.6); 2.5251 (5.6); 2.5203 (8.4); 2.5116 
                   
               
               
                   
                   
                 (102.5); 2.5072 (205.6); 2.5026 (265.8); 
                   
               
               
                   
                   
                 2.4980 (188.6); 2.4935 (89.0); 2.3385 (0.5); 
                   
               
               
                   
                   
                 2.3340 (1.2); 2.3294 (1.6); 2.3248 (1.1); 
                   
               
               
                   
                   
                 2.3204 (0.5); 2.0759 (2.8); 1.6407 (10.7); 
                   
               
               
                   
                   
                 1.6232 (10.8); 1.6099 (0.6); 1.6012 (0.5); 
                   
               
               
                   
                   
                 1.1427 (0.7); 1.1300 (1.9); 1.1218 (5.0); 
                   
               
               
                   
                   
                 1.1166 (2.7); 1.1104 (1.9); 1.1026 (5.8); 
                   
               
               
                   
                   
                 1.0983 (5.0); 1.0936 (5.0); 1.0856 (4.8); 
                   
               
               
                   
                   
                 1.0819 (5.6); 1.0734 (2.1); 1.0609 (0.5); 
                   
               
               
                   
                   
                 −0.0002 (1.8) 
                   
               
               
                   
               
               
                 1-84 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.3685 (1.9); 9.3652 (2.0); 9.2962 (0.7); 9.2790 (0.7); 9.2373 (2.0); 9.2339 (1.9); 8.3586 (3.1); 7.9187 (1.0); 7.9150 (1.6); 7.9114 (1.0); 7.5991 (0.9); 7.5937 (1.3); 7.5902 (1.1); 7.5576 (1.1); 7.5529 (1.5); 7.5477 (0.8); 6.0321 (0.5); 6.0147 (0.8); 5.9974 (0.5); 3.3326 (23.3); 2.5254 (0.7); 2.5119 (13.0); 2.5075 (25.5); 2.5029 (33.2); 2.4984 (24.6); 2.4941 (12.2); 2.0765 (0.7); 1.7112 (16.0); 1.6215 (2.8); 1.6042 (2.8) 
                 483.0 
               
               
                   
               
               
                 I-85 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.3791 (2.7); 9.3761 (2.0); 9.3288 (1.2); 9.3124 (1.1); 8.6100 (2.7); 8.6071 (2.0); 8.3606 (3.0); 7.9493 (2.1); 7.9459 (2.1); 7.6179 (2.0); 7.6147 (2.0); 7.5640 (2.0); 7.5596 (1.9); 6.1850 (0.8); 6.1675 (1.0); 6.1506 (0.6); 5.7637 (3.3); 3.3379 (44.6); 2.6795 (0.5); 2.6759 (0.5); 2.5111 (71.9); 2.5068 (70.1); 2.3378 (0.5); 1.7163 (16.0); 1.6385 (4.0); 1.6214 (3.6) 
                 483.2 
               
               
                   
               
               
                 1-86 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.3747 (10.3); 9.3714 (10.1); 9.2592 (4.1); 9.2511 (11.5); 9.2477 (10.9); 9.2425 (4.1); 8.3607 (16.0); 7.5392 (5.0); 7.5355 (6.3); 7.5306 (4.9); 7.4006 (5.8); 7.2155 (5.6); 6.0495 (0.6); 6.0323 (2.6); 6.0150 (4.1); 5.9977 (2.6); 5.9801 (0.5); 5.7650 (2.1); 3.9979 (0.9); 3.9907 (1.8); 3.9832 (2.6); 3.9757 (3.6); 3.9685 (2.6); 3.9608 (1.8); 3.9537 (0.9); 3.3388 (148.8); 2.9813 (0.5); 2.8953 (0.5); 2.6818 (0.8); 2.6774 (1.1); 2.6729 (0.8); 2.5306 (4.1); 2.5171 (72.7); 2.5129 (135.6); 2.5084 (171.7); 2.5039 (125.6); 2.4996 (61.4); 2.3397 (0.8); 2.3353 (1.1); 2.3310 (0.8); 1.6306 (15.2); 1.6132 (15.2); 1.3606 (0.5); 0.8495 (1.1); 0.8304 (5.0); 0.8153 (5.8); 0.8011 (1.6); 0.7736 (0.3); 0.7591 (0.3); 0.7045 (2.4); 0.6863 (7.3); 0.6736 (1.8); 0.6660 (1.4) 
                 460.4 
               
               
                   
               
               
                 1-87 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.3862 (10.4); 9.3833 (10.5); 9.2921 (3.8); 9.2749 (3.8); 8.6176 (10.4); 8.6147 (10.4); 8.3573 (16.0); 7.5634 (4.6); 7.5598 (6.1); 7.5547 (5.0); 7.4276 (5.7); 7.2195 (5.4); 6.1988 (0.6); 6.1820 (2.5); 6.1647 (3.9); 6.1474 (2.5); 6.1305 (0.5); 4.0000 (0.8); 3.9929 (1.7); 3.9854 (2.5); 3.9779 (3.4); 3.9706 (2.5); 3.9630 (1.7); 3.9560 (0.9); 3.3862 (0.4); 3.3378 (547.8); 2.6804 (2.4); 2.6760 (3.3); 2.6716 (2.4); 2.5293 (11.9); 2.5157 (201.9); 2.5115 (392.7); 2.5070 (510.4); 2.5025 (383.5); 2.3383 (2.3); 2.3338 (3.2); 2.3293 (2.3); 1.6414 (14.6); 1.6240 (14.6); 0.8488 (1.1); 0.8323 (4.7); 0.8297 (4.6); 0.8148 (5.6); 0.8007 (1.6); 0.7583 (0.3); 0.7044 (2.0); 0.6862 
                 460.3 
               
               
                   
                   
                 (6.9); 0.6661 (1.3); 0.0044 (0.5) 
                   
               
               
                   
               
               
                 1-88 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.2972 (1.5); 9.2807 (1.5); 8.6395 (6.8); 7.5993 (2.0); 7.5955 (2.6); 7.5912 (2.0); 7.4682 (2.4); 7.2296 (2.3); 6.0074 (1.1); 5.9904 (1.6); 5.9734 (1.1); 4.0081 (0.4); 4.0011 (0.7); 3.9934 (1.1); 3.9861 (1.4); 3.9790 (1.1); 3.9715 (0.8); 3.9644 (0.4); 3.3413 (224.8); 2.6811 (1.1); 2.6767 (1.5); 2.6725 (1.1); 2.5299 (5.6); 2.5121 (185.8); 2.5077 (237.0); 2.5033 (176.3); 2.3458 (16.0); 2.3348 (1.8); 2.3303 (1.3); 1.6057 (5.9); 1.5883 (5.9); 0.8537 (0.6); 0.8384 (2.0); 0.8201 (2.4); 0.8062 (0.8); 0.7112 (0.9); 0.6928 (2.9); 0.6733 (0.6) 
                 479.3 
               
               
                   
               
               
                 1-89 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.1693 (0.8); 9.1529 (0.8); 8.6719 (3.9); 8.3127 (3.3); 7.4031 (1.6); 7.3760 (1.1); 7.3706 (1.3); 7.3670 (0.9); 7.0471 (1.0); 7.0427 (1.3); 7.0381 (0.9); 6.0281 (0.5); 6.0111 (0.8); 5.9941 (0.5); 5.7637 (4.0); 3.3408 (22.8); 2.8955 (1.6); 2.7366 (1.4); 2.5302 (0.5); 2.5167 (8.5); 2.5124 (16.5); 2.5079 (21.5); 2.5033 (16.1); 2.4990 (8.0); 2.0034 (0.4); 1.9909 (0.6); 1.9785 (0.4); 1.9700 (0.3); 1.6895 (16.0); 1.6226 (3.0); 1.6051 (3.0); 1.0361 (0.4); 1.0251 (1.1); 1.0196 (1.2); 1.0092 (0.6); 1.0042 (1.1); 0.9988 (1.1); 0.9885 (0.4); 0.7672 (0.4); 0.7564 (1.3); 0.7515 (1.3); 0.7442 (1.2); 0.7392 (1.3); 0.7279 (0.4) 
                 448.1 
               
               
                   
               
               
                 1-90 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.1393 (0.8); 9.1225 (0.8); 8.6321 (3.9); 7.4145 (1.7); 7.3876 (1.2); 7.3824 (1.4); 7.3787 (1.0); 7.0438 (1.0); 7.0396 (1.4); 7.0350 (1.0); 6.0025 (0.6); 5.9853 (0.9); 5.9681 (0.6); 3.3352 (24.6); 2.5255 (0.6); 2.5119 (10.8); 2.5078 (20.3); 2.5034 (25.6); 2.4989 (18.8); 2.3401 (8.4); 2.0766 (1.7); 2.0090 (0.3); 2.0004 (0.4); 1.9881 (0.7); 1.9755 (0.4); 1.9671 (0.4); 1.6877 (16.0); 1.5986 (3.1); 1.5812 (3.1); 1.0327 (0.4); 1.0218 (1.2); 1.0164 (1.3); 1.0059 (0.6); 1.0009 (1.2); 0.9956 (1.2); 0.9855 (0.4); 0.7653 (0.5); 0.7548 (1.3); 0.7500 (1.3); 0.7426 (1.3); 0.7378 (1.3); 0.7266 (0.4); −0.0002 (3.9) 
                 462.1 
               
               
                   
               
               
                 1-91 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.3604 (2.1); 9.3571 (2.0); 9.2346 (2.1); 9.2313 (1.9); 9.0946 (0.8); 9.0775 (0.8); 8.3508 (3.2); 7.3375 (1.8); 7.3325 (1.9); 7.3261 (1.5); 7.0275 (1.0); 7.0232 (1.4); 7.0187 (0.9); 6.0183 (0.5); 6.0011 (0.8); 5.9837 (0.5); 3.3330 (28.8); 2.5249 (0.9); 2.5071 (28.2); 2.5027 (35.5); 2.4983 (26.0); 1.9922 (0.3); 1.9837 (0.4); 1.9714 (0.6); 1.9587 (0.4); 1.9505 (0.3); 1.7528 (0.4); 1.6770 (16.0); 1.6253 (3.1); 1.6079 (3.1); 1.0237 (0.4); 1.0129 (1.1); 1.0074 (1.2); 0.9969 (0.6); 0.9921 (1.1); 0.9865 (1.1); 0.9765 (0.4); 0.7475 (0.5); 0.7368 (1.3); 0.7321 (1.2); 0.7248 (1.2); 0.7199 (1.3); 0.7085 (0.4); −0.0002 (3.3) 
                 443.2 
               
               
                   
               
               
                 1-92 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.3739 (2.4); 9.3709 (2.3); 9.1280 (0.7); 9.1107 (0.8); 8.6036 (2.4); 8.6006 (2.2); 8.3484 (3.4); 7.3707 (1.6); 7.3672 (1.0); 7.3494 (1.1); 7.3439 (1.3); 7.3402 (0.9); 7.0287 (0.9); 7.0239 (1.2); 7.0194 (0.8); 6.1714 (0.5); 6.1541 (0.8); 6.1368 (0.5); 3.3289 (26.4); 2.6754 (0.4); 2.6709 (0.5); 2.6666 (0.4); 2.5245 (1.7); 2.5196 (2.6); 2.5110 (31.3); 2.5066 (60.8); 2.5020 (78.4); 2.4975 (56.8); 2.4930 (27.2); 2.3335 (0.4); 2.3288 (0.5); 2.3244 (0.3); 1.9892 (0.4); 1.9769 (0.6); 1.9640 (0.4); 1.6923 (2.5); 1.6777 (16.0); 1.6360 (3.0); 1.6186 (3.0); 1.0260 (0.4); 1.0152 (1.2); 1.0096 (1.1); 1.0053 (0.6); 0.9994 (0.7); 0.9942 (1.2); 
                 443.2 
               
               
                   
                   
                 0.9887 (1.1); 0.9784 (0.4); 0.7520 (0.5); 
                   
               
               
                   
                   
                 0.7413 (1.2); 0.7362 (1.2); 0.7292 (1.2); 
                   
               
               
                   
                   
                 0.7239 (1.3); 0.7128 (0.4); −0.0002 (2.9) 
                   
               
               
                   
               
               
                 1-93 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.5332 (1.0); 9.5166 (1.0); 8.6247 (6.7); 8.6216 (1.2); 8.3914 (1.3); 8.3876 (2.4); 8.3838 (1.4); 8.3368 (0.3); 8.2640 (1.3); 8.2597 (2.0); 8.2556 (1.3); 8.1770 (1.4); 8.1727 (2.3); 8.1683 (1.2); 6.0419 (0.7); 6.0248 (1.1); 6.0076 (0.7); 3.3963 (0.3); 3.3300 (73.1); 3.3216 (11.3); 2.6758 (0.5); 2.6713 (0.7); 2.6667 (0.5); 2.5249 (2.4); 2.5201 (3.4); 2.5114 (41.6); 2.5069 (83.8); 2.5023 (109.6); 2.4976 (78.7); 2.4931 (37.2); 2.3337 (0.5); 2.3291 (0.7); 2.3245 (0.5); 2.1038 (0.5); 2.0950 (0.5); 2.0831 (1.0); 2.0758 (2.3); 2.0711 (0.6); 2.0625 (0.5); 1.7734 (16.0); 1.6217 (4.0); 1.6043 (4.0); 1.1552 (0.3); 1.1369 (0.8); 1.1185 
                 510.1 
               
               
                   
                   
                 (0.3); 1.0375 (1.4); 1.0336 (1.6); 1.0169 
                   
               
               
                   
                   
                 (1.4); 1.0127 (1.5); 0.8941 (0.6); 0.8874 
                   
               
               
                   
                   
                 (0.8); 0.8819 (1.1); 0.8761 (1.3); 0.8709 
                   
               
               
                   
                   
                 (1.1); 0.0080 (0.8); −0.0002 (29.1); −0.0086 
                   
               
               
                   
                   
                 (0.8) 
                   
               
               
                   
               
               
                 1-94 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 1H-NMR (400.2 MHz, d6-DMSO) δ = 9.4179 (0.8); 9.4002 (0.9); 9.3134 (2.4); 9.3106 (2.5); 8.4684 (0.9); 8.3811 (2.6); 8.3782 (2.8); 8.3278 (3.6); 8.1304 (0.8); 8.0133 (1.0); 8.0094 (1.8); 8.0057 (1.1); 7.8063 (1.2); 7.8040 (1.1); 7.6790 (1.2); 6.2783 (0.6); 6.2610 (0.9); 6.2436 (0.6); 3.3303 (29.9); 2.6719 (0.4); 2.5253 (1.0); 2.5119 (23.2); 2.5075 (48.2); 2.5030 (63.8); 2.4984 (45.4); 2.4939 (21.2); 2.3299 (0.4); 2.0761 (2.4); 1.7271 (16.0); 1.6806 (3.2); 1.6632 (3.2); 0.1459 (0.4); 0.0079 (3.3); −0.0002 (91.5); −0.0086 (2.9); −0.1497 (0.4) 
                 489.1 
               
               
                   
               
               
                 1-95 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (600.1 MHz, d 6 -DMSO): δ = 10.6231 (0.2); 10.5596 (0.1); 9.4016 (0.2); 9.3900 (0.2); 9.3123 (0.4); 9.3105 (0.3); 9.1405 (0.1); 9.1325 (0.1); 8.3717 (0.4); 8.3699 (0.4); 8.3277 (0.5); 8.0054 (0.2); 8.0031 (0.3); 8.0008 (0.2); 7.8009 (0.2); 7.6765 (0.2); 6.2709 (0.1); 6.2594 (0.2); 6.2478 (0.1); 3.3203 (16.0); 3.0766 (0.3); 2.8694 (0.7); 2.8613 (0.7); 2.7988 (0.1); 2.7908 (0.1); 2.6139 (0.1); 2.5227 (0.4); 2.5197 (0.5); 2.5165 (0.6); 2.5075 (7.5); 2.5048 (14.0); 2.5018 (18.1); 2.4988 (13.2); 2.3857 (0.1); 2.0086 (0.2); 1.9676 (0.2); 1.7248 (2.6); 1.6765 (0.6); 1.6649 (0.6); 1.4014 (0.1); 1.1062 (1.0); 1.0871 (1.5); 1.0375 (1.0); 1.0091 (0.2); 0.8773 (0.2); 0.8651 (0.4); 0.8530 (0.2); 0.8365 
                 503.2 
               
               
                   
                   
                 (0.5); 0.8249 (0.5); 0.7979 (0.2); −0.0001 
                   
               
               
                   
                   
                 (0.2 
               
               
                   
               
               
                   1) ‘abs’ denotes that the compound was obtained in an enantiomerically enriched or pure form with the major stereoisomer having the absolute configuration depicted in the drawing. 
               
               
                   2) ‘lowT’ denotes that the measurement was conducted at a temperature of 260 Kelvin. 
               
               
                   3) The stated mass corresponds to the peak from the isotope pattern of the [M + H] +  ion with the highest 5 intensity. 
               
               
                 # denotes that the [M − H] −  ion was recorded. 
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 (Intermediates) 
               
            
           
           
               
               
               
               
            
               
                   
                   
                   
                 ESI Mass 
               
               
                 Intermediate 
                 Structure 1)   
                 NMRPeak List 2)   
                 (m/z) 3)   
               
               
                   
               
               
                 Intermediate 5A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (400 MHz, CDCl 3 ): δ = 1.79 (s, 6 H) 7.76-7.77 (m, 1 H), 8.06-8.07 (m, 1 H), 8.09-8.10 (m, 1 H). 
                   
               
               
                   
               
               
                 Intermediate 9A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (600 MHz, CDCl 3 ): δ = 13.56 (bs, 1H), 8.43 (s, 1 H), 8.31 (s, 1 H), 8.14 (s, 1H), 2.99-2.95 (m, 1H), 1.14-1.07 (m, 4H). 
                   
               
               
                   
               
               
                 Intermediate 10A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 280.9 #   
               
               
                   
               
               
                 Intermediate 14A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 358.9 #   
               
               
                   
               
               
                 Intermediate 17A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR(400.2 MHz, d 6 -DMSO) δ = 9.7694 (1.7); 7.8727 (13.8); 5.3331 (16.0); 3.3330 (6.9); 2.5083 (12.7); 2.5040 (16.5); 2.4997 (12.5) 
                 141.0 
               
               
                   
               
               
                 Intermediate 19A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (DMSO-d 6 , 400 MHz): 9.11 (d, 1H), 8.80 (br d, 3H), 8.61 (dd, 1H), 8.45 (s, 1H), 8.13 (d, 1H), 5.39 (m, 1H), 1.63 (d, 3H). 
                 215.2 
               
               
                   
               
               
                 Intermediate 22A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 245.1 
               
               
                   
               
               
                 Intermediate 24A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 255.1 [amine + H] +   
               
               
                   
               
               
                 Intermediate 25A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm]= 13.63 (br s, 1H), 7.99 (s, 1H), 7.77 (s, 1H), 7.66 (s, 1H), 4.23 (s, 2H). 
                 246.0 
               
               
                   
               
               
                 Intermediate 26A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400 MHz, DMSO-d 6 ): δ [ppm]= 8.07 (s, 1H), 7.77-7.73 (m, 1H), 7.57 (s, 1H), 1.72 (s, 6H). 
                   
               
               
                   
               
               
                 Intermediate 28A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (DMSO-d 6 , 400 MHz): δ = 13.5 (brs, 1 H), 8.20 (s, 1 H), 8.01-8.02 (m, 2 H), 7.38 (s, 1 H). 
                 294.8 
               
               
                   
               
               
                 Intermediate 29A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 249.0 #   
               
               
                   
               
               
                 Intermediate 30A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (DMSO-d 6 , 400 MHz): δ = 13.5 (brs, 1 H), 7.80 (m, 1 H), 7.65 (m, 1 H), 7.61 (m, 1 H), 2.29 (s, 3 H). 
                 213.0 
               
               
                   
               
               
                 Intermediate 35A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (DMSO-d 6 , 400 MHz): δ = 8.14 (s, 1H), 8.03-7.99 (m, 1H), 7.94 (s, 1H), 7.69-7.61 (m, 2H), 7.39-7.27 (m, 2H). 
                 344.9 #   
               
               
                   
               
               
                 Intermediate 38A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 207.2 
               
               
                   
               
               
                 Intermediate 40A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 207.2 
               
               
                   
               
               
                 Intermediate 42A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 221.2 
               
               
                   
               
               
                 Intermediate 44A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 209.1 
               
               
                   
               
               
                 Intemediate 48A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (400 MHz, D6-DMSO): δ = 2.95 (s, 3H), 4.65 (m, 2H), 7.75 (m, 1H), 7.9 (m, 1H), 7.95 (m, 1H), 13.5 (br, 1H). 
                 247.1 #   
               
               
                   
               
               
                 Intermediate 50A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (400 MHz, D6-DMSO): δ = 0.65 (m, 2H), 0.83 (d, 2H), 3.99 (m, 1H), 7.27 (s, 1H), 7.41 (s, 1H), 7.58 (m, 1H), 13.51 (s, 1H). 
                 261.0 #   
               
               
                   
               
               
                 Intermediate 51A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (400 MHz, D6-DMSO): δ = 13.55 (bs, 1H, COOH), 7.88 (m, 1H), 7.73 (m, 1H), 7.64 (m, 1H), 1.72 (s, 6H). 
                 283.9 #   
               
               
                   
               
               
                 Intermediate 52A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (400 MHz, D6-DMSO): δ = 13.55 (bs, 1H, COOH), 7.75 (m, 1H), 7.70 (m, 1H), 7.51 (m, 1H), 1.73 (s, 6H). 
                 238.0 #   
               
               
                   
               
               
                 Intermediate 54A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (DMSO-d 6 , 400 MHz): 9.40 (s, 1H), 9.29 (s, 1H), 8.55 (s, 1H), 6.55 (br s, 2H, NH 2 ), 5.34-5.28 (m, 1H), 1.66 (d, 3H). 
                 216.1 [amine + H] +   
               
               
                   
               
               
                 Intermediate 56A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 216.1 [amine + H] +   
               
               
                   
               
               
                 Intermediate 58A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 256.2 [amine + H] +   
               
               
                   
               
               
                 Intermediate 59A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 274.2 [amine + H] +   
               
               
                   
               
               
                 Intermediate 60A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (400 MHz, D6-DMSO): δ = 14.20 (bs, 1H, COOH), 7.96 (s, 1H), 7.85 (s, 1H), 1.74 (s, 6H). 
                 223.1 #   
               
               
                   
               
               
                 Intermediate 61A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR(400.2 MHz, d 6 -DMSO): δ = 8.7292 (0.9); 7.9513 (1.1); 7.9302 (0.9); 5.3597 (0.4); 3.7138 (1.1); 3.7099 (1.1); 3.6997 (1.2); 3.6788 (1.3); 3.6667 (1.3); 3.6227 (1.6); 3.5686 (16.0); 3.4928 (0.4); 2.9946 (1.0); 2.9600 (1.0); 2.6904 (1.6); 2.5264 (0.5); 2.5088 (19.3); 2.5045 (24.0); 2.5000 (17.4); 2.4177 (6.5); 1.6326 (2.7); 1.6158 (2.6); 1.1647 (0.6); 1.1475 (0.4); 1.1358 (0.4); 1.1212 (0.5); 1.1081 (0.6); −0.0002 (0.9) 
                 289.2 [amine + H] +   
               
               
                   
               
               
                 Intermediate 62A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 for analytical data, see description of preparation 
                   
               
               
                   
               
               
                 Intermediate 63A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 for analytical data, see description of preparation 
                   
               
               
                   
               
               
                 Intermediate 64A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 for analytical data, see description of preparation 
                   
               
               
                   
               
               
                 Intermediate 70A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (DMSO-d 6 ) δ = 8.38-8.40 (m, 1H), 8.36-8.38 (m, 1H), 8.26-8.28 (m, 1H), 1.91 (s, 3H), 1.79 (s, 6H). 
                 268.1 
               
               
                   
               
               
                 Intermediate 71A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H-NMR (400 MHz, DMSO-d 6 ): δ = 9.36 (s, 1H), 8.78 (s, 2H, NH 2 ), 8.52 (s, 1H), 8.50 (bs, 1H), 8.39 (s, 1H), 8.17 (bs, 1H), 5.07-5.45 (m, 1H), 1.67-1.65 (d, 3H). 
                 234.2 [amine + H] +   
               
               
                   
               
               
                 Intermediate 72A 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   1 H NMR (400 MHz, D6-DMSO): δ = 13.20 (bs, 1H, COOH), 7.49 (s, 2H), 7.06 (s, 1H), 2.05-2.01 (m, 1H), 1.69 (s, 6H), 1.03-0.99 (m, 2H), 0.73-0.69 (m, 2H). 
                 244.1 #   
               
               
                   
               
               
                   1) ′abs′ denotes that the compound was obtained in an enantiomerically enriched or pure form with the major stereoisomer having the absolute configuration depicted in the drawing. 
               
               
                   2) ′lowT′ denotes that the measurement was conducted at a temperature of 260 Kelvin. 
               
               
                   3) The stated mass corresponds to the peak from the isotope pattern of the [M + H] +  ion with the highest 5 intensity. 
               
               
                   # denotes that the [M − H] −  ion was recorded. 
               
            
           
         
       
     
     BIOLOGICAL EXAMPLES 
       Rhipicephalus  ( Boophilus )  microplus —In-Vitro Contact Tests Larval Cattle Tick (Strain Parkhurst, Resistant Against Synthetic Pyrethroids) 
     9 mg compound is solved in 1 mL acetone and diluted with acetone to the desired concentration. 250 μL of the test solution is filled in 25 mL glass test tubes and homogeneously distributed on the inner walls by rotation and tilting on a shaking device (2 h at 30 rpm). With a compound concentration of 900 ppm, an inner surface of 44.7 cm 2  and a homogeneous distribution, a dose of 5 μg/cm 2  is achieved. 
     After the solvent has evaporated, each test tube is filled with 20-50 cattle tick larvae ( Rhipicephalus microplus ), closed with a perforated lid and incubated in a horizontal position at 85% relative humidity and 27° C. in an incubator. After 48 hours efficacy is determined. The larvae are patted on the ground of the tubes and negative geotactic behavior is recorded. Larvae that climb back to the top of the vial in a manner comparable to untreated control larvae are marked as alive, larvae not climbing back up comparable to untreated control larvae but are moving uncoordinatedly or only twitching their legs are marked as moribund, tick larvae remaining on the bottom and not moving at all are counted as dead. 
     A compound shows a good efficacy against  Rhipicephalus microplus , if at a compound concentration of 5 μg/cm 2  an efficacy of at least 80% is monitored. An efficacy of 100% means all larvae are dead or moribund; 0% means no larvae are dead or moribund. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 5 μg/cm 2  (=500 g/ha): I-7, I-19, I-21, I-25, I-26, I-27, I-28, I-33, I-35, I-42, I-44, I-45, I-46, I-48, I-58, I-59, I-60, I-65. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 5 μg/cm 2  (=500 g/ha): I-1, I-6, I-9, I-52, I-54. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 5 μg/cm 2  (=500 g/ha): I-2. 
       Rhipicephalus  ( Boophilus )  microplus —Iniectiontest
     Solvent: dimethyl sulfoxide   

     To produce a suitable preparation of active compound, 10 mg of active compound are dissolved in 0.5 mL solvent, and the concentrate is diluted with solvent to the desired concentration. 
     Five adult engorged female ticks ( Rhipicephalus microplus ) are injected with 1 μL compound solution into the abdomen. The ticks are transferred into replica plates and incubated in a climate chamber. 
     After 7 days egg deposition of fertile eggs is monitored. Eggs where fertility is not visible are stored in a climate chamber till hatching after about 42 days. An efficacy of 100% means all eggs are infertile; 0% means all eggs are fertile. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 20 μg/rick: I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-10, I-12, I-13, I-14, I-15, I-16, I-46, I-47. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 20 μg/tick: I-11. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 4 μg/tick: I-2, I-3, I-4, I-6, I-7, I-9, I-10, I-12, I-14, I-15, I-16, I-18, I-19, I-20, I-23, I-25, I-28, I-46, I-47. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 4 μg/tick: I-8, I-11, I-13. 
       Ctenocephalides felis —In-Vitro Contact Tests Adult Cat Flea 
     9 mg compound is solved in 1 mL acetone and diluted with acetone to the desired concentration. 250 μL of the test solution is filled in 25 mL glass test tubes and homogeneously distributed on the inner walls by rotation and tilting on a shaking device (2 h at 30 rpm). With a compound concentration of 900 ppm, an inner surface of 44.7 cm 2  and a homogeneous distribution, a dose of 5 μg/cm 2  is achieved. 
     After the solvent has evaporated, each test tube is filled with 5-10 adult cat fleas ( Ctenocephalides felis ), closed with a perforated lid and incubated in a lying position at room temperature and relative humidity. After 48 hours efficacy is determined. The fleas are patted on the ground of the tubes and are incubated on a heating plate at 45-50° C. for at most 5 minutes Immotile or uncoordinated moving fleas, which are not able to escape the heat by climbing upwards, are marked as dead or moribund. 
     A compound shows a good efficacy against  Ctenocephalides felis , if at a compound concentration of 5 μg/cm 2  an efficacy of at least 80% is monitored. An efficacy of 100% means all fleas are dead or moribund; 0% means no fleas are dead or moribund. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 5 μg/cm 2  (=500 g/ha): I-6, I-35, I-44, I-46, I-58. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 5 μg/cm 2  (=500 g/ha): I-30, I-33, I-42, I-59, I-60. 
       Ctenocephalides felis —Oral Test
     Solvent: dimethyl sulfoxide   

     To produce a suitable preparation of active compound, 10 mg of active compound are dissolved in 0.5 mL solvent, and the concentrate is diluted with cattle blood to the desired concentration. 
     Approximately 20 adult unfed cat fleas ( Ctenocephalides  felts) are placed in flea chambers. The blood chamber, sealed with parafilm on the bottom, are filled with cattle blood supplied with compound solution and placed on the gauze covered top of the flea chamber, so that the fleas are able to suck the blood. The blood chamber is heated to 37° C. whereas the flea chamber is kept at room temperature. 
     After 2 days mortality in % is determined. 100% means all the fleas have been killed; 0% means none of the fleas have been killed. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 ppm: I-1, I-2, I-3, I-5, I-6, I-10, I-23, I-46. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 100 ppm: I-8, I-25. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 100 ppm: I-19. 
       Rhipicephalus sanguineus —In-Vitro Contact Tests with Adult Brown Dog Ticks 
     9 mg compound is solved in 1 mL acetone and diluted with acetone to the desired concentration. 250 μL of the test solution is filled in 25 mL glass test tubes and homogeneously distributed on the inner walls by rotation and tilting on a shaking device (2 h at 30 rpm). With a compound concentration of 900 ppm, an inner surface of 44.7 cm 2  and a homogeneous distribution, a dose of 5 μg/cm 2  is achieved. 
     After the solvent has evaporated, each test tube is filled with 5-10 adult brown dog ticks ( Rhipicephalus sanguineus ), closed with a perforated lid and incubated in a lying position at room temperature and relative humidity. After 48 hours efficacy is determined. The ticks are patted on the ground of the tubes and are incubated on a heating plate at 45-50° C. for at most 5 minutes Immotile or uncoordinated moving ticks, which are not able to escape the heat by climbing upwards, are marked as dead or moribund. 
     A compound shows a good efficacy against  Rhipicephalus sanguineus , if at a compound concentration of 5 μg/cm 2  an efficacy of at least 80% is monitored. An efficacy of 100% means all ticks are dead or moribund; 0% means no ticks are dead or moribund. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 5 μg/cm 2  (=500 g/ha): I-33, I-46, I-59. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 5 μg/cm 2  (=500 g/ha): I-15, I-21, I-35, I-42, I-44, I-58. 
       Diabrotica balteata —Spray Test
     Solvent: 78.0 parts by weight of acetone
       1.5 parts by weight of dimethylformamide   
       Emulsifier: alkylarylpolyglycol ether   

     To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent, and the concentrate is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. 
     Soaked wheat seeds ( Triticum aestivum ) are placed in a multiple well plate filled with agar and some water and are incubated for 1 day to germinate (5 seeds per well). The germinated wheat seeds are sprayed with a test solution containing the desired concentration of the active ingredient. Afterwards each unit is infected with 10-20 larvae of the banded cucumber beetle ( Diabrotica balteata ). 
     After 7 days efficacy in % is determined. 100% means all the seedlings have grown up like in the untreated, uninfected control; 0% means none of the seedlings have grown. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 500 g/ha (=160 μg/well): I-4, I-5, I-6, I-24, I-27. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 g/ha (=32 μg/well): I-13, I-15, I-18, I-24, I-26, I-27, I-28, I-29, I-30, I-33, I-35, I-37, I-38, I-39, I-42, I-43, I-45, I-48, I-49, I-50, I-51, I-53, I-56, I-58, I-59, I-60, I-61, I-62, I-63, I-64, I-66, I-67, I-69, I-70, I-71, I-72, I-73, I-74, I-75, I-76, I-77, I-78, I-79, I-80, I-81, I-82, I-83, I-86, I-88, I-89, I-90. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 100 g/ha (=32 μg/well): I-40, I-87, I-93. 
       Meloidogyne incognita —Test
     Solvent: 125.0 parts by weight of acetone   

     To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent, and the concentrate is diluted with water to the desired concentration. Vessels are filled with sand, a solution of the active ingredient, a suspension containing eggs and larvae of the southern root-knot nematode ( Meloidogyne incognita ) and salad seeds. The salad seeds germinate and the seedlings grow. Galls develop in the roots. 
     After 14 days the nematicidal activity is determined on the basis of the percentage of gall formation. 100% means no galls were found and 0% means the number of galls found on the roots of the treated plants was equal to that in untreated control plants. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 20 ppm: I-39, I-52. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 20 ppm: I-9, I-24, I-25, I-61. 
       Myzus persicae —Oral Test
     Solvent: 100 parts by weight acetone   

     To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent, and the concentrate is diluted with water to the desired concentration. 
     50 μL compound solution is filled in microtiter plates and 150 μL IPL41 insect medium (33%+15% sugar) is added to obtain a total volume of 200 μL per well. Afterwards the plates are sealed with parafilm through which a mixed population of the green peach aphid ( Myzus persicae ) can suck on the compound preparation. 
     After 5 days mortality in % is determined. 100% means all aphids have been killed and 0% means none of the aphids have been killed. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 20 ppm: I-27. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 4 ppm: I-27, I-33, I-35, I-46. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 4 ppm: I-29, I-30, I-34. 
       Myzus persicae —Spray Test
     Solvent: 78.0 parts by weight acetone
       1.5 parts by weight dimethylformamide   
       Emulsifier: alkylarylpolyglycol ether   

     To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. 
     Chinese cabbage ( Brassica pekinensis ) leaf disks infected with all instars of the green peach aphid ( Myzus persicae ), are sprayed with a preparation of the active ingredient of the desired concentration. 
     After 5 days mortality in % is determined. 100% means all aphids have been killed and 0% means none of the aphids have been killed. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 g/ha: I-42, I-43, I-44, I-46, I-66, I-73, I-74. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 100 g/ha: I-27, I-37, I-40, I-45, I-56, I-58, I-59. 
       Nezara viridula —Spray Test
     Solvent: 78.0 parts by weight of acetone
       1.5 parts by weight of dimethylformamide   
       Emulsifier: alkylarylpolyglycol ether   

     To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent, and the concentrate is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. 
     Barley plants ( Hordeum vulgare ) are sprayed with a test solution containing the desired concentration of the active ingredient and are infested with larvae of the southern green stink bug ( Nezara viridula ). 
     After 4 days mortality in % is determined. 100% means all the stink bugs have been killed; 0% means none of the stink bugs have been killed. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 500 g/ha: I-27, I-37, I-38, I-42, I-43, I-44, I-45, I-51, I-52, I-56, I-58, I-59, I-64, I-66, I-70, I-71, I-73, I-74, I-75. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 500 g/ha: I-55. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 g/ha: I-4, I-6, I-27, I-35, I-42, I-43, I-44, I-45, I-46, I-58, I-59, I-74. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 100 g/ha: I-38, I-55, I-56. 
       Nilaparvata lugens —Spray Test
     Solvent: 78.0 parts by weight of acetone
       1.5 parts by weight of dimethylformamide   
       Emulsifier: alkylarylpolyglycol ether   

     To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. 
     Rice plants ( Oryza sativa ) are sprayed with a preparation of the active ingredient of the desired concentration and the plants are infested with the brown planthopper ( Nilaparvata lugens ). 
     After 4 days mortality in % is determined. 100% means all planthoppers have been killed and 0% means none of the planthoppers have been killed. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 500 g/ha: I-38, I-51, I-66. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 g/ha: I-4, I-6. 
       Spodoptera frugiperda —Spray Test
     Solvent: 78.0 parts by weight acetone
       1.5 parts by weight dimethylformamide   
       Emulsifier: alkylarylpolyglycol ether   

     To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. 
     Maize ( Zea mays ) leaf sections are sprayed with a preparation of the active ingredient of the desired concentration. Once dry, the leaf sections are infested with fall armyworm larvae ( Spodoptera frugiperda ). After 7 days mortality in % is determined. 100% means all caterpillars have been killed and 0% means none of the caterpillars have been killed. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 500 g/ha: I-3, I-6, I-24, I-27. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 g/ha: I-24, I-25, I-27, I-28, I-33, I-35, I-37, I-38, I-39, I-40, I-42, I-43, I-44, I-46, I-49, I-51, I-52, I-53, I-54, I-55, I-56, I-57, I-58, I-59, I-60, I-61, I-64, I-66, I-67, I-69, I-70, I-71, I-72, I-73, I-74, I-75, I-76, I-77, I-78, I-79, I-80, I-81, I-82, I-83, I-84, I-85, I-86, I-87, I-88, I-92, I-93. 
     In this test, for example, the following compounds from the preparation examples showed good activity of 83% at an application rate of 100 g/ha: I-21, I-48. 
       Aedes aegypti  Test (AEDSAE Surface Treatment &amp; Contact Assay)
     Solvent: Aceton+2000 ppm rapeseed oil methyl ester (RME)   

     In order to produce a sufficient, active ingredient containing solution it is necessary to solve the test compound in the solvent-mix (acetone at 2 mg/ml/RME 2000 ppm). This solution is pipetted onto a glazed tile and after evaporation of the acetone, adult mosquitoes of the species  Aedes aegypti  strain MONHEIM are placed onto the dried surface. The exposure time is 30 minutes. 
     Mortality in percent (%) is determined 24 hours after contact of the insects to the treated surface. 100% mortality means that all tested insects are dead, whereas 0% means that no insect died. 
     The following examples showed in this test efficacy of 80-100% at a surface concentration of 20 mg/m 2 : I-27, I-33, I-35, I-42, I-43, I-44, I-45, I-46, I-53, I-56. 
     The following examples showed in this test efficacy of 80-100% at a surface concentration of 4 mg/m 2 : I-27, I-33, I-35, I-42, I-43, I-44, I-45, I-46, I-56. 
       Culex quinquefasciatus  Test (CULXFA Surface Treatment &amp; Contact Assay)
     Solvent: Aceton+2000 ppm rapeseed oil methyl ester (RME)   

     In order to produce a sufficient, active ingredient containing solution it is necessary to solve the test compound in the solvent-mix (acetone at 2 mg/ml/RME 2 000 ppm). This solution is pipetted onto a glazed tile and after evaporation of the acetone, adult mosquitoes of the species  Culex Quinquefasciatus  strain P00 are placed onto the dried surface. The exposure time is 30 minutes. Mortality in percent (%) is determined 24 hours after contact of the insects to the treated surface. 100% mortality means that all tested insects are dead, whereas 0% means that no insect died. 
     The following examples showed in this test efficacy of 80-100% at a surface concentration of 20 mg/m 2 : I-33, I-35, I-37, I-42, I-43, I-44, I-45, I-46. 
     The following examples showed in this test efficacy of 80-100% at a surface concentration of 4 mg/m 2 : I-42, I-43, I-44, I-45. 
       Musca domestica  Test (MUSCDO Surface Treatment &amp; Contact Assay)
     Solvent: Aceton+2000 ppm rapeseed oil methyl ester (RME)   

     In order to produce a sufficient, active ingredient containing solution it is necessary to solve the test compound in the solvent-mix (acetone at 2 mg/ml/RME 2000 ppm). This solution is pipetted onto a glazed tile and after evaporation of the acetone, adult flies of the species  Musca domestica  strain WHO-N are placed onto the dried surface. The exposure time is 30 minutes. 
     Mortality in percent (%) is determined 24 hours after contact of the insects to the treated surface. 100% mortality means that all tested insects are dead, whereas 0% means that no insect died. 
     The following examples showed in this test efficacy of 80-100% at a surface concentration of 20 mg/m 2 : I-33, I-35, I-38, I-42, I-43, I-44, I-45. 
     The following examples showed in this test efficacy of 80-100% at a surface concentration of 4 mg/m 2 : I-33, I-35, I-42, I-43, I-44, I-45, I-46.